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Abstract	  
	  
The	  acute	  respiratory	  distress	  syndrome	  (ARDS)	  remains	  a	  major	  cause	  of	  morbidity	  
and	   mortality	   in	   the	   intensive	   care.	   Despite	   improvements	   in	   intensive	   care	   and	  
advances	   in	   respiratory	   support,	  mortality	   remains	  high	  with	  no	  active	   treatments.	  
Tumour	  necrosis	  factor	  (TNF)	  is	  a	  cytokine	  that	  has	  been	  implicated	  in	  ARDS	  for	  over	  
30	  years	  but	  its	  precise	  roles	  remain	  elusive.	  It	  signals	  through	  two	  main	  receptors	  –	  
the	  p55	  TNF	  receptor	  and	  p75	  TNF	  receptor.	  	  
	  
The	   first	  aspect	  of	   this	   thesis	   investigated	   the	   roles	  of	  TNF	   receptors	   (TNFR)	   in	   the	  
early	   phase	   of	   acute	   acid-­‐induced	   lung	   injury.	   Using	   genetically	  modified	  mice	  we	  
discovered	   that	   alveolar	   oedema,	   as	   a	   result	   of	   acid	   aspiration,	   was	   specifically	  
mediated	   through	   the	   p55-­‐TNFR,	   whereas,	   the	   p75-­‐TNFR	   promoted	   a	   protective	  
effect.	   Alveolar	   oedema	   formation	  occurred	   through	   an	   effect	   independent	   to	   the	  
downstream	   inflammatory	   events,	   but	   instead	   through	   the	   activation	   of	   TNF/p55-­‐
TNFR/caspase-­‐8	  death	  signalling	  specifically	  in	  the	  alveolar	  epithelium.	  Furthermore,	  
this	   death-­‐signalling	   axis	   led	   to	   a	   reduced	   alveolar	   epithelial	   fluid	   clearance	   rate.	  
Epithelial	   dysfunction	   occurred	   prior	   to	   epithelial	   cell	   death	   and	   pharmacological	  
blockade	   of	   caspase-­‐8	   rescued	   epithelial	   function	   with	   improvements	   in	   gas	  
exchange,	  suggesting	  that	  the	  activation	  of	  caspase-­‐8	  per	  se	  induced	  this	  functional	  
deficit	  in	  the	  alveolar	  epithelium.	  	  
	  
The	  second	  part	  of	  the	  thesis	  describes	  the	  development	  of	  a	  longer-­‐term	  model	  of	  
acid	   aspiration	   aimed	   at	   extending	   investigation	   into	   the	   later,	   arguably	   more	  
clinically	   relevant,	   phases	   of	   lung	   injury	   (0-­‐10	   days).	   Mice	   showed	   respiratory	  
physiology	   that	   reached	   clinical	   ARDS	   criteria	   with	   significant	   inflammation	   and	  
epithelial/endothelial	   injury,	   which	   importantly,	   resolved	   facilitating	   investigation	  
into	   reparative	   processes.	   This	   model	   was	   further	   characterised	   using	   novel	   flow	  
cytometry	   protocols	   to	   examine	   the	   compartmental	   location	   of	   leukocytes	   during	  
the	   various	   phases	   of	   ARDS.	   This	  model	   provides	   a	   translational	   platform	   to	   allow	  
investigation	  into	  the	  injurious,	  inflammatory,	  and	  resolution	  mechanisms	  of	  ARDS.	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1 Introduction	  
1.1	   The	  lung	  in	  normal	  physiology	  
The	   human	   respiratory	   system	   consists	   of	   upper	   (the	   nasal	   and	   oral	   cavities,	  
pharynx,	   larynx	   and	   trachea)	   and	   lower	   airways	   (the	   bronchi,	   bronchioles	   and	  
terminal	   bronchioles),	   and	   terminate	   in	   a	   vast	   air-­‐blood	   interface	   provided	   by	  
millions	   of	   alveolar-­‐capillary	   units	   (1).	   The	   process	   of	   respiration	   involves	   a	  
coordinated	   neuronal	   activity	   producing	   an	   inspiratory	   and	   expiratory	   cycle	  
facilitating	  the	  movement	  of	  gas	   into	  and	  out	  of	  the	  lung	  delivering	  oxygen	  to,	  and	  
removing	   carbon	   dioxide,	   the	   end	   product	   of	   cellular	   metabolism,	   from	   these	  
alveolar-­‐capillary	   units.	   This	   interface	   between	   the	   outside	   environment	   and	   the	  
circulating	  blood	  provide	  a	  surface	  area	  of	  over	  70m2	  across	  which	  gas	  exchange	  can	  
occur	   (2).	   Unlike	   any	   other	   tissue	   bed	   the	   lung	   is	   exposed	   to	   the	   entire	   cardiac	  
output	   and	   hence,	   the	   lung	   has	   the	   potential	   to	   not	   only	   be	   affected	   by,	   but	   also	  
have	   significant	   influence	   upon,	   the	   rest	   of	   the	   body.	   Indeed,	   it	   is	   now	   well	  
established	   that	   the	   lung	   is	   able	   to	  modulate	  multiple	   endocrine	   factors	   and	   also	  
influence	  injury	  and	  inflammation	  at	  remote	  sites.	  
1.1.1 The	  lung	  in	  a	  constant	  state	  of	  alert	  	  
It	   is	   this	   direct	   exposure	   of	   the	   alveolus	   to	   the	   external	   environment,	   which	  
necessitates	   the	   lung	   to	   develop	  mechanisms	   whereby	   any	   harmful	   particles	   that	  
enter	  can	  be	  extruded	  or	  eliminated	   in	  a	  timely	  manner,	  without	  causing	  collateral	  
tissue	  damage.	  With	  each	  breath	  the	  respiratory	  system	  is	  bombarded	  with	  particles.	  
These	   range	   from	  pollutants	   in	   the	   air,	   to	   oropharyngeal	   contents	   that	   have	   been	  
aspirated,	   to	   infectious	   agents	   such	   as	   bacteria,	   fungi,	   or	   viruses.	   The	   upper	  
respiratory	   system	   has	   developed	   physical	   mechanisms	   to	   prevent	   this	   entry.	   For	  
instance,	  the	  epiglottis	  prevents	  food	  from	  entering	  the	  trachea	  during	  swallowing;	  
the	  cough	  reflex	  extrudes	  particles	  that	  may	  have	  bypassed	  this	  epiglottic	  defence;	  a	  
‘sticky’	  mucus	  layer	  on	  the	  inner	  surface	  of	  the	  trachea	  and	  major	  bronchi	  prevents	  
particles	  accessing	  the	  lung	  parenchyma;	  and	  cilia	  on	  the	  bronchial	  epithelium	  waft	  
these	  trapped	  particles	  up	  and	  out	  of	  the	  respiratory	  tract	  (1).	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However,	   inevitably	   some	   particles	   do	   get	   through	   these	   physical	   defences	   and	  
access	   the	   distal	   pulmonary	   tree.	   Here,	   within	   the	   distal	   bronchioles	   and	   alveoli,	  
there	   is	   a	   cellular	   and	   molecular	   defence	   system,	   which	   wages	   war	   against	   this	  
resilient	  unwanted	  matter.	   In	  health,	  these	  mainly	  comprise	  alveolar	  macrophages,	  
floating	   in	   a	   sea	   of	   surfactant	  within	   the	   alveolus;	   and	   dendritic	   cells,	   located	   just	  
beneath	   the	   alveolar/bronchial	   epithelium,	   protruding	   dendrites	   into	   the	  
alveolar/bronchial	   lumen	   actively	   looking	   for	   foreign	   antigen.	   This	   surfactant	   is	   a	  
phospholipid	  layer	  lining	  the	  inside	  of	  the	  alveoli,	  primarily	  preventing	  their	  collapse	  
inwards	  by	  maintaining	  a	  reduced	  surface	  tension.	  However,	  surfactant	  also	  serves	  a	  
defensive	   purpose	   as	   it	   contains	   numerous	  molecules	   that	   bind	   a	   diverse	   array	   of	  
foreign	   molecular	   patterns	   facilitating	   presentation	   to	   immune	   cells	   for	   their	  
clearance.	  If	  these	  defences	  are	  breached	  there	  is	  a	  cavalry	  recruited	  from	  the	  blood	  
to	  fight	  these	  invaders	  on	  the	  battlefield	  that	  is	  the	  alveolar	  space.	  Inevitably,	  in	  such	  
circumstances,	   there	   is	   collateral	   damage	   to	   the	   alveolar	   space.	   If	   the	   battle	   ends	  
through	  clearance	  or	  tolerance	  of	  the	   invading	  matter,	   there	  begins	  a	  clear	  up	  and	  
reparative	  process,	  to	  restore	  the	  lung	  to	  working	  order,	  in	  preparation	  for	  the	  next	  
battle.	  Unfortunately,	  when	  clearance,	  tolerance,	  and	  resolution	  do	  not	  occur	  after	  
an	  acute	  insult,	  the	  collateral	  damage	  to	  the	  lung	  can	  lead	  to	  acutely	  devastating	  and	  
life-­‐threatening	  forms	  of	  lung	  injury.	  	  
1.1.2 The	  alveolar-­‐capillary	  unit	  –	  the	  site	  of	  action…	  
The	  alveolar-­‐capillary	   interface	   (figure	  1.1	  and	  1.2)	   is	  a	  unique	   tissue	   interface	  and	  
can	  be	  likened	  to	  a	  large	  dam	  with	  air	  on	  one	  side	  (the	  alveolus)	  and	  water	  (blood)	  
on	   the	  other.	   Efficient	   gas	  exchange	   relies	  on	  a	   combination	  of	   factors	   including	  a	  
large	  surface	  area,	  a	  concentration	  gradient	  and	  a	  small	  thickness	  for	  diffusion.	  The	  
alveolar-­‐capillary	   unit	   is	   designed	   to	   maximise	   the	   efficiency	   through	   which	   this	  
process	  occurs.	  Firstly,	  as	  mentioned	  the	  lung	  consists	  of	  millions	  of	  alveoli	  which	  are	  
maintained	   in	  an	  open	   state	  by	   surfactant	   lining	   their	   inner	   surface.	  Alveolar	  walls	  
are	  lined	  by	  two	  types	  of	  alveolar	  epithelial	  cell	  (AEC)	  -­‐	  type	  I	  and	  type	  II.	  These	  are	  
closely	   apposed	   to	   the	   pulmonary	   capillary	   endothelium.	   An	   interstitial	   layer	  
containing	   a	   basement	  membrane	   aids	   this	   close	   apposition.	   This	   interstitial	   layer	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also	  harbours	  numerous	  immune	  cells	  including	  interstitial	  macrophages,	  fibroblasts,	  
myofibroblasts	   and	   dendritic	   cells.	   There	   are	   also,	   resident	   within	   the	   alveoli,	  
sentinel	  cells	  called	  alveolar	  macrophages,	  and	  these	  present	  an	  important	  first	  line	  
of	   defence.	   These	   alveolar	   and	   interstitial	   leukocytes	   are	   exposed	   to	   the	   outside	  
world,	  and	  hence	  survey	  and	  sample	  the	  alveolar	  space	  and	  additionally	  have	  close	  





Figure	  1.1.	  The	  alveolus	  
The	  terminal	  alveolar	  ducts	  ends	   in	  a	  number	  of	  air	  sacs	  called	  alveoli.	  Each	  alveoli	  
has	  walls	  comprised	  of	  alveolar	  epithelial	  cells	   (AEC)	  and	   is	   lined	  by	  a	  phospholipid	  
layer	   of	   surfactant.	   This	   layer	   reduces	   the	   surface	   tension	   within	   the	   alveolus	  
preventing	   its	   collapse.	   Furthermore,	   the	   surfactant	   layer	   consists	   of	   proteins	   that	  
facilitate	   protection	   from	   foreign	   material	   including	   bacteria.	   This	   aids	   resident	  
alveolar	   macrophages	   to	   respond	   in	   an	   appropriate	   manner	   to	   the	   constant	  
exposure	   to	   the	   outside	  world.	   The	   interstitial	   space	   also	   contains	   a	   vast	   array	   of	  
resident	   cells	   including	   dendritic	   cells	   and	   interstitial	   macrophages.	   Such	   resident	  
leukocytes	   detect	   and	   engulf	   any	   foreign	   materials	   that	   enter	   the	   alveolus.	  
Overwhelming	  activation	  leads	  to	  significant	  exudation	  and	  inflammation	  within	  the	  
lung.	   This	   occurs	   through	   activation	  of	   the	   epithelial	   and	   endothelial	   cells	   and	   the	  
release	   of	   chemokines	   and	   cytokines.	   Endothelial	   and	   epithelial	   cells	   subsequently	  
upregulate	  cell	  adhesion	  molecules	  on	  their	  cell	  surface	  attracting	  leukocytes	  such	  as	  
neutrophils	   and	   monocytes	   from	   the	   vasculature	   into	   the	   interstitial	   and	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1.1.3 The	  pulmonary	  capillary	  endothelium	  –	  a	  silk	  lining	  
The	  lung	  endothelium	  produces	  a	  continuous	  monolayer	  providing	  an	  intimal	   lining	  
of	   pulmonary	   blood	   vessels	   separating	   blood	   components	   from	   interstitial	   tissue	  
layers.	  This	  layer	  provides	  a	  large	  surface	  area	  (120m2)	  with	  the	  main	  function	  of	  gas	  
exchange,	   as	   well	   as	   host	   defence,	   surveillance,	   and	   homeostasis	   (2).	   The	   lung	  
endothelium	   is	   in	   contact	   with	   the	   entire	   cardiac	   output	   and	   this	   unique	   feature	  
places	  it	  in	  a	  position	  to	  control	  systemic	  physiology.	  The	  pulmonary	  circulation	  is	  a	  
low	   pressure,	   high	   flow	   system	   enabling	   small	   changes	   in	   vascular	   tone	   to	   have	  
significant	   impact	   upon	   cardiovascular	   physiology	   as	   well	   as	   gas	   exchange.	   For	  
instance,	  hypoxic	  vasoconstriction	  in	  response	  to	  local	  alveolar	  hypoxia	  leads	  to	  only	  
those	   alveoli	   that	   are	   ventilated	   being	   perfused	   improving	   ventilation	   perfusion	  
matching	  (V/Q)	  and	  ultimately	  making	  gas	  exchange	  as	  efficient	  as	  possible.	  During	  
states	  of	  injury	  where	  there	  is	  damage	  to	  the	  alveolar	  structure	  and	  damage	  to	  the	  
underlying	   pulmonary	   microvasculature,	   there	   is	   remodelling	   and	   scarring	   which	  
ultimately	  disrupts	  this	  efficiency	  of	  the	  pulmonary	  vasculature	  to	  maintain	  V/Q	  as	  1.	  
This	   leads	   to	   ventilated	   lung	   areas	   not	   being	   perfused	   (i.e.	   increasing	   dead	   space;	  
V/Q=∞)	   and	   non-­‐ventilated	   areas	   being	   perfused	   (i.e.	   shunt;	   V/Q=0).	   Overall,	   this	  
significantly	   disables	   the	   lung	   from	   performing	   its	   primary	   function,	   namely	   gas	  
exchange.	  
	  
The	  endothelium	  also	  functions	  to	  keep	  plasma	  and	  cellular	  constituents	  within	  the	  
circulation.	   This	   is	   crucial	   in	   the	   pulmonary	   circulation	   as	   a	   unique	   feature	   is	   the	  
presence	  of	  a	  dry	  alveolar	  space	  and	  a	  thin	  alveolar-­‐capillary	  barrier	  to	  facilitate	  gas	  
exchange.	   When	   the	   endothelium	   is	   disrupted	   there	   is	   a	   leak	   of	   plasma	   into	   the	  
interstitial	   space,	   and	   eventually	   into	   the	   alveolar	   space,	   leading	   to	   impaired	   gas	  
exchange	   ability	   of	   the	   lungs.	   The	   endothelium	   is	   the	   first	   barrier	   that	   has	   to	   be	  
overcome	   to	   produce	   alveolar	   oedema.	   Endothelial	   cells	   are	   able	   to	   prevent	   large	  
plasma	  proteins	  (such	  as	  albumin)	  from	  entering	  the	  interstitial	  space	  whilst	  enabling	  
small	  molecules	   to	  move	   across	   and	   this	   process	   is	   called	   protein	   sieving	   (3).	   This	  
results	  in	  a	  higher	  plasma	  protein	  concentration	  and	  hence	  a	  higher	  plasma	  oncotic	  
pressure	   in	   comparison	   to	   respective	   tissue	   pressures	   enabling	   retention	   of	  water	  
within	  the	  vasculature.	  Failure	  of	  the	  endothelium	  to	  prevent	  large	  proteins	  crossing	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the	  barrier	  leads	  to	  a	  reversal	  of	  oncotic	  gradients	  with	  subsequent	  vascular	  hyper-­‐
permeability	  and	  filtration.	  	  
	  
Another	  major	  role	  of	  the	  endothelium	  is	  to	  facilitate	  the	  recruitment	  of	  the	  ‘cavalry’	  
–	   blood	   derived	   leukocytes.	   This	   is	   achieved	   through	   signals	   emanating	   from	   the	  
alveolus	  causing	  the	  endothelium	  to	  upregulate	  cell	  adhesion	  molecules	  enabling	  the	  
adhesion,	   rolling	   and	   transmigration	   of	   ‘circulating’	   leukocytes	   into	   the	   interstitial	  
and	  alveolar	  space.	  Unlike	  other	  vascular	  beds,	  the	  pulmonary	  circulation	  is	  different	  
in	   that	   there	   is	   an	   unusually	   large	   amount	   of	   physiological	   sequestration	   of	  
leukocytes	   from	   the	   systemic	   circulation.	   This	   is	   secondary	   to	   the	   significant	  
deformation	   required	   of	   leukocytes,	   for	   them	   to	   migrate	   through	   the	   pulmonary	  
microcirculation	   (4,	   5).	   Although	   this	   close	   leukocyte/endothelial	   interaction	   is	  
regarded	  as	  an	  important	  process	  within	  the	  lung,	  the	  exact	  mechanisms	  of	  this	  so-­‐
called	  ‘margination’	  are	  still	  unclear	  and	  under	  immense	  scrutiny	  by	  lung	  researchers	  
worldwide.	   However,	   it	   is	   well	   established	   that	   the	   lung	   endothelium	   has	   a	  
constitutive	  expression	  of	  some	  cell	  adhesion	  molecules	  such	  as	  ICAM-­‐1	  and	  PECAM,	  
as	  well	  as,	  an	  inducible	  expression	  of	  others	  such	  as	  E-­‐,	  P-­‐selectin	  and	  VCAM	  (6).	  It	  is	  
important	   to	   appreciate	   that	   this	   ‘marginated’	   pool	   of	   leukocytes	   is	   in	   dynamic	  
equilibrium	  with	   the	  non-­‐marginated	   ‘circulating’	  pool,	  which	   in	   turn	   is	   in	  dynamic	  
equilibrium	  with	  the	  ‘bone-­‐marrow’	  pool.	  This	  is	  discussed	  later	  but	  it	  is	  clearer	  that	  
the	  lung	  endothelium	  has	  the	  potential	  to	  dramatically	   influence	  the	  state	  of	  these	  
leukocytes	   as	   they	   ‘marginate’	   or	   ‘circulate’	   through	   the	   pulmonary	  
microvasculature.	  	  
1.1.4 The	  pulmonary	  epithelium	  –	  the	  dam	  and	  the	  pump	  
The	  alveolar	  epithelium	  is	  composed	  of	  an	  equal	  number	  of	  two	  cell	  types	  –	  alveolar	  
epithelial	   type	   I	   (AEC	   I)	  and	  type	   II	   (AEC	   II)	  cells.	  They	  have	  distinct	  structures	  with	  
AEC	   I	   cells	   having	   a	   flattened	   structure	   and	   covering	   95%	   of	   the	   alveolar	   septal	  
surface.	   Functionally,	  AEC	   I	   cell	  morphology	   is	   specialised	   for	   gas	   exchange.	  AEC	   II	  
cells	  have	  a	  cuboidal	  structure	  covering	  the	  rest	  of	  the	  septal	  surface	  and	  are	  located	  
near	   the	   corners	   where	   alveoli	   meet.	   Both	   contain	   vesicles	   that	   can	   transport	  
substances	  in	  each	  direction	  across	  the	  air-­‐blood	  interface.	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The	  cytoplasm	  of	  AEC	  II	  cells	  have	  prominent	  amounts	  of	  endoplasmic	  reticulum	  and	  
Golgi	  complexes	  which	  aid	  the	  production	  of	  vesicles	  containing	  surfactant	  proteins	  
which	  prevent	  alveolar	  collapse.	  In	  addition,	  both	  types	  of	  epithelium	  are	  involved	  in	  
the	   prevention	   of	   alveolar	   flooding	   through	   the	   promotion	   of	   a	   tight	   intercellular	  
barrier.	   Alveolar	   epithelial	   cells	   are	   joined	   to	   each	   other	   by	   tight	   junctions	   and	  
provide	  a	  barrier	  to	  diffusion	  of	  fluid	  into	  the	  alveolar	  space.	  The	  tight	  junctions	  can	  
be	   described	   as	   the	   “cement”,	   binding	   the	   epithelial	   cells,	   the	   “bricks”,	   forming	   a	  
dam	  with	  air	  on	  one	  side	  and	  fluid	  on	  the	  other.	  This	  “cement”	  is	  linked	  closely	  with	  
the	  actin-­‐myosin	  cytoskeleton	  (figure	  1.2).	  In	  addition	  to	  this	  barrier	  function,	  which	  
prevents	   flooding	   of	   the	   alveoli,	   both	   cell	   types	   express	   pumps	   and	   channels	   to	  
transport	   ions	   and	   solutes	   allowing	   the	   control	   of	   the	   constitution	   of	   the	   alveolar	  
lining	   fluid	   (or	   hypophase).	   The	   predominant	   active	  mechanism	   is	   that	   of	   sodium	  
transport	   by	   Na+/K+	   ATPase	   transporters	   located	   on	   the	   basal	   surface	   of	   the	  
epithelium	  thereby	  creating	  an	  electrochemical	  gradient	  allowing	  movement	  of	  Na+	  
though	  apical	  epithelial	  Na+	  channels	  (ENaC).	  This	  gradient	  drives	  the	  movement	  of	  
water	  out	  of	  the	  alveolus	  through	  paracellular	  and	  transcellular	  (aquaporins)	  routes,	  
a	  process	  called	  alveolar	  fluid	  clearance	  (7).	  
	  
Surfactant	  mostly	  consists	  of	  90%	  phospholipids,	  however,	  approximately	  10%	  of	  its	  
constitution	  is	  protein,	  mainly	  four	  surfactant	  proteins	  –	  A	  to	  D.	  Type	  2	  AECs	  produce	  
all	   four	   surfactant	   proteins.	   Surfactant	   protein	   B	   and	   C	   are	   hydrophobic,	  with	   the	  
former	  playing	  a	  significant	  role	   in	  reducing	  alveolar	  surface	  tension,	  and	  the	  latter	  
has	   been	   found	   to	   bind	   endotoxin.	   SP-­‐A	   and	   -­‐D	   are	   part	   of	   the	   collectin	   family	   of	  
molecules	   and	   help	   in	   host	   defence	   by	   acting	   as	   opsonins	   facilitating	   enhanced	  
uptake	  of	  foreign	  matter	  (e.g.	  bacteria)	  or	  debris	  (e.g.	  apoptotic	  cells)	  by	  phagocytes,	  
such	  as	  alveolar	  macrophages	  (8).	  	  	  
1.1.5 The	  resident	  alveolar	  macrophage	  –	  the	  gate	  keeper	  
Resident	   alveolar	   macrophages	   within	   the	   alveolus	   provide	   surveillance	   against	  
invading	  foreign	  material	  (infectious	  and	  non-­‐infectious),	  and	  are	  at	  centre-­‐stage	  of	  
any	  acute	  immune	  response	  within	  the	  lung.	  They	  comprise	  95%	  of	  all	  immune	  cells	  
within	  the	  airspace	  in	  the	  healthy	  lung.	  They	  express	  a	  number	  of	  receptors	  allowing	  
Chapter	  1	  
Introduction	  
	   27	  
them	  to	  sense	  the	  nearby	  environment	  as	  well	  as	  interact	  with	  the	  lung	  epithelium	  
and	   other	   immune	   cells.	   These	   include	   scavenger	   receptors,	   integrins,	  
immunoglobulin	   superfamily	   receptors	   (Fc	   receptor;	   Triggering	   receptor	   expressed	  
on	   myeloid	   cells	   (TREM))	   and	   toll-­‐like	   receptors	   (TLR)	   (9).	   These	   interactions	   are	  
crucial	  for	  not	  only	  for	  the	  recognition	  of	  infectious	  agents	  through	  the	  presentation	  
of	  pathogen	  associated	  molecular	  patterns	  (PAMPs,	  such	  as	  endotoxin,	   lipoteichoic	  
acid,	   and	   zymogen)	   (10),	   but	   also	   for	   clearance	   of	   tissue	   debris	   consisting	   of	  
apoptotic/necrotic	   cells	   (11),	   and	   recognition	   of	   sterile	   injury	   through	   the	  
recognition	  of	  damage	  associated	  molecular	  patterns	  (DAMPs,	  such	  as	  ATP,	  DNA	  and	  
formyl	  peptides)	  (12,	  13).	  The	  ligation	  and	  signalling	  through	  PAMP	  receptors	  (TLR-­‐2,	  
-­‐3,	   -­‐4,	   -­‐6,	   -­‐9)	   and	   the	   increasing	   variety	   of	  DAMP	   receptors	   (TLRs,	   RAGE,	  Dectin-­‐1,	  
P2Y	  P2X,	  CD14,	  CD44)	   leads	  to	  the	  elaboration	  of	  pre-­‐made	  and	  the	  transcriptional	  
upregulation	  of	  pro-­‐inflammatory	  cytokines	  (e.g.	  TNF	  and	  IL-­‐6)	  and	  chemokines	  (e.g.	  
CCL-­‐2,	   IL-­‐8),	   expression	   of	   cell	   adhesion	   molecules	   on	   the	   lung	   endothelium,	   and	  
subsequent	   recruitment	   of	   blood	   derived	   leucocytes	   such	   as	   neutrophils	   and	  
inflammatory	  monocytes.	   In	  contrast,	   the	   recognition	  of	  apoptotic	   cells	   is	  a	   crucial	  
switch	  to	  promote	  anti-­‐inflammatory	  mechanisms	  and	  the	  eventual	  resolution	  of	  the	  
inflammatory	  response	  (14,	  15).	  This	  plasticity	  in	  macrophage	  phenotype	  is	  crucial	  in	  
determining	  the	  alveolar	  milieu	  throughout	  the	  course	  of	  any	  injurious	  response.	  	  
Chapter	  1	  
Introduction	  
	   28	  


































































































over( 95%( of( the( wall( of( the( alveolus.( The( epithelium( is( bound( -ghtly( together( by( mul-ple(
transmembrane( (occludins,( claudins,( cadherins)( and( cytoplasmic( protein( (zona( occludens)( that(




of( MLC( kinase( leading( to( phosphoryla-on( of( MLC( and( subsequent( increases( in( paracellular(





transport(of(water(out(of( the(alveolus( into( the( inters--um.(This(process( is( called(alveolar(ﬂuid(
clearance(and(can(occur(through(transcellular((aquaporin(channels)(or(paracellular(routes.(Apical(




	   29	  
	  
Figure	  1.2.	  Components	  of	  the	  alveolar-­‐capillary	  barrier	  
The	  alveolus	  is	  formed	  of	  type	  1	  and	  type	  2	  alveolar	  epithelial	  cells	  (AECs).	  Cuboidal	  
type	   2	   AECs,	   found	   on	   the	   corners	   of	   adjoining	   alveoli,	   produce	   terminally	  
differentiated	   type	   1	   AECs	   that	   take	   on	   a	   thin	   stretched	   appearance	   forming	   over	  
95%	  of	  the	  wall	  of	  the	  alveolus.	  The	  epithelium	  is	  bound	  tightly	  together	  by	  multiple	  
transmembrane	   (occludins,	   claudins,	   cadherins)	   and	   cytoplasmic	   protein	   (zona	  
occludens)	  that	  are	  cross	  linked	  together	  and	  bound	  to	  the	  intracellular	  actin-­‐myosin	  
cytoskeletal	   scaffold.	   This	   actin	   myosin	   scaffold	   is	   controlled	   through	   multiple	  
cytoplasmic	  signalling	  pathways.	  Myosin	  light	  chain	  (MLC)	  is	  the	  principal	  regulatory	  
component	  of	  actomyosin	  condensation	  and	  contraction,	  and	  hence,	  cell	  shape	  and	  
permeability.	  Multiple	  mediators	  (most	  notably	  TNF)	  induce	  activation	  of	  MLC	  kinase	  
leading	   to	   phosphorylation	   of	   MLC	   and	   subsequent	   increases	   in	   paracellular	  
permeability.	   Such	   adhesion	  molecules	   also	   exist	   between	  endothelial	   cells	   but	  do	  
not	  show	  as	  tight	  a	  regulation	  as	  the	  epithelium.	  The	  basal	  cell	  membrane	  (vascular	  
facing)	   of	   the	   epithelium	   also	   contains	   a	   significant	   number	   of	   Na+/K+	   ATPase	  
transporters	  that	  actively	  transport	  3	  Na+	  out	  of	  the	  cell	  and	  2	  K+	  ions	  into	  the	  cells	  
creating	   a	   concentration	   gradient	   for	   Na+.	   This	   facilitates	   entry	   of	   Na+	   from	   apical	  
sodium	  channels	   (ENaC)	  and	  drives	  an	  osmotic	  gradient	   for	   the	   transport	  of	  water	  
out	  of	  the	  alveolus	  into	  the	  interstitium.	  This	  process	  is	  called	  alveolar	  fluid	  clearance	  
and	   can	   occur	   through	   transcellular	   (aquaporin	   channels)	   or	   paracellular	   routes.	  
Cystic	   fibrosis	   transmembrane	   regulator	   (CFTR)	   is	   located	   on	   the	   apical	   surface	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1.2 The	  acute	  respiratory	  distress	  syndrome	  
The	   acute	   respiratory	   distress	   syndrome	   (ARDS)	   was	   first	   described	   in	   1967	   by	  
Ashbaugh	   et	   al	   (16)	   who	   described	   12	   patients	   exhibiting	   “…severe	   dyspnoea,	  
tachypnoea,	  cyanosis	   that	   is	   refractory	  to	  oxygen	  therapy,	   loss	  of	   lung	  compliance,	  
and	   diffuse,	   bilateral	   alveolar	   infiltrates	   seen	   on	   chest	   X-­‐ray”.	   Since	   these	   initial	  
descriptions	   there	   have	   been	   multiple	   attempts	   to	   classify	   this	   heterogeneous	  
syndrome.	   In	   1994	   an	   American-­‐European	   Consensus	   Conference	   (AECC)	   defined	  
ARDS	   as	   acute	   onset	   hypoxaemia	   (PaO2/FiO2	   ≤	   200mmHg)	   with	   bilateral	   diffuse	  
infiltrates	   on	   chest	   radiograph,	   in	   the	   absence	   of	   left	   atrial	   hypertension.	   At	   this	  
time,	  a	  less	  severe	  form	  of	  ARDS	  was	  described	  as	  acute	  lung	  injury	  (ALI),	  which	  had	  
the	   same	   characteristics	   except	   for	   a	   PaO2/FiO2	   ≤	   300mmHg	   and	   hence,	   also,	   by	  
definition	   included	  all	  ARDS	  cases	   (table	  1.1)	   (17).	   In	  2012,	   the	  definition	  has	  been	  
revised	   in	  an	  attempt	  to	   improve	  the	  criterion	  up	  on	  which	  future	  clinical	  care	  and	  
research	  could	  be	  conducted	  (18,	  19).	  This	  was	  described	  as	  “the	  Berlin	  definition	  of	  
ARDS”	   (table	   1.2)	   and	   has	   been	   shown	   to	   correlate	   well	   with	   the	   classic	  
histopathological	   findings,	   i.e.	   diffuse	   alveolar	   damage	   (DAD),	   which	   characterise	  
ARDS	  (20).	  
	  
	   Timing	   Oxygenation	   Chest	  Radiograph	   Pulmonary	  Artery	  
Wedge	  Pressure	  
ALI	   Acute	  
Onset	  




No	  evidence	  of	  left	  
atrial	  hypertension	  
ARDS	   Acute	  
Onset	  




No	  evidence	  of	  left	  
atrial	  hypertension	  
	  












	   31	  
	   MILD	   MODERATE	   SEVERE	  
Timing	   Acute	  onset	  within	  1	  week	  of	  a	  known	  clinical	  insult	  or	  
new/worsening	  respiratory	  symptoms	  
Hypoxaemia	   PaO2/FiO2:	  201-­‐300	  
PEEP	  ≤	  5	  cmH20	  
PaO2/FiO2	  ≤	  200	  
PEEP:	  5-­‐10	  cmH20	  
PaO2/FiO2	  ≤	  100	  
PEEP	  ≥	  10	  cmH20	  




Bilateral	  opacities—not	  fully	  explained	  by	  effusions,	  lobar/lung	  




N/A	   N/A	   VE	  Corr	  >	  10L/min	  
Crs	  <	  40ml/cmH20	  
	  
Table	  1.2.	  The	  2012	  Berlin	  definition	  of	  ALI/ARDS	  
VE	  Corr	  -­‐	  corrected	  minute	  ventilation	  =	  VE	  x	  PaCO2/40	  
Crs	  -­‐	  respiratory	  system	  compliance	  
	  
1.2.1 Epidemiology.	  
ARDS	   continues	   to	   be	   a	   significant	   cause	   of	   morbidity	   and	   mortality	   and	   has	   an	  
incidence	   of	   75/100,000	   and	   effects	   over	   190,000	   patients	   in	   the	   US	   (21),	   which	  
extrapolates	  to	  an	  annual	  UK	  incidence	  of	  33,000	  occupying	  450,000	  ICU	  days	  (ARDS	  
Foundation	  (USA)).	  This	  implicates	  a	  massive	  health	  economic	  burden	  to	  NHS	  UK	  in	  
terms	  of	   ICU	  bed	  occupancy	   (costing	  on	  average	  £1300-­‐1500	  per	  day).	  Hence,	   the	  
discovery	  of	  new	   innovations	  and	   therapies	   to	   reduce	   this	   impact,	   in	   an	  era	  when	  
health	  budgets	  are	  reducing	  in	  real	  terms,	  is	  an	  absolute	  necessity.	  	  
1.2.2 Aetiology.	  	  
ARDS	  can	  be	  caused	  by	  a	  number	  of	  insults	  (table	  1.3),	  each	  of	  which	  culminates	  in	  a	  
syndrome	  presenting	  with	   severe	  non-­‐cardiogenic	  pulmonary	  oedema	  causing	   life-­‐
threatening	   hypoxaemia	   often	   necessitating	   the	   implementation	   of	   mechanical	  
ventilatory	  support.	  Aetiologies	  are	  broadly	  classified	  into	  pulmonary	  (or	  direct)	  and	  
extra-­‐pulmonary	   (or	   indirect)	   insults.	   This	   is	   related	   to	   the	   direction	   of	   the	   insult,	  
with	  pulmonary	   insults	  arising	  from	  the	  alveolar	  space	  (e.g.	  pneumonia,	  aspiration)	  
and	  extra-­‐pulmonary	  insults	  being	  derived	  from	  systemic	  injury	  (e.g.	  non-­‐pulmonary	  
sepsis,	   trauma,	  pancreatitis,	  cardiopulmonary	  bypass).	   It	   is	   important	  to	  appreciate	  
that	  the	  direction	  through	  which	  any	  insult	  mediates	  lung	  injury,	  that	  is,	  alveolar	  to	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systemic	  (pulmonary)	  and	  systemic	  to	  alveolar	  (extra-­‐pulmonary)	  will	  have	  markedly	  
different	   underlying	   pathophysiological	   mechanisms,	   although	   certain	   aetiologies	  
may	  share	   final	  common	  pathways.	   Importantly,	   this	  heterogeneity	  of	  mechanisms	  
will	   certainly	   have	   been	   a	   major	   reason	   as	   to	   why	   no	   effective	   pharmacological	  
therapy	   has	   to	   date	   been	  delivered.	   This	   is	   compounded	  by	   the	   neglect	   of	   clinical	  
research	  to	  investigate	  the	  separate	  diseases	  leading	  to	  ARDS	  in	  combination	  with	  a	  
lack	   of	   mechanistic	   research	   to	   define	   the	   distinct	   differences	   between	   these	  
‘directions’.	   This	   is	   exemplified	   by	   the	   testing	   of	   compounds	   on	   non-­‐clinically	  
relevant	   animal	   models,	   and	   the	   reliance	   on	   data	   derived	   from	   single	   models,	   as	  
opposed	   to,	   testing	   any	   intervention	   on	   multiple	   models.	   In	   particular,	   the	  
recruitment	  of	  patients	  into	  clinical	  trials	  of	  ARDS	  in	  the	  absence	  of	  true	  disease	  or	  
biomarker-­‐based	   stratification	   may	   be	   flawed.	   Indeed,	   certain	   sub-­‐groups	   may	  





Common	   Common	  
Pneumonia	   Systemic	  non-­‐pulmonary	  sepsis	  
Gastric	  aspiration	   Severe	  Trauma	  
Less	  Common	  	   Less	  Common	  	  
Pulmonary	  contusion	   Cardiopulmonary	  bypass	  
Near-­‐drowning	   Drug	  overdose	  
Inhalational/Burn	  injury	   Acute	  pancreatitis	  
Reperfusion	  pulmonary	  oedema	  
One-­‐lung	  ventilation	  	  
Fat	  emboli	  
Transfusion	  of	  blood	  products	  
	  
Table	  1.3.	  The	  clinical	  associations	  with	  ARDS	  
	  
1.2.3 Outcomes.	  	  
Mortality	   significantly	   increases	   after	   2	   weeks	   of	   the	   syndrome	   and	   is	   mainly	   a	  
consequence	   of	   non-­‐respiratory	   causes	   i.e.	   sepsis	   and	   multi-­‐organ	   dysfunction	  
syndrome.	  Early	  mortality	  (within	  72	  hours	  of	  onset)	  is	  attributed	  to	  the	  underlying	  
illness	  or	  injury.	  Respiratory	  failure	  per	  se	  is	  a	  contributing	  factor	  to	  the	  death	  of	  24%	  
of	   patients	   and	   the	   primary	   cause	   of	   death	   in	   only	   9-­‐16%	   of	   patients	   (22-­‐24).	  
Furthermore,	  prognosis	  is	  better	  if	  recovery	  occurs	  within	  2	  weeks	  (21).	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Phua	  et	  al	  performed	  a	  systematic	  review	  of	  89	  studies	  and	  concluded	  that	  baseline	  
mortality	  risk	  was	  40-­‐45%	  in	  observational	  studies	  and	  35-­‐40%	  in	  randomised	  control	  
trials	   (25).	   It	  was	   also	   shown	   in	   this	   study	   that	  mortality	   had	   not	   decreased	   since	  
1994.	  Assuming	  an	  incidence	  of	  33,000	  in	  the	  UK	  and	  a	  mortality	  rate	  of	  40%,	  ARDS	  
carries	   a	   high	   attributable	   mortality	   of	   13,200	   deaths	   per	   year.	   To	   place	   this	   in	  
context,	  data	  from	  the	  Office	  of	  National	  Statistics	  placed	  the	  number	  of	  deaths	  per	  
year	   from	   acute	   myocardial	   infarction,	   lung	   cancer,	   and	   breast	   cancer	   at	   23,704,	  
31,089,	  and	  10,397,	  respectively	  (Office	  of	  National	  Statistics	  (UK)).	  	  
	  
There	  are	  no	  active	  therapies	  other	  than	  supportive	  organ	  support.	  For	  decades,	  this	  
therapy	   consisted	   of	   ventilatory	   support	   in	   combination	   with	   diuretic	   therapy.	  
Ironically,	  the	  only	  positive	  clinical	  study	  that	  has	  shown	  a	  proven	  mortality	  benefit	  
was	  a	  trial	  that	  showed	  us	  that	  mechanical	  ventilation	  itself	  produces	  a	  form	  of	  lung	  
injury	   known	   as	   ventilator-­‐induced	   lung	   injury	   (VILI)	   which	   exacerbates	   the	  
underlying	   syndrome.	   This	   clinical	   study	   compared	   ventilation	   with	   6ml/kg	   versus	  
12ml/kg	  and	  showcased	  that	  limiting	  the	  stretch	  imposed	  by	  the	  ventilator	  reduced	  
mortality	  by	  7%	  (26).	  Despite	  this	  landmark	  study,	  the	  systematic	  review	  by	  Phua	  et	  
al	   also	   found	   that	   mortality	   remained	   unchanged	   (25),	   highlighting	   a	   number	   of	  
problems	   in	   implementing	   research	   findings	   to	   the	   bedside.	   Currently,	   novel	   and	  
sophisticated	  improvements	  of	  old	  technologies	  such	  as	  veno-­‐venous	  extracorporeal	  
membrane	   oxygenation	   (VV-­‐ECMO)	   may	   enable	   severe	   forms	   of	   ARDS	   to	   be	  
successfully	   supported	   such	   that	   iatrogenic	   injury	   from	   the	   ventilator	   can	   be	  
minimised.	  This	  seemed	  a	  successful	  strategy	  in	  recent	  flu	  pandemics	  in	  the	  UK	  (27)	  
and	   Australasia	   (28).	   Further	   analysis	   of	   mortality	   once	   these	   techniques	   have	  
embedded	   themselves	   into	   routine	   clinical	   practice	   may	   show	   improvements	   in	  
survival.	  
	  
An	   alternative	   explanation	   for	   this	   unchanged	   mortality	   is	   that	   despite	   improved	  
ventilator	   strategies	   and	   general	   delivery	   of	   intensive	   care,	   ARDS	   is	   a	   changing	  
phenomenon	   occurring	   in	   sicker	   and	   more	   elderly	   patients.	   This	   is	   particularly	  
relevant	  in	  view	  of	  the	  fact	  that	  one	  of	  the	  predictors	  of	  poor	  prognosis	  is	  age	  over	  
55	  (29)	  and	  that	  those	  between	  60	  and	  69	  years	  of	  age	  have	  a	  three	  times	  higher	  risk	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for	  developing	  ARDS	  (30),	  and	  those	  over	  70	  have	  a	  higher	  risk	  of	  death	  (hazard	  ratio	  
2.5)	  (31).	  Hence,	  with	  an	  aging	  global	  population,	  and	  given	  that	  intensive	  care	  units	  
are	  admitting	  older	  patients	  with	  more	  complex	  disease	  interactions,	  the	  projected	  
burden	  and	  health	  economic	  impact	  of	  critical	  illness,	  and	  more	  specifically	  ARDS,	  is	  
predicted	   to	   increase.	   These	   factors	  highlight	   the	  urgent	   requirement	   for	   effective	  
therapies	  to	  target	  the	  underlying	  pathobiology	  of	  this	  devastating	  condition.	  
	  
1.3 Injury	  and	  inflammation	  in	  ARDS	  
1.3.1 Diffuse	  alveolar	  damage	  is	  the	  cardinal	  histopathological	  feature	  of	  ARDS	  
The	  characteristic	  histological	  feature	  of	  ARDS	  is	  diffuse	  alveolar	  damage	  (DAD).	  This	  
histological	   description	   was	   first	   noted	   by	   Hamman	   and	   Rich	   in	   association	   with	  
“usual”	   interstitial	  pneumonia	  (UIP)	  (32).	  Katzenstein	  reviewed	  associations	  of	  DAD	  
with	  oxygen	  therapy,	  shock,	  and	  other	  related	  factors.	  Many	  of	  these	  related	  factors	  
are	   now	   the	   well-­‐known	   clinical	   associations	   of	   ARDS	   as	   shown	   in	   table	   1.3.	   This	  
important	   review	  connecting	   the	  pathological	   findings	   to	   the	  current	  clinical	  entity	  
known	   as	   ARDS	   also	   points	   out,	   quite	   correctly,	   that	   1)	   the	   “recognition	   of	   DAD	  
should	  stimulate	  a	  thorough	  search	  for	  and	  subsequent	  eradication	  of	  the	  underlying	  
cause”,	   and	   2)	   that	   “DAD	   is	   not	   a	   diagnosis;	   it	   is	   a	   concept	   which	   is	   useful	   in	  
understanding	  the	  pathogenesis	  of	  a	  group	  of	  similar	  pulmonary	  lesions	  which	  result	  
from	  numerous	   and	   dissimilar	   agents”	   (33).	   Current	   clinical	   research	   strategies	   do	  
not	   often	   appreciate	   these	   two	   statements	   and	   often	   amalgamate	   aetiologies,	  
recruiting	   all	   ARDS	  patients	   into	   clinical	   trials,	   as	   opposed	   to	   those	   specific	   groups	  
with	  distinct	  diagnoses.	  More	  sophisticated	  trial	  designs	  are	  an	  absolute	  necessity	  to	  
improve	  the	  translation	  of	  therapies	  to	  the	  bedside.	  	  
1.3.2 DAD	  is	  characterised	  by	  two	  overlapping	  phases	  
Exudative	  phase	  	  
The	   insult	   leads	   to	   a	   marked	   increase	   in	   alveolar	   capillary	   barrier	   permeability	  
leading	   to	   the	   flooding	  of	   the	  alveolar	   space	  with	  a	  proteinaceous	   fluid	   containing	  
immunoglobulin,	   fibrin	   and	   complement.	   The	   fluid	  organises	   around	  alveolar	  walls	  
leading	  to	  the	  formation	  of	  hyaline	  membranes.	  There	  is	  also	  translocation	  of	  blood-­‐
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derived	   leukocytes	   from	   the	   pulmonary	  microvasculature	   through	   the	   interstitium	  
into	   the	   alveolar	   space.	   Overall,	   the	   alveolus	   is	   consumed	   by	   fluid,	   leukocytes,	  
cellular	   debris	   and	   fibrin	   clots,	   dissipating	   the	   available	   space	   and	   worsening	   the	  
diffusion	  barrier	  for	  gas	  exchange	  to	  occur.	  
Fibro-­‐proliferative	  phase	  
Quite	   early	   on	   in	   the	   progression	   of	   ARDS	   there	   is	   epithelial	   mesenchymal	  
transformation	  (EMT)	  leading	  to	  the	  infiltration	  of	  myofibroblasts	  which	  start	  laying	  
a	   collagen	   scaffold	   for	   proliferation	   and	   repair.	   Hence,	   there	   is	   focal	   interstitial	  
fibrosis	  and	  hyperplasia	  of	  the	  alveolar	  lining.	  Unlike	  UIP,	  DAD	  associated	  with	  ARDS	  
does	  not	  always	  enter	  a	  fibrotic	  phase.	  Most	  ARDS	  recovers	  without	  fibrosis	  but	  this	  
can	   be	   quite	   variable.	   This	   phase,	   if	   it	   occurs	   in	   ARDS,	   tends	   to	   show	   significant	  
interstitial	  and	  alveolar	  fibrosis	  with	  vascular	  myointimal	  thickening.	  The	  amount	  of	  
total	  lung	  collagen	  can	  double	  (34).	  
	  
Interestingly,	   there	   is	   considerable	  overlap	  between	   these	  phases	  of	  DAD	   in	  ARDS.	  
However,	  the	  clinical	  picture	  is	  often	  blurred	  by	  superimposed	  ventilator-­‐associated	  
pneumonia	  and	  sepsis;	  the	  major	  causes	  of	  morbidity	  and	  mortality	  during	  the	  later	  
stages	  of	  ARDS.	  	  
1.3.3 Alveolar-­‐capillary	  barrier	  dysfunction	  in	  ARDS	  
The	  first	  and	  primary	  physiological	  deterioration	  in	  ARDS	  is	  the	  development	  of	  non-­‐
cardiogenic	   alveolar	   oedema	   as	   a	   result	   of	   alveolar	   capillary	   barrier	   dysfunction.	  
ARDS	   is	   the	   most	   rapidly	   deteriorating	   state	   of	   respiratory	   pathophysiology	   with	  
alveolar	   oedema	   sometimes	   occurring	   within	  minutes	   to	   hours	   of	   the	   antecedent	  
insult.	   This	   oedema	   formation	   and	   subsequent	   V/Q	   mismatch	   (with	   significantly	  
increased	   intrapulmonary	   shunt)	   determines	   the	   deteriorations	   in	   arterial	  
oxygenation	   necessitating	   mechanical	   ventilation	   to	   ensure	   survival.	   Mechanical	  
ventilatory	   support	   with	   general	   anaesthesia	   and	   other	   organ	   support	   introduce	  
further	   deleterious	   impacts,	   such	   as	   shock,	   VILI,	   and	   ventilator	   associated	  
pneumonia,	  upon	  an	  already	  injured	  lung.	  The	  mechanisms	  of	  oedema	  formation	  are	  
still	   poorly	   understood.	   Certainly,	   the	   exclusion	   of	   a	   raised	   pulmonary	   capillary	  
pressure	   as	   a	   result	   of	   cardiogenic	   insults	   is	   important	   to	   subsequently	   direct	   the	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underlying	   injury	   at	   the	   pulmonary	   capillary	   endothelium	   and/or	   the	   alveolar	  
epithelium.	   This	   is	   often	   difficult	   to	   entirely	   exclude	   given	   that	   sepsis	   can	   lead	   to	  
myocardial	   depression	   and	   diastolic	   dysfunction	   (35).	   Hence,	   the	   Berlin	   definition	  
takes	  this	  into	  account	  by	  stating	  that	  the	  hypoxaemia	  not	  fully	  explained	  by	  cardiac	  
failure	  or	  fluid	  overload	  should	  also	  constitute	  the	  definition	  of	  ARDS.	  	  
	  
Depending	   on	   the	   insult,	   either	   or	   both	   of	   these	   layers	   comprising	   the	   air-­‐fluid	  
interface	   are	   ‘hit’.	   Very	   recent	   data	   from	   Ware	   and	   colleagues	   suggests	   that	  
intrapulmonary	   insults	   lead	   to	   higher	   biomarkers	   of	   epithelial	   injury	   (surfactant	  
protein	  D	  and	  RAGE)	  and	  extrapulmonary	  insults	  induce	  greater	  levels	  of	  endothelial	  
biomarkers	   (Ang2)	   in	   the	   plasma	  of	  ARDS	  patients	   (36).	   The	   alveolar	   epithelium	   is	  
immediately	   exposed	   to	   intrapulmonary	   insults	   and	   hence	   there	   is	   often	   an	  
immediate	   increase	   in	   epithelial	   permeability.	   This	   is	   also	   usually	   associated	   with	  
concomitant	  increases	  in	  endothelial	  permeability	  due	  to	  the	  proximity	  of	  these	  two	  
layers.	  This	  loss	  of	  epithelial	  mucosal	  protection	  promotes	  fluid	  leak	  into	  the	  alveolar	  
space.	   In	  contrast,	  pre-­‐clinical	   studies	  have	  shown	  that	  endothelial	   injury	  occurs	   in	  
nearly	   all	   models	   of	   extra-­‐pulmonary	   ARDS	   but	   that	   epithelial	   injury	   may	   not	  
necessarily	  occur	  (37).	  Furthermore,	  indirect	  insults	  do	  not	  always	  generate	  alveolar	  
oedema	   and	   hence,	   endothelial	   injury	   alone	   may	   be	   insufficient	   to	   induce	   the	  
extensive	  alveolar	  oedema	  generated	  in	  ARDS.	  	  
	  
There	   is	   several	   data	   as	   to	   why	   epithelial	   dysfunction	   leads	   to	   a	   state	   of	   rapidly	  
progressive	   alveolar	   oedema	   formation.	   Firstly,	   the	   epithelial	   layer	   provides	   over	  
92%	  of	  the	  resistance	  to	  albumin	  flux	  during	  normal	  physiology	  (38).	  Intrapulmonary	  
insults	  induce	  significant	  damage	  to	  the	  alveolar	  epithelium	  and	  this	  damage	  is	  easily	  
transmitted	   to	   the	   endothelium,	   either	   directly	   by	   the	   insult	   itself	   (due	   to	   loss	   of	  
mucosal	  barrier	  defences)	  or	   through	  signalling	   from	  the	  alveolar	   space	   (39-­‐42).	   In	  
comparison,	  extra-­‐pulmonary	   forms	  of	   lung	   injury	  may	  show	  a	  maintained	  alveolar	  
epithelial	   tight	   junction	   integrity	  and/or	  sufficient	  alveolar	  epithelial	   fluid	  clearance	  
(in	   combination	   with	   interstitial	   lymphatic	   clearance)	   to	   prevent	   the	   flooding	   of	  
alveolar	   airspace.	   It	   is	   only	   when	   interstitial	   lymphatic	   clearance	   is	   overwhelmed	  
and/or	  alveolar	  fluid	  clearance	  is	  reduced	  that	  indirect	  causes	  may	  induce	  leak	  into	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the	   alveolar	   space.	   This	   was	   corroborated	   by	   two	   studies	   in	   which	   sheep	   were	  
exposed	  to	  intravenous	  endotoxin	  (43)	  and	  septic	  shock	  (44).	  In	  the	  latter,	  Pittet	  et	  al	  
infused	  live	  P.	  aeroginasa	   into	  the	  lung	  perfusate	  of	  a	  sheep	  isolated	  perfused	  lung	  
preparation	   and	   found	   that	   there	   were	   significant	   increases	   in	   lung	   endothelial	  
permeability	  with	   an	   increased	   interstitial	   oedema,	   however,	   there	  was	  no	   impact	  
upon	   the	   lung	   epithelial	   permeability.	   They	   surmised	   from	   this	   that	   the	   epithelial	  
barrier	  was	  more	  resistant	  than	  the	  endothelium	  to	  gram-­‐negative	  shock.	  	  
	  
Overall,	   in	  ARDS	  the	  endothelium	  and	  epithelial	  barriers	  lose	  their	  ability	  to	  control	  
protein	   and	   fluid	   influx	   (45)	   which	  may	   be	   dependant	   on	   the	   type,	   intensity,	   and	  
‘direction’	   of	   insult.	   Epithelial	   injury	   and	   dysfunction	   seem	   to	   be	   an	   absolute	  
necessity	   for	   the	   development	   of	   alveolar	   oedema	   through	   not	   only	   increased	  
permeability	   but	   also	   reduced	   resolution	   of	   alveolar	   oedema	   through	   active	  
clearance	  mechanisms	  (46).	  
1.3.4 Inflammatory	  mechanisms	  of	  endothelial	  injury	  in	  ARDS	  
Endothelial	  activation	  and	  dysfunction	  remains	  integral	  to	  the	  development	  of	  ARDS,	  
in	  that,	  it	  not	  only	  promotes	  interstitial	  oedema	  formation,	  but	  also,	  is	  necessary	  for	  
leukocyte	  migration	   into	   the	   interstitial	   and	   alveolar	   spaces	   of	   the	   lung.	  However,	  
the	   aetiology	   and	   direction	   of	   lung	   injury	   is	   likely	   to	   significantly	   influence	   the	  
manner	  in	  which	  the	  endothelium	  is	  activated.	  
	  
The	   first	   pathophysiological	   impact	   on	   the	   lung	   during	   systemic,	   non-­‐pulmonary	  
aetiologies	  of	  ARDS	   is	   likely	   to	  be	  pulmonary	  capillary	  endothelial	  activation,	  given	  
the	   exposure	   of	   this	   layer	   to	   molecular	   and	   cellular	   constituents	   within	   the	  
circulation.	  This	  may	  occur	  through	  the	  interaction	  of	  molecular	  mediators	  released	  
from	   the	   site	   of	   injury/infection	   acting	   directly	   on	   corresponding	   receptors	   on	   the	  
pulmonary	   capillary	   endothelium.	  Alternatively,	   this	  may	  occur	   through	   leukocytes	  
that	   have	   been	   primed/activated	   at	   a	   distant	   site	   of	   injury	   which	   subsequently	  
migrate	   or	   are	   trap	   in	   the	   pulmonary	   vasculature,	   thereby,	   inducing	   pulmonary	  
capillary	  endothelial	  activation	  through	  cell-­‐cell	   interactions	  (47).	   Indeed,	  there	   is	  a	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school	   of	   thought	   that	   the	   lung	  actively	   sequesters	   activated	  neutrophils	   from	   the	  
circulation	  in	  an	  attempt	  to	  “de-­‐prime”	  them	  (48).	  	  
	  
In	   the	   case	   of	   direct	   injury,	   although	   there	   is	   significant	   epithelial	   injury,	   the	  
proximity	  of	  the	  endothelia	  makes	  endothelial	  dysfunction	  inevitable.	  Whether	  this	  
is	   a	   direct	   consequence	   of	   the	   pulmonary	   injury/infection	   or	   a	   signalling	   cascade	  
from	   injured	   epithelium	   is	   still	   under	   investigation.	   For	   instance,	   Kuebler	   et	   al	  
showed	   that	   intra-­‐alveolar	   microinjection	   of	   TNF-­‐alpha	   induces	   epithelial	  
phospholipase-­‐A2	   activation	   leading	   to	   release	   of	   calcium	   and	   activation	   of	  
endothelial	   pro-­‐inflammatory	   responses	   (P-­‐selectin	   expression)	   within	   minutes	   of	  
delivery	   (39),	   suggesting	   a	   signalling	   communication	   between	   epithelial	   and	  
endothelial	   layers.	  Westphalen	  et	  al	  also	  found	  in	  a	  rat	  model	  of	  acid-­‐induced	  lung	  
injury	   that	   a	   direct	   impact	   upon	   the	   alveolar	   epithelial	   cell	   membrane	   initiates	  
endothelial	  cell	  pro-­‐inflammatory	  signalling	  through	  reactive	  oxygen	  species	  (42).	  
	  
It	   seems	   that	   regardless	   of	   pulmonary	   or	   systemic	   ‘direction’	   of	   aetiology,	   the	  
response	  of	  the	  pulmonary	  capillary	  endothelium	  includes	  activation	  of	  intracellular	  
signalling	  cascades	  such	  as	  mitogen-­‐activated	  protein	  (MAP)	  kinases,	  phosphokinase-­‐
C,	   and	   intracellular	   calcium.	   This	   pro-­‐inflammatory	   phenotype	   possesses	   an	  
upregulated	  surface	  expression	  of	   leukocyte	  adhesion	  molecules	  (such	  as	  E-­‐	  and	  P-­‐
selectin),	   an	   increased	   production	   of	   reactive	   oxygen/nitrogen	   species	   (ROS/RNS),	  
and	  an	   increased	  secretion	  of	  chemokines	   (such	  as	   IL-­‐8).	  The	   intimate	  proximity	  of	  
the	   endothelium	   surface	   to	   circulating	   mediators	   is	   enhanced	   by	   the	   acute	  
degradation	  of	   an	   endothelial	   surface	   layer	   called	   the	   glycocalyx.	   This	   degradation	  
has	  been	  shown	  in	  intravenous	  endotoxin	  model	  of	  sepsis	  to	  increase	  the	  availability	  
of	   ICAM-­‐1	  and	  VCAM	  on	  the	  endothelial	   surface	   thus	   facilitating	   the	   tethering	  and	  
firm	  adhesion	  of	  neutrophils	  to	  the	  endothelial	  surface	  (49).	  Subsequently,	  the	  local	  
secretion	  of	   proteases	   (e.g.	   elastin)	   by	   leukocytes	  breaks	  down	   intercellular	   bonds	  
between	  endothelial	  cells	  facilitating	  their	  transmigration	  into	  the	  alveolar-­‐capillary	  
interstitial	   space.	   The	   interactions	   between	   neutrophils,	   monocytes,	   platelets	   and	  
endothelial	  cells	  leads	  to	  the	  release	  of	  more	  toxic	  mediators	  such	  as	  ROS/RNS	  (e.g.	  
peroxide;	  peroxynitrite),	  cytokines	  (e.g.	  TNF),	  proteases,	  and	  procoagulant	  molecules	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(e.g.	   thrombin),	   thereby	   amplifying	   this	   pro-­‐inflammatory	   and	   injurious	   response.	  
These	  toxic	  cellular	  and	  molecular	  mediators	  enhance	  vascular	  permeability	  through	  
further	   disruption	   of	   intercellular	   adhesion	   molecules	   and	   the	   intracellular	   actin-­‐
myosin	   cytoskeleton	   (50),	   thereby	   promoting	   intercellular	   gaps.	   Intercellular	  
adherens	   junctions	  consisting	  of	  molecules	  such	  as	  VE-­‐cadherin	  maintain	  tight	  cell-­‐
cell	  adhesion	  between	  endothelial	  cells,	  and	  maintain	  endothelial	  barrier	  integrity.	  A	  
number	  of	   investigations	  have	  found	  that	  the	   loss	  of	   intercellular	   junctions	  such	  as	  
cadherins	   leads	   to	   the	   formation	   of	   intercellular	   gaps	   that	   lead	   to	   a	   failure	   in	  
endothelial	   protein	   sieving	   and	   increased	   microvascular	   permeability	   and	  
hyperfiltration,	   allowing	   plasma	   constituents	   into	   the	   interstitial	   space	   (3,	   51).	  
Furthermore,	   stretch	   of	   endothelial	   cells	   through	   mechanical	   ventilation	   can	   also	  
enhance	  vascular	  permeability	  adding	  further	  insult	  to	  injury	  (52,	  53).	  	  
1.3.5 Apoptosis	  as	  a	  mechanism	  of	  epithelial	  injury	  in	  ARDS	  
Experimental	   models	   utilising	   direct	   insults	   seem	   to	   produce	   greater	   alveolar	  
oedema	  than	  indirect	  insults	  suggesting	  a	  larger	  impact	  to	  the	  alveolar	  epithelium.	  In	  
addition	  to	  barrier	   function,	   the	  alveolar	  epithelium	  is	  essential	   in	  clearing	  alveolar	  
oedema	  and	  maintaining	  homeostasis	   of	   the	   alveolar	   lining	   fluid.	   The	  mechanisms	  
that	   lead	  to	   injury	  to	  the	  alveolar	  epithelium	  have	  received	   less	  attention	  than	  the	  
endothelium,	  partly	  due	  to	  difficulties	  in	  harvesting	  and	  maintaining	  the	  phenotype	  
of	  primary	  type	  1	  AEC	  cell	  cultures.	  
	   	  
The	   discovery	   that	   apoptosis	   (programmed	   cell	   death)	   of	   alveolar	   epithelial	   cells	  
occurs	   in	  ARDS	  has	  been	  a	  pivotal	   finding.	  Historically,	   the	  pathways	   for	  cell	  death	  
have	  been	  placed	  into	  the	  distinct	  categories	  of	  apoptosis	  or	  necrosis.	  Apoptosis	  is	  a	  
controlled	  form	  of	  cell	  death	  leading	  to	  a	  staged	  cellular	  demise	  avoiding	  the	  release	  
of	  toxic	  intracellular	  debris,	  which	  contains	  numerous	  DAMPs.	  Necrosis	  on	  the	  other	  
hand	   is	   associated	   with	   cell	   swelling,	   cell	   membrane	   rupture	   and	   release	   of	  
intracellular	   contents	   to	   the	   outside	   with	   toxic	   inflammatory	   consequences.	  
However,	  this	  concept	  of	  apoptosis	  versus	  necrosis	  is	  too	  simplistic	  and	  it	  is	  now	  fair	  
to	  say	  that	  there	  are	  much	  more	  complicated	  aspects	  to	  cellular	  death.	  Not	  only	  has	  
apoptosis	  been	   implicated	   in	   the	  development	  of	   injury	  but	  also	   it	   is	   crucial	   in	   the	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resolution	   and	   repair	   processes	   of	   ARDS.	   In	   normal	   physiology,	   a	   balanced	   tissue	  
homeostasis	   and	  cellular	   turnover	  determines	  growth	   through	   the	  number	  of	   cells	  
scheduled	  for	  ‘death’	  and	  the	  number	  to	  be	  ‘born’	  through	  mitosis.	  Thus	  removal	  of	  
cells	   through	   apoptosis	   is	   integral	   to	   whole	   body	   homeostasis	   which	   is	   why	   cell	  
death	   pathways	   are	   “programmed”	   into	   each	   and	   every	   cell.	   Disturbances	   in	   this	  
balance	  lead	  to	  dangerous	  consequence	  through	  the	  formation	  of	  cancers	  and	  organ	  
dysfunction.	  To	  understand	  the	   implications	  of	  alveolar	  apoptosis,	  we	  need	  initially	  
to	   have	   an	   appreciation	   of	   the	   signalling	   cascades	   and	   organelles	   involved	   during	  
cellular	  death.	  	  
	  
Apoptosis	   can	   be	   initiated	   through	   either	   extrinsic	   or	   intrinsic	  mechanisms	   (figure	  
1.3).	  The	  intrinsic	  pathway	  involves	  the	  release	  of	  mitochondrial	  products,	  including	  
cytochrome	  c,	   in	  response	  to	  various	   forms	  of	  cellular	  stress	  such	  as	  DNA	  damage,	  
heat,	  reactive	  oxygen	  species,	  radiation,	  and	  viral	  proteins.	  The	  released	  cytochrome	  
c	  binds	  to	  apoptotic	  protease	  activating	  factor	  1	  (APAF-­‐1),	  leading	  to	  the	  recruitment	  
of	  caspase-­‐9	  forming	  the	  ‘apoptosome’	  complex.	  Caspase-­‐9	  propagates	  the	  caspase	  
cascade	  through	  activation	  of	  the	  effector	  caspases	  (-­‐3,	   -­‐7,	  and	  -­‐10),	  which	   in	  turn,	  
activate	  the	  machinery	  required	  for	  cellular	  demise.	  
	  
The	  extrinsic	  pathway	  involves	  the	  activation	  of	  one	  or	  more	  members	  of	  the	  death	  
receptor	   family	   on	   the	   cell	   surface	   that	   includes	   the	   p55	   TNF	   receptor,	   Fas,	   DR4	  
(TRAIL-­‐R1),	   DR5	   (TRAIL-­‐R2)	   and	   DR6.	   These	   receptors	   all	   possess	   an	   intracellular	  
death	   domain,	   which	   on	   ligand-­‐receptor	   interaction	   leads	   to	   the	   recruitment	   of	  
intracellular	   adaptor	   molecules,	   forming	   the	   ‘death-­‐inducing	   signalling	   complex’	  
(DISC),	   which	   in	   turn,	   activates	   caspase-­‐8.	   The	   activation	   of	   caspase-­‐8	   is	   a	   critical	  
juncture,	   as	   from	   here	   on,	   depending	   on	   the	   cell	   type,	   there	   are	   two	   pathways	  
through	  which	   the	   extrinsic	   death	   signal	   can	   be	   propagated,	   dependent	   upon	   the	  
extent	   to	   which	   procaspase-­‐3	   is	   converted	   to	   caspase-­‐3.	   In	   type	   A	   cells,	   there	   is	  
sufficient	   activation	   of	   caspase-­‐3	   in	   order	   to	   proceed	   to	   the	   final	   pathways	   of	   cell	  
death.	   By	   contrast,	   type	   B	   cells	   require	   additional	   help	   to	   activate	   caspase-­‐3.	   This	  
additional	  help	  comes	  through	  caspase-­‐8	  activating	  pro-­‐apoptotic	  molecules	  Bid,	  Bad	  
and	  Bax,	  on	  the	  mitochondrial	  outer	  membrane	  to	  activate	  apoptosome	  formation.	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The	   finding	   that	   type	   2	  AECs	   expressed	   Fas	   (54),	   a	  member	  of	   the	  death	   receptor	  
superfamily,	  sparked	  the	  first	  thoughts	  as	  to	  the	  involvement	  of	  epithelial	  apoptosis	  
in	  ARDS	  pathobiology.	  Subsequently,	  Hagimoto	  and	  colleagues	  showed	  not	  only	  was	  
Fas/Fas	   ligand	  mRNA	  upregulated	   in	   the	   lungs	  of	  mice	  exposed	   to	  bleomycin	   (55),	  
but	   also	   that	   inhalation	   of	   a	   Fas	   activating	   antibody	   led	   to	   increased	   epithelial	  
apoptosis	   and	   alveolar	   inflammation.	   Matute-­‐Bello	   subsequently	   showed	   that	  
biologically	   active	   soluble	   Fas	   ligand	   (FasL)	   is	   found	   in	   the	   alveolar	   space	   of	   ARDS	  
patients	   and	   induces	   the	   apoptosis	   of	   distal	   lung	   epithelial	   cells,	   which	   could	   be	  
blocked	   by	   anti-­‐Fas	   and	   anti-­‐FasL	   antibodies	   (56).	   Furthermore,	   the	   instillation	   of	  
recombinant	  human	  FasL	  into	  rabbit	  lungs	  induces	  ARDS	  through	  alveolar	  epithelial	  
apoptosis	   (57).	   Albertine	   and	   co-­‐workers	   found	   10%	   of	   alveolar	   lining	   cells	   were	  
apoptotic	   in	  post-­‐mortem	   investigation	  of	  patients	  who	  died	  with	  ARDS	   (58).	   They	  
found	   that	   pulmonary	   oedema	   fluid	   from	   ARDS	   patients	   had	   increased	  
concentrations	   of	   Fas	   and	   FasL	   compared	   to	   the	   hydrostatic	   oedema	   controls.	  
Additionally,	   both	   epithelial	   and	   inflammatory	   cells	   within	   the	   alveolar	   space	  
expressed	   both	   Fas	   and	   FasL.	   Hence,	   the	   last	   decade	   of	   investigations	   into	   the	  
mechanisms	  through	  which	  FasL/Fas	  lead	  to	  lung	  injury	  remain	  quite	  primitive	  with	  a	  
significant	  lack	  mechanistic	  approaches.	  This	  has	  recently	  been	  addressed	  in	  a	  study	  
performed	  by	  Herrero	  et	  al	  that	  found	  that	  the	  human	  FasL	  was	  prone	  to	  modulation	  
by	   oxidants	   and	   proteases	   within	   the	   alveolar	   microenvironment	   (59).	   This	  
modulation	  included	  the	  cleavage	  of	  stalk	  regions	  of	  FasL	  (required	  for	  its	  bioactivity)	  
by	  matrix	  metalloproteinase	  (MMP)-­‐7,	  as	  well	  as,	  the	  oxidation	  of	  FasL	  leading	  to	  the	  
multimerisation	   of	   FasL.	   Of	   note,	   cleavage	   reduced	   activity	   of	   FasL	   and	  
oxidation/multimerisation	  enhanced	   it,	  and	  this	  study	  found	  that	  human	  ARDS	  BAL	  
contained	   a	   significant	   quantity	   of	   non-­‐cleaved	   (i.e.	  with	   stalk	   region),	  methionine	  
oxidised	  and	  aggregated	  FasL.	  
	  
Other	  death	  receptors	  in	  the	  extrinsic	  pathway	  (including	  TNF	  (60-­‐65)	  and	  TRAIL	  (66,	  
67))	   and	   proteins	   in	   the	   intrinsic	   apoptotic	   pathway	   (68)	   have	   been	   implicated	   in	  
development	   of	   epithelial	   cell	   death	   in	   various	   models	   of	   lung	   injury.	   However,	  
overall,	  investigations	  into	  the	  role	  of	  cell	  death	  in	  ARDS	  are	  still	   in	  their	  infancy.	  In	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particular	   very	   few	   have	   localised	   signalling	   pathways	   to	   the	   actual	   cell	   type	   and	  
furthermore	   there	   is	   little	   mechanistic	   insight	   into	   how	   epithelial	   apoptosis	   may	  
induce	   the	   important	   pathophysiological	   manifestations	   observed	   in	   lung	   injury,	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Figure	  1.3.	  Apoptosis	  signalling	  pathways	  
Apoptosis	  or	  programmed	  cell	  death	  can	  be	  activated	  through	  two	  main	  pathways	  –	  
the	   intrinsic	   and	   extrinsic.	   The	   intrinsic	   pathway	   is	   activated	   by	   multiple	   distinct	  
intracellular	   conditions	   and	   is	   regulated	   by	   mitochondria.	   In	   response	   to	   these	  
stressors	  there	   is	  activation	  of	  pro-­‐apoptotic	  mediators	   including	  Bid,	  BAK	  and	  BAX	  
within	  the	  mitochondria	  inducing	  permeabilisation	  of	  the	  mitochondrial	  membranes	  
(via	  the	  mitochondrial	  permeability	  transition,	  or	  MPT).	  This	   leads	  to	  mitochondrial	  
swelling	  and	  release	  of	  cytochrome	  c	  into	  the	  cytoplasm.	  In	  combination	  with	  dATP	  
and	   APAF,	   cytochrome	   c	   forms	   the	   apoptosome	   leading	   to	   activated	   caspase-­‐9,	  
which	  subsequently	  activates	  caspase-­‐3.	  The	  extrinsic	  pathway	  is	   initiated	  by	  death	  
receptor	  activation	  (p55	  TNF	  receptor,	  Fas,	  DR3/4/5/6).	  This	  leads	  to	  the	  formation	  
of	  the	  death	  inducing	  signalling	  complex	  (DISC)	  that	  activates	  caspase-­‐8.	  Caspase-­‐8	  is	  
a	  crucial	  checkpoint	  in	  apoptosis	  progression.	  If	  sufficient	  caspase-­‐3	  activation	  occurs	  
then	   apoptosis	   proceeds	   through	   this	   route.	   If	   insufficient	   caspase-­‐3	   activation	  
occurs,	  then	  caspase-­‐8	  can	  lead	  to	  cleavage	  of	  Bid.	  Truncated	  Bid	  translocates	  onto	  
the	  inner	  mitochondrial	  membrane	  where	  it	  activates	  BAK	  activation,	  induces	  MPT,	  
with	  the	  subsequent	  release	  of	  cytochrome	  c	  and	  activation	  of	  the	  intrinsic	  pathway.	  	  
	  
(APAF,	  apoptotic	  protease	  activating	  factor;	  BAK,	  BH	  antagonist	  or	  killer;	  BID,	  BH3-­‐
interacting	   domain	   death	   agonist;	   cIAP,	   cellular	   inhibitor	   of	   apoptosis;	   dATP,	  
deoxyadenosine	   triphosphate;	   DD,	   death	   domain;	   DISC,	   death	   inducing	   signalling	  
complex;	   FADD,	   Fas	   associated	   death	   domain;	   MPT,	   mitochondrial	   permeability	  
transition;	  RIP,	  receptor	   interacting	  protein	  kinase;	  TRADD,	  TNF	  receptor	  associated	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1.3.6 Alveolar	  fluid	  clearance	  as	  an	  index	  of	  epithelial	  function	  
Alveolar	  fluid	  clearance	  is	  driven	  through	  the	  vectorial	  transport	  of	  sodium	  from	  the	  
alveolar	   space	   into	   the	   interstitial	   space	   thereby	   creating	   an	   electrochemical	  
gradient	   for	   the	   transport	  of	  water	   (figure	  1.2).	   This	   sodium	  gradient	   is	   formed	  by	  
the	   presence	   of	   Na+/K+	   ATPase	   channels	   in	   the	   basal	   surface	   of	   the	   alveolar	  
epithelium.	   Hence,	   the	   alveolar	   epithelium	   is	   a	   highly	   energy	   consuming	   layer.	  
Sodium	   enters	   the	   epithelium	   from	   the	   alveolar	   lining	   fluid	   through	   epithelial	   Na+	  
channels	  (ENaC)	  located	  in	  the	  apical	  surface.	  	  
	  
The	  first	  evidence	  in	  humans	  to	  suggest	  that	  active	  transport	  of	   ions	  facilitated	  the	  
clearance	  of	  oedema	  from	  the	  alveoli	  was	  found	  by	  Matthay	  and	  Wiener-­‐Kronish	  in	  
1990.	  This	  study	  found	  that	  alveolar	  fluid	  clearance	  is	  better	  in	  patients	  who	  resolve	  
clinically	  from	  ARDS,	  and	  in	  those	  who	  have	  low	  fluid	  clearance	  in	  the	  first	  12	  hours	  
post-­‐intubation	   showed	   a	   poor	   prognosis	   (46).	  Ware	   and	  Matthay	   obtained	   serial	  
samples	  of	  lavage	  from	  a	  larger	  cohort	  of	  patients	  with	  ALI/ARDS	  and	  calculated	  AFC	  
through	  the	   increase	   in	  protein	  concentration	  over	   time	   (69).	  They	   found	  that	  AFC	  
was	  impaired	  in	  56%	  of	  patients	  with	  ARDS	  with	  maximal	  clearance	  only	  occurring	  in	  
13%	  of	  patients.	   In	  particular,	   those	  with	  higher	   levels	  of	  AFC	   showed	   significantly	  
improved	  hospital	  mortality,	  and	  reduced	  number	  of	  ventilator	  days,	  with	  a	  trend	  to	  
improved	  oxygenation.	  	  
	  
There	   has	   been	   significant	   investigation	   into	   strategies	   that	   may	   stimulate	   the	  
resolution	   of	   pulmonary	   oedema	   through	   augmenting	   intrinsic	   mechanisms	   of	  
alveolar	   fluid	   clearance.	   The	   compounds	   that	   have	   received	   the	   most	   interest	  
include	  beta-­‐adrenergic	  agonists	   (e.g.	   salbutamol,	  albuterol)	  and	  have	  been	  shown	  
to	  augment	  AFC	  in	  preclinical	  (70-­‐73)	  as	  well	  as	  ex	  vivo	  human	  lung	  studies	  (74).	  The	  
BALTI	  study	  showed,	  as	  proof	  of	  concept,	  some	   improvement	   in	  extravascular	   lung	  
water	   in	   ARDS	   patients	   treated	   with	   intravenous	   salbutamol	   (75).	   The	   larger	  
multicentre,	   randomised	   controlled	   follow-­‐up	   study,	   the	   BALTI-­‐2,	   showed	   no	  
improvement	   in	   outcomes	   and	  was	   stopped	   early	   as	   the	   salbutamol	   arm	   showed	  
greater	   harm	   (76).	   Additionally,	   a	   recent	   study	   led	   by	   the	   ARDS	   Clinical	   Trials	  
Network	   showed	   no	   benefit	   with	   aerosolised	   albuterol	   (77).	   Hence,	   this	   has	   left	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many	   investigators	   to	   contemplate	   reasons	   for	   these	   failures	   and	   think	   of	   new	  
directions	   and	   mechanisms	   to	   enhance	   AFC.	   One	   of	   the	   major	   issues	   has	   always	  
been	   whether	   the	   injured	   alveolar	   epithelium	   is	   able	   to	   increase	   its	   activity	   and	  
whether	  driving	  an	  injured	  cell	  to	  increase	  its	  activity	  would	  actually	  be	  beneficial	  or	  
harmful.	  Furthermore,	  before	  the	  implementation	  of	  clinical	  trials	  such	  as	  these,	  we	  
should	   have	   a	   better	   idea	   as	   to	   the	   mechanisms	   that	   drive	   epithelial	   injury	   and	  
dysfunction	   in	  ARDS.	  For	   instance,	   there	  are	  no	  studies	   investigating	   links	  between	  
epithelial	   apoptosis	   and	   alveolar	   fluid	   clearance	   in	   ARDS.	   If	   the	   majority	   of	   the	  
epithelium	   is	   compromised	   then	   enhancing	   AFC	   may	   be	   futile.	   Rather	   a	   more	  
sophisticated	  approach	  to	  rescue	  the	  epithelium	  may	  be	  more	  applicable.	  
1.3.7 Pulmonary	  inflammation	  in	  ARDS	  
A	  hallmark	  observation	  of	  ARDS	  is	  the	  accumulation	  of	  inflammatory	  leukocytes	  and	  
leukocyte-­‐derived	  mediators,	  in	  particular	  neutrophils,	  within	  the	  alveolar	  space	  (78-­‐
80).	   The	   oedema	   fluid	   within	   the	   alveolar	   space	   has	   a	   vast	   array	   of	   cellular	   and	  
molecular	   mediators,	   some	   of	   which	   are	   locally	   produced,	   but	   many	   have	  
translocated	   from	   the	  plasma	   compartment.	   The	   kinetics	   of	   cellular	   recruitment	   is	  
difficult	  to	  investigate	  in	  clinical	  ARDS	  and	  hence	  extrapolation	  has	  to	  be	  made	  from	  
experimental	  models.	  However,	  the	  question	  of	  	  ‘what	  is	  (are)	  the	  initiating	  factor(s)	  
leading	   to	   ARDS	   and	   how	   do	   the	   pathways	   initiated	   by	   direct	   or	   indirect	   insults	  
converge	  to	  induce	  alveolar	  capillary	  barrier	  dysfunction?’	  remains	  unanswered.	  It	  is	  
hypothesised	   that	   direct	   insults	   induce	   the	   activation	   of	   resident	   alveolar	  
macrophages	   and	   epithelial	   damage,	   whereas,	   circulating	   factors	   (cellular	   and	  
molecular)	   and	   endothelial	   dysfunction	  may	   be	   integral	   to	   indirect	   causes	   such	   as	  
pancreatitis.	  However,	  the	  final	  common	  pathways	  involve	  damage	  to	  both	  epithelial	  
and	  endothelial	  barriers	  and	  hence,	  promoting	  alveolar	  oedema.	  
	  
Depletion	   of	   alveolar	   macrophages	   has	   been	   shown	   to	   attenuate	   intra-­‐tracheal	  
endotoxin-­‐	   (81),	   ventilator-­‐	   (82),	   and	   acid-­‐	   (83)	   induced	   lung	   injury,	   suggesting	   a	  
pivotal	   role	   to	   initiate	   alveolar	   inflammatory	   cascades.	   It	   is	   likely	   that	   once	  
parenchymal	   injury	   has	   occurred,	   regardless	   of	   route,	   there	   is	   an	   influx	   of	   blood-­‐
derived	   leukocytes	   that	   either	   aggravate	   the	   injury	   or	   promote	   resolution/repair.	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Elucidating	   this	   ‘resolution	   switch’	   is	   the	   ‘holy	   grail’	   of	   inflammation	   research.	  
Transcription	  of	  more	  downstream	   inflammatory	  mediators	   such	  as	   IL-­‐6,	   IL-­‐8	   from	  
lung	  parenchyma,	   in	   addition	   to	   alveolar	  macrophages,	   also	  upregulates	   leukocyte	  
adhesion	   molecules	   on	   the	   endothelial	   surface	   activating	   leukocytes	   which	  
eventually	   transmigrate	   into	   the	   alveolar	   space,	   further	   amplifying	   inflammatory	  
cascades	  (84,	  85).	   It	  has	  been	  shown	  that	  persistently	   increased	   levels	  of	  cytokines	  
(TNF,	  IL-­‐1β,	  IL-­‐6,	  and	  IL-­‐8)	  in	  the	  lungs	  correlate	  with	  a	  poor	  outcome	  in	  ARDS	  (86).	  
Whether	   this	   is	   cause	   or	   effect	   remains	   undetermined.	   Regardless	   of	   the	   initial	  
driver,	  neutrophils	  and	  monocytes	  have	  been	  shown	  to	  be	  important	  components	  of	  
the	   inflammatory	   response	   that	   characterises	   ARDS.	   	   Other	   studies	   investigating	  
indirect	   aetiologies	   have	   shown	   that	   the	   activation	   of	   complement	   protein	   C5a	   (a	  
circulating	   complement	   mediator)	   induces	   neutrophil	   activation	   in	   the	   blood	   and	  
sequestration	   into	   the	   pulmonary	   vasculature	   (87).	   Additionally,	   experimental	  
studies	   of	   lung	   injury	   have	   shown	   that	   neutrophil	   depletion	   is	   protective	   (88)	   and	  
that	  monocyte	  depletion	  attenuates	  injury	  (89).	  	  
	  
In	  contrast,	  it	  has	  also	  been	  shown	  that	  leukocytes	  do	  not	  contribute	  significantly	  to	  
barrier	   dysfunction.	  Wiener-­‐Kronish	   et	   al	   (43)	   and	  Martin	   et	   al	   (90)	   showed	   large	  
numbers	   of	   neutrophils	   crossing	   into	   the	   alveolar	   space	   in	   sheep	   and	   man,	  
respectively,	   with	   endothelial	   permeability	   changes	   in	   the	   absence	   of	   epithelial	  
changes	   in	  permeability.	   In	  addition,	  ARDS	  also	  occurs	   in	  neutropenic	  patients	  and	  
those	   with	   bone	   marrow	   failure,	   which	   supports	   the	   view	   that	   leukocytes,	   whilst	  
integral	   in	   some	   aspects	   of	   ARDS,	   may	   not	   be	   absolutely	   necessary	   in	   its	  
pathobiology	  (91-­‐94).	  Although	  neutropenic	  recovery	  has	  also	  been	  associated	  with	  
a	   near	   5-­‐fold	   increased	   risk	   of	   ARDS	   development,	   this	   risk	   is	   only	   apparent	   if	  
complicated	   by	   pneumonia	   (95).	   Hence,	   it	   is	   crucial	   to	   appreciate	   the	   context	   in	  
which	   leukocytes	   are	   recruited	   to	   the	   lung	   parenchyma	   as	   they	   may	   play	   quite	  
divergent	   roles	   depending	   on	   the	   phase	   and	   type	   of	   lung	   injury	   -­‐	  
injurious/inflammatory/infectious	   versus	   reparative/resolving.	   For	   instance,	  
neutrophil	  mediated	  responses	  are	  crucial	  to	  fight	  bacterial	  infection	  in	  the	  context	  
of	   pneumonia	  whereas	   collateral	   damage	   to	   self	  may	   ensue	   in	   sterile	   lung	   injury.	  
Interestingly,	  not	  all	  pneumonias	  develop	  into	  ARDS	  and,	  in	  the	  majority	  of	  patients,	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neutrophils	   are	  present	   in	   the	  alveolar	   space	   to	  perform	   their	  duties,	   that	   is,	   fight	  
microbial	   infection	  without	   causing	   significant	   self-­‐	   or	   collateral	   harm.	   In	   addition,	  
neutrophil	  transmigration	  has	  also	  been	  recently	  shown	  to	  promote	  epithelial	  repair	  
in	  an	  intratracheal	  model	  of	  lung	  inflammation	  through	  beta-­‐catenin	  signalling	  (96).	  
Additionally,	   as	   we	   shall	   see,	   leukocytes	   (predominantly	   monocytes	   and	  
lymphocytes)	   continue	   to	   migrate	   into	   the	   alveolar	   space	   and	   depending	   on	   the	  
situation	  can,	  with	  one	  hand,	  promote	  inflammatory	  consequences	  during	  the	  acute	  
phase	   (97),	   and	   with	   the	   other,	   direct	   repair	   and	   resolution	   (98-­‐100),	   or	   even	  
potentiate	  lung	  fibrosis	  (101).	  	  
	  
Importantly,	   syndromes	   such	   as	   ARDS	   and	   sepsis	   characterised	   by	   perpetuating	  
inflammation,	   are	   associated	   with	   an	   increased	   neutrophil	   lifespan	   (102).	   Studies	  
have	   shown	   that	   the	   alveolar	  microenvironment	   in	  ARDS	  patients	   can	  prolong	   the	  
survival	   of	   neutrophils.	   For	   instance,	   Matute-­‐Bello	   incubated	   normal	   human	  
neutrophils	   with	   ARDS	   BAL	   and	   found	   an	   anti-­‐apoptotic	   effect	   that	   could	   be	  
ameliorated	  through	  the	  immunodepletion	  of	  G-­‐CSF	  and	  GM-­‐CSF	  (103).	  It	  is	  also	  well	  
established	  that	  the	  apoptosis	  of	  leukocytes	  is	  crucial	  to	  initiate	  resolution	  and	  repair	  
processes	  by	  limiting	  inflammation	  and	  the	  degree	  of	  tissue	  injury	  (14).	  	  
	  
Leukocytes	  can	  take	  on	  different	  roles	  depending	  on	  their	   interactions	  with	  nearby	  
molecular	  and	  cellular	  mediators.	  Hence,	  leukocytes	  can	  adopt	  different	  phenotypes	  
at	   different	   stages	   of	   inflammation	   and	   resolution.	   This	   ability	   of	   leukocytes	   to	  
control	  and	  switch	  their	  responsiveness	  is	  integral	  for	  resolution	  and	  recovery	  and	  it	  
is	   this	   dysregulated	   control	   switch	   that	   may	   be	   at	   the	   centre	   stage	   of	   ARDS	  
pathogenesis.	   Hence,	   understanding	   the	   context	   in	   which	   a	   leukocyte	   has	   been	  
called	   to	   the	   lung	   is	   an	   important	   concept	   to	   investigate	   and	   appreciate	   clinically.	  
Furthermore,	   most	   research	   in	   lung	   leukocyte	   recruitment	   utilises	   endotoxin	  
administration	  and	  hence,	  produce	  significant	  levels	  of	  alveolar	  inflammation	  but	  in	  
the	  context	  of	  sustained	  and	  overwhelming	  activation	  of	  one	  initial	  pathway,	  that	  of	  
TLR-­‐4	  activation.	  Many	  of	  these	  endotoxin	  models	  also	  lack	  the	  physiological	  indices	  
which	  define	  ARDS	  e.g.	  hypoxaemia	  (37).	  The	  exact	   inflammatory	  mechanisms	  that	  
trigger	   these	   early	   inflammatory	   events	   in	   more	   clinically	   relevant	   forms	   of	   lung	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injury	  (such	  as	  acid	  aspiration,	  pneumonia,	  or	  trauma)	  have	  received	  relatively	  little	  
attention.	  The	  key	  question	  of	  how	  inflammation	  produces	  physiological	   injury	  and	  
dysfunction	  surmounting	  to	  the	  high	  morbidity	  and	  mortality	  seen	  in	  ARDS	  remains	  
unanswered.	  	  
	  
It	   is	  unlikely	   that	   all	   the	   cellular	   and	  molecular	  mediators	   implicated	   in	   lung	   injury	  
are	   amenable	   to	   blockade,	   and	   even	  more	   unlikely	   that	   research	   will	   unravel	   the	  
intricate	   nature	   of	   their	   relationships,	   particularly	   in	   such	   a	   heterogeneous	  
syndrome.	   What	   seems	   more	   sensible	   is	   the	   blockade	   of	   either	   more	   proximal	  
inflammatory	   paradigms	   that	   set	   downstream	   inflammatory	   cascades	   into	  motion	  
(prophylactic/	   early	   phase	   strategies),	   or	   to	   target	   and	   investigate	   paradigms	   that	  
promote	   resolution	  and	   repair	  once	  dysregulated	   inflammation	   is	   established	   (late	  
phase	  strategies).	  	  
	  
1.4 Resolution	  of	  injury	  and	  inflammation	  in	  ARDS	  
The	  ideal	  response	  to	  injury	  should	  ensure	  removal	  of	  any	  harmful	  stimuli,	  followed	  
by	  a	  decline	  in	  the	  inflammatory	  response	  limiting	  damage	  to	  self.	  There	  should	  be	  in	  
parallel	   successful	   repair	   of	   tissue	   enabling	   it	   to	   return	   to	   normal	   structure	   and	  
function.	  There	   is	  now	  convincing	  evidence	   that	   inflammation	  does	  not	   just	   simply	  
‘fizzle	  out’.	   In	   contrast,	   resolution	  of	   inflammation,	   repair	   and	   recovery,	   involves	  a	  
highly	   coordinated	   and	   actively	   controlled	   series	   of	   events.	   ARDS	   shows	  
overwhelming	  inflammation	  due	  to	  disturbed	  mechanisms	  that	  control	  resolution	  of	  
oedema	   and	   inflammation.	   The	   hallmarks	   for	   tissue	   recovery	   and	   resolution	   of	  
inflammation	  can	  be	  described	  in	  three	  overlapping	  phases	  (figure	  1.4).	  	  
1.4.1 Phase	  1:	  “The	  stop	  signal”	  
Firstly,	   the	   early	   phase	   of	   resolution	   removes	   the	   inciting	   stimulus,	   ceases	   further	  
proinflammatory	   leukocyte	   recruitment,	   and	   promotes	   catabolism	   of	   pro-­‐
inflammatory	  mediators	  with	  a	  controlled	  anti-­‐inflammatory	  response.	  There	  is	  now	  
more	  evidence	  that	  this	  phase	  of	  resolution	  is	  triggered	  even	  earlier	  than	  previously	  
thought.	  Within	  hours	  of	  the	  initial	  stimulus	  there	  is	  a	  switch	  between	  the	  formation	  
of	   pro-­‐inflammatory	   eicosanoids	   (e.g.	   prostaglandins,	   leukotrienes	   and	   platelet	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activating	   factor)	   to	   the	  anti-­‐inflammatory	  eicosanoids	   (including	   lipoxins,	   resolvins	  
and	   protectins)	   (104).	   This	   switch	   is	   triggered	   by	   the	   neutrophils	   themselves	   (via	  
neutrophil-­‐platelet	   interactions)	   in	   an	   attempt	   to	   limit	   the	   inflammatory	   response	  
(105,	   106).	   More	   importantly,	   these	   mediators	   also	   prevent	   further	   neutrophil	  
trafficking,	  reduce	  vascular	  permeability,	  promote	  exudative	  monocyte	  entry,as	  well	  
as,	  the	  ingestion/clearance	  of	  debris	  and	  apoptotic	  neutrophils,	  which	  are	  integral	  to	  
later	  stages	  of	  resolution	  (107).	  	  
	  
The	   ability	   to	   initiate	   this	   shut	   down	   of	   proinflammatory	   leukocyte	   activity	   is	   an	  
important	  checkpoint	  for	  resolution	  of	  inflammation.	  Indeed,	  the	  resolution	  interval	  
is	   an	   experimental	   index	   defined	   by	   the	   time	   taken	   for	   numbers	   of	   infiltrated	  
neutrophils	   in	   the	   inflamed	   tissue	   to	   decline	   from	   their	   peak	   by	   50%	   (104).	   This	  
decline	   is	   dependent	   on	   constitutive	   apoptosis	   programme	   of	   neutrophils	   that	  
consequently	  imparts	  a	  limited	  life	  span	  of	  24	  hours	  or	  less.	  Perpetuated	  neutrophil	  
mediated	   inflammation	  as	   a	   result	  of	   abnormal	   (delayed)	   apoptosis	   can	   indeed	  be	  
detrimental	   in	   the	   overzealous	   inflammatory	   processes	   that	   occur	   in	   ARDS.	   For	  
example,	   studies	  have	   shown	   that	  bronchoalveolar	   lavage	   fluid	   from	  patients	  with	  
established	  ARDS	  prolongs	   the	   survival	   of	   neutrophils	   through	  disrupted	   apoptosis	  
(103).	  
	  
A	   variety	   of	   cytokines	   (including	   IL-­‐1	   receptor	   antagonist,	   IL-­‐4,	   IL-­‐10,	   and	   IL-­‐13)	   as	  
well	   as	   the	   soluble	   forms	   of	   their	   receptors	   (including	   soluble	   TNF	   receptors,	   IL-­‐6	  
receptors)	  are	  also	  implicated	  in	  this	  phase.	  One	  of	  the	  most	  studied,	  IL-­‐10,	  has	  been	  
shown	  to	  block	  the	  synthesis	  of	  a	  number	  of	  pro-­‐inflammatory	  cytokines	  (including	  
IFN-­‐γ,	   IL-­‐1,	   TNF,	   IL-­‐12),	   chemokines	   (such	   as	   IL-­‐8,	   and	  CCL2)	   and,	   is	   often	   released	  
from	   macrophages	   that	   have	   changed	   their	   phenotype	   response	   having	   ingested	  
debris	   and	   apoptotic	   neutrophils.	   IL-­‐4	   and	   IL-­‐13	   also	   influence	  
monocyte/macrophage	  phenotype	  by	  increased	  endocytic	  activity	  through	  increased	  
expression	   of	   scavenger	   receptors	   to	   recognise	   and	   increase	   parasite	   killing;	  
stimulation	   of	   mRNA	   of	   proteins	   such	   as	   matrix	   metalloproteinases	   and	   collagen	  
types,	  all	  of	  which	  are	  crucial	  in	  enhancing	  tissue	  repair	  and	  fibrosis.	  IL-­‐10	  and	  TGFβ	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on	  the	  other	  hand	  can	  deactivate	  monocytes	  and	  reduce	  expression	  of	  MHC	  class	  II	  
molecules	  used	  for	  antigen	  presentation	  to	  cytotoxic	  T-­‐cells.	  
1.4.2 Phase	  2:	  “Clearing	  up	  the	  mess”	  
Secondly,	  a	  clearance	  phase	  of	  resolution	   is	   initiated.	  A	  short	   time	  after	  neutrophil	  
infiltration	  into	  damaged/infected	  tissue	  the	  adaptive	  system	  is	  activated	  with	  T-­‐cell	  
infiltration	   into	   the	   tissue.	   Cell-­‐cell	   interactions	   with	   resident	   macrophages,	  
exudative	  monocytes	  and	  dendritic	  cells	  (DC)	  leads	  to	  the	  release	  of	  mediators	  such	  
as	   TGFβ	   and	   IL-­‐10	   promoting	   apoptosis	   of	   neutrophils	   and	   their	   uptake	   by	  
macrophages.	  
	  
Cell	   death	   can	   proceed	   through	   a	   spectrum,	   which	   ranges	   from	   the	   programmed	  
form	  termed	  apoptosis,	  or	  a	  less	  ordered	  process	  termed	  necrosis.	  As	  discussed	  with	  
the	  epithelium,	  apoptosis	  is	  the	  ideal	  way	  for	  cells	   in	  the	  body	  to	  die	  as	  it	  prevents	  
the	  activation	  of	  proinflammatory	  responses	  against	  intracellular	  molecular	  patterns,	  
which	  are	  released	  with	  necrotic	  cell	  death.	  Neutrophil	  apoptosis	  can	  be	  modulated	  
by	   a	  number	  of	   agents,	   including	  GM-­‐CSF,	  which	  delays	   apoptosis,	   and	  endotoxin,	  
FasL,	  TRAIL	  and	  TNF,	  all	  of	  which	  promote	  neutrophil	  apoptosis.	  	  
	  
More	   importantly,	   apoptotic	   cells	   upregulate	   recognition	   signals	   facilitating	   their	  
uptake	   by	   macrophages.	   These	   include	   thrombospondin-­‐1,	   annexin-­‐1,	  
phosphatidylserine	   and	   lysophosphatidylcholine.	   The	   mechanisms	   that	   dictate	  
neutrophil	   apoptosis	   are	   beyond	   the	   scope	   of	   this	   section	   but	   it	   is	   important	   to	  
appreciate	   that	  apoptotic	  neutrophils	  are	  non-­‐functional	  but	   retain	   their	  histotoxic	  
cellular	   constituents,	   and	   hence,	   delayed	   uptake	   by	   macrophages	   will	   lead	   to	  
secondary	   necrosis,	   amplifying	   inflammatory	   responses	   through	   release	   of	  
intracellular	   DAMPs.	   Indeed,	   the	  mechanisms	   through	  which	   apoptotic	   cells	   signal	  
their	   own	   disposal	   is	   crucial	   for	   the	  macrophage	   switch	   from	  pro-­‐inflammatory	   to	  
pro-­‐resolving	   phenotypes	   (14,	   108).	   This	   plasticity	   to	   their	   environment	   makes	  
macrophages	  vital	   regulators	  and	  effectors	  of	   local	   immune	   responses	   (figure	  1.5).	  
Influx	  of	  blood-­‐derived	  monocytes	  increases	  total	  tissue	  macrophage	  numbers	  (109,	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110)	  to	  help	   initially	   fight	   the	   inflammatory	  battle	  but	  then	  to	  subsequently	  switch	  
phenotype	  to	  clear	  debris	  and	  efferocytose	  apoptotic	  neutrophils.	  	  
	  
After	  clearance	  of	  neutrophils	  and	  debris,	  T-­‐cells	  continue	  to	  be	  present	  producing	  
TH2	  cytokines,	  such	  as	  IL-­‐4	  and	  IL-­‐13,	  which	  regulate	  resident	  tissue	  macrophages.	  As	  
a	   consequence,	   these	   resident	   macrophages	   take	   on	   a	   wound	   healing	   phenotype	  
leading	  to	  myofibroblast	  proliferation	  and	  collagen	  deposition.	  The	  extent	  of	  which	  is	  
most	  likely	  dependent	  on	  the	  severity	  of	  epithelial	  damage	  in	  ARDS	  (111).	  The	  fate	  of	  
these	   exudative	   macrophages	   are	   still	   uncertain	   but	   there	   is	   evidence	   suggesting	  
that	   they	  too	  undergo	  constitutive	  apoptosis	  and	  that	   this	  may	  occur	  either	   locally	  
(112)	  or	  after	  emigration	  to	  local	  lymph	  nodes	  (113).	  	  
1.4.3 Phase	  3	  –	  “Re-­‐establishing	  order	  and	  function”	  
So,	   once	   the	   battlefield	   has	   been	   cleared,	   we	   return	   to	   the	   overall	   goal,	   that	   is,	  
functional	  recovery	  and	  catabasis,	  which	  requires	  recovery	  of	  cellular	  structure	  and	  
function	   at	   a	   microscopic	   and	   macroscopic	   level,	   improvement	   in	   cellular	   bio-­‐
energetics,	   as	   well	   as,	   controlled	   apoptosis	   and	   replacement	   of	   damaged	  
parenchymal	  cells.	   It	   remains	  unclear	  as	   to	  why	  certain	  patients	  heal	  whilst	  others	  
repair	  through	  fibrosis.	  For	  instance,	  ARDS	  can	  lead	  to	  a	  protracted	  fibrotic	  phase.	  It	  
is	   also	   clear	   that	   fibrosis	   occurs	   much	   earlier	   at	   the	   onset	   of	   inflammation	   and,	  
factors	  (such	  as	  TGFβ),	  which	  regulate	  resolution,	  also	   influence	  fibrosis.	   Increasing	  
evidence	  suggests	  that	  parenchymal	  cell	  death	  may	  dictate	  acute	  and	  chronic	  fibrotic	  
responses	  (114).	  For	  instance,	  Sisson	  et	  al	  showed	  that	  targeted	  injury	  to	  the	  type	  II	  
alveolar	  epithelium	  induces	  collagen	  deposition	  and	  lung	  scarring	  (115).	  This	  may	  be	  
due	   to	   an	   inability	   to	   produce	   type	   1	   AECs,	   or	   that	   epithelial	   death	   leads	   to	   a	  
reduction	   in	   signals,	   such	   as	   prostaglandin	   E2	   (116),	   that	   are	   important	   in	  
suppressing	  protein	  production	  by	  lung	  fibroblasts.	  In	  addition,	  damaged	  epithelium	  
may	  be	  promoting	  pro-­‐fibrotic	  factors	  to	  activate	  local	  fibrosis.	  	  
	  
Hence,	   although	   it	  would	   be	   attractive	   to	   promote	   timely	   apoptosis	   of	   leukocytes	  
thereby	  switching	  on	  resolution	  mechanisms,	  a	  potential	  side	  effect	  of	  this	  approach	  
may	  be	  tissue	  scarring	  if	  parenchymal	  apoptosis	  is	  inadvertently	  activated.	  There	  lies	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the	   double-­‐edged	   sword	   in	   any	   strategy	   targeting	   apoptosis	   and	   hence,	  





Figure	  1.4.	  The	  phases	  of	  resolution	  in	  lung	  inflammation	  
The	  mechanisms	  portrayed	  here	  are	  separated	  to	  aid	  description	  but	  actually	  occur	  
simultaneously.	   The	   dysregulation	   of	   these	   phases	   likely	   lead	   to	   continual	  
inflammation	   and	   malresolution.	   A)	   Injurious	   insult	   induces	   classical	   activation	   of	  
resident	   tissue	   macrophages.	   B)	   Activated	   macrophages	   release	   reactive	   oxygen	  
species,	   cytokines	   and	   chemokines.	   C)	   Molecular	   mediators	   released	   from	  
macrophages	  leads	  to	  epithelial	  and	  endothelial	  activation	  with	  recruitment	  of	  early	  
phase	   neutrophils	   and	   monocytes.	   D)	   Barrier	   dysfunction	   leads	   to	   oedema	  
formation.	   E)	  Migrated	   leukocytes	   release	  opsonins	   (e.g.	   complement)	   to	   facilitate	  
removal	   of	   insult.	   F)	   Early	   resolution	  mediators	   (e.g.	   lipoxins,	   resolvins,	   protectins)	  
are	   released	   as	   a	   consequence	   of	   neutrophil	   platelet	   interactions,	   limiting	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overzealous	   inflammatory	  actions.	  G)	  Activation	  of	  T-­‐cell	  responses.	  H)	   Interactions	  
with	  T-­‐cells	   induces	  a	  phenotype	  change	   in	  macrophages,	  monocytes	  and	  dendritic	  
cells.	  I)	  At	  the	  same	  time	  neutrophils	  undergo	  apoptosis	  heralding	  the	  initiation	  and	  
amplification	   of	   the	   resolution	   process.	   J)	   Apoptotic	   neutrophils	   are	   taken	   up	   by	  
alveolar	  macrophages	  inducing	  further	  phenotypic	  class	  switching.	  K)	  This	  involves	  a	  
macrophage	  switch	  from	  pro-­‐inflammatory	  to	  pro-­‐resolving	  phenotypes.	  (L)	  There	  is	  
an	   influx	   of	   blood-­‐derived	   cells	   to	   help	   clear	   the	   debris	   including	   dead	   tissue	   and	  
apoptotic	   leukocytes.	   M)	   T-­‐cells	   continue	   to	   be	   present	   and	   release	   IL-­‐4/-­‐13	  
regulating	   tissue	   macrophages	   inducing	   a	   wound	   healing	   phenotype.	   N)	   These	  
macrophages	   induce	   myofibroblast	   proliferation	   and	   collagen	   deposition	   through	  
further	   release	   of	   TGFβ.	   O)	   The	   fate	   of	   exudative	   leukocytes	   after	   restoration	   of	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1.4.4 Translational	  therapies	  promoting	  resolution	  in	  critical	  care	  
It	   is	   unclear	   as	   to	   why	   an	   initial	   focused	   inflammatory	   response	   becomes	  
maladaptive	  in	  critical	  illness.	  There	  are	  significant	  challenges	  to	  bedside	  translation	  
of	  biological	  therapies	  to	  treat	  conditions	  such	  as	  sepsis	  and	  ARDS.	  A	  major	  hurdle	  is	  
that	   patients	   do	   not	   present	   at	   time	   zero	   and	   often	   have	   overwhelming	  
inflammation	  on	  presentation.	  
Prevention	  is	  better	  than	  cure	  
Much	  of	  the	  recent	  improvement	  in	  mortality	  is	  a	  result	  of	  improved	  delivery	  of	  care	  
attenuating	  perpetual	  inflammation	  as	  result	  of	  iatrogenic	  insults	  such	  as	  ventilation,	  
invasive	  monitoring,	  and	  nosocomial	  infection.	  The	  first	  significant	  breakthrough	  was	  
the	  use	  of	  low	  tidal	  volumes	  to	  prevent	  iatrogenic	  ventilator	  induced	  lung	  injury	  (26).	  
However,	   simple	   measures	   such	   as	   30o	   head	   up	   tilt	   to	   reduce	   gastric	   aspiration;	  
venous	   thromboembolic	   prophylaxis;	   regular	   turning	   to	   prevent	   pressure	   ulcers;	  
closed	  loop	  suctioning	  to	  prevent	  nosocomial	  infection;	  stress	  ulcer	  protection	  have	  
dramatically	  reduced	  the	  incidence	  of	   iatrogenic	   insults	  during	  the	  critical	  care	  stay	  
of	  many	  patients.	  
Anti-­‐inflammatory	  strategies	  
A	  major	   focus	   of	   research	   over	   the	   past	   few	   decades	   has	   been	   to	   elucidate	   anti-­‐
inflammatory	   strategies.	   These	   strategies	   are	   fraught	   with	   difficulty	   as	   they	   may	  
promote	   an	   immune	   compromised	   state	   with	   the	   augmentation	   of	   uncontrolled	  
‘compensatory	   anti-­‐inflammatory	   response	   syndrome’.	   For	   instance,	   low	   levels	   of	  
pro-­‐inflammatory	  mediators,	  such	  as	  nitric	  oxide,	  TNF-­‐α	  and	  IL-­‐6,	  have	  been	  shown	  
to	  be	  both	  pro-­‐resolving	  and	  reparative	  (117,	  118).	  This	  may	  explain	  why	  the	  bench	  
to	   bedside	   translation	   of	   cytokine-­‐based	   blocking	   therapies	   in	   the	   absence	   of	  
mechanistic	  insights	  has	  increased	  mortality	  in	  some	  studies	  of	  sepsis.	  The	  temporal	  
relationship	  between	  this	   initial	  anti-­‐inflammatory	  response	  and	  the	  progression	  of	  
the	   first	  and	  second	  phases	  of	   resolution	   (as	  described	  earlier)	  may	  determine	   the	  
susceptibility	  to	  nosocomial	  infection	  –	  a	  major	  cause	  of	  morbidity	  and	  mortality	  in	  
intensive	  care.	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Enhancing	  active	  resolution	  phase	  mediators	  
The	  notion	  of	  active	  resolution	  mechanisms	  is	  so	  recent	  that	  well-­‐known	  agents	  such	  
as	   glucocorticoids	   and	   aspirin	   have	   been	   labelled	   as	   anti-­‐inflammatory	  whereas	   in	  
actual	  fact	  they	  are	  significantly	  pro-­‐resolving	  in	  nature.	  For	  instance,	  glucocorticoids	  
have	  been	  shown	  to	  enhance	  (119)	  and	  inhibit	  neutrophil	  apoptosis	  (120,	  121)	  but	  a	  
major	   influence	   on	  macrophage	   phenotype	   imparts	   vital	   resolving	   effects	   through	  
induction	  of	  annexin	  A1	  (122)	  and	  increased	  neutrophil	  efferocytosis	  (123).	  Overall,	  
glucocorticoids	   have	   been	   shown	   to	   reduce	   pro-­‐inflammatory	   cytokine	   release,	  
reduce	   neutrophil	   trafficking,	   increase	   neutrophil	   apoptosis	   and	   efferocytosis,	   and	  
reparative	   macrophage	   phenotype	   switching	   –	   all	   key	   steps	   in	   inflammatory	  
resolution.	  	  
	  
More	  recent	  advances	  have	  discovered	  the	  lipoxin,	  resolvin	  and	  protectin	  classes	  of	  
the	  eicosanoid	   family,	  which	  serve	  to	  actively	  promote	  homeostasis	  and	  resolution	  
of	   inflammation	   (124,	  125).	   For	   instance,	   lipoxin	  A2	  has	  been	   shown	   to	   reinstitute	  
epithelial	   barrier	   function	   in	   experimental	   ALI	   (126)	   and	   resolvin	   D2	   improved	  
survival	  in	  a	  model	  of	  microbial	  sepsis	  induced	  by	  caecal	  ligation	  and	  puncture	  (127).	  
Hence,	   enhancing	   the	   effects	   of	   endogenous	  pro-­‐resolving	  mediators	  may	  prove	   a	  
better	  therapeutic	  option.	  Interestingly,	  aspirin	  influences	  resolution	  within	  hours	  of	  
the	  onset	  of	  inflammation	  through	  the	  production	  of	  lipoxin	  A4	  precursors	  (128).	  
	  
In	  addition	  to	  molecular	  mediators,	  cellular	  mediators	  also	  direct	   the	  path	  through	  
which	   inflammation	  may	  proceed.	  This	   involves	  a	  concerted	  crosstalk	  between	   the	  
acute	  innate	  and	  the	  regulatory	  adaptive	  arms	  of	  the	  immune	  system.	  Recruitment	  
of	   exudative	   macrophages	   is	   an	   important	   phase,	   in	   particular,	   once	   these	   early	  
phase	  monocyte	  derived	  myeloid	  cells	  ingest	  apoptotic	  cells,	  the	  resolution	  phase	  is	  
well	  underway	  (129,	  130).	  	  More	  recently	  a	  certain	  subset	  of	  T-­‐cells	  called	  regulatory	  
T-­‐cells,	   which	   are	   identified	   by	   the	   cell	   surface	   markers	   CD4,	   CD25	   and	   the	  
transcription	   factor	   FoxP3,	   have	   been	   shown	   to	   reduce	   proinflammatory	   cytokine	  
production,	   increase	  TGFβ	  levels	  and	  increase	  neutrophil	  apoptosis	   in	  experimental	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Further	   insights	   into	   the	   mechanisms	   through	   which	   infiltrating	   cells	   die	   may	  
improve	   our	   understanding	   as	   to	   how	   we	   may	   be	   able	   to	   manipulate	   leukocyte	  
apoptosis	  to	  help	  promote	  resolution,	  especially	   in	  states	  of	  critical	   illness	   in	  which	  
leukocyte	  apoptosis	  is	  delayed.	  There	  is	  potential	  scope	  for	  manipulating	  neutrophil	  
apoptosis	   and	   enhancing	   their	   uptake	   by	   macrophages,	   thus	   promoting	   pro-­‐
resolving	  reparative	  macrophage	  phenotypes.	  Additionally,	  the	  diagnostic	  evaluation	  
of	  macrophage	  phenotype	  in	  intensive	  care	  may	  give	  insights	  into	  the	  immune	  status	  
of	   patients	   allowing	   the	   implementation	   of	   personalised	   therapies	   to	   promote	  
resolution.	  
	  
Most	  excitingly,	  the	  future	  role	  of	  cell	   therapy	  has	  been	  significantly	  fuelled	  by	  the	  
application	   of	   mesenchymal	   stem	   cells	   (MSCs)	   in	   experimental	   models	   of	   critical	  
illness.	  The	  heterogeneous	  and	  plastic	  nature	  of	  these	  cells	  allowing	  them	  to	  adapt	  
and	   respond	   appropriately	   to	   various	   inflammatory	  milieus	   in	   a	   reparative	   fashion	  
has	   shown	   significant	   therapeutic	   potential.	   MSCs	   have	   been	   shown	   to	   improve	  
experimental	  ALI,	  bacterial	  pneumonia,	  and	  gram-­‐negative	  sepsis.	  Unfortunately,	  the	  
application	   of	   MSCs	   in	   critical	   illness	   is	   still	   relatively	   devoid	   of	   mechanisms.	  
However,	  there	  is	  emerging	  evidence	  that	  these	  may	  include	  paracrine	  effects	  such	  
as	   secretion	   of	   growth	   factors	   such	   as	   KGF	   and	   anti-­‐bacterial	   proteins;	   and	  
immunomodulatory	   effects	   on	   circulating	   monocytes,	   tissue	   macrophages	   and	   T-­‐
cells	  (131).	  
Aiming	  for	  full	  functional	  recovery	  
Mitochondrial	  abnormalities	  and	  dysfunction	  have	  now	  been	  shown	  to	  be	  integral	  in	  
the	  pathogenesis	  of	  sepsis	  and	  multi-­‐organ	  failure	  and	  can	  be	  induced	  by	  a	  variety	  of	  
soluble	   mediators	   including	   nitric	   oxide	   and	   reactive	   oxygen	   species,	   as	   well	   as,	  
through	  the	  activation	  of	  apoptosis	   signalling.	  Mitochondrial	  biogenesis	  most	   likely	  
occurs	   at	   a	   transcriptional	   level	   involving	  nuclear	   regulators	   such	  as	  PGC-­‐1α	   (132),	  
which	   integrates	   multiple	   external	   signals	   including	   ROS/RNS.	   Furthermore,	  
endocrine	   factors	  such	  as	   thyroid	  hormones	  also	   influence	  mitochondrial	   recovery.	  
Hence,	  strategies	  aimed	  at	  ‘jump	  starting’	  mitochondria	  are	  attractive	  as	  repair	  and	  
recovery	   would	   undoubtedly	   require	   energy	   (133).	   Another	   approach	   involves	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mesenchymal	  stem	  cells	  which	  have	  more	  recently	  been	  visually	  captured	  to	  adopt	  a	  
‘trojan	  horse’	  strategy	  to	  deliver	  mitochondria,	  packaged	  in	  microvesicles,	  to	  injured	  
alveolar	  epithelial	  cells	  improving	  tissue	  bioenergetics	  and	  thereby	  preventing	  injury	  
and	  promoting	  recovery	  (134).	  	  
	  
1.5 Tumour	  necrosis	  factor	  biology	  
1.5.1 The	  discovery	  of	  TNF	  
The	   events	   that	   culminated	   in	   the	   discovery	   of	   TNF	   can	   only	   be	   described	   as	   a	  
remarkable	   series	   of	   landmark	   investigations	   that	   have	   changed	   the	   face	   of	  
medicine.	   In	  1888,	  Bruns	  described	  the	  treatment	  of	  sarcoma	  with	   the	   injection	  of	  
streptococcus	   erysipelatis	   leading	   to	   regression	   and	   cure	   of	   tumour	   in	   3	   out	   of	   5	  
patients.	   In	   1891,	   William	   B.	   Coley	   extended	   this	   observation	   further	   in	   9	   more	  
patients	   to	   produce	   Coley’s	   toxin,	   a	   mixture	   of	   a	   Streptococcus	   and	   Serratia	  
organisms,	  with	  the	  theory	  that	  a	  stimulation	  of	  the	  immune	  system	  can	  cure	  cancer	  
(135).	   Shear	   showed	   that	   endotoxin	   from	   bacteria	   was	   responsible	   for	   tumour	  
regression	   (136)	   and	   Algire	   showed	   endotoxin	   induced	   haemorrhagic	   necrosis	   in	  
tumour	  (137).	  Finally,	  TNF	  was	  first	  named	  in	  1975	  by	  Carswell	  and	  colleagues	  as	  a	  
substance	   released	   by	   macrophages	   in	   response	   to	   endotoxin	   leading	   to	   the	  
haemorrhagic	   necrosis	   of	   tumours	   (138).	   It	   was	   subsequently	   found	   to	   have	   the	  
same	  molecular	  structure	  as	  cachectin	  as	  discovered	  by	  Beutler	  and	  Cerami	  in	  1985	  
(139,	   140).	   TNF	   has	   mainly	   been	   regarded	   as	   a	   pleiotropic	   cytokine	   strongly	  
implicated	  in	  inflammation,	  but	  there	  still	  remains	  considerable	  controversy	  as	  to	  its	  
precise	  roles,	  due	  to	  the	  complex	  nature	  of	  TNF	  signalling	  (141).	  Indeed,	  an	  editorial	  
in	  Nature	   in	  1987,	   in	   connection	  with	   the	  publication	   for	   the	   role	  of	   TNF	   in	   septic	  
shock,	  stated	  that	  the	  “anti-­‐tumour	  action,	  role	  in	  inflammation	  and	  immunity,	  and	  
toxicity…”	  are	  precisely	  why	  TNF	  has	  gained	  so	  much	  interest	  (142).	  	  
	  
TNF	  was	   found	   to	   be	   a	  member	   of	   a	  much	   larger	   family	   with	   homology	   to	   other	  
mediators	   being	   investigated	   at	   the	   time.	   For	   instance,	   Granger	   et	   al	   discovered	  
lymphotoxin,	   which	   was	   a	   lymphocyte-­‐derived	   mediator	   that	   caused	   tumour	  
regression	   (143).	  Agarwal	   and	   colleagues	   initially	  purified	   lymphotoxin	  protein	  and	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found	   a	   30%	   homology	   in	   protein	   sequence	   between	   lymphotoxin	   and	   TNF.	   In	  
particular,	  with	  the	  view	  that	  they	  also	  had	  common	  cell	  surface	  receptors,	  TNF	  and	  
lymphotoxin	  were	  subsequently	  named	  TNF-­‐α	  and	  TNF-­‐β,	  respectively.	  This	  heralded	  
the	  discovery	  of	  multiple	  ligands	  and	  receptors,	  which	  are	  now	  part	  of	  the	  extended	  
TNF	   superfamily	   (141).	   For	   consistency,	   TNF-­‐α	   will	   be	   referred	   as	   TNF	   for	   the	  
remainder	  of	  the	  thesis.	  
	  
1.5.2 TNF	  ligand	  and	  its	  receptors	  
TNF	  is	  the	  quintessential	  proinflammatory	  cytokine	  and	  a	  central	  proximal	  controller	  
in	   the	   production	   of	   proinflammatory	   consequences.	   Hence,	   its	   role	   in	   the	  
pathobiology	   of	   many	   diseases	   and	   syndromes	   has	   mainly	   focussed	   on	   this	  
inflammatory	  aspect.	  Myeloid	  cells	  such	  as	  monocytes	  and	  macrophages	  secrete	  TNF	  
in	   large	  quantities	   in	   response	   to	   TLR-­‐4	   signalling	   and	  NFκB	  activation,	   and	  hence,	  
TNF	  is	  highly	  abundant	  in	  inflamed	  tissue.	  	  
	  
TNF	  is	  initially	  formed	  as	  a	  26	  kDa	  transmembrane	  protein	  which	  is	  expressed	  on	  the	  
cell	  surface	  as	  a	  stable	  homotrimer.	  It	  is	  present	  in	  two	  forms	  –	  a	  membrane	  bound	  
and	   a	   soluble	   form.	   TNF-­‐alpha	   converting	   enzyme	   (TACE	   or	   ADAM17),	   a	  
metalloproteinase	   enzyme,	   cleaves	   the	   transmembrane	   TNF	   homotrimer	   thereby	  
releasing	  a	  bioactive	  51	  kDa	  soluble	  TNF	  homotrimer	  (144).	  This	  soluble	  homotrimer	  
dissociates	  below	  the	  nanomolar	  range	  rendering	  it	  inactive.	  	  
	  
Over	  the	  decade	  following	  the	  discovery	  of	  TNF	  ligand,	  two	  distinct	  receptors	  for	  TNF	  
were	  characterised	  (145,	  146),	  and	  called	  TNF	  receptor	  1	  (TNFR1,	  p55,	  CD120a)	  and	  
TNF	   receptor	   2	   (TNFR2,	   p75,	   CD120b).	  Whilst	   both	   receptors	   are	   able	   to	   bind	   the	  
membrane	   bound,	   as	  well	   as,	   the	   soluble	   form	  of	   TNF,	   the	   p55	   TNF	   receptor	  was	  
found	  to	  have	  greater	  affinity	  for	  the	  soluble	  form	  and	  the	  p75	  TNF	  receptor	  to	  the	  
membrane	  expressed	  form	  (147,	  148).	  Furthermore,	   the	  complexity	  of	  TNF	  biology	  
increased	   further	   by	   the	   discovery	   that	   TACE	   could	   also	   cleave	   the	   cell	   surface	  
expressed	  receptors	  to	  produce	  soluble	  forms	  (149-­‐151).	  The	  shedding	  of	  TNF	  and	  its	  
receptors	  has	  dramatic	  effects	  on	  its	  biology.	  Firstly,	  not	  only	  are	  soluble	  receptors	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unable	   to	   mediate	   intracellular	   signals	   (as	   compared	   to	   their	   non-­‐shed	   surface	  
expressed	   counterparts),	   but	   secondly,	   the	   soluble	   receptors	   also	   bind	   to	   free	  
soluble	  TNF	  and	  hence,	  quench	  its	  ability	  to	  activate	  cell	  surface	  expressed	  receptors	  
that	  have	  not	  been	  shed.	  This	  complex	  dynamic	  regulation	  of	  TNF	  and	  its	  receptors	  
at	  the	  cell	  surface	  is	  seldom	  appreciated.	  
1.5.3 Molecular	  mechanisms	  and	  functional	  consequences	  of	  TNF	  receptor	  
signalling	  	  
The	  p55	  TNF	  receptor	  (TNFR)	  is	  constitutively	  expressed	  on	  most	  cells	  and	  tissues.	  In	  
contrast,	   the	   expression	   of	   the	   p75	   TNFR	   is	   more	   regulated	   with	   high	   expression	  
found	   on	   leukocytes,	   myocytes,	   endothelial	   cells,	   and	   human	   mesenchymal	   stem	  
cells.	   Historically,	   p55	   TNFR	   signalling	   has	   been	   thought	   to	   be	   the	   predominant	  
pathway	   through	  which	   the	   cellular	   effects	   of	   TNF	   occur.	   In	   view	  of	   the	   profound	  
cytotoxic	  effects,	  the	  p55	  TNFR	  pathway	  has	  been	  well	  characterised.	  The	  p75	  TNFR	  
pathway	  has	  been	  thought	  to	  play	  predominantly	  modulatory	  roles	  of	  either	  “ligand	  
passing”	   (enhancing	   p55	   TNFR	   signalling)	   or	   sequestering	   excess	   TNF	   through	   its	  
soluble	   receptor	   form	   (152).	   However,	   it	   is	   now	   more	   apparent	   that	   both	   TNF	  
receptors	  initiate	  distinct	  signalling	  pathways	  and	  different	  cellular	  responses	  (153).	  	  
p55	  TNFR	  signalling	  
The	   ligation	   of	   the	   p55	   TNFR	   leads	   to	   two	   distinct	   consequences	   –	   1)	   cell	   survival	  
through	   pro-­‐inflammatory	   gene	   transcription,	   and	   2)	   cell	   death	   through	   pro-­‐
apoptotic	  cascades.	  At	  the	  molecular	  level,	  the	  binding	  of	  TNF	  to	  the	  p55	  TNFR	  leads	  
to	   an	   immediate	   conformational	   change	   in	   the	   intracellular	   component	   of	   the	  
receptor	   allowing	   the	   recruitment	   of	   TNF	   receptor	   associated	   death	   domain	  
(TRADD).	   TRADD	   acts	   as	   a	   docking	   protein	   allowing	   multiple	   mediators,	   including	  
receptor	  interacting	  protein	  kinase-­‐1	  (RIP1),	  TNF	  receptor	  associated	  factor	  (TRAF-­‐2)	  
and	   cellular	   inhibitors	   of	   apoptosis	   protein	   (cIAP)	   -­‐1	   and	   -­‐2,	   to	   attach	   to	   this	  
intracellular	   TNFR1	   signalling	   complex.	   The	   attachment	   of	   RIP1	   occurs	   within	  
minutes	  of	  p55	  TNFR	  ligation.	  This	  undergoes	  ubiquitination	  by	  TRAF2	  and	  cIAP1/2,	  
leading	   to	   the	   formation	   of	   polyubiquitin	   chains	   that	   act	   as	   a	   scaffold	   for	   the	  
attachment	  of	  multiple	  subunits	  to	  the	   initial	  p55	  TNFR	  intracellular	  death	  domain.	  
For	   instance,	  NFκB	  essential	  modulator	  (NEMO)	   is	  an	  adaptor	  protein	  that	  binds	  to	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ubiquitinated	   RIP1.	   This	   mediates	   the	   first	   of	   two	   pro-­‐inflammatory	   signalling	  
cascades,	  that	  of	  classical	  NFκB	  activation	  (through	  IκB	  recruitment).	  The	  second	  pro-­‐
inflammatory	   survival	   signal	   occurs	   through	   the	   MAPK	   pathway	   –	   leading	   to	   p38	  
MAPK,	   c-­‐Jun	  N-­‐terminal	   kinase	   (JNK)	   and	  activator	  protein-­‐1	   (AP-­‐1)	   activation.	   The	  
alternative	  route	  of	  p55	  TNFR	  activation	  is	  the	  recruitment	  of	  procaspase-­‐8,	  instead	  
of	  NEMO,	  to	  RIP1	  and	  its	  subsequent	  conversion	  to	  caspase-­‐8.	  This	  caspase-­‐8	  signal	  
leads	   to	   the	   activation	   of	   caspase-­‐3,	   which	   executes	   cell	   death.	   If	   this	   caspase-­‐8	  
signal	   is	   inhibited,	   a	   new	   signalling	   complex	   (the	   necroptosome)	   is	   formed,	  which	  
leads	  to	  cell	  death	  through	  a	  caspase	  independent	  pathway	  called	  necroptosis.	  
	  
Interestingly,	   most	   cells	   do	   not	   die	   when	   treated	   with	   TNF	   and	   only	   do	   so	   when	  
exposed	  to	  protein	  synthesis	  inhibitors	  such	  as	  cyclophosphamide	  suggesting	  that	  a)	  
TNF	  activates	  the	  expression	  of	  survival	  genes	  to	  block	  cell	  death;	  and	  b)	  the	  proteins	  
required	  to	  execute	  cell	  death	  are	  pre-­‐made	  and	  independent	  of	  protein	  synthesis.	  It	  
is	   now	   established	   that	   NFκB	   activation	   supresses	   the	   TNF-­‐induced	   cell	   death	  
programme	  (154-­‐156).	  The	  serine	  proteases	  comprising	  the	  caspase	  family	  are	  pre-­‐
made	   within	   the	   cell	   whereas	   the	   anti-­‐apoptotic	   NFκB	   pathway	   requires	   the	  
synthesis	  of	  new	  proteins	   suggests	   cell	   death	   to	  be	   the	  default	   pathway	  after	  p55	  
TNFR	  ligation.	  However,	  given	  that	  the	  time	  required	  for	  gene	  transcription	  is	  likely	  
to	  be	  much	  slower	  than	  the	  time	  taken	  for	  caspase-­‐3	  activation	  and	  that	  cells	  do	  not	  
die	  immediately,	  suggests	  that	  a	  more	  proximal	  switch	  should	  exist	  in	  the	  decision	  of	  
whether	  a	  cell	  lives	  or	  dies.	  
	  
In	  fact,	  this	  initial	  interaction	  of	  RIP1	  with	  either	  NEMO	  or	  procaspase-­‐8	  appears	  to	  
be	  the	  first	  of	  two	  control	  points	  that	  determine	  whether	  a	  cell	  survives	  or	  dies	  from	  
p55	  TNFR	   ligation.	   	  This	  switch	   is	  determined	  by	  the	  ubiqitination	  of	  RIP1,	  which	   is	  
essential	   for	   the	  binding	  of	  NEMO	  and	   the	  subsequent	  activation	  of	   IκB	  and	  NFκB.	  
RIP1	  polyubiquitination,	  forming	  a	  linear	  ubiquitin	  chain	  assembly	  complex	  (LUBAC)	  
off	   of	   RIP1,	   is	   performed	   by	   TRAF2	   in	   collaboration	   with	   ubiquitin	   conjugating	  
enzyme	   E2	   (also	   known	   as	   UBC13)	   (157,	   158).	   Non-­‐ubiquitinated	   RIP1	   is	   a	   non-­‐
essential	  enhancer	  of	  caspase-­‐8	  activation.	  Hence,	  p55	  TNFR	  activation	  immediately	  
represents	   an	   important	   rheostat	   that	   determines	   whether	   a	   cell	   is	   destined	   to	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survive	   or	   die	   (159).	   This	   first	   “live/die”	   switch	   is	   independent	   of	   new	   protein	  
synthesis.	   If	   this	   first	   switch	   fails	   (i.e.	   the	   ubiquitination	   of	   RIP1,	   attachment	   of	  
NEMO	  and	  hence	  inaccessibility	  of	  procaspase-­‐8	  to	  RIP1)	  as	  a	  result	  of	  degradation	  
of	   E3	   ligases	   (which	   are	   responsible	   for	   ubiquitination),	   then	   there	   is	   a	   second	  
control	   point	   at	   the	   level	   of	   NFκB	   transcription.	   This	   second	   controller	   provides	   a	  
later,	   but	   more	   protracted	   cell	   survival	   signal,	   and	   is	   dependant	   on	   the	   NFκB	  
mediated	   transcription	  of	  an	  anti-­‐apoptotic	  protein	  called	  cFLIP.	  Most	   importantly,	  
this	   NFκB	   transcription	   can	   occur	   through	   a	   variety	   of	   pathways	   e.g.	   p75	   TNFR	  
activation.	  
p75	  TNFR	  signalling	  
The	  p75	  TNFR,	  on	  the	  other	  hand,	  has	  no	  death	  domain	  and	  has	  been	  shown	  to	  have	  
distinctive	  cell	  signalling	  pathways.	  TNF	  binding	  induces	  the	  trimerisation	  of	  the	  p75	  
TNFR	  leading	  to	  the	  recruitment	  of	  TRAF2.	  The	  binding	  of	  TRAF2	  leads	  to	  the	  binding	  
of	   TRAF3	   and	   cIAP-­‐1	   and	   -­‐2	   to	   the	   signalling	   complex.	   It	   has	  been	   shown	   that	   the	  
activation	  of	  NF-­‐κB	  element	  correlates	  with	  TRAF2	  protein	  levels	  (155,	  160).	  Hence,	  
p75	  TNFR	  signalling	  can	  promote	  cell	  survival	  (161)	  through	  this	  NF-­‐κB	  activation	  as	  
well	   as	   the	   induction	   of	   anti-­‐apoptotic	   pathways	   including	   the	   Protein	   kinase	   B	  
(PkB)/AKT	  pathways	  (162).	  However,	  in	  some	  circumstances	  certain	  residues	  of	  p75	  
TNFR	  can	  also	  degrade	  TRAF2	  negatively	  regulating	  the	  NF-­‐κB	  response.	  In	  addition,	  
there	  is	  crosstalk	  between	  both	  TNFRs	  where	  TRAF2	  degradation	  and	  lack	  of	  NF-­‐κB	  
transcription	  (by	  p75	  TNFR)	  augments	  p55	  TNFR	  induced	  cytotoxicity	  (163).	  There	  is	  
controversy	  as	  to	  whether	  the	  p75	  TNFR	  complex	  has	  any	  intrinsic	  enzyme	  activity.	  
The	  majority	  of	  literature	  suggests	  it	  does	  not	  but	  there	  is	  some	  evidence	  to	  suggest	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Figure' 1.6' Survival( versus( death( signalling( through( the( p55( TNF( receptor.( Within( minutes( of(
liga;on(of(the(p55(TNF(receptor(by(TNF(there(is(recruitment(of(RIPA1(to(the(intracellular(receptor(
complex.( If( RIPA1( is( ubiqui;nated( by( TRAFA2,cIAPA1/2( in( collabora;on( with( UBC13( a( linear(
ubiqui;n( chain( assembly( complex( is( formed( allowing( proteins( such( as( NEMO( to( dock( to( RIPA1(
inducing( IKK( and( IκBα( assembly( and( ac;va;on( of( the( NFκB( transcrip;on( factor.( If( RIPA1(
ubiqui;na;on( is( blocked,( for( instance( through( a( degrada;on( in( the( enzymes( responsible( e.g.(
UBC13( and( E3( ligases,( then( there( is( a( switch( to( the( forma;on( of( a( death( inducing( signalling(
complex( (DISC).( Furthermore,( RIPA1( is( a( nonAessen;al( enhancer( of( caspaseA8( leading( to( its(
ac;va;on(and(death(signalling.(This(represents(the(ﬁrst(live/die(switch(at(the(receptor(level.(If(this(
switch( is( ac;vated( there( is( a( backAup( switch( through( NFκB( transcrip;on( which( leads( to( the(
transcrip;on(of(an;Aapopto;c(proteins(cIAPA1/2,(cFLIP(and(TRAFA1/2.(These(proteins(prevent(the(
ac;va;on( of( eﬀector( caspases( and( the( ﬁnal( stages( of( cell( death.( Importantly( other( receptors/
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Figure	  1.6.	  Survival	  versus	  death	  signalling	  through	  the	  p55	  TNF	  receptor	  
Within	  minutes	  of	   ligation	  of	   the	  p55	  TNF	   receptor	  by	  TNF	   there	   is	   recruitment	  of	  
RIP1	  to	  the	  intracellular	  receptor	  complex.	  If	  RIP1	  is	  ubiquitinated	  by	  TRAF2,	  cIAP-­‐1/2	  
in	   collaboration	   with	   UBC13	   a	   linear	   ubiquitin	   chain	   assembly	   complex	   is	   formed	  
allowing	  proteins	  such	  as	  NEMO	  to	  dock	  to	  RIP-­‐1	  inducing	  IKK	  and	  IκBα	  assembly	  and	  
activation	   of	   the	   NFκB	   transcription	   factor.	   If	   RIP-­‐1	   ubiquitination	   is	   blocked,	   for	  
instance	   through	   a	   degradation	   in	   the	   enzymes	   responsible	   e.g.	   UBC13	   and	   E3	  
ligases,	  then	  there	  is	  a	  switch	  to	  the	  formation	  of	  a	  death	  inducing	  signalling	  complex	  
(DISC).	   Furthermore,	   RIP-­‐1	   is	   a	   non-­‐essential	   enhancer	   of	   caspase-­‐8	   leading	   to	   its	  
activation	  and	  subsequent	  death	  signalling.	  This	   represents	   the	   first	   live/die	  switch	  
at	   the	   receptor	   level.	   If	   this	   switch	   is	   activated	   there	   is	   a	   back-­‐up	   switch	   through	  
NFκB	  transcription,	  which	  leads	  to	  the	  transcription	  of	  anti-­‐apoptotic	  proteins	  cIAP-­‐
1/2,	  cFLIP	  and	  TRAF-­‐1/2.	  These	  proteins	  prevent	  the	  activation	  of	  effector	  caspases	  
and	   the	   final	   stages	  of	   cell	   death.	   Importantly	   other	   receptors/signalling	  pathways	  
that	  activate	  NFκB	  transcription	  can	  contribute	  through	  this	  survival	  pathway.	  	  
	  
(cIAP,	  cellular	  inhibitor	  of	  apoptosis;	  cFLIP,	  Cellular	  FLICE	  (FADD-­‐like	  IL-­‐1β-­‐converting	  
enzyme)-­‐inhibitory	   protein;	   DD,	   death	   domain;	   DISC,	   death	   inducing	   signalling	  
complex;	   FADD,	   Fas	   associated	   death	   domain;	   IKK,	   I	   kappa	   kinase;	   LUBAC,	   linear	  
ubiquitin	  chain	  assembly	  complex;	  	  NEMO,	  NF-­‐κB	  essential	  modulator;	  P,	  phosphate;	  
RIP,	   receptor	   interacting	   protein	   kinase;	   TRADD,	   TNF	   receptor	   associated	   death	  
domain;	  TRAF,	  TNF	  receptor	  associated	  factor;	  TRAIL,	  TNF	  related	  apoptosis	  inducing	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1.6 TNF	  and	  critical	  illness	  
1.6.1 TNF	  –	  elusive	  in	  clinical	  ARDS	  
Since	  the	  discovery	  that	  TNF	  and	  cachectin	  were	  one	  and	  the	  same,	  the	  role	  of	  TNF	  
in	   ARDS	   has	   been	   heavily	   investigated.	   Millar	   and	   colleagues	   found	   a	   significant	  
upregulation	   in	   all	   5	   patients	   analysed	   with	   ARDS	   compared	   to	   non-­‐ARDS	   control	  
patients	   (165).	   Marks	   and	   colleagues	   performed	   measurements	   of	   serial	   plasma	  
samples	  for	  TNF	  on	  86	  patients	  (166).	  They	  found	  that	  over	  a	  third	  of	  patients	  with	  
septic	  shock	  showed	  the	  presence	  of	  TNF	  in	  plasma,	  and	  that	  these	  levels	  peaked	  on	  
admission	   and	   reduced	   over	   the	   first	   12-­‐24	   hours	   thereafter.	   Patients	   with	   septic	  
shock	   showed	   increased	   levels	   compared	   to	   patients	   in	   shock	   from	   non-­‐septic	  
causes.	   Importantly,	   this	   study	   found	   that	   those	   patients	   in	   septic	   shock	   with	  
detectable	   TNF	   levels	   showed	   a	   significantly	   higher	   propensity	   to	   develop	   ARDS	  
compared	   to	   those	   in	   septic	   shock	  without	  measureable	  TNF	   in	   their	  plasma	   (55%	  
versus	   26%,	   respectively).	   Furthermore,	   those	   with	   measureable	   TNF	   showed	   a	  
higher	  parenchymal	  lung	  injury	  score	  with	  a	  doubling	  in	  mortality	  (81%	  versus	  43%).	  
Hyers	   et	   al	   corroborated	   these	   results,	   also	   showing	   that	   septic	   shock	   led	   to	  
significantly	   higher	   serum	   levels	   of	   TNF	   compared	   to	   non-­‐septic	   patients.	  
Importantly,	  this	  study	  analysed	  the	  alveolar	  levels	  of	  TNF	  and	  found	  that	  these	  were	  
higher	  in	  ARDS	  patients	  than	  normal	  subjects.	  These	  levels	  were	  highest	  in	  the	  first	  
24	   hours	   (167).	   The	  most	   common	   causes	   of	   ARDS	   in	   this	   study	   were	   sepsis	   and	  
aspiration	  of	  gastric	  contents.	  Gastric	  aspiration	  led	  to	  a	  significantly	  higher	  BAL	  level	  
of	  TNF	  compared	  to	  the	  non-­‐aspirated	  ARDS	  group.	  	  
	  
Hence,	   TNF	   is	   upregulated	   early	  within	   the	   first	   day	   in	   the	   BALF	   of	   ARDS	   patients	  
(167)	   and	   sustained	   release	   of	   TNF	   is	   not	   required	   for	   lung	   injury	   development	   in	  
sepsis	   (168).	   In	  addition	   to	   the	  acute	  kinetics	  of	  TNF	  upregulation,	   the	   role	  of	  TNF	  
has	  been	  further	  confused	  by	  the	  inconsistencies	  in	  measurement	  of	  TNF	  which	  has	  
been	   shown	   to	   be	   heavily	   dependant	   on	   the	   experimental	   assays	   utilised	   (169).	  
Furthermore,	   there	   is	   suggestion	   that	   TNF	  may	   indeed	  mediate	   its	   effects	   through	  
cell-­‐cell	   contact	  mechanisms	   through	   the	  membrane	  expressed	  TNF	  as	  opposed	   to	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its	  soluble	  form	  (170).	  In	  view	  of	  all	  of	  these	  factors,	  it	  is	  not	  surprising	  that	  the	  role	  
of	  TNF	  in	  the	  pathogenesis	  of	  ALI/ARDS	  has	  remained	  elusive	  and	  controversial.	  	  
1.6.2 TNF	  in	  sepsis	  –	  ‘clinical	  trials	  and	  tribulations…’	  
In	   the	   80’s	   and	   90’s,	   there	   was	   considerable	   evidence	   from	   animal	   and	   human	  
studies	   that	   TNF	   played	   a	   significant	   role	   in	   sepsis	   and	   ARDS.	   However,	   the	  
mechanisms	  through	  which	  TNF	  functions,	  in	  particular,	  the	  receptors	  through	  which	  
its	   actions	   were	   mediated	   had	   not	   been	   investigated	   and	   despite	   the	   paucity	   of	  
mechanistic	  detail,	  clinical	  trials	  applying	  anti-­‐TNF	  agents	  to	  sepsis	  were	  performed.	  
One	  of	  the	  first	  studies	  was	  conducted	  by	  Fisher	  et	  al	  and	  showed	  that	  although	  the	  
anti-­‐TNF	  monoclonal	   antibody	   did	   not	   demonstrate	   a	   survival	   benefit	   in	   all	   study	  
patients,	   those	  with	   elevated	   TNF	   plasma	   levels	   showed	   improved	   survival	   with	   a	  
higher	  dose	  of	   intravenously	  administered	  antibody	  (86%	  versus	  50%,	  respectively)	  
(171).	  All	  other	  studies	  have	  to	  date	  failed	  to	  show	  benefit	  with	  global	  TNF	  blockade	  
in	  sepsis	  (172-­‐174).	  When	  we	  analyse	  the	  evidence	  for	  ARDS,	  again,	  animal	  studies	  
show	   significant	   improvements	   but	   there	   is	   a	   lack	   of	   clinical	   data	   to	   support	   TNF	  
blockade	  in	  ARDS.	  	  	  
	  
There	  are	  multiple	  reasons	  for	  these	  failures.	  	  
1. Sepsis	  and	  ARDS	  are	  not	  diseases	  but	  heterogeneous	  syndromes	  caused	  by	  
varying	  aetiologies.	  Many	  clinical	  trials	  group	  meningococcal	  and	  peritoneal	  
sepsis	  as	  one	  entity,	  or	  group	  pulmonary	  oedema	   induced	  by	  Streptococcal	  
pneumoniae	   with	   that	   induced	   by	   pancreatitis.	   This	   may	   be	   very	  
inappropriate	   given	   the	   potentially	   varying	   mechanisms	   of	   injury.	  
Furthermore,	  different	  aetiologies	  may	  have	  a	  variable	  dependence	  on	  TNF	  
mediated	  pathways.	  Hence,	  it	  is	  no	  surprise	  that	  beneficial	  effects	  are	  absent	  
when	   such	   patients	   are	   grouped	   together	   in	   a	   clinical	   trial	   –	   regardless	   of	  
power.	  	  
	  
2. The	   underlying	   scientific	   rationale	   is	   flawed.	   An	   example	   of	   this	   is	   the	  
recently	   published	   ACCESS	   trial	   investigating	   the	   MD2-­‐TLR-­‐4	   antagonist	  
Eritoran	   (175).	   This	   double	   blind,	   large	  multicentre	   study	   administered	   this	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drug	  to	  all	  septic	  patients.	  However,	  the	  baseline	  infectious	  characteristics	  of	  
patients	   recruited	   within	   this	   trial	   showed	   that	   only	   32%	   of	   patients	   had	  
confirmed	  gram-­‐negative	  septicaemia.	  Nearly	  30%	  had	  gram-­‐positive	  sepsis,	  
10%	  had	  mixed	  positive	  and	  negative	  sepsis;	  23%	  of	  unknown	  sepsis;	  3%	  with	  
fungal	  sepsis;	  and	  4%	  showed	  no	  evidence	  of	  infection	  at	  all!	  Gram-­‐negative	  
infections	  mediate	   their	   effects	   through	   TLR-­‐4	   (176)	  whereas	   gram-­‐positive	  
infections	  predominantly	   through	  TLR-­‐2	  pathways	   (177,	  178).	  Hence,	   a	   trial	  
investigating	  the	  effect	  of	  this	  drug	  solely	  on	  gram-­‐negative	  infections	  would	  
seem	   scientifically	   valid	   whereas	   the	   ACCESS	   study	   recruitment	   criteria	  
seemed	  irrational	  (179).	  Furthermore,	  the	  multiple	  positive	  results	  in	  animal	  
studies,	  which	   are	   often	   conducted	  with	   a	   single	   insult/model,	   corroborate	  
this	  view	  that	  more	  homogenous	  populations	  need	  to	  be	  studied.	  Clinically,	  
for	  example,	  patients	  with	  higher	  serum	  TNF	  levels	  seem	  to	  benefit	  from	  TNF	  
blockade	   (171).	   Furthermore,	   although	   alveolar	   TNF	   levels	   in	   human	   ARDS	  
are	   greater	   than	   in	   normal	   controls,	   it	   is	   significantly	   higher	   in	   those	   with	  
ARDS	   secondary	   to	   gastric	   aspiration	   compared	   to	  non-­‐aspiration	   causes	  of	  
ARDS	   (167).	   Hence,	   recruiting	   those	   patients	   with	   elevated	   TNF	   levels	   to	  
receive	   anti-­‐TNF	   strategies,	   or	   those	   patients	  with	   detectable	   endotoxin	   to	  
receive	   a	   drug	   such	   as	   Eritoran	  may	   lead	   to	   better	   trial	   designs	   leading	   to	  
personalised	   targeted	   therapies/studies	   in	   the	   intensive	   care.	   Hence,	  
biomarker	  based	  recruitment	  to	  clinical	  trials	  may	  improve	  translation,	  as	  has	  
occurred	   in	   other	   medical	   specialties	   such	   as	   cardiology	   e.g.	   troponin	  
directed	   therapies.	  A	   thorn	   in	   the	   side	  of	   TNF	  based	   therapy	   to	   this	   is	   that	  
plasma	  measurements	  of	  TNF	  do	  not	  reflect	  the	  amount	  of	  bioactive	  TNF	  at	  a	  
tissue	   level,	   and	   hence,	   more	   sophisticated	   strategies	   may	   be	   required	   to	  
correctly	  decide	  who	  may	  benefit	  from	  TNF	  blocking	  strategies.	  
	  
3. The	   timing	   of	   administration	   is	   often	   quite	   variable.	   We	   have	   already	  
discussed	  that	  TNF	  is	  upregulated	  very	  acutely	  in	  response	  to	  stimuli	  such	  as	  
endotoxin	  and	  hence,	   early	  drug	  administration	   to	  block	  TNF	   is	   likely	   to	  be	  
more	  beneficial	   than	   late.	  This	   is	  exemplified	   in	  the	  study	  by	  Abraham	  et	  al	  
that	  used	  a	  p55-­‐IgG	  fusion	  protein	  to	  block	  TNF	  mediated	  effects	  in	  sepsis.	  It	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was	  found	  that	  this	  compound	  led	  to	  better	  outcomes	  when	  administered	  to	  
those	  with	  early	  severe	  sepsis	  as	  opposed	  to	  those	  established	  septic	  shock	  
(173).	   Total	   TNF	   blocking	   agents	   varying	   from	   mouse/humanised	   anti-­‐TNF	  
polyclonal/monoclonal	  antibodies	   to	  p55/p75	   receptors	  and	   fusion	  proteins	  
have	  been	  investigated	  in	  clinical	  trials.	  None	  have	  shown	  significant	  benefit	  
and	   some	   have	   shown	   a	  worsened	   survival,	   in	   particular,	   the	   p75	   receptor	  
fusion	  proteins	  (174).	  These	  have	  been	  prematurely	  applied	  to	  clinical	  studies	  
in	   the	  absence	  of	   true	  mechanistic	   insights	   as	   to	  how	  TNF	   functions	  during	  
the	  various	  stages	  of	  critical	  illness.	  The	  strategy	  to	  produce	  total	  blockade	  of	  
TNF	  signalling	  may	  be	  very	  wrong.	  TNF	  has	  a	   role	   in	  normal	  physiology	  and	  
also	   signals	   through	   two	   receptors,	  which	   have	  distinct	   signalling	   pathways	  
(153).	   Furthermore,	   the	   shedding	   of	   the	   TNF	   receptors	   also	   impacts	   upon	  
their	   ability	   to	   signal	   the	   effects	   of	   TNF	   ligand.	   Hence,	   in	   view	   of	   the	  
complicated	  biology	  of	  TNF	   ligand	  and	   receptors,	   reducing	   the	  downstream	  
effects	  of	  TNF	  ligand	  may	  be	  a	  rather	  naïve	  approach	  and	  a	  targeted	  strategy	  
of	  the	  consequences	  of	  specific	  receptor	  signalling	   in	  specific	  cell	  types	  may	  
be	   better.	   Furthermore,	   research	   into	   the	   precise	   mechanisms	   and	   under	  
which	  circumstances,	  TNF	  and	  its	  receptors	  mediate	  physiologically	  relevant	  
deterioration	  is	  an	  absolute	  necessity.	  
	  
4. There	   is	   a	   lack	   of	   translational	   animal	  models	   of	   critical	   illness	   that	   truly	  
mimic	   the	   clinical	   situation.	   Recently	   for	   sepsis,	   there	   has	   been	   significant	  
controversy	  with	  respect	  to	  the	  extent	  to	  which	  models	  such	  as	  intravenous	  
endotoxin	  and	  caecal	  ligation	  and	  puncture	  mimic	  the	  clinical	  situation	  (180).	  
This	  is	  particularly	  relevant	  in	  view	  of	  the	  failure	  to	  see	  benefit	  from	  Xigris,	  or	  
activated	  protein	  C,	  for	  the	  treatment	  of	  severe	  sepsis	  (181,	  182)	   leading	  to	  
the	  subsequent	  withdrawal	  of	  the	  drug.	  This	  fundamental	  translational	  gap	  is	  
also	   present	   in	   ARDS	   research,	   but	   the	   ARDS	   research	   community	   has	  
published	   multiple	   recent	   reports	   on	   how	   best	   to	   model	   this	   devastating	  
condition	   in	   animals	   (37,	   183-­‐191).	   One	   of	   the	   most	   valuable	   has	   been	   a	  
workshop	   report	   by	   the	   American	   Thoracic	   Society	   and	   this	   is	   summarised	  
later	  in	  this	  chapter	  (192).	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Fundamentally,	   the	   application	   of	   anti-­‐TNF	   therapeutics	   in	   the	   absence	   of	   clear	  
mechanisms	  has	  been	  premature	  and	  detrimental	   to	   the	   translation	  of	  biologics	   in	  
critical	   illness.	   This	   thesis	   concentrates	   on	   the	   pre-­‐clinical	   end	   of	   the	   spectrum	   as	  
defined	  by	  the	  points	  3	  and	  4	  above.	  It	  aims	  to	  identify	  the	  roles	  and	  mechanisms	  of	  
each	  TNF	  receptor	  in	  mediating	  physiologically	  and	  pathologically	  relevant	  effects	  of	  
TNF	  in	  experimental	  ARDS	  and	  attempts	  to	  address	  the	  translational	  gap	  that	  exists	  
between	  the	  pre-­‐clinical	  and	  clinical	  elements	  of	  ARDS.	  	  
	  
1.7 Mechanisms	  of	  TNF	  in	  ARDS	  pathobiology	  
Just	   as	   it	   is	   easier	   to	   reach	   a	   destination	   if	   you	   know	   the	   route	   and	   have	   a	  map,	  
mechanistic	  insights	  into	  how	  TNF	  may	  mediate	  its	  effects	  in	  ARDS	  will	  better	  enable	  
TNF-­‐based	  therapeutics	  to	  be	  successfully	  translated	  and	  applied	  at	  the	  bedside.	  This	  
section	  describes	  the	  experimental	  studies	  that	  have	  so	  far	  discovered	  various	  roles	  
of	  TNF	  in	  ARDS.	  Unsurprisingly,	  TNF	  has	  been	  found	  to	  have	  quite	  divergent	  effects	  
on	   the	   development	   of	   lung	   injury.	   It	   promotes	   endothelial	   and	   epithelial	  
permeability	   leading	   to	   the	   formation	   of	   pulmonary	   oedema,	   but	   in	   contrast	   has	  
been	   found	   to	   enhance	   alveolar	   fluid	   clearance	   mechanisms	   mediating	   the	  
resolution	   of	   pulmonary	   oedema	   (193).	   Its	   classical	   role	   as	   a	   pro-­‐inflammatory	  
cytokine	  is	  also	  well	  established	  and	  these	  aspects	  and	  the	  experiments	  that	   led	  to	  
their	  discovery	  will	  be	  explored	  further	  within	  this	  section.	  	  
1.7.1 TNF	  and	  acid	  aspiration	  
In	  1946	  Curtis	  Mendelson	  first	  described	  the	  aspiration	  of	  stomach	  contents	  leading	  
to	   acute	   pneumonitis	   in	   66	   women	   undergoing	   obstetric	   anaesthesia.	  Within	   this	  
landmark	   observation	   he	   described	   the	   development	   of	   two	   syndromes	   that	  
resulted	   from	   the	   aspiration	   of	   gastric	   contents.	   The	   first	   syndrome	   involved	  
complete	   or	   partial	   laryngeal/bronchial	   obstruction	   leading	   to	   atelectasis	   and	  was	  
responsive	   to	   bronchial	   toilet	   and	   external	   stimulation.	   However,	   the	   second	  
syndrome	  was	  one	  akin	  to	  ARDS	  and	  occurred	  as	  a	  result	  of	  the	  aspiration	  of	  liquid	  
material	   into	   the	   distal	   airspaces.	   This	   led	   to	   an	   “asthmatic-­‐like	   syndrome”	  which	  
progressed	   to	   cyanosis,	   tachycardia	   and	   dyspnoea,	   and	  was	   associated	  with	   X-­‐ray	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changes	   consistent	   with	   alveolar	   consolidation,	   and	   has	   been	   misdiagnosed	   as	  
bronchopneumonia	   or	   primary	   cardiac	   failure	   (despite	   the	   “previous	   normal	  
condition	   of	   the	   heart”).	  He	  went	   onto	   to	   perform	  animal	   experiments	   and	   found	  
that	   within	   this	   condition	   hydrochloric	   acid	   was	   responsible	   for	   this	   pulmonary	  
congestion,	   and	   was	   similar	   to	   chlorine	   and	   phosgene	   induced	   lung	   pathology	  
following	   war	   gas	   injury	   (194).	   Most	   interestingly,	   the	   description	   of	   aspiration	  
pneumonitis	  by	  Mendelson	  preceded	  Ashbaugh’s	  seminal	  description	  of	  ARDS	  (16).	  
Ever	   since,	   aspiration	   pneumonitis	   has	   become	   a	   well-­‐recognised	   complication	  
resulting	   from	   any	   cause	   of	   unconsciousness,	   for	   instance,	   trauma,	   general	  
anaesthesia,	  drug	  overdose	  etc.…	  Hence,	  numerous	  animal	  models	  of	  acid	  aspiration	  
have	   been	   established	   to	   investigate	   this	   phenomenon.	   One	   of	   the	   first	   rodent	  
models	   was	   developed	   and	   characterised	   by	   Kennedy	   and	   colleagues	   in	   rats.	   This	  
found	   experimental	   acid	   aspiration	   to	   follow	   a	   biphasic	   pathogenesis	   showing	   an	  
acute	   physicochemical	   phase	   (<1	   hour)	   and	   a	   second	   neutrophil	   mediated	   phase	  
occurring	  between	  2-­‐4	  hours	  (195).	  	  
	  
Of	  particular	  importance	  to	  the	  work	  presented	  in	  this	  thesis,	  it	  was	  found	  that	  this	  
experimental	  acid-­‐induced	  lung	  injury	  seemed	  to	  be	  an	  excellent	  translational	  model	  
to	   investigate	   the	   role	   of	   TNF,	   corroborating	   clinical	   studies	   showing	   that	   alveolar	  
TNF	  is	  upregulated	  early	  in	  ARDS	  caused	  by	  clinical	  gastric	  aspiration	  (167).	  Goldman	  
and	   colleagues	  were	   the	   first	   to	   apply	   TNF	   antisera	   intravenously	   in	   experimental	  
acid	   aspiration	   and	   showed	   that	   local	   and	   systemic	   leukocyte	   sequestration	   was	  
mediated	   through	   a	   TNF-­‐induced	   increase	   in	   endothelial	   cell	   adhesion	   molecule	  
expression	  (196).	  However,	  this	  study	  also	  suggested	  that	  the	  early	  mechanisms	  (<1	  
hour)	   through	   which	   TNF	   mediated	   barrier	   dysfunction	   after	   acid	   aspiration	   was	  
independent	   of	   neutrophils,	   which	   were	   recruited	   at	   2-­‐3	   hours	   post-­‐insult.	  
Furthermore,	   only	   a	  modest	   reduction	   in	   leukocyte	   sequestration	   (30%)	   could	   not	  
account	  for	  the	  significant	  physiological	  protection	  (60%	  reduction	  in	  oedema)	  seen	  
with	  TNF-­‐alpha	  anti-­‐sera.	  Davidson	  et	  al	  also	  found	  that	  intratracheal	  anti-­‐TNF-­‐alpha	  
antisera	  led	  to	  significant	  reductions	  in	  lung	  injury	  indices	  (protein	  permeability	  and	  
wet/dry	  weight	  ratio)	  as	  well	  as	  neutrophil	   infiltration.	  This	  study	  also	  showed	  that	  
inhibition	  of	   intra-­‐alveolar	  TNF	  also	   led	   to	  an	   improved	  oxygenation	   (197).	  Overall,	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these	   data	   show	   that	   TNF	   is	   important	   in	   acid-­‐induced	   ALI/ARDS	   but	   that	   total	  
blockade	  does	  not	  completely	  ameliorate	  lung	  injury	  and	  that	  alveolar	  targeting	  may	  
be	  more	  beneficial	  in	  that	  some	  relevant	  physiological	  protection	  is	  accrued.	  
1.7.2 TNF	  and	  alveolar-­‐capillary	  permeability	  
TNF	  promotes	  neutrophil-­‐endothelial	   interactions	  through	  a	  variety	  of	  mechanisms	  
including	  complement	  activation	  and	  cell	  adhesion	  molecule	  upregulation	   in	   septic	  
shock.	  As	  a	  result	  of	  this	  data	  from	  experimental	  and	  clinical	  sepsis,	  most	  subsequent	  
research	   focussed	   on	   the	   impact	   of	   circulating	   TNF	   on	   endothelial	   permeability.	  
Stephens	  et	  al	  performed	  one	  of	  first	  studies	  linking	  TNF	  to	  sepsis-­‐induced	  ARDS	  in	  
1988	   (198).	   Within	   this	   study,	   five	   groups	   of	   guinea	   pigs	   were	   studied	   with	   the	  
separate	   groups	   receiving	   an	   inoculum	   of	   E.	   coli,	   LPS	   or	   saline	   and	   two	   further	  
groups	  receiving	  a	  low	  and	  high	  dose	  of	  recombinant	  human	  TNF.	  The	  high	  dose	  of	  
TNF	  led	  to	  similar	  levels	  of	  permeablility	  and	  oedema	  as	  seen	  in	  the	  E.	  coli	  group	  and	  
also	  led	  to	  a	  worsening	  arterial	  oxygenation	  and	  alveolar	  neutrophilia.	  This	  provided	  
the	  first	  notion	  that	  TNF	  could	  contribute	  to	  alveolar-­‐capillary	  permeability	  in	  ARDS.	  
This	   was	   supported	   by	   a	   study	   by	   Horvath	   et	   al	   which	   found	   intravenous	   TNF	   to	  
produce	  pulmonary	  endothelial	  dysfunction	  and	  microvascular	  permeability	  in	  sheep	  
made	  neutropenic	  through	  exposure	  to	  hydroxyurea,	  and	  hence,	  this	  effect	  seemed	  
to	   be	   neutrophil	   independent	   (199).	   Goldblum	   and	   colleagues	   also	   found	   that	   the	  
intravenous	   administration	   of	   recombinant	   human	   TNF	   to	   rabbits	   increased	  
pulmonary	  microvascular	  permeability	  in	  vivo	  with	  increases	  in	  lung	  wet/dry	  weight	  
ratios	   and	   alveolar	   protein	   levels	   (200).	   The	   same	   study	   reported	   an	   increased	  
albumin	  transfer	  in	  pulmonary	  artery	  endothelial	  cell	  monolayers	  suggesting	  a	  direct	  
effect	   of	   TNF	  on	   the	   endothelium.	  However,	   it	   is	   uncertain	   in	   these	   studies	   if	   this	  
effect	  of	  TNF	  was	  a	  result	  of	  direct	  impact	  on	  the	  lung	  or	  an	  indirect	  one	  through	  the	  
induction	  of	  circulatory	  collapse.	  Work	  within	  our	  group	  confirmed	  a	  direct	  effect	  of	  
TNF	  on	  the	  endothelium	  by	  showing	  that	  the	  upregulation	  of	  cell	  adhesion	  molecules	  
on	  pulmonary	  endothelial	  cells	  is	  predominantly	  mediated	  by	  the	  p55	  TNF	  receptor,	  
with	   p75	   mediating	   a	   minor	   role	   (201).	   It	   is	   now	   thought	   that	   the	   impact	   on	  
endothelial	   permeability	   by	   TNF	   is	   mediated	   through	   changes	   in	   microtubule	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arrangements	   within	   endothelial	   cells	   leading	   to	   shape	   changes	   and	   loss	   of	   tight	  
junction	  regulation	  (50).	  
	  
Whilst	   the	   mechanisms	   of	   TNF-­‐induced	   microvascular	   permeability	   are	   well	  
investigated,	   the	   effects	   on	   alveolar	   epithelium	   are	   less	   established.	   The	   first	  
investigation	   found	   TNF	   to	   increase	   epithelial	   permeability	   in	   a	   model	   of	  
Corynebacterium	   parvum	   induced	   alveolitis	   (202).	   This	   study	   found	   epithelial	  
permeability	   peaking	   at	   8	   hours	   with	   an	   associated	   increase	   in	   TNF	   within	   the	  
alveolar	   space.	   Furthermore,	   the	   TNF	  was	   produced	   by	  macrophages,	   rather	   than	  
neutrophils,	  and	  an	  anti-­‐TNF	  antibody	  attenuated	  the	  epithelial	  permeability.	  Hence,	  
the	   authors	   concluded	   that	   macrophage	   derived	   TNF	   played	   a	   major	   role	   in	   the	  
epithelial	  permeability	  induced	  in	  this	  model	  of	  acute	  alveolitis.	  	  
1.7.3 TNF	  and	  alveolar	  fluid	  clearance	  –	  the	  ups	  and	  downs	  
TNF	   has	   been	   shown	   to	   have	   quite	   divergent	   roles	   in	   alveolar	   fluid	   clearance.	   A	  
number	  of	   investigators	  have	   shown	  alveolar	   fluid	   clearance	   (AFC)	   to	  be	   increased	  
through	   TNF-­‐dependent	   mechanisms.	   Rezaiguia	   et	   al	   showed	   in	   a	   model	   of	  
Pseudomonas	   aeroginosa	   pneumonia	   that	   AFC	   was	   enhanced	   through	   a	   TNF	  
dependant	  enhancement	  of	  epithelial	  sodium	  transport	  (193).	  Furthermore,	  TNF	  has	  
been	   shown	   to	   enhance	  AFC	   in	   a	  model	   of	   ischaemia-­‐reperfusion	   injury	   (203)	   and	  
chronic	  bronchial	  inflammation	  induced	  by	  ovalbumin	  (204).	  In	  addition,	  endotoxin,	  
a	  potent	  stimulator	  of	  TNF	  production,	  has	  also	  been	  shown	  to	  enhance	  AFC	  (205).	  	  
	  
These	  experiments	  showing	  that	  TNF	  could	  actually	  reduce	  alveolar	  oedema	  through	  
promoting	   AFC	   surprised	  many	   and	   led	   to	   an	   extensive	   search	   for	  mechanisms	   to	  
explain	  these	  observations.	  A	  major	  breakthrough	  was	  the	  discovery	  of	  a	  lectin-­‐like	  
domain	  on	  the	  TNF	  molecule	   (206),	  a	  site	  on	  the	  molecule	  not	  associated	  with	  the	  
receptor	  binding	  domains,	  and	   implicated	   in	   the	  direct	   trypanocidal	  activity	  of	  TNF	  
through	  lectin-­‐carbohydrate	  interactions	  (207,	  208).	  This	  effect	  was	  independent	  to	  
the	  regions	  that	  associate	  with	  receptor	  binding	  (206).	  Initially	  it	  was	  postulated	  that	  
this	   trypanosomal	   lysing	   activity	   of	   the	   TNF	   could	   be	   due	   to	   an	   ability	   of	   the	   TNF	  
trimer	   to	   penetrate	   cell	  membranes	   in	   a	   pH	   and	   temperature	   dependent	  manner	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(208,	  209),	  forming	  pores	  potentially	  allowing	  itself	  to	  act	  as	  a	  sodium	  channel	  (210,	  
211),	  leading	  to	  influx	  of	  sodium	  with	  subsequent	  lysis.	  Later,	  it	  was	  found	  that	  TNF	  
through	   its	   lectin-­‐like	   domain	   promotes	   membrane	   conductance	   activities	   in	  
endothelia	   and	   peritoneal	  macrophages	   (212)	   by	   interacting	  with	   endogenous	   ion	  
channels	   (213).	   Subsequently,	   Fukuda	  and	   colleagues	   linked	   this	   lectin-­‐like	  domain	  
activation	   of	   ion	   channels	   to	   the	   positive	   effect	   of	   TNF	  on	   alveolar	   fluid	   clearance	  
(214).	  This	  study	  found	  that	  recombinant	  TNF	  upregulated	  AFC	  independent	  of	  beta-­‐
agonist	  mediated	  effects	  but	  dependant	  on	  amiloride	   sensitive	   sodium	  currents.	  A	  
triple	   TNF	   mutant	   (lacking	   the	   lectin-­‐domain	   activity)	   did	   not	   simulate	   alveolar	  
sodium	  and	  fluid	  transport,	  as	  was	  induced	  by	  wild-­‐type	  TNF.	  Elia	  et	  al	  found	  that	  the	  
instillation	  of	  TNF	   in	  mice	   lacking	  both	  TNF	   receptors	   induced	  a	   similar	   increase	   in	  
AFC	  as	  compared	  to	  WT	  animals,	  suggesting	  that	  TNF	  receptor-­‐independent	  effects	  
were	   predominant	   in	   uninjured	   mouse	   lungs.	   Furthermore,	   the	   intratracheal	  
instillation	  of	  an	  Ltip	  peptide	  (which	  mimics	  the	  activity	  of	  the	  lectin-­‐like	  domain	  of	  
TNF	   and	   does	   not	   activate	   either	   TNF	   receptors)	   even	   further	   enhanced	   AFC	   rate	  
(215).	  
	  
Given	  that	  TNF-­‐receptor	  mediated	  signalling	  can	  enhance	  oedema	  formation,	  Braun	  
et	   al	   attempted	   to	   dissect	   the	   pathways	   that	   lead	   to	   TNF’s	   opposing	   role	   in	   lung	  
oedema	  formation	  and	  liquid	  clearance	  (216).	  They	  utilised	  various	  pharmacological	  
compounds	  to	  differentially	  inhibit	  either	  or	  both	  of	  1)	  the	  lectin-­‐like	  domain	  and	  2)	  
the	  receptor	  binding	  sites	  of	  TNF.	  Indeed,	  they	  found	  that	  these	  two	  distinct	  areas	  of	  
the	   TNF	  molecule	  mediate	   quite	   differential	   actions	   on	   the	   ability	   of	   the	   lungs	   to	  
clear	   fluid.	  Firstly,	   in	  their	  setting,	  TNF	  alone	  was	  unable	  to	  enhance	  AFC,	  and	  only	  
did	  so	  when	  the	  TNFR1	  binding	  site	  was	  blocked	  using	  a	  soluble	  p55	  TNFR	  construct.	  
They	  found	  N,N’-­‐diacetylchitobiose,	  a	  carbohydrate	  epitope	  which	  inhibits	  the	  lectin-­‐
like	  domain,	  to	  subsequently	  inhibit	  this	  increase	  in	  AFC.	  Furthermore,	  TNF	  through	  
its	  p55	  TNFR	  receptor-­‐binding	  site	  showed	  deleterious	  effects	  on	  lung	  mechanics	  and	  
inhibition	   of	   AFC,	   suggesting	   opposing	   roles	   for	   TNF	   receptor	   dependant	   and	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To	   summarise	   the	   involvement	   of	   TNF	   in	   AFC	   it	   can	   be	   said	   that	   TNF	   promotes	  
receptor	   independent	   and	   dependent	   effects	   on	   alveolar	   fluid	   clearance.	   The	  
mechanisms	  for	  the	  former	  are	  mediated	  through	  this	  lectin-­‐like	  domain	  of	  the	  TNF	  
trimer	   enhancing	   sodium	   and	   water	   transport.	   The	   Ltip	   compound	   (based	   on	   the	  
lectin-­‐like	  domain)	   is	  currently	  undergoing	  pre-­‐clinical	  studies	  to	  look	  at	  the	  impact	  
of	   this	   (217-­‐219).	   In	   contrast,	   the	   mechanisms	   for	   the	   TNF-­‐receptor	   dependent	  
effects	  that	  lead	  to	  a	  negative	  impact	  on	  alveolar	  fluid	  clearance	  are	  still	  unknown.	  In	  
particular,	   the	   roles	  of	   the	   receptor	  dependant	  downregulation	  of	  AFC	   in	   clinically	  
relevant	   models	   of	   lung	   injury	   has	   not	   been	   discerned.	   This	   requires	   careful	  
investigation	   and	   interpretation	   given	   the	   complex	   nature	   of	   TNF	   ligand	   and	   TNF	  
receptor	  biology	  during	  injury	  (shedding,	  internalisation,	  decoy	  effects)	  during	  tissue	  
injury.	  
1.7.4 Differential	  effects	  of	  TNF	  receptors	  
The	   functional	   relevance	   of	   the	  majority	   of	   TNF	   (soluble	   or	  membrane)	  mediated	  
effects	   is	  meaningless	  without	   an	   appreciation	   as	   to	  how	   these	   are	   transduced	  by	  
the	  receptors.	  This	  aspect	  has	  been	   ignored	   in	   investigations	   looking	  at	   the	  role	  of	  
TNF.	   As	   both	   receptors	   are	   also	   amenable	   to	   shedding	   through	   TACE,	   the	  
physiological	   impacts	  are	  often	  difficult	  to	  discern.	  However,	  over	  the	  past	  decade,	  
the	   development	   of	   mice	   deficient	   in	   either	   or	   both	   of	   the	   TNF	   receptors	   has	  
facilitated	   a	   more	   in	   depth	   analysis	   of	   TNF	   receptor	   mediated	   effects	   in	   multiple	  
disease	  models.	  Peschon	  and	  colleagues	  developed	  single	  and	  double	  TNF	  receptor	  
knockout	   mice	   and	   subjected	   them	   to	   pulmonary	   and	   systemic	   endotoxin	  
administration	   with	   variable	   doses	   (220).	   This	   study	   found	   that	   the	   systemic	  
administration	  of	  endotoxin	  (in	  mice	  sensitised	  by	  D-­‐gal)	  produced	  100%	  lethality	  in	  
WT	  strain	  whereas	  p55	  deficient	   strain	   showed	  no	  mortality.	   In	   contrast	  when	   the	  
endotoxin	   dose	   was	   reduced	   slightly	   to	   produce	   a	   lower	   level	   of	   mortality	   in	  WT	  
animals	   the	   p75	   deficient	   animals	   tended	   to	   a	   slightly	   elevated	   mortality.	   When	  
endotoxin	   was	   administered	   intranasally,	   the	   p75	   deficient	   animals	   showed	  
increased	   neutrophil	   influx.	   Hence,	   this	   suggested	   that	   endotoxin	  mediated	   shock	  
requires	  p55	  and	  not	  p75	  TNFR	  signalling,	  but	  also	  that	  p75	  TNFR	  	  may	  confer	  some	  
protection	  through	  reduced	  inflammation.	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Fontaine	  et	  al,	  found	  that	  the	  two	  TNF	  receptors	  showed	  antagonistic	  functions	  in	  a	  
model	   of	   retinal	   ischaemia.	   This	   study	   showed	   that	   neurodegeneration	   was	  
mediated	   through	   the	   p55	   TNFR	  whereas	   the	   p75	   TNFR	  mediated	   protection	   and	  
that	   this	   protective	   effect	   correlated	   with	   the	   activation	   of	   the	   Akt/PKB	   pathway	  
(162).	  Ebach	  et	  al	  found	  that	  the	  two	  receptors	  showed	  opposing	  effects	  in	  a	  model	  
of	  sepsis	  induced	  by	  caecal	  ligation	  and	  puncture	  (221).	  Al-­‐Lamki	  showed	  differential	  
regulation	  and	  function	  of	  the	  TNF	  receptors	  in	  a	  murine	  heart	  organ	  culture	  model	  
(222).	   They	   showed	   that	  whilst	   signalling	   through	   the	  p55	  TNFR	   induces	   apoptosis	  
and	  mediates	  cell	  death;	  signalling	  through	  the	  p75	  TNFR	  signals	  cell	  cycle	  entry	  and	  
proliferation	   and	   subsequently,	   activates	   repair	   mechanisms.	   Monden	   and	  
colleagues	  examined	  the	  roles	  of	  TNF	  receptors	  in	  a	  model	  of	  myocardial	  infarction	  
and	  found	  that	  ventricular	  dysfunction	  was	  mediated	  through	  p55	  TNFR	  pathways,	  
whereas,	   p75	   TNFR	   deletion	   led	   to	   exacerbated	   injury	   and	   inflammation	   (223).	  
Finally,	  data	  from	  our	  laboratory	  examined	  the	  roles	  of	  these	  receptors	  in	  a	  model	  of	  
alveolar	   oedema	   formation	   induced	   by	   high	   stretch	   mechanical	   ventilation.	   This	  
study	  again	   found	  divergent	   roles	   for	   the	   two	   receptors,	  with	  p55	  TNFR	  mediating	  
injury	  and	  the	  p75	  TNFR	  conferring	  protection	  (224).	  
	  
These	   set	   of	   data	   examining	   the	   roles	   for	   these	   receptors	   during	  models	   of	   acute	  
inflammation	   question	   the	   original	   notion	   of	   the	   p75	   TNFR	   simply	   playing	   an	  
auxiliary	   role	   in	   TNF	   signalling	   through	   the	   ‘ligand	   passing’	   of	   TNF	   to	   its	   p55	  
counterpart	  (152).	  They	  suggest	  that	  not	  only	  is	  injury	  mediated	  specifically	  through	  
the	  p55	  TNFR	  but	  also	  that	  the	  p75	  TNFR	  has	  distinct	  signalling	  pathways	  that	  confer	  
protection.	  Hence,	  overall	   these	  data	   support	   the	   therapeutic	  paradigm	  of	   specific	  
blockade	  at	  the	  p55	  TNFR	  and	  activation	  of	  p75	  TNFR	  signalling,	  as	  opposed	  to	  global	  
TNF/TNFR	  blocking	  strategies.	  
1.7.5 TNF	  and	  the	  Takata	  lab	  
To	   summarise,	   studies	   in	   the	   late	   1980’s	   and	   early	   1990’s	   by	  Goldblum	   (200)	   and	  
Goldman	   (196)	   implicated	   a	   role	   for	   TNF	   in	   the	   formation	   of	   pulmonary	   oedema.	  	  
However,	  since	  these	  investigations	  there	  have	  been	  very	  few	  studies	  that	  dissected	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these	  roles	   further.	  A	  surge	   in	  the	   investigation	  of	  ventilator	   induced	   lung	   injury	   in	  
the	  1990’s	  suggested	  a	  role	  for	  TNF	  in	  this	  form	  of	  lung	  injury,	  although	  studies	  were	  
performed	   using	   conventional	   ventilation	   in	   rabbit	   models	   of	   saline	   lung	   lavage.	  
Takata	  et	  al	  found	  the	  upregulation	  of	  intra-­‐alveolar	  TNF	  gene	  expression	  in	  rabbits	  
ventilated	   with	   conventional	   ventilation	   after	   surfactant	   depletion	   (through	   saline	  
lavage)	   (225).	   Imai	   et	   al	   showed	   that	   the	   intra-­‐tracheal	   application	   of	   an	   anti-­‐TNF	  
antibody	   attenuated	   deteriorations	   in	   oxygenation	   and	   respiratory	  mechanics	   in	   a	  
similar	  rabbit	  model	  (226).	  	  Our	  group	  went	  onto	  show	  that	  TNF	  was	  upregulated	  in	  
the	  alveolar	  space	  in	  a	  mouse	  model	  of	  stretch	  induced	  lung	  injury	  (227,	  228)	  and,	  as	  
discussed,	  induced	  this	  oedema	  formation	  in	  this	  model	  specifically	  through	  its	  p55	  
TNFR	  (224).	  This	  brings	  us	  to	  the	  current	  state	  of	  play	  within	  our	  group.	  	  
	  
The	  aim	  of	  this	  thesis	  was	  to	  ascertain	  if	  this	  differential	  receptor	  signalling	  was	  also	  
true	   in	  other	  models	  of	  ARDS,	  and	  determine	  the	  exact	  mechanisms	  though	  which	  
TNF	   influenced	  oedema.	  Given	  the	   large	  translational	  gap	  that	  exists	  between	  pre-­‐
clinical	  and	  clinical	  studies	  in	  ARDS	  it	  was	  important	  to	  replicate	  such	  a	  phenomenon	  
in	  a	  more	  clinically	  relevant	  model	  of	  ARDS.	  This	  brings	  us	  onto	  the	  next	  section	  of	  
ARDS	   and	   how	   to	   develop	   a	   truly	   translational	  model	  with	   clinically	   relevant	   end-­‐
points.	  
	  
1.8 Pre-­‐clinical	  modelling	  of	  ARDS:	  Mice	  treatments	  work;	  human	  
treatments	  fail…	  50	  years	  of	  frustration.	  
	  
The	  manifestations	  of	  ARDS	  have	  been	  well	  characterised	  in	  humans	  -­‐	  an	  acute	  onset	  
of	   refractory	  hypoxaemia	  secondary	   to	   increased	  permeability	  pulmonary	  oedema.	  
This	  often	  necessitates	  mechanical	  ventilation	  and	  organ	  support.	  Currently,	  there	  is	  
no	  pharmacological	   therapy	   for	  ARDS	  despite	  multiple	   studies	   showcasing	  positive	  
therapeutic	  effects	   in	  animals.	  This	  deficit	   in	  bench	  to	  bedside	  translation	  can	  only	  
be	  addressed	  through	  the	  examination	  of	  the	  translational	  pathway.	  Is	  the	  answer	  as	  
simple	  as	  ‘humans	  are	  more	  complex	  then	  animals’?	  This	  may	  be	  the	  major	  dilemma	  
that	   is	  currently	   limiting	  bench	  to	  bedside	  translation	  of	  therapeutics	  within	  critical	  
care.	  As	  a	  clinician	  performing	  basic	  science	  research,	  certain	  questions	  have	  to	  be	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addressed	   to	   sensibly	   set	   out	   a	   bench	   to	   bedside	   strategy	   in	   critical	   care.	   Are	   the	  
complexities	  of	  ARDS	  not	  very	  well	  reproduced	  in	  pre-­‐clinical	  models?	  Is	  this	  leading	  
to	  a	  lack	  of	  understanding	  in	  the	  pathophysiology	  of	  ARDS	  deterring	  research	  in	  non-­‐
meaningful	   directions?	   Are	   we	   targeting	   the	   wrong	   molecules?	   Are	   potential	  
therapeutics	  applied	  to	  clinical	  studies	  prematurely	  without	  an	  understanding	  of	  the	  
mechanism	   through	  which	   they	  may	  benefit	   patients?	   Is	   the	  patient	   population	   in	  
critical	  care	  too	  heterogeneous	  such	  that	  a	  single	  therapeutic	  intervention	  would	  not	  
lead	  to	  a	  clinically	  relevant	  benefit?	  	  
	  
In	  order	  to	  improve	  our	  understanding	  into	  the	  circumstances	  in	  which	  a	  drug	  would	  
be	  expected	  to	  work	  (or	  more	  importantly,	  not	  work),	  compounds	  need	  to	  be	  tested	  
in	  more	   than	  one	  pre-­‐clinical	  model	  and	  one,	  which	   ideally	   recapitulates	  all	  of	   the	  
relevant	   features	   of	   clinical	   ARDS.	   The	   investigation	   of	   TNF	   mediated	   oedema	  
formation	   in	   a	   pre-­‐clinical	  model	   of	   ARDS	   that	   shows	   all	   the	   characteristics	   of	   the	  
human	   condition	   is	   crucial	   to	   determine	   which	   patients	   may	   benefit	   from	  
manipulation	  of	  a	  specific	  aspect	  of	  a	  pathway.	  The	  determination	  of	  a	  cell	  specific	  
mechanism	  would	  also	  allow	  application	  to	  a	  more	  homogenous	  patient	  population.	  
However,	   this	   requires	   the	   development	   of	   robust	   pre-­‐clinical	   models	   to	   deliver	  
reliable	  and	  reproducible	  data.	  
	  
It	   is	   important	   to	  appreciate	   that	  animal	  models	   can	  and	  will	  never	   reproduce	   the	  
complexities	   of	   the	   human	   condition.	   Examples	   of	   such	   complexities	   include	   the	  
heterogeneous	   causality	   of	   ARDS;	   the	   host	   susceptibilities	   and	   co-­‐morbidities	   (e.g.	  
age	  and	  chronic	  illness);	  the	  kinetics	  of	  human	  ARDS;	  and	  the	  iatrogenic	  influences	  of	  
critical	   care	   (e.g.	   general	   anaesthesia,	   mechanical	   ventilation,	   and	   nosocomial	  
infections).	   Animal	   experiments	   often	  mainly	   investigate	   only	   specific	   aspects	   and	  
targets	  of	  ARDS	  pathogenesis	  (e.g.	  endotoxin	  and	  leukocyte	  mediated	  mechanisms;	  
bleomycin	  and	  mechanisms	  leading	  to	  fibrosis).	  Furthermore,	  only	  certain	  end-­‐points	  
are	  measured	  (e.g.	  neutrophil	  sequestration	  and	  permeability)	  and	  these	  often	  have	  
very	  little	  direct	  relevance	  to	  the	  human	  condition	  given	  that	  patients	  are	  intubated	  
and	   admitted	   to	   ICU	   on	  merit	   of	   their	   clinical	   deterioration	   (mainly	   based	   on	   the	  
extent	   to	   which	   gas	   exchange	   and	   circulation	   is	   compromised).	   Hence	   for	   ARDS,	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more	  emphasis	  on	  respiratory	  physiological	  parameters	  such	  as	  gas	  exchange	  would	  
certainly	   be	   more	   clinically	   applicable	   and	   may	   improve	   experimental	   relevance.	  
Reiss	  et	   al	   have	   recently	  published	  an	  excellent	   review	   supporting	   the	   inclusion	  of	  
gas	   exchange	  measurements	   in	   experimental	   studies	   of	   ARDS	   (188).	   Hence,	  many	  
targets	   have	   been	   shown	   to	   ameliorate	   indices	   of	   ALI	   in	   animals	   that	   are	   often	  
irrelevant	   to	   the	   human	   setting.	   The	   reproducibility	   of	   mechanisms	   in	   multiple	  
animal	  models,	  at	  various	  stages	  (early	  and	  late;	  injury	  and	  resolution),	  focussed	  on	  
clinically	   relevant	  end-­‐points	  of	  ARDS	  would	  surely	   improve	  the	  robustness	   for	  any	  
scientific	  translation	  to	  the	  human	  condition.	  
	  
Nevertheless,	   animal	   models	   provide	   an	   important	   intermediary	   step	   in	   the	  
translational	  pathway	  to	  understand	  the	  pathobiology	  of	  ALI,	  discover	  novel	  targets,	  
investigate	   the	  mechanisms	  of	  action,	  and	   test	  novel	   therapeutic	  compounds	  prior	  
to	  their	  application	  in	  humans.	  One	  major	  hurdle	  is	  that	  most	  preclinical	  models	  do	  
not	   reproduce	   the	  severity	  and	   temporal	  profile	  of	   the	  human	  ARDS.	  For	   instance,	  
most	   models	   only	   enable	   investigation	   into	   the	   acute	   phase	   of	   ARDS	   (within	   48	  
hours)	   but	   not	   into	   the	   later	   phases,	   arguably	   the	   phase	   in	   which	   most	   patients	  
present	   to	   (and	   die	   in)	   the	   ICU.	   Investigation	   of	   early	   phases	   will	   help	   deliver	  
prophylactic/preventative	  therapies	   in	  patients	  with	  a	  high	   likelihood	   in	  developing	  
ARDS	   e.g.	   post	   one-­‐lung	   ventilation;	   witnessed	   aspiration	   etc….	   However,	   much	  
more	   investment	   is	   required	   to	   investigate	   mechanisms	   and	   drug	   effects	   in	  
established	   ARDS,	   in	   particular,	   its	   resolution/repair;	   and	   this	   may	   allow	   more	  
therapeutic	   windows	   to	   be	   available	   during	   these	   complex	   later	   phases	   of	   the	  
syndrome.	  	  
	  
Currently,	  the	  only	  models	  that	  enable	   investigation	  into	  such	  later	  time-­‐points	  are	  
the	  inhaled/intratracheal	  endotoxin,	  pneumonia,	  and	  inhaled	  bleomycin	  model.	  The	  
endotoxin	  model	   utilises	   single	   receptor	   over-­‐activation,	   that	   of	   TLR-­‐4,	   and	   hence	  
may	   bias	   many	   conclusions.	   Indeed,	   TLR-­‐4	   ligation	   within	   this	   model	   leads	   to	  
significant	  neutrophilic	  infiltration	  with	  minimal	  increases	  in	  lung	  water	  content	  and	  
unsatisfactory	  deteriorations	  in	  respiratory	  mechanics	  or	  arterial	  oxygenation.	  In	  our	  
hands,	  high	  dose	  intratracheal	  LPS	  (20μg)	  led	  to	  minimal	  changes	  in	  peak	  inspiratory	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pressure	   and	   arterial	   oxygenation	   over	   3	   hours,	   but	   induced	   significant	   neutrophil	  
infiltration	  (229).	  Most	  pneumonia	  models	  also	  lead	  to	  a	  similar	  pattern	  of	  injury	  but	  
have	   an	   added	   complication	   in	   that	   bacterial	   susceptibilities	   differ	   significantly	  
between	  man	   and	  mouse	   (230,	   231).	  With	   this	   in	  mind,	   these	   first	   two	  models	   of	  
injury,	   albeit	   having	   high	   aetiological	   relevance,	   have	   questionable	   physiological	  
translation	   to	   ARDS	   given	   that	   alveolar	   oedema	   and	   arterial	   hypoxaemia	   is	   mild.	  
They	  may	  be	  more	  appropriate	  models	   for	   the	   investigation	  of	   lung	   infections	  that	  
do	   not	   progress	   to	   ARDS.	   In	   contrast,	   the	   bleomycin	   model	   develops	   significant	  
hypoxaemia	  but	  its	  translatability	  is	  hindered	  by	  the	  severe	  fibrotic	  reaction	  and	  the	  
significant	  variability	  within	  the	  model	  (232).	  Additionally,	  the	  bleomycin	  model	  does	  
not	   induce	   injury	   if	   the	  preparation	   is	  above	  a	  pH	  of	  5.0	   (personal	  correspondence	  
with	  Professor	  Rachel	  Chambers,	  Rayne	  Institute,	  University	  College	  London).	  
1.8.1 The	  ideal	  model	  of	  ARDS	  –	  the	  experts’	  opinion	  
Observational	   clinical	   studies	  allow	  the	  development	  of	  paradigms	  and	  hypotheses	  
with	   regards	   to	   the	   pathogenesis	   of	   ARDS.	   However,	   since	   the	   first	   description	   of	  
ARDS	   by	   Ashbaugh	   in	   1967	   (16),	   in	   which	   the	   majority	   of	   the	   observations	   still	  
remain	  valid	  and	  are	  used	  to	  some	  degree	  in	  the	  most	  recent	  Berlin	  definition,	  there	  
has	  been	  relatively	  little	  advance	  in	  therapy.	  Animal	  models	  allow	  a	  bridge	  between	  
the	  bedside	  and	  the	  bench,	  in	  particular,	  as	  sampling	  (such	  as	  lung	  biopsy)	  is	  fraught	  
with	  difficulty	   in	  patients	  already	  at	  the	  extremes	  of	  respiratory	  physiology.	  Recent	  
developments	   using	   ex	   vivo	   and	   in	   vivo	   human	  models	  will	   strengthen	   this	   divide	  
(74,	  187).	  Ex	  vivo	  models	  utilising	  rejected	  transplant	  lungs	  to	  perform	  ex	  vivo	  lung	  
perfusion	  are	  facilitating	  the	  step	  from	  animal	  to	  human	  experimentation.	  However,	  
given	  these	  organs	  have	  already	  been	  rejected	  for	  transplantation	  there	  is	  significant	  
uncertainty	   as	   to	   the	   heterogenous	   nature	   of	   injury	   and	   care	   of	   organs	   prior	   to	  
experimentation.	  Furthermore,	  limited	  procurement	  may	  reduce	  the	  extent	  to	  which	  
experiments	   can	   be	   performed.	   Although	   they	   also	   prove	   very	   expensive,	   these	  
models	  have	  a	  definite	  role	  in	  the	  translational	  pathway	  between	  mouse	  and	  man.	  In	  
vivo	   human	   models	   of	   lung	   injury	   (such	   as	   inhaled	   endotoxin	   and	   one	   lung	  
ventilation)	  may	  also	  provide	  a	  step	  between	  phase	  1	  studies	  in	  normal	  volunteers	  to	  
phase	  2	   studies	   in	  patients.	   These	   in	   vivo	  models	  are	   conceptual	  models	   that	  may	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allow	   investigation	   of	   distinct	   pathways	   in	   a	   homogenous	   population	   with	   minor	  
injury	   (as	   in	   the	   case	   of	   inhaled	   endotoxin)	   or	   subclinical	   injury	   (given	   that	   the	  
incidence	  of	  ARDS	   is	  only	  2-­‐4%	  and	  8%	   in	  patients	  undergoing	  one-­‐lung	  ventilation	  
for	  lobectomy	  and	  pneumonectomy,	  respectively)	  (187).	  
	  
Regardless,	  correctly	  performed	  experimentation	   in	  robust	  animal	  models	  continue	  
to	  provide	  the	  cleanest	  experimental	  set-­‐ups	  to	  investigate	  mechanisms	  of	  disease.	  
Hence,	   given	   the	   expense	   of	   human	   in	   vivo	   and	   ex	   vivo	   models,	   experiments	  
performed	   in	   animal	  models	   should	   be	   used	   to	   deliver	  more	  mechanistic	   insights	  
into	  the	  pathobiology	  and	  mechanisms	  of	  action	  of	  novel	  compounds	  prior	  to	  human	  
application	   (ex	   vivo,	   in	   vivo,	   or	   patient-­‐based	   studies).	   Importantly,	   the	   expanding	  
potential	   for	   the	   development	   of	   novel	   genetic	   backgrounds	   in	   mice	   to	   elucidate	  
important	   mechanisms	   in	   disease	   pathogenesis,	   makes	   the	   development	   of	   an	  
optimal	  mouse	  ARDS	  model	   even	  more	   valuable.	  Unfortunately,	   there	   is	   no	   single	  
mouse	  model	   that	  recapitulates	  all	  of	   the	  features	  of	  clinical	  ARDS	  with	  many	  only	  
allowing	   focussed	   research	   on	   particular	   aspects	   e.g.	   endotoxin	   and	   neutrophil	  
mediated	  mechanisms	  or	  TLR-­‐4	  mediated	   inflammation;	  bleomycin	  and	  fibrosis.	  An	  
overview	  of	  every	  model	  of	  ARDS	  is	  beyond	  the	  scope	  of	  this	  thesis	  but	  please	  refer	  
to	  an	  excellent	  and	  thorough	  review	  article	  by	  Matute-­‐Bello	  et	  al,	  which	  provides	  an	  
excellent	  update	  of	  animal	  models	  in	  ARDS	  (37).	  	  	  
	  
A	  major	  step	  to	   inform	  the	  research	  community	  as	   to	  what	  constitutes	  ARDS	   in	  an	  
experimental	   setting	  was	   the	   production	   of	   guidelines	   by	   an	   ATS	  workshop	   (192).	  
This	   workshop	   report	   sent	   questionnaires	   to	   22	   international	   experts	   to	   establish	  
opinions	  on:	  
1. Which	  features	  constitute	  ARDS	  in	  animal	  models?	  
2. Which	  measurements	  should	  be	  used	  to	  define	  these	  features?	  
	  
They	   suggested	   that	   the	   main	   features	   required	   of	   an	   animal	   model	   should	   be	   a	  
rapid	  onset	  within	  24	  hours	  of:	  
1. Histological	  tissue	  injury	  
2. Altered	  alveolar	  capillary	  barrier	  function	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3. Inflammatory	  response	  
4. Physiological	  derangement	  
1.8.2 Histological	  evidence	  of	  injury	  
Experimental	  models	  often	  show	  a	  patchy	  distribution	  of	  lung	  damage	  as	  compared	  
to	  the	  classic	  DAD	  found	  in	  human	  ARDS,	  as	  discussed	  previously.	  However,	  it	  can	  be	  
said	  that	  ARDS	  in	  humans	  often	  results	  from	  unilateral	  consolidation	  with	  increased	  
extravascular	   lung	  water	   in	   one	   lung	   that	   spreads	   to	   the	   other.	   No	   animal	  model	  
reproduces	   the	   features	   and	   kinetics	   of	   DAD.	   However,	   it	   is	   also	  well	   known	   that	  
histological	   scoring	   systems	   vary	   considerably	   and	   hence,	   the	   requirement	   of	  
standardised	  blinded	  scoring	  enabling	  comparisons	  of	   injury	  between	  experiments,	  
as	  well	   as,	   between	   groups	  of	   investigators.	   The	  histological	   features	   depend	   very	  
much	  on	  the	  model	  being	  utilised,	  as	  a	  model	  producing	  only	  neutrophil	  infiltration	  
with	   no	   oedema	   formation	   or	   hypoxaemia	   should	   preclude	   it	   from	   representing	   a	  
model	   of	   ARDS	   (188).	   The	   report	   suggested	   a	   strict	  morphometric	   scoring	   system	  
shown	   in	   table	   1.4.	   The	   exact	   details	   of	   the	   score	   are	   described	   in	   the	   methods	  
section.	   It	   is	   import	   to	   appreciate	   the	   propensity	   for	   this	   scoring	   system	   to	   over	  
evaluate	   the	   lung	   injury	   scoring	   in	   models	   that	   induce	   a	   high	   level	   of	   neutrophil	  
recruitment.	  However,	  the	  use	  of	  a	  consistent	  scoring	  system	  may	  enable	  valid	  inter-­‐





Score	  per	  field	  
	  
0	   1	   2	  
i.	  Neutrophils	  in	  the	  alveolar	  space	   None	   1-­‐5	   >5	  
ii.	  Neutrophils	  in	  the	  interstitial	  space	   None	   1-­‐5	   >5	  
iii.	  Hyaline	  membranes	   None	   1	   >1	  
iv.	  Proteinaceous	  debris	  filling	  the	  airspaces	   None	   1	   >1	  
v.	  Alveolar	  septal	  thickening	   None	   2x-­‐4x	   >4x	  
Score	  =	  [20*(i)	  +	  14*(ii)	  +	  7*(iii)	  +	  7*(iv)	  +	  2*(v)]	  /	  (number	  of	  fields	  *	  100)	  
	  
Table	  1.4.	  Lung	  injury	  scoring	  system	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1.8.3 Altered	  alveolar	  capillary	  barrier	  function	  
Hypoxaemia	   is	   always	   present	   in	   ARDS	   (by	   definition)	   and	   is	   mediated	   by	   1)	   an	  
increased	   permeability	   pulmonary	   oedema	   (as	   opposed	   to	   increased	   pulmonary	  
capillary	  pressure	  seen	  in	  cardiogenic	  causes)	  and	  2)	  ventilation/perfusion	  mismatch	  
leading	   to	   increased	   intrapulmonary	   shunt.	   Dysfunction	   of	   the	   alveolar	   capillary	  
barrier	  occurs	  early	  in	  its	  pathogenesis	  and	  leads	  to	  leakage	  of	  plasma	  proteins	  into	  
the	  alveolar	  space.	  There	  are	  a	  variety	  of	  methodologies	  used	   to	  measure	  alveolar	  
capillary	   barrier	   dysfunction.	   The	   most	   common	   is	   the	   measurement	   of	   alveolar	  
protein	   content	   or	   other	   high	   molecular	   weight	   proteins	   such	   as	   IgM.	   This	  
measurement	   is	   suitable	   for	   early	   measurements	   as	   later	   measurements	   may	   be	  
influenced	  by	  alveolar	  fluid	  clearance	  and	  or	  protein	  clearance	  leading	  to	  erroneous	  
readings.	   An	   alternative	   method	   is	   the	   use	   of	   a	   labelled	   protein	   injected	  
intravenously	   and	   its	  measurement	   in	   the	  alveolar	   space	  after	   a	  defined	  period	  of	  
time.	   The	   ratio	   of	   alveolar	   to	   plasma	   label	   allows	   a	   calculation	   of	   a	   permeability	  
index.	   Another	   approach	   is	   the	   measurement	   of	   increased	   lung	   water	   content	  
through	  wet:dry	  weight	  ratio.	  
1.8.4 Inflammatory	  responses	  
Inflammation	   is	   also	   a	   key	   feature	   of	   ARDS,	   although	   whether	   an	   inflammatory	  
response	   is	   responsible	   for,	   or	   a	   response	   to,	   an	  ARDS	   insult	   remains	   unknown.	  A	  
neutrophil	   response	   is	   found	   in	  most	   patients	  with	   ARDS	   and	   there	   are	   increased	  
concentrations	  of	  pro-­‐inflammatory	  mediators	  during	   the	   injurious	  phase	  of	  ARDS.	  
Hence,	   BAL	   counts	   through	   differential	   cytology	   is	   the	   easiest	   route	   for	  
quantification	  of	   inflammatory	  cell	  numbers.	  Additionally,	   through	  a	  morphological	  
analysis	   most	   cell	   types	   can	   be	   generally	   distinguished.	   Another	   method	   of	  
measuring	  cellular	  inflammatory	  activity	  is	  an	  assessment	  of	  myeloperoxidase	  (MPO)	  
activity.	  MPO	  is	  a	  glycoprotein	  expressed	  in	  myeloid	  cells	  and	  most	  abundantly	  in	  the	  
azurophilic	   granules	   of	   activated	   neutrophils.	   Hence,	   the	  measurement	   can	   give	   a	  
surrogate	   marker	   for	   neutrophilic	   inflammation.	   Finally,	   the	   analysis	   of	   BAL	   for	  
soluble	   mediators	   using	   ELISA	   also	   allows	   a	   quantitation	   of	   the	   pro-­‐inflammatory	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These	   are	   very	   basic	   methodologies	   that	   should	   form	   the	   minimum	   of	   any	  
inflammatory	   assessment.	   However,	   although	   BAL	   provides	   alveolar	   localisation,	  
activated	   leukocytes	   are	   often	  more	   adherent	   and	   hence	  may	   not	   be	   recoverable	  
through	  any	   lavage	  procedure.	  This	  so-­‐called	   ‘disappearance	  reaction’	  may	  mislead	  
the	   interpretation	  of	  many	   inflammatory	  measurements.	   Furthermore,	   the	   cellular	  
source	   of	   many	   molecular	   mediators	   cannot	   be	   completely	   apparent.	   Finally,	   the	  
role	   of	   cells	   not	  within	   the	   alveolar	   compartment	   (i.e.	  within	   the	   interstitium	   and	  
vascular	   space)	   cannot	   be	   measured	   using	   the	   lavage	   technique	   and	   more	  
sophisticated	   techniques,	   such	   as	   isolated	   perfused	   apparatus	   (217,	   233-­‐237)	   and	  
intravital	   microscopy	   (238),	   are	   now	   revolutionising	   inflammation	   research.	   The	  
combination	   with	   immunohistochemical	   or	   flow	   cytometric	   techniques	   further	  
enables	   the	   phenotypic	   characterisation	   of	   various	   cell	   types	   but	   also	   the	   cellular	  
expression	   (whole	   cell	   and	   cell	   surface)	   of	   a	   variety	   of	   chemical	   and	   molecular	  
mediators	  e.g.	  cell	  adhesion	  molecules,	  cytokines,	  reactive	  oxygen	  species	  etc.….	  	  
1.8.5 Physiological	  derangement	  
The	  primary	  derangement	  seen	  in	  clinical	  ARDS	  is	  a	  life	  threatening	  deterioration	  in	  
gaseous	  exchange.	  Hence,	  the	  measurement	  of	  an	  increased	  alveolar-­‐arterial	  oxygen	  
difference	  is	  extremely	  relevant.	  However,	  the	  measurement	  of	  oxygenation	  can	  be	  
inconsistent,	   particularly	   in	   rodent	   lungs	   because	   of	   their	   propensity	   to	   collapse.	  
Hence,	   rigorous	   standardisation	   is	   crucial	   and	   should	   include	   standardised	   lung	  
volume	  history	   (i.e.	   recruitment),	  PEEP,	  FiO2,	  and	  anaesthesia/surgical	  preparation.	  
The	  measurement	  of	  respiratory	  mechanics	  also	  requires	  significant	  standardisation	  
to	   robustly	   produce	   consistency	   between	   experiments,	   models,	   and	   time-­‐points.	  
Once	   achieved,	   however,	   these	   can	   provide	   very	   relevant	   indicators	   of	   oedema	  
development	   and/or	   resolution.	   The	   translation	   of	   physiological	   measurements	  
needs	   to	   appreciate	   differences	   between	   mouse	   and	   human	   lung	   physiology.	   In	  
particular,	  differences	  in	  lung	  and	  chest	  wall	  compliance	  between	  humans	  and	  mice	  
have	  major	   impacts	   upon	   the	   development	   of	   lung	   injury.	   This	  was	   apparent	   in	   a	  
recent	  publication	  from	  our	  group	  by	  Wilson	  et	  al,	  which	  showed	  that	  tidal	  volumes	  
shown	  to	  be	  injurious	  in	  human	  ARDS	  do	  not	  necessarily	  induce	  injury	  in	  mice	  (239).	  
Furthermore,	  the	  effects	  of	  mechanical	  ventilation	  of	  mice	  at	  different	  tidal	  volumes	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with	  different	  recruitment	  strategies	  induces	  different	  types	  of	  injury	  i.e.	  ventilator-­‐
induced	  versus	  atelectasis-­‐induced	  lung	  injury.	  Furthermore,	  a	  recent	  study	  from	  our	  
laboratory	   examined	   differences	   in	   injury	   between	   mice	   exposed	   to	   high	   tidal	  
volume	   ventilation	   (30mls/kg)	   with	   PEEP	   (3cmH2O)	   and	   regular	   recruitment	  
(volutrauma)	   with	   mice	   receiving	   low	   tidal	   volume	   (7mls/kg)	   without	   PEEP	   and	  
regular	   recruitment	   (atelectrauma).	   Interestingly,	   these	   two	   groups	   show	   similar	  
degrees	  of	  pulmonary	  oedema	  as	  measured	  by	  BALF	  protein,	  but	  show	  significantly	  
different	   measurements	   of	   respiratory	   system	   elastance	   (237).	   Hence,	   the	  
standardisation	   of	   mechanical	   ventilation	   and	   volume	   history	   before	   basing	  
interpretations	  on	  respiratory	  mechanics	  data	  is	  crucial	  and	  often	  under	  appreciated.	  	  
	  
This	   workshop	   report	   provided	   a	   base	   for	   the	   development	   of	   a	  mouse	  model	   of	  
ARDS	   (as	   shown	   in	  chapters	  6	  and	  7)	   that	   incorporated	  all	  of	   these	  measurements	  
and	  one	  that	  should	  provide	  a	  translational	  platform	  for	  the	  investigation	  of	  various	  
components	   of	   injury,	   inflammation,	   resolution,	   and	   repair.	   In	   particular,	   linking	  
these	   components	   to	   clinically	   relevant	   physiological	   indices	   seen	   in	   patients	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1.9 Hypotheses	  and	  Aims	  
The	  principal	  aims	  of	  this	  work	  were	  two-­‐fold:	  
1. Determine	   the	   mechanism	   by	   which	   TNF	   and	   its	   receptors	   induce	   pulmonary	  
oedema	  during	  the	  acute	  phase	  of	  a	  more	  clinically	  relevant	  experimental	  model	  
of	  ARDS.	  	  
2. Develop	  translational	  mouse	  models	  of	  ARDS	  that	  reproduce	  all	  of	  the	  features	  of	  
the	  clinical	  condition	  but	  importantly	  allowing	  investigation	  of	  TNF	  receptor	  based	  
therapeutics	  in	  the	  later	  phases	  of	  ARDS,	  in	  particular	  resolution	  and	  recovery.	  
	  
1.10 Overview	  of	  thesis	  
The	   data	   presented	   in	   this	   thesis	   is	   a	   continuation	   of	   on	   going	   work	   within	   the	  
laboratory	  to	  elucidate	  the	  roles	  of	  TNF	  and	  its	  receptors	   in	   lung	  injury.	   I	  hope	  this	  
introductory	   chapter	   has	   delivered	   a	   rationale	   as	   to	   how	   we	   got	   to	   where	   we	  
currently	   are	   in	   ARDS	   research,	   in	   particular,	   with	   respect	   to	   TNF,	   and	   the	   many	  
mistakes	   and	   breakthroughs	   that	   have	   been	   made	   to	   unravel	   this	   devastating	  
condition.	   The	   five	   main	   aspects	   covered	   in	   the	   introduction	   (the	   lung	   in	   normal	  
physiology;	   the	   acute	   respiratory	   distress	   syndrome;	   TNF	   biology;	   TNF	   and	   critical	  
illness;	   and	   pre-­‐clinical	   modelling	   of	   ARDS)	   sets	   the	   scene	   for	   the	   aims	   and	  
experiments	  presented	  in	  the	  following	  chapters.	  	  
	  
Chapter	   2	   describes	   the	   methods	   and	   materials	   utilised	   to	   explore	   these	   roles.	  
Methodological	   enhancements	   included	   the	   in	   vivo	   models	   of	   acid-­‐induced	   lung	  
injury,	  the	  development	  of	  a	  protocol	  to	  measure	  alveolar	  fluid	  clearance,	  and	  novel	  
flow	   cytometric	   protocols	   to	   measure	   the	   activity	   of	   cellular	   death	   signalling	   and	  
compartmental	  localisation	  of	  leukocytes.	  
	  
The	  investigation	  of	  aim	  1	  is	  described	  in	  Chapters	  3,	  4,	  and	  5.	  Chapter	  3	  describes	  
the	  development	  of	   an	  acid	  aspiration	  model	   to	   facilitate	   the	   investigation	   for	   the	  
roles	   of	   TNF	   and	   its	   receptors	   during	   the	   acute	   phase	   of	   oedema	   formation	   (0-­‐3	  
hours).	  This	  chapter	  confirms	  that	  differential	  TNF	  receptor	  signalling	  also	  occurs	  in	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acid-­‐induced	   lung	   injury	   with	   the	   p55	   TNFR	   playing	   an	   injurious	   role	   and	   the	   p75	  
TNFR	  potentially	  attenuating	  injury	  and	  inflammation.	  
	  
Chapter	   4	   discusses	   the	   novel	   finding	   that	   p55	   TNFR	   activation	   promotes	   oedema	  
formation	   through	   the	   activation	   of	   death	   signalling,	   as	   opposed	   to	   the	   well-­‐
investigated	   classic	   pro-­‐inflammatory	  pathways.	   The	  activity	  of	   caspase-­‐8	   in	  whole	  
lung	  homogenates	  increases	  dramatically	  within	  90	  minutes	  of	  acid	  aspiration	  in	  WT	  
animals	  but	  is	  attenuated	  in	  p55	  TNFR	  deficient	  animals.	  Furthermore,	  using	  a	  novel	  
flow	  cytometric	  protocol	  utilising	  a	  fluorescent	  caspase-­‐8	  probe,	  this	  chapter	  shows	  
that	  this	  early	  caspase-­‐8	  activity	  is	  confined	  to	  the	  type	  1	  alveolar	  epithelium.	  
	  
Chapter	   5	   links	   the	   TNF/p55-­‐TNFR/caspase-­‐8	   axis	   to	   alveolar	   epithelial	   function	  
through	  the	  measurement	  of	  alveolar	  fluid	  clearance	  (AFC).	  This	  chapter,	  for	  the	  first	  
time,	   describes	   how	   activation	   of	   death	   signalling	   per	   se	   influences	   AFC.	  
Furthermore,	   using	   a	   pharmacological	   approach	   to	   inhibit	   caspase-­‐8	   activation	  we	  
show	   that	   the	   degree	   to	   which	   caspase-­‐8	   is	   activated	   determines	   the	   level	   of	  
deterioration	  in	  AFC.	  Finally,	  to	  confirm	  alveolar	  macrophages	  as	  the	  source	  of	  TNF,	  
we	  depleted	  macrophages	  using	   intra-­‐tracheal	  clodronate	   liposome	   instillation	  and	  
found	  a	  protective	  effect	   through	  a	   reduced	  upregulation	  of	  alveolar	  TNF,	   reduced	  
caspase-­‐8	   activation,	   and	   improved	   AFC	   and	   arterial	   oxygenation.	   The	   early	   time-­‐
points	   and	   lack	   of	   significant	   apoptosis	   display	   a	   novel	   paradigm	   that	   caspase-­‐8	  
signalling	   may	   itself	   determine	   epithelial	   dysfunction	   in	   ARDS,	   as	   opposed	   to	  
completed	  cell	  death	  per	  se.	  
	  
The	  investigation	  of	  aim	  2	  is	  described	  in	  chapters	  6	  and	  7.	  Chapter	  6	  describes	  the	  
development	  of	  a	  model	  of	  acid-­‐induced	  lung	  injury	  allowing	  the	  investigation	  of	  not	  
only	   the	   injurious/inflammatory	  phases	  but	  also	   the	   resolving/reparative	  phases	  of	  
ARDS.	  Given	  our	  initial	  findings	  involved	  a	  very	  early	  time	  point	  (90	  minutes)	  which,	  
was	   prior	   to	   significant	   neutrophil	   infiltration	   into	   the	   lungs,	   it	   was	   important	   to	  
facilitate	  the	  investigation	  into	  more	  later	  phases	  of	  ARDS,	  arguably,	  more	  clinically	  
relevant	   phases.	   Furthermore,	   it	   was	   important	   to	   investigate	   the	   role	   of	  
inflammation	   during	   later	   phases	   in	   determining	   epithelial	   death	   signalling,	   in	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particular,	   given	   that	   many	   patients	   present	   after	   2-­‐3	   days	   as	   opposed	   to	   90	  
minutes.	   This	   model	   provides	   an	   excellent	   translational	   platform	   to	   base	   such	  
mechanistic	  studies	  and	  evaluate	  the	  effects	  of	  potential	  TNF	  based	  pharmacological	  
strategies	   in	   the	   pre-­‐clinical	   arena.	   Given	   the	   importance	   of	   resolution	   and	   repair	  
within	   lung	   injury,	   chapter	   7	   describes	   a	   through	   cellular	   characterisation	   of	   this	  
model	   so	   as	   to	   determine	   the	   leukocytes	   present	   within	   the	   lung.	   Excitingly,	   this	  
chapter	   describes	   a	   novel	   flow	   cytometry	   protocol	   to	   evaluate	   the	   presence	   of	  
leukocytes	  in	  all	  three	  compartments	  of	  the	  lung	  –	  alveolar,	  interstitial,	  and	  vascular.	  
I	  hope	  this	  model	  will	  be	  of	  substantial	  value	  for	  many	  investigators	  in	  this	  field	  given	  
that	   it	   encompasses	   virtually	   all	   of	   the	   recommended	  measurements	   described	   in	  
the	  ATS	  workshop	  discussed	  earlier.	  	  
	  
As	  a	  clinician	  in	  the	  intensive	  care	  I	  feel	   it	   is	  crucial	  to	  investigate	  clinically	  relevant	  
indices	  within	  animal	  models	  and	  hence,	  the	  breadth	  of	  the	  work	  presented	  within	  
this	   thesis.	   Although,	   experiments	   defining	   the	   role	   of	   TNF	   are	   still	   on	   going	   by	  
others	  within	  the	  laboratory	  and	  not	  presented	  herein,	  I	  hope	  this	  is	  the	  beginning	  of	  
my	  journey	  within	  basic	  translational	  research	  in	  ARDS.	  Hence,	  I	  include	  Chapter	  8	  to	  
develop	   a	   final	   overarching	   discussion	   of	   the	   thesis,	   speculating	   on	   potential	  
paradigms,	  and	  elaborating	  on	  the	  future	  experimental	  and	  translation	  approaches	  
that	   may	   be	   pursued	   as	   a	   result	   of	   this	   thesis,	   in	   particular,	   the	   prospects	   of	  
pharmacological	  blockade	  of	  the	  p55	  TNFR	  in	  clinical	  ARDS.	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2 Materials,	  Methods	  and	  Protocols	  
2.1 Materials	  
The	  following	  tables	  describe	  the	  materials	  (reagents	  and	  equipment)	  utilised	  within	  
this	  thesis,	  as	  well	  as	  their	  application	  and	  from	  where	  they	  were	  obtained.	  
2.1.1 Reagents	  
Table	  2.1.	  In	  vivo	  reagents	  
	  
Reagent	   Constituents	   Application	   Source	  
Ketamine	   -­‐	   In	  vivo	   Imperial	  CBS	  
Xylazine	   -­‐	   In	  vivo	   Imperial	  CBS	  
Oxygen	  gas	  (cylinder)	   -­‐	   In	  vivo	   BOC	  
Air	  (piped)	   -­‐	   In	  vivo	   BOC	  
Normal	  Saline	   -­‐	   In	  vivo	   NHS	  supplies	  
Sterile	  water	   -­‐	   In	  vivo	   NHS	  supplies	  
Heparin	   -­‐	   In	  vivo	   Imperial	  CBS	  
Hydrochloric	  acid	  1M	   -­‐	   In	  vivo	   VWR	  
International	  
Bovine	  serum	  albumin	  
(BSA)	  –	  Low	  endotoxin	  
















Table	  2.2.	  Enzyme-­‐linked	  immunosorbant	  assay	  (ELISA)	  reagents	  
	  
Reagent	   Constituents	   Application	   Source	  
ELISA	  assay	  buffer	  
	  
1	  x	  PBS	  	  	  
0.5	  %	  BSA	  (w/v)	  
0.05	  %	  Tween-­‐20	  (v/v)	  




ELISA	  substrate	  reagent	   3,3ʹ′,5,5ʹ′-­‐
Tetramethylbenzidine	  
ELISA	   Invitrogen	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Table	  2.3.	  Flow	  Cytometry	  reagents	  
	  
Reagent	   Constituents	   Application	   Source	  





Flow	  cytometry	  buffer	   PBS	  with	  2%	  FCS	  	  
0.1%	  sodium	  azide	  









Dispase	  enzyme	   -­‐	   Caspase-­‐8	  
localisation	  
Invitrogen	  
DMEM/F12	   -­‐	   Caspase-­‐8	  
localisation	  
Invitrogen	  
HEPES	   -­‐	   Caspase-­‐8	  
localisation	  
Invitrogen	  










Table	  2.4.	  Cytology/histology	  reagents	  
	  
Reagent	   Constituents	   Application	   Source	  
Turk’s	  nuclear	  stain	   Gentian	  violet	  
6%	  acetic	  acid	  
Cytology	   Fisher	  
Scientific	  
4%	  paraformaldehyde	   -­‐	   Fixative	   VWR	  
International	  
Ethanol	   -­‐	   Re-­‐/De-­‐hydrant	   VWR	  
International	  
Xylene	   -­‐	   Re-­‐/De-­‐hydrant	   VWR	  
International	  
Nuclease	  free	  water	   -­‐	   TUNEL	  assay	   Invitrogen	  
Hydrogen	  peroxide	   -­‐	   TUNEL	  assay	   Invitrogen	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2.1.2 Commercial	  detection	  assays	  
Table	  2.5.	  Commercial	  detection	  and	  quantification	  kits	  
	  
Kit	   Constituents	   Source	  
TNF	  Duoset	   Capture	  Antibody	  
Conjugated	  Detection	  Antibody	  	  










Fas	  Ligand	  Duoset	  
Bradford	  protein	  assay	   450	  ml	  dye	  reagent	  (Coomassie	  Brilliant	  
Blue	  G-­‐250)	  	  
BSA	  standard	  
Bio-­‐Rad	  
DiffQuik	   Diff-­‐Quik	  Stain	  I:	  Eosin	  Y	  	  
Diff-­‐Quik	  Stain	  II:	  Thiazine	  Dye	  	  






in	  situ	  apoptosis	  
detection	  set	  
Proteinase	  K	  Solution	  
Terminal	  deoxynucleotidyl	  transferase	  
enzyme	  (TdT)	  Labeling	  Buffer	  
TdT	  Stop	  Buffer	  
B-­‐dNTP	  reaction	  Mix	  
TdT	  Enzyme	  	  
Strep-­‐HRP	  	  
DAB	  Solution	  	  
DAB	  Enhancer	  	  
Anti-­‐BrdU	  antibody	  	  
Strep-­‐Diluent	  	  
TACS-­‐Nuclease	  
TACS-­‐Nuclease	  Buffer	  	  
Methyl	  Green	  Counterstain	  	  
Trevigen	  
	  
Haemoatoxylin	  &	  Eosin	   Mayer’s	  haematoxylin	  
Eosin	  A	  Y	  solution	  
Sigma	  Aldrich	  
Masson’s	  Trichrome	   Biebrich	  Scarlet-­‐Acid	  Fuchsin	  Solution	  
Phosphomolybdic	  Acid	  Solution	  
Phosphotungstic	  Acid	  Solution	  




Fluorometric	  Assay	  Kit	  
Cell	  Lysis	  Buffer	  	  
2X	  Reaction	  Buffer	  	  
IETD-­‐AFC	  (caspase-­‐8)	  	  
LEHD-­‐AFC	  (caspase-­‐9)	  
Dithithreitol	  (DTT)	  	  
Biovision	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2.1.3 Pharmacological	  agents	  
Table	  2.6.	  Agonists,	  antagonists,	  inhibitors	  and	  depletion	  agents	  
	  
Reagent	   Application	   Source	  
Heparin	   In	  vivo	   Imperial	  CBS	  
Amiloride	   Alveolar	  fluid	  
clearance	  
Sigma	  Aldrich	  





Flow	  cytometry	   Immunochemistry	  









2.1.4 Instruments,	  equipment,	  and	  software	  
Table	  2.7.	  In	  vivo	  protocols	  
	  













Physiology	  data	   AD	  Instruments	  
	  
Chart	  software	   Physiology	  data	   AD	  Instruments	  
RapidLab	  248	  blood	  
gas	  machine	  




Table	  2.8.	  Enzyme-­‐linked	  immunosorbant	  assay	  (ELISA)	  protocols	  
	  
Enzyme-­‐linked	  immunosorbant	  assay	  (ELISA)	  protocols	  
Equipment	   Application	   Source	  
ELISA	  washer	   Plate	  washer	   Dynex	  Technologies	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Table	  2.9.	  Flow	  cytometry	  protocols	  
	  
Flow	  cytometry	  protocols	  













Centrifuge	   -­‐	   Kendro	  Lab	  
Products	  
CyAn	  ADP	  analyser	   Flow	  cytometer	   Beckman	  Coulter	  
	  
Table	  2.10.	  Miscellaneous	  equipment	  
	  
Equipment	   Application	   Source	  









microscope	  and	  a	  
digital	  AxioCam	  
camera	  
Light	  microscopy	   Zeiss	  
Olympus	  
	  
Table	  2.11.	  Software	  packages	  
	  
Software	   Application	   Source	  
SPSS	   Statistical	  analysis	   IBM	  
Prism	  v6	  	   Statistical	  analysis	   GraphPad	  
KS300	  v3.0	  
software	  
Histology	   Zeiss	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2.1.5 Flow	  cytometry	  antibodies	  
Table	  2.12.	  Flow	  cytometry	  antibodies	  
	  
Epitope	   Fluorophore	   Clone	   Final	  
concentration	  
Source	  
CD45	   PE	   30-­‐F11	   1/400	   BioLegend	  
	   PerCP	   30-­‐F11	   1/400	   BioLegend	  
	   PE-­‐Cy7	   30-­‐F11	   1/400	   BioLegend	  
CD11b	   PE	   M1/70	   1/400	   BioLegend	  
	   PE-­‐CF594	   M1/70	   1/400	   BD	  Biosciences	  
	   PerCP	   M1/70	   1/400	   BioLegend	  
	   Alexafluor	  647	   M1/70	   1/800	   BioLegend	  
	   APC-­‐eFluor	  780	   M1/70	   1/800	   eBioscience	  
CD11c	   PE-­‐Cy7	   N418	   1/400	   eBioscience	  
	   Alexa	  Fluor	  647	   N418	   1/800	   BioLegend	  
	   APC-­‐eFluor	  780	   N418	   1/800	   eBioscience	  
F4/80	   Alexa	  Fluor	  488	   CI:A3-­‐1	   1/400	   BioLegend	  
NK1.1	   PE-­‐Cy7	   PK136	   1/400	   BioLegend	  
Ly-­‐6C	   FITC	   AL-­‐21	   1/400	   BD	  Biosciences	  
Gr-­‐1	  	  
(Ly-­‐6G/Ly6C)	  
PerCP	   RB6-­‐8C5	   1/400	   BioLegend	  
CD103	   Alexa	  Fluor	  647	   2E7	   1/400	   BioLegend	  
I-­‐A/I-­‐E	  (MHC	  II)	   PerCP	   M5/114.15.2	   1/400	   BioLegend	  
CD4	   Alexa	  Fluor	  488	   L3T4	   1/400	   BioLegend	  
CD8a	   PerCP	   53-­‐6.7	   1/400	   BioLegend	  
CD25	   APC-­‐eFluor	  780	   PC61.5	   1/400	   eBioscience	  
TNFR1	   APC	   55R-­‐286	   1/25	   AbD	  Serotec	  
TNFR2	   APC	   TR75-­‐	  89	   1/25	   AbD	  Serotec	  
CD176	  	  
(Fas	  Ligand)	  
APC	   MFL3	   1/25	   eBioscience	  
TNFR1/2/Fas	   APC	   Armenian	   1/25	   eBioscience	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ligand	  Isotype	   hamster	  IgG	  
CD31	  (PECAM)	   Alexa	  Fluor	  647	   MEC	  13.3	   1/1000	   BioLegend	  
EpCAM	   PE	   G8.8	   1/400	   eBioscience	  
T1-­‐alpha	   PE-­‐Cy7	   8.1.1	   1/1000	   eBioscience	  
	  
2.2 Animals	  
All	  protocols	  were	  approved	  by	  the	  Ethical	  Review	  Board	  of	  Imperial	  College	  London	  
and	   the	   United	   Kingdom	   Home	   Office	   in	   accordance	   with	   the	   Animals	   (Scientific	  
Procedures)	  Act	  1986,	  United	  Kingdom.	  The	  project	  utilizes	  C57BL6	  wild	   type	   (WT,	  
Charles	   River,	   Margate,	   UK),	   p55	   TNF	   receptor	   knockout	   (p55KO,	   Jackson	  
Laboratories,	  USA),	  p75	  TNF	  receptor	  knockout	  (p75KO,	  Jackson	  Laboratories,	  USA),	  
or	   TNF	   receptor	  double	   knockout	   (DKO,	   Jackson	   Laboratories,	  USA)	  mice	   (220).	  All	  
mice	  were	  bred	  in	  house	  to	  between	  8	  and	  18	  weeks	  old	  and	  weighed	  between	  20-­‐
30g.	   Animals	   had	   free	   access	   to	   food	   and	   water.	   Genetically	   deficient	   animals	  
underwent	  genotyping	  at	  the	  start	  of	  the	  work.	  Given	  that	  surface	  expression	  of	  TNF	  
receptors	   were	   easily	   detectable	   using	   flow	   cytometry,	   animals	   also	   underwent	  
more	   frequent	   phenotyping	   (6-­‐monthly)	   to	   measure	   cell	   surface	   TNFR	  
expression/non-­‐expression.	  
	  
2.3 In	  vivo	  models	  of	  acid-­‐induced	  lung	  injury	  
Two	  models	  of	  acid	  aspiration-­‐induced	   lung	   injury	  were	  developed	  for	   this	  project.	  
The	   first	   involved	   acid	   aspiration	   followed	   by	   mechanical	   ventilation	   and	   was	  
primarily	  to	  investigate	  the	  acute	  phase	  of	  the	  injury	  (0-­‐3	  hours).	  The	  second	  model	  
was	   designed	   to	   allow	   investigation	   into	   later	   phases	   (0-­‐10	   days)	   after	   acid	  
aspiration.	   Both	   models	   involved	   mechanical	   ventilation	   to	   varying	   degrees	   for	  
measurement	  of	  respiratory	  mechanics.	  
Chapter	  2	  
Materials,	  methods	  &	  protocols	  
	   94	  
2.3.1 In	  vivo	  mechanical	  ventilation	  
Surgical	  preparation	  
Mice	   were	   anaesthetised	   using	   intraperitoneal	   ketamine	   (80mg/kg)	   and	   xylazine	  
(8mg/kg).	   Mice	   underwent	   tracheostomy	   and	   were	   ventilated	   with	   non-­‐injurious	  
8ml/kg	   tidal	   volume	   (VT),	   2.5-­‐3.0	   cmH2O	   positive	   end-­‐expiratory	   pressure	   (PEEP),	  
and	   respiratory	   rate	   (RR)	   of	   120	   breaths/minute	   using	   a	   custom-­‐made	   mouse	  
ventilator-­‐pulmonary	  function	  testing	  system	  with	  FiO2	  of	  1.0.	  	  In	  some	  experiments	  
the	   left	   carotid	   artery	   was	   cannulated	   for	  monitoring	   arterial	   blood	   pressure	   (BP)	  
and	  blood	  gases	  (ABG),	  and	  for	  saline	  infusion	  (0.4ml/hr).	  	  
Ventilator	  system	  
A	  flow-­‐controlled,	  time-­‐cycled	  jet	  ventilation	  system	  (photo	  2.1)	  was	  used	  to	  give	  a	  
predefined	  VT.	  In	  this	  custom-­‐made	  system,	  flow	  is	  generated	  from	  a	  high-­‐pressure	  
gas	   cylinder	   through	   the	   high	   resistance	   flow	   regulator.	   Thus,	   contact	   flow	   is	  
delivered	  when	   the	   inspiratory	   valve	  opens,	   regardless	   to	   the	   stiffness	  of	   the	   lung	  
connected	   to	   the	   ventilator.	   The	   inspiratory	   flow	   is	   measured	   by	   a	   pneumotache	  
(placed	   just	  before	   the	   tracheal	   tube),	  and	  adjusted	  by	   the	   flow	  regulator.	  A	   time-­‐
cycling	  ventilator	  controls	  inspiratory	  and	  expiratory	  solenoid	  valves	  and	  provides	  an	  
inspiratory:expiratory	  ratio	  of	  1:2.	  An	  end-­‐inspiratory	  occlusion	  technique	  is	  used	  to	  
measure	  respiratory	  mechanics	  (see	  section	  2.5.1).	  
	  
Chapter	  2	  
Materials,	  methods	  &	  protocols	  
	   95	  
	  
Figure	   2.1.	   Set	   up	   for	   mouse	   cardiorespiratory	   monitoring	   and	   mechanical	  
ventilation	  
	  
2.3.2 Acute	  acid	  aspiration:	  0-­‐3	  hours	  (relevance	  to	  chapters	  3/4/5)	  
After	   surgical	   preparation	   mice	   were	   ventilated	   as	   described	   above.	   Once	  
instrumentation	  was	  complete,	  baseline	  blood	  gases,	  peak	  inspiratory	  pressure	  (PIP)	  
and	  respiratory	  mechanics	  were	  recorded.	  Subsequently,	  50µl	  of	  0.15M	  HCl	  (pH<1.5)	  
or	  0.9%	  NaCl	  was	  instilled	  via	  the	  endotracheal	  tube	  using	  an	  intra-­‐tracheal	  catheter.	  
This	  was	  immediately	  followed	  by	  5	  sustained	  inflations	  of	  30cmH2O	  to	  ensure	  distal	  
pulmonary	  distribution	  of	  the	  acid.	  Subsequently	  ventilation	  was	  continued	  until	  the	  
specified	   time-­‐point	   for	   the	   experiment	   (no	  more	   than	   3	   hours).	   The	   volume	   and	  
molarity	   of	   the	   acid	   was	   initially	   determined	   by	   dose	   titration	   experiments	   (see	  
figure	  3.1)	   to	  attain	  a	  100%	   increase	   in	   respiratory	  elastance.	  Airway	  pressure,	  gas	  
flow,	   and	   mean	   BP	   were	   continuously	   monitored	   throughout	   the	   experimental	  
protocol,	  while	   respiratory	  mechanics	   and	   ABGs	  were	   assessed	   at	   pre-­‐determined	  
intervals.	   Sustained	   inflation	   of	   30cmH2O	   for	   5	   seconds	   was	   performed	   every	   30	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2.3.3 Resolution	  phase	  acid	  aspiration:	  0-­‐10	  days	  (relevance	  to	  chapters	  6/7)	  
WT	   male	   C57BL6	   mice	   aged	   10–12	   weeks	   were	   anaesthetised	   by	   intraperitoneal	  
injection	   of	   xylazine	   (6mg/kg)	   and	   ketamine	   (60mg/kg).	   At	   this	   point,	   a	   20µl/g	  
intraperitoneal	  fluid	  bolus	  of	  normal	  saline	  was	  administered.	  
Injury	  Induction	  
Anaesthetised	  mice	  were	  then	  vertically	  suspended	  on	  a	  custom	  made	  mount	  from	  
their	  incisors	  using	  a	  2/0	  suture	  (photo	  2.2).	  A	  non-­‐thermal	  light	  source	  was	  used	  to	  
transilluminate	  the	  trachea.	  Careful	  retraction	  of	  the	  tongue	  and	  laryngoscopy	  using	  
blunt	  curved	  forceps	  allowed	  a	  grade	  1-­‐2	  view	  of	  the	  vocal	  cords	  (photo	  2.2).	  A	  fine	  
catheter	   was	   subsequently	   guided	   1cm	   below	   the	   vocal	   cords	   and	   75µl	   of	   an	  
isoosmolar	   (to	   mouse	   plasma	   -­‐	   322mosmol/L)	   0.1M	   hydrochloric	   acid	   (pH	   1.0)	  
solution	  was	   instilled.	  Animals	  were	   left	  suspended	  for	  one	  minute	  and	  placed	   in	  a	  
custom-­‐made	   murine	   high	   dependency	   recovery	   area	   (photo	   2.3).	   During	   this	  
recovery	   period	   they	   were	   actively	   warmed	   and	   given	   humidified	   gases	   with	  
reducing	   FiO2	   from	   1.0	   to	   0.21	   over	   4	   hours.	   To	   ensure	   even	   distribution	   of	   the	  
instillate	  mice	  were	  rotated	  every	  5	  minutes	  until	  spontaneously	  moving.	  After	  this	  
recovery	   period	   they	   were	   placed	   in	   isolated	   ventilated	   cages	   with	   air	   and	   free	  
access	  to	  food	  and	  water.	  After	  predefined	  time-­‐points	  (days	  after	  acid	   instillation)	  
some	   animals	   underwent	   anaesthesia	   and	   instrumentation	   (as	   described)	   to	  
measure	   respiratory	   mechanics	   and	   arterial	   oxygenation.	   In	   animals	   where	   no	  
respiratory	  physiology	  measurements	  were	  performed	  then	  animals	  were	  sacrificed	  
under	  terminal	  anaesthesia.	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Figure	  2.2.	  Set	  up	  for	  orotracheal	  instillation	  of	  substances	  
	  
	  
Figure	  2.3.	  Mouse	  recovery	  unit	  
2.3.4 In	  vivo	  labelling	  of	  lung	  compartments	  (relevance	  to	  chapter	  7)	  
Chapter	  7	  describes	  an	  in	  vivo	  labelling	  approach	  to	  identify	  leukocyte	  subsets	  in	  the	  
various	  compartments	  of	  the	  lung	  to	  investigate	  the	  number,	  localisation,	  phenotype	  
and	   function	   of	   leukocytes	   in	   healthy	   and	   injured	  mouse	   lungs.	   Anaesthetised	  WT	  
mice	  underwent	  instillation	  of	  hydrochloric	  acid	  as	  described	  in	  the	  resolution	  phase	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right	  external	  jugular	  vein	  cannulation	  through	  which	  2µg	  of	  a	  PE	  anti-­‐CD45	  antibody	  
(diluted	   in	   100µl	   sterile	   PBS)	   was	   injected.	   At	   the	   same	   time,	   animals	   underwent	  
systemic	   anticoagulation	   and	   five	   minutes	   after	   injection	   of	   the	   antibody	   animals	  
were	   exsanguinated	   under	   terminal	   anaesthesia.	   The	   thoracic	   cavity	   was	   exposed	  
through	   a	   midline	   sternotomy	   and	   the	   lungs	   gently	   teased	   from	   their	   pleural	  
adhesions.	  Subsequently,	  5-­‐0	  silk	  sutures	  was	  placed	  carefully	  around	  the	  right	  and	  
left	  main	  bronchi.	  One	  or	  both	  lungs	  underwent	  instillation	  with	  0.5ml	  or	  1ml	  sterile	  
PBS	  containing	  2µg	  of	  a	  PE-­‐Cy7	  anti-­‐CD45	  antibody	  and	  removed	  from	  the	  thoracic	  
cavity.	  Lungs	  remained	  exposed	  to	  the	  intratracheal	  antibody	  for	  5	  minutes.	  Whole	  
blood	  was	  also	  attained	  for	  analysis	  via	  the	  external	   jugular	  venous	  cannula	  and/or	  
cardiac	   puncture.	   Lungs	   were	   processed	   using	   the	   flow	   cytometry	   protocol	   as	  
described	  later	  in	  section	  2.6.3.	  The	  precise	  gating	  and	  identification	  strategies	  used	  
to	   determine	   the	   specific	   cell	   types	   and	   their	   compartmental	   localisation	   are	  
described	  in	  detail	  in	  chapter	  7.	  
	  
2.4 Harvesting	  of	  experimental	  samples	  
2.4.1 Bronchoalveolar	  lavage	  
At	   the	   end	   of	   each	   protocol,	   mice	   were	   sacrificed	   via	   intra-­‐arterial	   anaesthetic	  
overdose.	  BALF	  was	  sampled	  with	  750µl	  of	  normal	  saline	  if	  both	  lungs	  were	  lavaged	  
or	   400µl	   if	   unilateral	   lavage	   was	   being	   performed.	   During	   unilateral	   lavage,	   a	  
thoracotomy	  was	  performed	  and	  the	  left	  main	  bronchus	  identified	  and	  tied	  off.	  The	  
recovered	  BAL	  was	   transferred	   to	   an	  Eppendorf	   and	   centrifuged	  at	   1500rpm	   for	  5	  
minutes	  at	  4oC.	  The	  supernatant	  was	  pipetted	  off	  and	  aliquots	  stored	  at	  -­‐80oC.	  Cells	  
in	  BALF	  were	  counted	  by	  haemocytometer,	  and	  differential	  cytology	  was	  performed	  
on	  DiffQuik-­‐stained	  samples	  prepared	  by	  cytospin	  (Shandon	  Runcorn,	  UK).	  
2.4.2 Blood/plasma	  	  
Blood	  was	  sampled	  using	  a	  syringe	  containing	  10	   international	  units	  (iu)	  of	  heparin	  
by	   either	   cardiac	   puncture	  or	   through	   any	   external	   jugular	   or	   carotid	   arterial	   lines	  
that	   had	   been	   inserted	   during	   the	   protocol.	   This	   was	   placed	   into	   Eppendorfs	   for	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centrifugation	  at	   4000rpm	   for	   5	  minutes	   at	   4oC.	   The	   supernatant	  was	  pipetted	  off	  
and	  aliquots	  stored	  at	  -­‐80oC.	  
2.4.3 Lung	  tissue	  preparation	  
Lungs	  were	  carefully	  dissected	  to	  ensure	  minimal	  trauma.	  They	  were	  detached	  from	  
their	   surrounding	   ligatures	   and	   removed	   by	   identifying	   the	   respective	   bronchi	  
supplying	  each	  lobe,	  ligating	  as	  close	  as	  possible	  to	  the	  lung	  tissue,	  thus,	  ensuring	  the	  
removal	  of	  all	  peri-­‐bronchial	  lymphoid	  tissue.	  Furthermore,	  to	  standardise	  (as	  much	  
as	  possible)	  the	  influence	  of	  blood	  within	  the	  pulmonary	  vasculature,	  animals	  were	  
systemically	   anti-­‐coagulated	   (20iu	   heparin)	   and	   exsanguinated	   through	   the	  
transection	   of	   major	   vessels	   leading	   to	   and	   arising	   from	   the	   heart	   (internal	   and	  
external	   jugular	   veins,	   internal	   carotid,	   inferior	   vena	   cava,	   and	   aorta).	   Three	  
recruitment	  manoeuvres	  led	  to	  the	  release	  of	  blood	  from	  the	  transected	  vessels	  and	  
hence,	  ensured	  the	  emptying	  of	  pulmonary	  vessels	  present	  in	  West’s	  zone	  2	  and	  3.	  
Retrieved	   lungs	   underwent	   a	   number	   of	   analyses	   including	   assessment	   of	  wet/dry	  
weight,	   flow	   cytometric	   and	   some	   lungs	   were	   snap	   frozen	   in	   liquid	   nitrogen	   and	  
stored	  at	  -­‐80oC	  for	  later	  analysis.	  
	  
2.5 Physiological	  measurements	  
2.5.1 Respiratory	  mechanics	  
The	  mechanical	  properties	  of	  the	  lung	  can	  be	  described	  in	  terms	  of	  its	  resistive	  and	  
elastic	  properties.	  Respiratory	  mechanics	  were	  measured	  using	   the	  end-­‐inspiratory	  
occlusion	  technique,	  as	  described	  by	  Ewart	  et	  al	   (240),	  which	  allows	  differentiation	  
between	  these	  elements	  of	  the	  lungs.	  This	  involves	  both	  solenoid	  valves	  being	  closed	  
and	   producing	   zero	   flow	   at	   the	   end	   of	   inspiration.	   This	   allows	   calculation	   of	   the	  
elastic	  and	  resistive	  components	  of	  the	  respiratory	  system	  through	  measurement	  of	  
airway	  pressure	  and	  gas	  flow	  (figure	  2.4).	  This	  was	  of	  particular	   importance,	  as	  the	  
intratracheal	   instillation	   of	   fluid	   will	   affect	   both	   components	   and,	   both	   influence	  
peak	  inspiratory	  pressure	  readings.	  Preliminary	  experiments	  in	  both	  models	  showed	  
increases	   in	   respiratory	   system	   elastance	   (Ers)	   with	   increasing	   acid	   molarity	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  Figure	  2.4.	  Measurement	  and	  calculation	  of	  respiratory	  mechanics	  
	  
2.5.2 Arterial	  blood	  gas	  analysis	  
After	   tracheostomy	   and	   low	   tidal	   volume	   ventilation,	   the	   left	   internal	   carotid	  was	  
exposed	  and	  cannulated.	  This	  was	  attached	  to	  a	  pressure	  transducer	  and	  a	  syringe	  
pump,	   through	   which	   an	   infusion	   of	   heparinised	   saline	   was	   continuously	  
administered	   (0.4ml/hr).	   This	   enabled	   measurement	   of	   blood	   pressure	   as	   well	   as	  
arterial	   blood	   gas	   analysis.	   Blood	   (approx.	   70µl)	   was	   sampled	   using	   a	   heparinised	  
capillary	   tube	   and	   analysed	   with	   a	   RapidLab	   248	   blood	   gas	   analyser.	   After	   blood	  
sampling	   a	   75µl	   bolus	   of	   heparinised	   saline	  was	   administered	   through	   the	   carotid	  
line.	  
2.5.3 Wet/Dry	  weight	  assessment	  	  
Left	   lungs	   were	   removed	   and	   briefly	   rinsed	   in	   saline	   and	   blotted.	   They	   were	  
immediately	  weighed	  and	  subsequently	  dried	  at	  60oC	  for	  24	  hours,	  after	  which	  they	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2.5.4 Protein	  Assay	  
BALF	   protein	  measurement	  was	   performed	   using	   the	   Bradford	  method	   as	   per	   the	  
BioRad	   protein	   assay	   kit.	   The	   kit	   utilises	   the	   shift	   in	   absorption	   of	   light,	   which	   is	  
proportional	  to	  the	  extent	  to	  which	  the	  dye	  Coomassie	  Brilliant	  Blue	  G-­‐250	  binds	  to	  
protein.	   Standards	  of	  BSA	  were	  prepared	   through	   serial	  dilution	  and	  both	   samples	  
and	  standards	  were	  analysed	  in	  triplicate.	  The	  dye	  reagent	  was	  added	  to	  each	  well	  
and	  plates	  analysed	  after	  10	  minutes	  using	  a	  colorimetric	  plate	  reader.	  
2.5.5 Lung	  permeability	  index	  
Some	  animals	  underwent	  insertion	  of	  a	  right	  external	  jugular	  line	  for	  administration	  
of	  100µl	  of	  AlexaFluor	  594-­‐conjugated	  albumin	   (Invitrogen).	  This	  was	  administered	  
at	   30	   minutes	   before	   the	   end	   of	   the	   experiment.	   After	   termination	   of	   the	  
experiment,	  blood	  and	  BALF	  were	   sampled	  as	  described	  above.	  Neat	   supernatants	  
(50µl)	  (and	  saline	  for	  blank	  control	  wells)	  were	  pipetted	  into	  a	  black	  96-­‐well	  plate	  in	  
triplicate.	  Alveolar-­‐capillary	  barrier	  permeability	  index	  was	  calculated	  by	  the	  ratio	  of	  
spectroscopic	  analysis	  (Biotek)	  of	  BALF:plasma	  fluorescence.	  
	  
2.6 Inflammatory	  measurements	  
2.6.1 ELISA	  
BALF	   levels	   of	   soluble	   mediators	   (TNF,	   IL-­‐6,	   MIP-­‐2,	   KC,	   MCP-­‐1,	   RAGE,	   FasL)	   were	  
measured	  with	  sandwich	  ELISA.	  All	  measurements	  were	  performed	  using	  a	  validated	  
Duoset	   ELISA	   (R&D).	   96-­‐well	   plates	   were	   coated	   overnight	   with	   respective	   anti-­‐
mouse	   capture	   antibody	   diluted	   in	   PBS.	   After	   blocking	   and	   washing,	   50µl	   of	  
standards	  and	  samples	  were	  added	  in	  duplicate	  and	  incubated	  at	  room	  temperature	  
for	  2	  hours.	  Respective	  biotinylated	  detection	  antibodies	  were	  added	  after	  washing	  
and	  again	  incubated	  at	  room	  temperature	  for	  2	  hours.	  Horseradish	  peroxidase	  (HRP)	  
was	  added	  after	  washing	  and	   incubated	   for	  20	  minutes.	  After	  a	   final	  wash	  cycle,	  a	  
substrate	  mixture	  (3,3ʹ′,5,5ʹ′-­‐Tetramethylbenzidine	  (TMB)	  –	  Sigma	  Aldrich)	  was	  added	  
for	   colour	   development	   over	   20-­‐30	  minutes	   at	  which	   point	   2N	   sulphuric	   acid	  was	  
used	  as	  a	  stop	  solution.	  The	  plate	  was	  then	  read	  at	  450nm	  in	  a	  MRX	  II	  absorbance	  
colorimetric	  plate	  reader.	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2.6.2 Lung	  cytology	  
BAL	  was	  centrifuged	  as	  described	  above	  to	  attain	  BALF	  supernatant.	  The	  cell	  pellet	  
was	   resuspended	   in	   500µl	   of	   0.9%	   NaCl,	   of	   which	   120µl	   was	   used	   for	   cytospin	  
preparation	   and	   50µl	   was	   stained	   with	   10µl	   of	   Turk’s	   nuclear	   stain	   for	  
haemocytometer	   counts.	   Differential	   cytology	   was	   performed	   on	   DiffQuik	   stained	  
cytospin	  slides	  and	  proportions	  of	  leukocytes	  were	  attained	  with	  counts	  up	  to	  a	  total	  
of	   300	   cells	   per	   slide.	   The	   total	   BAL	   cell	   count	   was	   attained	   through	  
haemocytometric	   analysis	   allowing	   the	   calculation	   of	   numbers	   of	   individual	  
leukocyte	  populations	  based	  on	  cellular	  morphology.	  
2.6.3 Lung	  leukocyte	  quantification	  using	  flow	  cytometry	  
Flow	   cytometry	   was	   utilised	   to	   determine	   leukocyte	   numbers	   and	   phenotype	   in	  
whole	  lung	  single	  cell	  suspension.	  	  
Preparation	  of	  single	  cell	  suspension	  
Lungs	   underwent	   mechanical	   disruption	   using	   a	   GentleMacs	   tissue	   dissociator	  
(Miltenyi	   Biotec)	   for	   1	   minute	   in	   2mls	   of	   intracellular	   (IC)	   fixative.	   This	   technique	  
allows	   immediate	   fixation	   and	   dissociation	   enabling	   the	   best	   stability	   of	   epitopes.	  	  
The	   fixation	   reaction	   was	   stopped	   through	   the	   addition	   of	   20mls	   of	   ice-­‐cold	   flow	  
cytometry	  wash	  buffer	  (FWB	  -­‐	  PBS	  with	  2%	  FCS,	  0.1%	  sodium	  azide,	  and	  5mM	  EDTA).	  
The	   suspension	  was	   subsequently	   sieved	   through	   a	   40µm	   filter	   and	  washed	   again	  
with	  ice-­‐cold	  20mls	  FWB.	  The	  lung	  cell	  suspension	  was	  subsequently	  centrifuged	  at	  
4oC	  at	  200rpm.	  The	  cell	  pellet	  was	  resuspended	  in	  1ml	  of	  FWB	  and	  placed	  on	  ice.	  	  
Staining	  protocols	  
Extracellular	   staining	   was	   performed	   by	   incubation	   of	   single	   cell	   suspension	   with	  
fluorochrome-­‐conjugated	   antibodies	   for	   30	   minutes	   in	   the	   dark	   at	   room	  
temperature	   or	   4oC,	   dependant	   on	   experimental	   protocol.	   Antibody	   stocks	   were	  
prepared	   in	   FWB	   to	   attain	   the	   final	   concentrations	   stated	   in	   table	   2.12.	   After	  
incubation	   4mls	   of	   FWB	   was	   added	   to	   stop	   the	   antibody	   reaction	   and	   samples	  
centrifuged	  at	   2000rpm	  at	   4oC	   for	   5	  minutes.	   Cells	  were	   resuspended	   in	   FWB	  and	  
kept	   on	   ice	   until	   analysed	   using	   a	   7-­‐channel	   CyAn	   ADP	   flow	   cytometer	   (Beckton	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Coulter).	   Prior	   to	   analysis	   the	   addition	   of	   AccuCheck	   counting	   beads	   (Invitrogen)	  
enabled	  cell	  counts	  to	  be	  calculated.	  
Cell	  identification	  
The	   leukocytes	   analysed	   during	   the	   acute	   phase	   acid	   aspiration	   included	   resident	  
alveolar	  macrophages,	   neutrophils	   and	  monocytes.	   Resident	   alveolar	  macrophages	  
were	   identified	   as	   CD45+F4/80+CD11c+CD11b-­‐	   population	   with	   high	   auto-­‐
fluorescence.	   Neutrophils	   and	   monocytes	   were	   gated	   using	   CD45+CD11b+NK1.1-­‐	  
events	  with	  subsequent	  gates	  separating	  these	  two	  cell	  types.	  Both	  neutrophils	  and	  
monocytes	  express	  the	  marker	  Gr-­‐1	  and	  this	  consists	  of	  two	  main	  fragments	  –	  Ly-­‐6C	  
and	   Ly-­‐6G.	   Both	   fragments	   are	   required	   for	   the	   recognition	   by	   the	   Gr-­‐1	   antibody	  
used	   in	   these	  experiments	   (clone	  RB6-­‐8C5).	  Mouse	  monocytes	  are	  classified	   into	  2	  
types:	   inflammatory	   (Ly-­‐6Chi,	   Gr-­‐1hi,	   CCR2hi,	   CX3CR1lo)	   and	   non-­‐inflammatory	   (Ly-­‐
6Clo,	  Gr-­‐1lo,	  CCR2lo,	  CX3CR1hi)	  subsets.	  Our	  group	  has	  previously	  found	  that	  the	  cell-­‐
fixation	  procedure	  used	  to	  prepare	  the	  lung	  cell	  suspension	  leads	  to	  a	  denaturation	  
of	   the	   Gr-­‐1	   epitope	   specifically	   on	   monocytes.	   Hence,	   this	   leads	   to	   the	   loss	   of	  
recognition	  of	  the	  Ly-­‐6G	  fragment	  by	  the	  anti-­‐Gr-­‐1	  antibody	  on	  monocytes.	  Hence,	  
Gr-­‐1	  could	  not	  be	  used	  to	  distinguish	  between	  these	  two	  monocyte	  subsets	  (241).	  In	  
effect,	  the	  Gr-­‐1	  antibody	  functioned	  as	  a	  “Ly-­‐6G	  antibody”	  which	  could	  only	  be	  used	  
to	  recognize	  the	  Ly-­‐6G	  epitope	  on	  neutrophils,	  and	  not	  monocytes.	  To	  overcome	  this	  
technical	   issue,	   the	   addition	   of	   an	   antibody	   specifically	   against	   Ly-­‐6C	   enabled	   the	  
distinction	  between	   the	   two	  monocyte	  populations.	   Thus,	   events	   showing	  positive	  
staining	  with	   this	   Ly-­‐6C	   antibody	  were	  defined	  as	   Ly-­‐6Chi.	   For	   ease	  of	   explanation,	  
the	   Gr-­‐1	   antibody	   will	   now	   be	   referred	   to	   as	   a	   “Ly-­‐6G	   antibody”.	   To	   summarise,	  
neutrophiils	  were	  gated	  as	  Ly-­‐6CinterLy-­‐6Ghi;	  and	  monocytes	  were	  separated	  into	  their	  
two	  subsets	  –	  inflammatory	  (Ly-­‐6Chi	  Ly-­‐6Glo)	  and	  non-­‐inflammatory	  (Ly-­‐6Clo	  Ly-­‐6Glo).	  	  	  
2.7 In	  situ	  measurement	  of	  alveolar	  fluid	  clearance	  
2.7.1 Overview	  
To	  gain	  a	  quantification	  of	  alveolar	  epithelial	  function	  we	  examined	  the	  rate	  at	  which	  
the	   lungs	   clear	   fluid	   (alveolar	   fluid	   clearance	   -­‐	  AFC)	  over	   a	  defined	  period	  of	   time.	  
AFC	  was	  ascertained	  by	   the	   increase	   in	   concentration	  of	   a	   tracheally	   instilled	  non-­‐
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permeable	  tracer	  (AlexaFluor	  594-­‐conjugated	  BSA)	  within	  the	  BALF	  over	  a	  30-­‐minute	  
period	  using	  an	  adaptation	  of	  a	  published	  in	  situ	  model	  (242).	  	  
2.7.2 Surgical	  Preparation	  
Animals	  underwent	  anaesthesia,	  tracheostomy	  and	  low	  tidal	  volume	  ventilation	  for	  a	  
brief	  period	  on	  FiO2	  of	  1.0	  (in	  total	  less	  than	  15	  minutes)	  and	  maintained	  at	  a	  temp	  
of	   36.5-­‐38oC.	   Animals	   were	   given	   20iu	   heparin	   intravenously	   through	   an	   external	  
jugular	  vein	  cannulation	  and	  after	  3	  minutes,	  an	  arterial	  blood	  sample	  was	  taken	  for	  
blood	   gas	   analysis.	   Animals	   were	   exsanguinated	   under	   anaesthetic	   overdose	  
(through	   transection	   of	   the	   carotid	   artery,	   internal	   and	   external	   jugular	   veins,	  
inferior	  vena	  cava	  and	  aorta)	   to	  reduce	  the	   impact	  of	  pulmonary	  vascular	  pressure	  
on	   alveolar	   fluid	   clearance.	   Each	   animal	   then	   underwent	   3	   further	   recruitment	  
manoeuvres	  to	  standardise	   lung	  recruitment	  between	  animals	  and	  time	  points	  and	  
empty	  pulmonary	  vessels	  present	  in	  West’s	  zone	  2	  and	  3.	  
2.7.3 Measurement	  protocol	  	  
Mice	  underwent	  intratracheal	  instillation	  with	  700µl	  of	  isoosmolar	  5%	  low	  endotoxin	  
BSA	   (Sigma-­‐Aldrich)	   containing	  50µg/ml	  of	  AlexaFluor	   594-­‐conjugated	   (AF594)	  BSA	  
(Invitrogen).	   Without	   disconnecting	   the	   instillation	   syringe,	   the	   plunger	   was	  
withdrawn	  to	  400µl	  and	  reinstilled,	  and	  immediately	  after	  this	  “flush”	  manoeuvre	  a	  
first	  aliquot	  of	  200µl	  was	  removed	  as	  a	  t=0	  reference	  sample.	  This	  ensured	  adequate	  
mixing	   of	   instillate	   with	   alveolar	   contents	   and	   a	   homogenous	   distribution	   of	   the	  
instillation.	   The	   tracheostomy	  was	   clamped	   to	  prevent	   any	   loss	  of	   instillate,	  whilst	  
the	   instillation	   syringe	  was	   disconnected	   to	   immediately	   place	  mice	   on	   a	   custom-­‐
made	   continuous-­‐positive-­‐airway	   pressure	   (CPAP)	   system	   delivering	   a	   FiO2	   1.0	   at	  
8cmH2O.	   On	   connection	   of	   the	   tracheal	   tube	   to	   the	   CPAP	   system	   the	   clamp	   was	  
removed	  such	  that	  the	  positive	  pressure	  and	  a	  30o	  head	  up	  tilt	  ensured	  delivery	  of	  
the	   instillate	   into	   the	   distal	   airspaces.	   A	   heating	   pad	   and	   overhead	  warming	   light	  
source	  was	  used	  to	  maintain	  intra-­‐thoracic	  temperature	  (measured	  through	  an	  intra-­‐
oesophageal	   probe)	   at	   36.5-­‐38oC	   throughout	   the	   protocol.	   These	   measures	   are	  
aimed	   to	   maintain	   stable	   alveolar	   epithelial	   function	   throughout	   the	   period	   of	  
measurement	  in	  this	  in	  situ	  model.	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At	  the	  end	  of	  the	  30	  minutes,	  the	  tracheal	  tube	  was	  again	  clamped	  to	  prevent	  loss	  of	  
instillate	   whilst	   animals	   were	   removed	   from	   the	   CPAP	   system.	   The	   instillate	   was	  
withdrawn	   gently	   by	   attaching	   a	   new	   syringe	   onto	   the	   tracheal	   tube.	   	   A	   surgical	  
pneumothorax	  was	   induced	  through	  blunt	  dissection	  of	   the	  diaphragm	  to	   facilitate	  
maximum	   recovery	   of	   remaining	   instillate.	   BALF	   samples	  were	   then	   centrifuged	   at	  
3000g	   for	   5	   minutes	   and	   the	   supernatant	   analysed	   immediately	   for	   fluorescence	  
using	   a	   FLx800	   fluorescence	   microplate	   reader	   (Biotek).	   The	   fluorescence	   of	   the	  
original	   instillate	   (Fi),	   the	   t=0	   (F0)	   and	   the	   t=30	   (F30)	   sample	   was	   measured	   in	  
triplicate.	  The	  distal	  airways	  fluid	  clearance	  over	  30	  minutes	  was	  determined	  by	  the	  
equation:	  [1-­‐(F0/F30)]	  x100	  where	  F0	  is	  the	  fluorescence	  of	  the	  t=0	  reference	  sample	  
and	  F30	  is	  the	  fluorescence	  of	  the	  30-­‐minute	  sample.	  Pharmacological	   intervention	  
using	   amiloride	   (2mM)	   and	   isoproterenol	   (2mM)	   (added	   to	   the	   instillate)	   to	  
respectively	   inhibit	   and	   augment	   AFC	   was	   used	   to	   ensure	   that	   measurements	  
accurately	  reflected	  AFC.	  
	  
2.8 Tissue	  imaging	  
2.8.1 Background	  
The	   practicalities	   to	   attain	   a	   standardised	   measurement	   of	   lung	   injury	   through	  
histological	  assessment	  require	  considerable	  attention	  to	  detail.	  Unlike	  solid	  organs,	  
sectioning	   of	   the	   lung	   can	   be	   fraught	   with	   difficulty	   with	   significant	   potential	   for	  
artefacts.	   The	   standardisation	   of	   lung	   inflation	   (using	   a	   specified	   transpulmonary	  
pressure)	   prior	   to	   fixation	   is	   crucial	   to	   allow	   consistencies	   between	   experimental	  
groups.	  	  
2.8.2 Preparation	  of	  lungs	  
Animals	   were	   systemically	   heparinised	   and	   euthanised	   through	   exsanguination	  
under	  terminal	  anaesthesia,	  as	  already	  described.	  They	  were	  tracheostomised	  and	  a	  
careful	   thoracotomy	   was	   performed	   avoiding	   damage	   to	   the	   lungs.	   Sutures	   were	  
placed	  behind	  the	  main	  bronchi	  of	  the	   lung	  to	  be	  used	  for	  histological	  assessment.	  	  
The	  open	  chest	  enabled	  transpulmonary	  pressure	  to	  be	  zero	  prior	  to	  inflation.	  A	  fine	  
catheter	  was	  placed	  in	  the	  tracheostomy	  and	  lungs	  inflated	  to	  15cm	  pressure	  of	  4%	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paraformaldehyde	   solution	   (the	   relative	   density	   of	  water	   and	   parafmormaldehyde	  
are	   likely	   to	   be	   similar	   given	   the	   latter	   is	   dissolved	   in	   water).	   The	   sutures	   were	  
subsequently	   tied	   and	   the	   lungs	   removed	   and	   placed	   in	   a	   bijou	   containing	   4%	  
paraformaldehyde	  overnight.	  Lungs	  were	  subsequently	  placed	  in	  a	  tissue	  processor	  
for	   dehydration	   and	   rehydration	   prior	   to	   paraffin	   embedding.	   The	   lungs	   were	  
mounted	   in	   wax	   and	   5μm	   sections	   were	   obtained	   using	   a	   sledge	   microtome.	  
Sections	  were	  floated	  on	  a	  37oC	  water	  bath	  and	  collected	  on	  glass	  microscope	  slides	  
and	  allowed	  to	  dry	  at	  room	  temperature	  prior	  to	  histological	  staining.	  
2.8.3 Haematoxylin	  and	  Eosin	  staining.	  	  
Lung	  sections	  were	  placed	   in	  a	  65oC	  oven	  for	  15	  minutes	  to	  melt	  the	  paraffin	  wax.	  
The	   sections	   were	   de-­‐waxed	   by	   placing	   them	   in	   a	   xylene	   bath	   for	   10	   minutes.	  
Sections	  were	  rehydrated	  through	  a	  graded	  immersion	  in	  alcohols	  (absolute	  to	  90%	  
to	  70%	  alcohol)	  for	  30	  seconds	  each	  and	  then	  in	  distilled	  water	  for	  5	  minutes.	  They	  
were	  stained	  with	  Mayer’s	  haematoxylin	  for	  10	  minutes	  followed	  by	  washing	  in	  tap	  
water	  for	  5	  minutes.	  The	  slides	  were	  dipped	  in	  1%	  hydrochloric	  acid	  in	  70%	  ethanol	  
and	  washed	   again	   for	   5	  minutes.	   They	  were	   counterstained	  with	   1%	   eosin	   for	   10	  
minutes	   and	   dipped	   in	   water	   to	   remove	   any	   excess	   eosin.	   They	   underwent	  
dehydration	  in	  100%	  ethanol	  followed	  placement	  in	  a	  bath	  of	  xylene	  overnight	  prior	  
to	  mounting	  with	  DePex	  plus	  coverslip.	  
2.8.4 Masson’s	  Trichrome	  staining.	  	  
Paraffin	  embedded	  slides	  underwent	  deparaffinisation	  and	  rehydration	  in	  xylene	  and	  
graded	  ethanol.	  The	  slides	  were	  placed	  overnight	   in	  Bouin’s	  mordant	  solution.	  The	  
slides	  were	  washed	   in	   tap	  water	   for	   5	  minutes	   and	   then	   stained	   for	   5	  minutes	   in	  
working	  Weigert’s	   iron	   haematoxylin	   Solution	   (made	   fresh	   through	   the	   mixing	   of	  
equal	  volumes	  of	  solution	  A	  (1%	  Haematoxylin	  in	  95%	  ethanol)	  with	  solution	  B	  (1.2%	  
ferric	  chloride	  and	  1%	  Acetic	  acid	  in	  distilled	  water).	  Haematoxylin	  stained	  the	  nuclei	  
black.	   Slides	   were	   subsequently	   washed	   in	   running	   tap	   water	   for	   a	   further	   five	  
minutes.	  And	  rinsed	  in	  deionised	  water.	  Slides	  were	  then	  placed	  in	  Biebrich	  Scarlet-­‐
acid	   fuchsin	   for	   5	   minutes	   to	   stain	   cytoplasm	   and	  muscle	   red.	   This	   was	   rinsed	   in	  
deionised	   water.	   Slides	   were	   exposed	   to	   phosphomolybdic/phosphotungstic	   acid	  
solution	   for	  5-­‐10	  minutes.	  This	  enables	   the	  uptake	  of	   the	  next	  dye,	  aniline	  blue,	   in	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which	   the	   slides	  were	  placed	   for	  5	  minutes	   to	   stain	   the	   collagen	  blue.	   Slides	  were	  
rinsed	   again	   and	   differentiated	   in	   1%	   acetic	   acid	   for	   1	   minute.	   Finally,	   slides	  
underwent	   dehydration	   in	   100%	   ethanol	   and	   placed	   in	   xylene	   overnight	   prior	   to	  
mounting	  as	  previously	  described.	  
2.8.5 Histological	  lung	  injury	  scoring	  
A	   variety	   of	   scoring	   systems	   are	   available	   to	   quantify	   lung	   injury.	   A	   recent	   ATS	  
workshop	  proposed	  a	  histological	  system	  that	  incorporated	  simple	  graded	  scores	  for	  
a	   number	   of	   separate	   morphometric	   criteria	   (192).	   Lung	   injury	   scores	   were	  
quantified	   in	   a	   blinded	   manner	   in	   20	   random	   high-­‐power	   fields	   (x400	   original	  
magnification)	   according	   to	   the	   table	   2.13.	  Of	   note	   each	   field	   analysed	  had	   at	   the	  
minimum	  50%	  occupation	  by	  lung	  alveoli.	  The	  final	  injury	  score	  was	  derived	  from	  the	  





Score	  per	  field	  
0	   1	   2	  
A.	  Neutrophils	  in	  the	  alveolar	  space	   None	   1-­‐5	   >5	  
B.	  Neutrophils	  in	  the	  interstitial	  space	   None	   1-­‐5	   >5	  
C.	  Hyaline	  membranes	   None	   1	   >1	  
D.	  Proteinaceous	  debris	  filling	  the	  airspaces	   None	   1	   >1	  
E.	  Alveolar	  septal	  thickening	   None	   2x-­‐4x	   >4x	  
	  
Table	  2.13.	  Histological	  lung	  injury	  scoring	  method	  	  
(adapted	  from	  Matute-­‐bello	  et	  al	  (192))	  
	  
2.9 Apoptosis	  detection	  
2.9.1 TUNEL	  assay	  
The	   Terminal	   UTP	   Nick	   End-­‐Labilling	   (TUNEL)	   assay	   was	   developed	   in	   1992	   by	  
Gavrieli	  et	  al	  (243)	  and	  is	  a	  method	  for	  detecting	  cells	  that	  show	  DNA	  fragmentation.	  
It	   involves	   the	   use	   of	   the	   enzyme	   terminal	   deoxynucleotidyl	   transferase	   to	   attach	  
biotin-­‐conjugated	   dUTP	   onto	   the	   broken	   ends	   of	   the	   double	   stranded	   DNA.	   The	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TACS.XL	  diaminobenzidine	  in	  situ	  Apoptosis	  Detection	  Kit	  (Trevigen	  Ltd)	  was	  used	  to	  
detect	  the	  extent	  of	  morphological	  TUNEL	  positive	  staining	  in	  lung	  sections.	  Tissues	  
are	   first	   fixed	   in	   4%	   paraformaldehyde	   overnight	   to	   prevent	   the	   loss	   of	   low	  
molecular	   weight	   DNA	   fragments.	   Sections	   prepared	   from	   paraffin	   blocks	   of	   fixed	  
lungs	  were	  warmed	  to	  57oC	   for	  5	  minutes.	  They	  were	  subsequently	   immersed	   in	  2	  
changes	  of	  xylene,	  5	  minutes	  each,	  followed	  by	  graded	  immersion	  in	  100%,	  95%	  then	  
70%	   ethanol,	   5	   minutes	   each.	   Slides	   were	   placed	   in	   PBS	   for	   10	   minutes	   at	   room	  
temperature	  and	  carefully	  dried	  around	   the	  sample.	  The	  sample	  was	  covered	  with	  
50μl	  of	  proteinase	  K	  Solution	  and	  incubated	  for	  15	  minutes	  at	  room	  temperature,	  to	  
permeabilise	  the	  tissue	  making	  the	  DNA	  accessible	  to	  the	  labeling	  enzyme,	  prior	  to	  in	  
situ	  detection	  of	  apoptosis.	  The	  sections	  were	  washed	  twice	  in	  DNAse	  free	  (Roche)	  
deionised	  water	  for	  2	  minutes	  each.	  Endogenous	  peroxidase	  activity	  was	  quenched	  
using	  methanol	  (45mls	  100%)/hydrogen	  peroxide	  (5mls	  30%)	  quenching	  solution	  for	  
5	  minutes	  with	  a	  further	  wash	  step	  in	  PBS	  for	  1	  minute.	  The	  slide	  was	  immersed	  in	  
the	  terminal	  deoxynucleotidyl	  transferase	  enzyme	  (TdT)	  labeling	  buffer	  for	  5	  minutes	  
and	   then	   covered	   with	   50μl	   of	   labelling	   reaction	   mix	   to	   incorporate	   biotinylated	  
nucleotides	   into	   the	   3-­‐OH	   ends	   of	   the	   DNA	   fragments	   by	   the	   TdT	   enzyme.	   Slides	  
were	  incubated	  for	  60	  minutes	  at	  37oC	  in	  a	  humidity	  chamber.	  To	  generate	  a	  positive	  
control	   using	   TACS-­‐Nuclease,	   1μl	   of	   TACS-­‐Nuclease	  was	   added	   to	   50μl	   of	   labelling	  
reaction	   mixture.	   A	   hydrophobic	   cover	   slip	   was	   used	   to	   facilitate	   homogenous	  
distribution	   of	   labelling	   solution	   over	   the	   section.	   After	   60	   minutes	   the	   TdT	   stop	  
buffer	  was	  added	  to	  the	  slide	  for	  5	  minutes	  and	  washed	  twice	  with	  deionised	  H2O	  for	  
5	  minutes	  each	  to	  remove	  unbound	  conjugate.	  The	  sample	  was	  covered	  with	  50μl	  of	  
streptavadin-­‐HRP	   solution,	   and	   incubated	   for	   10	   minutes	   at	   37oC	   in	   a	   humidity	  
chamber.	  After	  washing	   twice	   in	  PBS	   for	   2	  minutes	  each,	   slides	  were	   immersed	   in	  
diaminobenzamine	   (DAB)	   solution	   for	   5	   minutes.	   Slides	   underwent	   a	   further	   two	  
washes	  in	  deionised	  water	  and	  were	  background	  stained	  with	  1%	  methyl	  green	  for	  2	  
minutes.	  Slides	  were	  dipped	  ten	  times	  each	  in	  2	  changes	  of	  deionised	  H2O,	  95%,	  and	  
100%	  ethanol	  and	  finally	  in	  xylene	  prior	  to	  mounting	  with	  DePex	  and	  glass	  coverslips.	  
The	   enzyme	   reaction	   generates	   an	   insoluble	   coloured	   precipitate	   where	   DNA	  
fragmentation	  has	  occurred.	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By	  principal	  TUNEL	  can	   label	  any	  3’	  hydroxyl	  end	  of	  DNA	  and	  hence,	  has	  also	  been	  
shown	  to	  produce	  false	  positives	   in	  cells	  undergoing	  necrosis	  and	  in	  the	  S-­‐phase	  of	  
the	   mitotic	   cell	   cycle	   (the	   phase	   in	   which	   DNA	   is	   replicated)	   (244).	   A	   recent	  
classification	   of	   cell	   death	   by	   a	   nomenclature	   committee	   on	   cell	   death	   (245)	  
discussed	   the	   controversies	   in	   defining	   cell	   death.	   They	   suggested	   that	   apoptosis	  
involves	  the:	  	  
1. Rounding-­‐up	  of	  the	  cell	  	  
2. Retraction	  of	  pseudopodes	  	  
3. Reduction	  of	  cellular	  and	  nuclear	  volume	  (pyknosis)	  	  
4. Nuclear	  fragmentation	  (karyorrhexis)	  	  
5. Minor	  modification	  of	  cytoplasmic	  organelles	  	  
6. Plasma	  membrane	  blebbing	  	  
7. Engulfment	  by	  resident	  phagocytes	  
Some	   investigators	  view	  TUNEL	  as	  an	   inadequate	  technique	  given	   its	  propensity	   to	  
overestimate	  the	  number	  of	  apoptotic	  cells.	  Hence,	  our	  counting	  of	  cells	  undergoing	  
apoptosis	  also	  included	  only	  those	  cells	  that	  matched	  strict	  morphological	  criteria	  for	  
apoptosis	   (i.e.	   condensed	   DAB	   staining	   in	   the	   nucleus	   i.e.	   pyknosis)	   to	   count	   the	  
number	  of	  cells	  per	  high	  power	  field	  that	  were	  TUNEL	  positive.	  	  
2.9.2 Caspase-­‐8/-­‐9	  activity	  assay	  
The	  caspase-­‐8/-­‐9	  fluorometric	  activity	  assay	  Kit	   (Biovision)	   is	  based	  on	  detection	  of	  
cleavage	  of	  substrate	  IETD-­‐AFC	  (for	  caspase-­‐8)	  and	  LEHD-­‐AFC	  (for	  caspase-­‐9)	  (AFC:	  7-­‐
amino-­‐4-­‐trifluoromethyl	  coumarin).	  The	  IETD-­‐AFC/LEHD-­‐AFC	  emits	  blue	  light	  (λmax	  =	  
400	  nm);	  upon	  cleavage	  of	  the	  substrate	  by	  caspase-­‐8,	  free	  AFC	  emits	  a	  yellow-­‐green	  
fluorescence	   (λmax	   =	   505nm),	  which	   can	   be	   quantified	   using	   a	   fluorescence	   plate	  
reader.	   Hence,	   snap	   frozen	   left	   lungs	   were	   defrosted	   and	   homogenised	   (using	   a	  
hand-­‐held	  homogeniser)	   for	  30	  seconds	   in	   the	  cell	   lysis	  buffer	   supplied	  and	  placed	  
on	   ice	  until	   incubation.	  Subsequently,	  50µl	  of	  homogenate,	  substrate,	  and	  reaction	  
buffer	  are	  incubated	  at	  37oC	  in	  black	  96-­‐well	  plates	  for	  fluorescence	  to	  be	  measured	  
after	  60	  minutes	  using	  a	  fluorescence	  microplate	  reader.	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2.9.3 Flow	  cytometric	  localisation	  of	  caspase-­‐8	  activity	  
The	   whole	   lung	   caspase-­‐8	   assay	   described	   above	   does	   not	   allow	   localization	   of	  
caspase-­‐8	   activity	   to	   specific	   cell	   types.	   Hence,	   a	   flow	   cytometry	   method	   was	  
developed	   to	   specifically	   localise	   and	  measure	   the	   activity	   of	   caspase-­‐8	  within	   the	  
major	   cell	   types	  of	   the	  uninjured	  and	   injured	   lungs	  of	  WT	  mice.	   In	   contrast	   to	   the	  
previous	   flow	   cytometry	   protocols	   (section	   2.6.3),	   this	   assay	   required	   the	  
preparation	   of	   live	   lung	   single-­‐cell	   suspensions	   given	   that	   formaldehyde	   fixation	  
quenches	   caspase	   activity.	   Hence,	   a	   previously	   published	   tissue-­‐digestion	   protocol	  
used	   to	   recover	  endothelial	   cells	  was	  modified	   to	  efficiently	   retrieve	  epithelial	  and	  
endothelial	  cells	  in	  an	  unfixed	  state	  into	  single	  cell	  suspension	  (66,	  246,	  247).	  One	  or	  
both	  lungs	  were	  instilled	  (through	  the	  tracheostomy),	  respectively,	  with	  0.5	  or	  1	  ml	  
DMEM	  containing	  1	  mg/ml	  sterile	   filtered	  dispase	  enzyme	  (Invitrogen).	  Lungs	  were	  
tied	   at	   the	   bronchus	   and	   removed	   as	   previously	   stated	   and	   placed	   in	   the	   same	  
dispase	  solution	  for	  30	  minutes	  at	  room	  temperature.	  Lung	  parenchyma	  was	  gently	  
separated	  from	  the	  bronchial	  tree	  and	  minced	  in	  ice-­‐cold	  sterile	  DMEM/2.5%	  HEPES	  
with	   0.01%	   DNase	   (Roche).	   This	   distal	   lung	   cell	   suspension	   was	   passed	   through	   a	  
40µm	  filter,	  washed	  with,	  and	  reconstituted	  in	  ice-­‐cold	  DMEM/2.5%	  HEPES.	  The	  lung	  
cell	   suspension	  was	   centrifuged	   at	   2000rpm	   at	   4oC.	   Subsequently,	   cell	   suspension	  
was	   incubated	  with	  a	   FAM-­‐IETD-­‐FMK	  caspase-­‐8	   reagent	   (Immunochemistry)	   for	  60	  
min	   at	   37oC	   in	   the	   dark,	   per	   the	   manufacturer’s	   instructions.	   This	   reagent	   is	   a	  
fluorochrome-­‐conjugated	   caspase-­‐8	   inhibitor–based	   compound	   that	   freely	  
permeates	   cells	   and	   binds	   specifically	   and	   covalently	   to	   activated	   intracellular	  
caspase-­‐8,	   and	   can	   be	   detected	   by	   flow	   cytometry	   (in	   the	   FITC	   channel).	   This	  was	  
followed	  by	  a	  15-­‐minute	  passive	  wash	  step	  where	  cells	  were	  washed,	  resuspended	  
and	   incubated	   in	   2mls	   DMEM/2.5%	   HEPES,	   for	   15	   minutes	   at	   37oC	   to	   allow	   any	  
unbound	  caspase-­‐8	  reagent	  to	  diffuse	  out	  of	  the	  cells.	  Cells	  were	  washed	  in	  4mls	  of	  
DMEM/2.5%	  HEPES	  and	  resuspended	  in	  500µl	  of	  DMEM/2.5%	  HEPES.	  Subsequently,	  
50µl	   of	   cell	   suspension	   were	   incubated	   on	   ice	   with	   antibody	   stock	   containing	  
fluorophore-­‐conjugated	  anti-­‐mouse	  antibodies	  to	  pan-­‐endothelial	  marker	  CD31,	  the	  
pan-­‐leukocyte	   marker	   CD45,	   the	   pan-­‐epithelial	   marker	   epithelial	   cell	   adhesion	  
molecule	  (EpCAM),	  and	  the	  type	  1	  alveolar	  epithelial	  cell	  (AEC)	  marker	  -­‐	  type	  1	  cell	  
alpha	   protein	   (t1α).	   After	   a	   final	   wash	   and	   reconstitution	   in	   ice-­‐cold	   DMEM/1%	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HEPES	   the	   samples	   were	   analysed	   by	   flow	   cytometry,	   as	   described	   above.	  
Importantly	  given	  that	  the	  lung	  cell	  suspensions	  were	  unfixed	  they	  were	  kept	  on	  ice	  
throughout	  the	  protocol,	  except	  during	  the	  incubation/wash	  steps	  for	  the	  FAM-­‐IETD-­‐
FMK	   caspase-­‐8	   reagent	   binding,	   to	   minimize	   changes	   to	   intracellular	   reactions.	  
Furthermore,	  a	  buffered	  cell	  culture	  media	  was	  used	  in	  all	  steps	  in	  order	  to	  allow	  the	  
optimal	  physiological	  environment	  as	  possible	  throughout	  the	  ex-­‐vivo	  processing.	  
	  
2.10 Interventional	  studies	  
2.10.1 Caspase-­‐8	  inhibition	  
Animals	  were	  anaesthetised	  and	  ventilated	  as	  per	  the	  acute	  acid	  model.	  To	  ascertain	  
the	  impact	  of	  caspase-­‐8	  inhibition	  on	  acid-­‐induced	  lung	  injury,	  4	  mg/kg	  of	  a	  selective	  
caspase-­‐8	   inhibitor	   Z-­‐VAD-­‐IETD	   (Becton	   Dickinson	   Biosciences),	   or	   DMSO	   as	   the	  
vehicle,	   was	   administered	   intravenously	   (via	   the	   external	   jugular)	   to	   WT	   mice	   5	  
minutes	  before	  intra-­‐tracheal	  acid	  instillation.	  	  
2.10.2 Alveolar	  macrophage	  depletion	  
WT	  mice	  underwent	  anaesthesia	  48	  hours	  before	  acid	  instillation	  for	  the	  orotracheal	  
instillation	   of	   75µl	   of	   clodronate	   or	   PBS	   containing	   liposomes	   (Encapsula	  
NanoSciences)	   to	   deplete	   the	   resident	   alveolar	   macrophage	   population.	   We	   have	  
previously	   found	   that	   48	   hours	   leads	   to	   a	   significant	   reduction	   in	   the	   alveolar	  
macrophage	   population	   (248).	   Animals	   subsequently	   underwent	   the	   acute	   acid	  
instillation	   protocol	   to	   determine	   the	   impact	   of	   alveolar	   macrophages	   on	   acid	  
aspiration.	   We	   confirmed	   a	   90%	   reduction	   in	   the	   resident	   alveolar	   macrophage	  
population	   (CD45+F4/80+CD11c+CD11b-­‐)	   through	   flow	   cytometric	   quantification	   of	  
lung	  single	  cell	  suspension.	  	  
	  
2.11 Statistical	  analysis	  
Data	   are	   expressed/presented	   as	   means±SD/column	   graphs	   (if	   parametric)	   or	  
median±interquartile	   range/box	   and	   whisker	   plots	   (if	   nonparametric).	   The	   model	  
assumption	  of	  normality	  of	  residuals	  was	  assessed	  by	  QQ	  plot	  and	  the	  Shapiro–Wilk	  
test.	  Statistical	  analyses	  of	  data	  were	  made	  using	  either	  a	  two-­‐tailed	  Student	  t	  test	  or	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one-­‐way	  ANOVA	  with	  Bonferroni	  tests	  for	  multiple	  comparisons	  (if	  parametric)	  and	  
Mann–Whitney/Kruskal–Wallis	  tests	  (if	  nonparametric).	  Time	  courses	  were	  analyzed	  
using	   a	   two-­‐way	   ANOVA	   or	   a	   t-­‐test	   of	   final	   end	   point	   values.	  We	   used	   Pearson’s	  
product-­‐moment	   correlation	   coefficients	   to	   test	   the	   relationships	   between	  
continuous	   variables.	   Analyses	   of	   normal	   distribution	   were	   performed	   using	   SPSS	  
version	   20	   (IBM)	   and	   statistical	   comparisons	   used	  GraphPad	   Prism	   version	   6.	   A	   p-­‐
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Tumour	  necrosis	  factor	  has	  been	  heavily	   implicated	  in	  the	  pathogenesis	  of	  ARDS	  in	  
pre-­‐clinical	  and	  clinical	   investigations.	  However,	  despite	   this	   intensive	   investigation	  
there	   has	   been	   no	   translation	   of	   anti-­‐TNF	   therapies	   into	  ARDS.	  One	   possibility	   for	  
this	   failure	   may	   be	   that	   therapies	   have	   targeted	   total	   blockade	   of	   TNF	   signalling.	  
Indeed,	  TNF	   signals	   through	   two	   receptors,	   the	  p55	  and	  p75	  TNF	   receptors,	  which	  
have	  been	  recently	  found	  to	  signal	  through	  quite	  distinct	  pathways.	  	  
	  
Within	   this	   chapter	   an	   acute	   phase	   model	   of	   acid-­‐induced	   lung	   injury	   has	   been	  
developed.	  Using	  wild	  type	  (WT)	  C57BL6	  mice	  and	  knockout	  mouse	  strains	   for	  p55	  
only	  (p55KO),	  p75	  only	  (p75KO),	  and	  both	  p55	  and	  p75	  (DKO),	  we	  showed	  that	  the	  
development	   of	   acute	   pulmonary	   oedema	   during	   the	   first	   three	   hours	   after	   intra-­‐
tracheal	  instillation	  of	  hydrochloric	  acid	  was	  specifically	  promoted	  through	  p55	  TNFR	  
activation.	   Genetic	   deletion	   of	   p55	   TNFR	   led	   to	   a	   protective	   effect	   with	   animals	  
showing	  improved	  respiratory	  mechanics,	  improved	  gas	  exchange,	  and	  reduced	  lung	  
oedema	   (as	   measured	   by	   protein	   permeability	   and	   wet/dry	   weight	   ratio).	  
Interestingly,	  p75KO	  and	  DKO	  animals	  showed	  either	  a	  similar	  or	  worse	  injury	  to	  WT	  
animals.	  	  
	  
Given	   that	   TNF	   is	   an	   important	   pro-­‐inflammatory	   cytokine	   we	   hypothesised	   that	  
injurious	   pro-­‐inflammatory	   signalling	   through	   p55	   TNFR	   induced	   the	  
pathophysiological	   derangements	   seen	   after	   acid	   aspiration.	   Interestingly,	   no	  
differences	   were	   found	   in	   the	   concentrations	   of	   inflammatory	   mediators	   in	  
bronchoalveolar	   lavage	   (e.g.	   interleukin-­‐6)	   and	   lung	   leukocytes	   (neutrophils	   and	  
monocytes,	  as	  evaluated	  using	  flow	  cytometry).	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3.1 Introduction	  
	  
TNF	  is	  important	  in	  the	  pathogenesis	  of	  lung	  injury,	  but	  despite	  significant	  research	  
the	   precise	   molecular	   and	   cellular	   pathways	   that	   mediate	   these	   effects	   remain	  
unclear.	   Therapeutic	   blockade	   of	   TNF	   has	   been	   performed	   through	   either	  
monoclonal	  antibodies	  against	  TNF	  or	   through	   the	  development	  of	  p55	  or	  p75-­‐IgG	  
fusion	  proteins	  with	  an	  aim	  to	  ‘mop	  up’	  circulating	  TNF	  (173,	  249-­‐251).	  As	  discussed	  
in	  the	  introduction,	  there	  are	  several	  potential	  considerations	  as	  to	  why	  these	  trials	  
have	  failed	  but	  one	  important	  aspect	  that	  has	  been	  completely	   ignored	  is	  that	  TNF	  
signals	   through	   two	   receptors	  which	   show	  distinct	   signalling	   pathways	   and	   hence,	  
potentially	  different	  cellular	  responses	  (153).	  TNF	   is	  simply	  the	  messenger	  whereas	  
the	   receptors	   are	   the	   effectors.	   Furthermore,	   the	   precise	   downstream	   biological	  
mechanisms	   of	   how	   TNF	   induces	   organ	   dysfunction	   in	   sepsis/ARDS	   are	   not	  
investigated	  in	  many	  experimental	  studies.	  
	  
Historically,	  p55	  TNFR	  signalling	  has	  been	  thought	   to	  be	   the	  predominant	  pathway	  
through	  which	  the	  cellular	  actions	  of	  TNF	  occur.	  It	  has	  been	  shown	  that	  the	  two	  cell	  
surface	   receptors	   for	   TNF	  may	   have	   divergent	   and	   sometimes	   opposing	   roles	   in	   a	  
number	  of	  models	  of	  acute	  inflammation	  including	  myocardial	  infarction,	  sepsis	  and	  
pneumonia	   (220-­‐223).	   Using	   genetic	   and	   pharmacological	   approaches,	   our	  
laboratory	   showed	   that	   pulmonary	   oedema	   formation	   is	   specifically	   mediated	  
through	  the	  p55	  TNFR,	  and	  that	  genetic	  deletion	  of	  the	  p75	  TNFR	  opposed	  alveolar	  
oedema	   formation	   during	   the	   early	   phases	   of	   ventilator-­‐induced	   lung	   injury	   (VILI)	  
(224,	  252).	   In	  these	  studies,	  mice	  deficient	   in	  the	  p55	  TNFR	  or	  mice	  treated	  with	  a	  
domain	  antibody	  against	  the	  p55	  TNFR	  were	  exposed	  to	  high	  stretch	  ventilation	  and	  
showed	  significant	  attenuation	  in	  injury	  as	  shown	  by	  respiratory	  mechanics,	  arterial	  
blood	   gases,	   and	   markers	   of	   endothelial-­‐epithelial	   permeability,	   in	   addition	   to,	  
improved	  survival.	  In	  view	  of	  this	  protection,	  we	  wished	  to	  investigate	  whether	  this	  
would	   also	   be	   true	   for	   other	   aetiologies	   of	   alveolar	   oedema	   in	   lung	   injury	   and	  
determine	  the	  mechanisms	  through	  which	  this	   injury	   (or	  protection	  when	  blocked)	  
was	  conveyed.	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The	  acid	  aspiration	  model	  was	  chosen	  as	  it	  is	  regarded	  as	  one	  of	  the	  most	  clinically	  
relevant	  models	  of	  experimental	  ARDS	  (253).	  It	  accounts	  for	  11%	  of	  all	  cases	  of	  ARDS	  
(21)	   and	   a	   number	   of	   clinical	   and	   experimental	   studies	   have	   demonstrated	   a	  
significant	   involvement	   of	   TNF	   in	  mediating	  ARDS	   resulting	   from	   gastric	   aspiration	  
(167,	   197).	   Hyers	   showed	   that	   clinical	   ARDS	   induced	   by	   gastric	   aspiration	   had	   a	  
significantly	   greater	   level	   of	   TNF	   in	   bronchoalveolar	   lavage	   fluid	   than	   the	   non-­‐
aspirated	  ARDS	  group	  (167).	  Acid	  aspiration	  produces	  overwhelming	  lung	  injury	  over	  
a	  very	  short	  dose	  range	  and	  hence	  often	  requires	  mechanical	  ventilation	  in	  rodents,	  
limiting	   the	   time	  period	   for	   investigation	   to	  hours.	   Early	   injury	  progresses	   through	  
two	  phases	  -­‐	  the	  first	  phase	  involves	  a	  direct	  physicochemical	  reaction	  with	  acid	  (the	  
nature	   of	   which	   remains	   unknown)	   leading	   to	   increased	   permeability,	   and	   the	  
second	   phase	   occurs	   at	   2-­‐4	   hours	   and	   is	   thought	   to	   involve	   neutrophils	   (195).	   A	  
number	   of	   other	   inflammatory	  mediators	   have	   also	   been	   implicated	   including	   IL-­‐6	  
(254),	  IL-­‐8	  (88,	  255),	  complement	  (256),	  and	  reactive	  oxygen	  species	  (257,	  258).	  Imai	  
and	  colleagues	  showed	  that	  acid	  aspiration	  lung	  injury	  involves	  the	  activation	  of	  Toll-­‐
like	   receptor	  4	   (TLR-­‐4)	  on	   lung	  macrophages	  and	  mice	  deficient	   in	  TLR-­‐4	  showed	  a	  
reduced	   cytokine	   storm	   and	   alveolar	   oedema	   (254).	   Modelska	   and	   colleagues	  
showed	   that	   blockade	   of	   IL-­‐8	   could	   ameliorate	   barrier	   dysfunction	   after	   acid	  
aspiration	   in	   rabbits	   (255).	  TNF	   is	   released	  early	  after	  experimental	   (196,	  197)	  and	  
clinical	  (166,	  167)	  acid	  aspiration	  and	  has	  been	  shown	  to	  be	  a	  proximal	  regulator	  of	  
many	  of	  the	  aforementioned	  mediators.	  However,	  despite	  the	  evident	  importance	  of	  
TNF	   in	   acid	   aspiration,	   total	   blockade	   does	   not	   completely	   ameliorate	   lung	   injury	  
(197)	  and,	  the	  exact	  roles	  of	  each	  TNF	  receptor	  remains	  unknown.	  Hence,	  we	  sought	  
to	  examine	  if	  the	  differential	  effects	  of	  its	  two	  receptors	  would	  explain	  some	  of	  the	  
inconsistencies	   found	   in	   investigating	   TNF	   in	   this	   very	   relevant	   model	   of	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3.2 Aims	  
The	   work	   within	   this	   chapter	   focuses	   on	   the	   investigation	   of	   the	   effects	   of	   TNF	  
receptor	  signalling	  on	  acid-­‐induced	  lung	  injury.	  The	  aims	  included:	  
1. The	   development	   of	   a	   reproducible	   model	   of	   experimental	   lung	   injury	  
induced	   by	   intra-­‐tracheal	   acid	   instillation	   to	   facilitate	   the	   measurement	   of	  
clinically	  relevant	  respiratory	  physiological	  parameters.	  
2. To	   investigate	   a)	   the	   physiological	   impact	   and	   b)	   the	   inflammatory	  
consequences	  of	  each	  TNF	  receptor	  in	  this	  model	  of	  experimental	  lung	  injury.	  
	  
3.3 	   Experimental	  design	  
3.3.1 Animals	  
This	  part	  of	  the	  project	  used	  a	  genetic	  approach	  using	  wild-­‐type	  (WT)	  male	  C57BL6	  
mice	  (Charles	  River,	  Margate,	  UK),	  and	  p55KO,	  p75KO,	  and	  DKO	  mice	  (all	   from	  The	  
Jackson	   Laboratory,	   USA)	   to	   ascertain	   the	   acute	   roles	   for	   these	   receptors	   in	   lung	  
injury	  induced	  by	  acid	  aspiration.	  
3.3.2 In	  vivo	  model	  
The	  previous	  work	  by	  Wilson	  et	  al	  in	  the	  mouse	  VILI	  model	  (224)	  highlighted	  an	  early	  
impact	   of	   TNF	   signalling	   upon	   the	   development	   of	   pulmonary	   oedema.	   Hence,	   an	  
acute	   model	   of	   acid	   aspiration	   was	   developed	   to	   investigate	   the	   formation	   of	  
oedema	  within	  a	  similar	  time	  frame.	  In	  brief,	  WT,	  p55KO,	  p75KO	  and	  DKO	  mice	  were	  
anaesthetised	   and	   tracheotomised	   for	   mechanical	   ventilation	   (FiO2	   1.0;	   VT:	   8-­‐9	  
mls/kg;	   PEEP:	   2.5-­‐3.0	   cmH2O;	   RR:	   120	   bpm)	   and	   underwent	   carotid	   cannulation.	  
After	   an	   initial	   recruitment	  manoeuvre	   (30	   cmH2O;	   5	   seconds)	   to	   standardise	   the	  
volume	   history	   of	   the	   lungs	   for	   the	   effects	   of	   surgery	   and	   anaesthesia,	   baseline	  
readings	  were	   taken.	  Subsequently,	  50μl	  of	  HCl	  or	   saline	  was	  administered	  via	   the	  
tracheal	   tube.	   Animals	   underwent	   5	   further	   pulmonary	   recruitment	   manoeuvres	  
immediately	  after	  acid	  instillation,	  and	  then	  every	  30	  minutes	  up	  to	  the	  termination	  
of	  the	  protocol.	  Subsequent	  physiological	  readings	  were	  taken	  prior	  to	  recruitment	  
manoeuvres.	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3.3.3 Respiratory	  physiology	  
At	   specified	   intervals	   indices	   of	   respiratory	   physiology	   were	   taken	   as	   previously	  
described.	   These	   included	   respiratory	  mechanics	  measurements,	   arterial	  blood	  gas	  
analysis,	  lung	  wet/dry	  weight	  ratio,	  alveolar	  protein,	  and	  permeability	  index.	  
3.3.4 Analysis	  of	  inflammation	  
At	  the	  end	  of	  the	  three-­‐hour	  protocol	  animals	  underwent	  unilateral	  bronchoalveolar	  
lavage	  for	  analysis	  of	  soluble	  mediators	  and	  cell	  counts.	  Right	  lungs	  were	  processed	  
for	   flow	   cytometric	   counting	   to	   quantify	   neutrophil	   and	   inflammatory	   monocyte	  
sequestration	  to	  the	  lung	  at	  3	  hours.	  Blood	  from	  WT	  and	  the	  three	  knockout	  strains	  
were	  analysed	  for	  TNF	  receptor	  expression	  on	  monocytes	  and	  neutrophils	  to	  ensure	  
phenotype.	  
3.3.5 Histological	  preparation	  
In	   another	   set	   of	   experiments,	   lungs	   of	   animals	   were	   also	   inflated	   at	   a	  
transpulmonary	   pressure	   of	   15cm	   height	   of	   4%	   paraformaldehyde.	   Lungs	   were	  




3.4.1 Acute	  acid	  aspiration	  model	  optimisation	  
The	   majority	   of	   previous	   reports	   have	   instilled	   50μl	   0.1M	   hydrochloric	   acid	   with	  
subsequent	  mechanical	  ventilation	   for	  a	  variable	  period	  of	   time	   (72,	  259-­‐261).	  The	  
tracheal	   instillation	  of	  50μl	  of	  Evan’s	  blue	  dye	   (via	  a	  catheter	   fed	   into	   the	   tracheal	  
tube)	   confirmed	   that	   the	   instillation	   technique	   produced	   an	   even	   bilateral	   distal	  
pulmonary	  distribution	  of	  the	  instilled	  fluid	  –	  bilateral	  injury	  being	  a	  prerequisite	  for	  
ARDS.	   Immediately	   after	   intratracheal	   instillation	   the	   fluid	  was	   driven	   distally	   into	  
the	  respiratory	  tract	  through	  the	  application	  of	  5	  deep	  inflations	  at	  30	  cmH2O.	   It	   is	  
well	   established	   that	   recruitment	  manoeuvres	   are	   required	   at	   regular	   intervals	   to	  
prevent	   atelectasis	   of	   mouse	   lungs	   (239,	   262,	   263).	   Deep	   inflations	   (again	   to	   30	  
cmH2O)	  were	  applied	  at	  intervals	  of	  30	  minutes	  in	  order	  to	  recruit	  for	  any	  atelectasis	  
component	   inevitable	   after	   instillation	   of	   fluid	   into	   the	   airways,	   prolonged	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mechanical	   ventilation,	   and	   injury	   progression	   (264).	   Respiratory	   mechanics	   (end-­‐
inspiratory	   occlusion	   technique)	   were	   measured	   before	   each	   recruitment	  
manoeuvre.	  
	  
A	   dose	   titration	   (keeping	   a	   fixed	   volume	   of	   50μl)	   was	   performed	   to	   ascertain	   a	  
clinically	   relevant	   degree	   of	   injury	   using	   two	   clinically	   relevant	   parameters	   –	  
respiratory	  mechanics	  (elastance)	  and	  arterial	  oxygenation	  (figure	  3.1).	  There	  was	  an	  
increasing	  elastance	  and	  worsening	  oxygenation	  as	  the	  number	  of	  protons	   instilled	  
into	  the	  lungs	  increased.	  The	  use	  of	  0.1M	  HCl,	  although	  producing	  a	  50%	  increase	  in	  
elastance	  did	  not	  produce	  significant	  changes	  in	  arterial	  oxygenation	  at	  three	  hours.	  
In	  contrast,	  0.25M	  HCl	  produced	  overwhelming	   injury	  with	  the	   loss	  of	   two	  animals	  
(severe	   hypotension	   with	   a	   blood	   pressure	   below	   50mmHg)	   by	   60	   minutes.	   A	  
concentration	  of	  0.15M	  was	  chosen,	  for	  subsequent	  studies,	  as	  it	  produced	  a	  100%	  
increase	   in	   elastance,	   a	   2.5	   fold	   reduction	   in	   arterial	   oxygenation	   (reaching	  
moderate/severe	  ARDS	   levels	   according	   to	   the	   revised	  Berlin	   criteria),	   and	  a	  100%	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Figure	  3.1.	  Development	  of	  acute	  acid	  aspiration	  lung	  injury	  model	  
A)	  Initial	  dose	  titration	  showed	  that	  fluid	  instillation	  caused	  an	  immediate	  increase	  in	  
elastance	   (Ers)	   due	   to	   fluid	   in	   the	   airway.	   During	   the	   instillation	   of	   saline	   or	   low	  
concentration	  of	  acid	  Ers	  returned	  back	  to	  near	  baseline.	  As	  dose	  of	  protons	  (i.e.	  the	  
pH	  of	  the	  acid	  was	  reduced,	  keeping	  volume	  constant),	  there	  was	  no	  recovery	  of	  Ers	  
from	  a	  dose	  of	  0.15M	  upwards.	  This	  dose	  of	  0.15M	  produced	  a	  sustained	  increase	  in	  
Ers	  after	  90	  minutes	  leading	  to	  an	  increase	  from	  baseline	  Ers	  of	  100%	  at	  3	  hours.	  The	  
0.25M	  acid	  dose	  led	  to	  a	  high	  mortality	  rate.	  B)	  There	  was	  a	  strong	  correlation	  with	  
proton	   dose	   and	   change	   in	   Ers	   over	   90	  minutes	   (Pearson	   r	   =	   0.995,	   P<0.0001).	   C)	  
Only	   acid	   doses	   above	   0.15M	   produced	   changes	   to	   oxygenation.	   D)	   0.15M	   acid	  
concentration	   produced	   deteriorations	   in	   oxygenation	   equivalent	   to	   ARDS	   levels	  
with	   a	   PaO2/FiO2	   of	   less	   than	   300.	   Green,	   amber	   and	   red	   lines	   demarcate	   mild,	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3.4.2 Alveolar	  oedema	  is	  mediated	  specifically	  through	  the	  p55	  TNF	  receptor	  in	  
acid-­‐induced	  lung	  injury.	  
	  
There	  were	  no	  differences	  in	  baseline	  tidal	  volume	  (VT),	  respiratory	  system	  elastance	  
(Ers),	   resistance	   (Rrs),	   peak	   inspiratory	   pressures	   (PIP),	   and	   arterial	   blood	   gases	  
between	   the	   animal	   groups	   (table	   3.1),	   indicating	   that	   respiratory	   mechanics	   and	  




Table	   3.1.	   Baseline	   respiratory	   mechanics	   and	   blood	   gas	   measurements	   in	   all	  
mouse	  strains	  
Baseline	   respiratory	   mechanics	   and	   blood	   gases	   before	   saline	   or	   acid	   instillation	  
showed	   no	   differences	   between	   groups.	   	   Note	   that	   RR	   (120bpm)	   and	   VT	   (minute	  
ventilation)	  were	  similar	  between	  groups	  leading	  to	  a	  similar	  PaCO2,	  confirming	  that	  
the	  same	  ventilatory	  strategy	  was	  applied	  to	  all	  strains	  of	  mice	  at	  the	  beginning	  of	  
the	  protocol.	  (N=6-­‐12	  per	  group;	  no	  statistical	  differences	  found	  between	  groups)	  
	  
3.4.3 Respiratory	  Mechanics	  	  
The	  measurement	  of	  respiratory	  mechanics	  is	  dynamic	  and	  Ers	  (calculated	  by	  [Pplat-­‐
PEEP]/VT)	   is	   dependant	   on	   the	   tidal	   volume	  delivered	   and	   the	   set	   PEEP.	  Hence,	   it	  
was	  important	  to	  standardise	  PEEP	  and	  VT	  throughout	  the	  course	  of	  injury.	  As	  can	  be	  
seen	  from	  figure	  3.2	  there	  were	  no	  changes	  in	  VT	  (over	  time)	  within	  the	  groups	  and	  
no	   differences	   in	   VT	   between	   groups	   throughout	   the	   3-­‐hour	   protocol,	   suggesting	  
	   WT	   p55KO	   p75KO	   DKO	  
VT	  (ml/kg)	   8.7±0.9	   8.7±0.4	   8.6±0.5	   8.9±0.7	  
PIP	  (cmH2O)	   10.7±0.7	   10.1±0.5	   9.9±0.6	   10.2±0.1	  
Ers	  
(cmH2O/ml/kg)	  
0.022±0.003	   0.021±0.002	   0.023±0.002	   0.021±0.001	  
Rrs	  
(cmH2O/ml/s)	  
1.8±0.3	   1.6±0.4	   1.6±0.1	   1.7±0.2	  
PaO2/FiO2	   456±37	   476±35	   453±30	   486±27	  
PaCO2	  (mmHg)	   43±7	   41±4	   43±4	   42±4	  
Chapter	  3	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that	   the	   measurements	   represent	   changing	   respiratory	   physiology	   and	   that	   the	  
instillation	  of	  fluid	  and	  development	  of	  oedema	  had	  no	  effect	  on	  the	  VT	  delivered	  by	  
the	  ventilator.	  	  
	  
Figure	  3.2.	  Ventilation	  settings	  between	  mouse	  strains	  
All	   strains	   were	   ventilated	   between	   8-­‐9mls/kg	   with	   no	   intra-­‐	   or	   inter-­‐strain	  
differences	   over	   the	   3	   hours	   protocol.	   A	   volume	   and	   flow	   controlled	   ventilation	  
system	  was	  used	  and	  hence	  this	  confirms	  that	  the	  observed	  changes	   in	  respiratory	  
mechanics	  reflects	  alterations	  to	  respiratory	  physiology.	  Furthermore,	  this	  confirms	  
that	  instillation	  of	  fluid	  into	  the	  alveolar	  space	  had	  no	  impact	  upon	  the	  tidal	  volume	  
delivered	   by	   the	   ventilator.	   (N=6-­‐12	   per	   group;	   no	   statistical	   differences	   found	  
between	  groups)	  
	  
The	   instillation	   of	   fluid	   into	   the	   tracheal	   tube	   led	   to	   an	   immediate	   worsening	   of	  
respiratory	  mechanics	  in	  all	  strains	  (figure	  3.3).	  This	  was	  entirely	  due	  to	  the	  presence	  
of	   fluid	   within	   the	   airways	   as	   saline	   instillation	   induced	   a	   similar	   increase	   to	   acid	  
instillation.	   After	   this	   immediate	   increase	   in	   Ers,	   acid	   aspiration	   in	   WT	   animals	  
showed	  a	   sustained	   increase,	  which	   further	   increased	   in	   the	   final	   60	  minutes,	   and	  
led	   to	   a	   significant	   1.8	   fold	   increase	   by	   the	   end	   of	   the	   three-­‐hour	   protocol.	   In	  
contrast,	  saline	  instillation	  led	  to	  a	  gradual	  reduction	  in	  Ers,	  presumably	  as	  fluid	  was	  
cleared	  or	  distributed	  from	  the	  lungs.	  	  
	  
The	   p75KO	   and	   DKO	   strains	   showed	   greater	   immediate	   increases	   in	   Ers	   (at	   30	  
minutes)	  but	  showed	  a	  similar	  gradient	  of	  increase	  to	  WT	  animals	  for	  the	  remainder	  
of	   the	   protocol.	   However,	   these	   strains	   ended	  with	   a	   significantly	   higher	   final	   Ers	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compared	   to	  WT	   animals,	   possibly	   due	   to	   this	   higher	   initial	   increase.	   In	   contrast,	  
animals	   deficient	   in	   the	   p55	   TNFR	   showed	   a	   similar	   trend	   to	   saline	   instilled	   sham	  
controls	  and	  showed	  a	  statistically	  significant	   improvement	  as	  early	  as	  90	  minutes.	  
Similar	  changes	  were	  also	  reflected	  by	  changes	  in	  the	  peak	  inspiratory	  pressure	  (PIP)	  
where	   p75KO	   and	   DKO	   animals	   showed	   greater	   increases	   by	   3	   hours;	   and	   p55KO	  
animals	   showed	   near	   complete	   protection.	   Interestingly,	   there	   was	   very	   little	  
difference	  in	  respiratory	  system	  resistance	  (Rrs)	  between	  the	  p55KO	  and	  WT	  groups,	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Figure	   3.3.	   Differences	   in	   respiratory	   mechanics	   between	   strains	   after	   acid	  
aspiration	  
The	  time	  course	  of	   respiratory	  mechanics:	  A)	   respiratory	  system	  elastance	   (Ers);	  B)	  
Peak	   inspiratory	   pressure	   (PIP)	   and	   C)	   respiratory	   system	   resistance	   (Rrs)	   over	   3	  
hours	  in	  WT	  and	  TNF	  receptor	  knockout	  strains	  exposed	  to	  acid-­‐induced	  lung	  injury.	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3.4.4 Arterial	  blood	  gas	  analysis	  
Mice	  were	  ventilated	  with	  a	  FiO2	  of	  1.0	  and	  PEEP	  of	  2.5-­‐3.0cmH2O,	  and	  underwent	  
hourly	  arterial	  blood	  gas	  analysis.	  The	  WT,	  p75KO	  and	  DKO	  strains	  showed	  significant	  
and	   immediate	   deteriorations	   in	   arterial	   oxygenation	   leading	   to	   PaO2/FiO2	   ratios	  
achieving	  clinical	  ARDS	  criteria	  of	  at	  least	  moderate	  severity	  (i.e.	  <200)	  (figure	  3.4).	  In	  
contrast,	   p55KO	   strains	   maintained	   arterial	   oxygenation	   at	   levels	   similar	   to	   saline	  
instilled	  sham	  controls.	  A	  statistically	  significant	  difference	  between	  WT	  and	  p55KO	  
strains	  was	  apparent	  even	  at	  60	  minutes	  after	  acid	  aspiration.	  Gas	  exchange	  in	  terms	  
of	  PaCO2	   showed	  a	  similar	  pattern,	   i.e.	  deterioration	   in	  WT,	  p75KO	  and	  DKO	  mice,	  
with	  significant	  improvement	  in	  p55KO	  mice.	  	  
	  
	  
Figure	  3.4.	  Differences	  in	  gas	  exchange	  between	  strains	  after	  acid	  aspiration	  
The	  time	  course	  and	  final	  measurements	  of	  arterial	  blood	  gases	  A)	  PaO2/FiO2	  ratio;	  
B)	   PaCO2	   over	   3	   hours	   in	  WT	   and	   TNF	   receptor	   knockout	   strains	   exposed	   to	   acid-­‐
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3.4.5 Lung	  water	  content	  
The	  above	  alterations	  in	  respiratory	  function	  most	  likely	  represent	  a	  combination	  of	  
pulmonary	  oedema	  development	   inducing	   intrapulmonary	   shunt	  and	  atelectasis	  of	  
alveolar	   units.	   Pulmonary	   oedema	   formation	   was	   assessed	   directly	   by	   assessing	  
wet/dry	   weight	   ratio	   (figure	   3.5	   A)	   of	   the	   lungs	   at	   the	   end	   of	   the	   protocol.	   As	  
anticipated,	   acid	   instillation	   induced	   significant	   pulmonary	  oedema	   in	  WT	  animals,	  
which	  was	  similar	  in	  p75KO	  and	  DKO	  mice,	  but	  greatly	  attenuated	  in	  p55KO	  mice.	  	  
3.4.6 Alveolar	  capillary	  barrier	  permeability	  
This	   was	   assessed	   using	   two	   methodologies.	   Firstly,	   the	   protein	   levels	   within	   the	  
BALF	   were	   determined	   (figure	   3.5	   B).	   This	   showed	   a	   significantly	   reduced	   protein	  
content	  in	  p55KO	  animals	  as	  compared	  to	  the	  other	  strains.	  In	  view	  of	  the	  significant	  
protection	   seen	   in	   p55KO	   animals	   we	   went	   on	   further	   to	   measure	   a	   more	   direct	  
parameter	   of	   permeability.	   BALF	   protein	   can	   be	   influenced	   by	   not	   only	   the	  
translocation	  of	  protein	  but	  also	  the	  clearance	  of	  fluid	  over	  the	  three-­‐hour	  protocol.	  
Hence,	   we	  measured	   the	   translocation	   of	   fluorescently	   labelled	   albumin	   from	   the	  
blood	   compartment	   to	   the	   alveolar	   space	   in	   the	   final	   30	   minutes	   of	   the	   3-­‐hour	  
protocol	   (figure	   3.5	   C).	   Both	   indices	   of	   permeability	   showed	   that	   p55KO	   animals	  
showed	   significantly	   better	   alveolar	   capillary	   barrier	   function	   as	   compared	   to	  WT	  
animals.	  DKO	  and	  p75KO	  animals	   showed	   levels	  of	   injury	   similar	   to	   the	  WT	  group.	  
Given	  the	  similar	   injury	  pattern	  to	  WT	  animals	  and	  in	  part	  due	  to	  poor	  breeding	  of	  
animals	  no	   further	   experiments	  were	  performed	  on	  DKO	  animals,	   and	  hence	   their	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Figure	   3.5.	   Differences	   in	   alveolar-­‐capillary	   barrier	   permeability	   between	   strains	  
after	  acid	  aspiration	  
Measures	  of	  lung	  oedema	  formation	  –	  A)	  Wet	  weight/dry	  weight;	  B)	  lavage	  protein	  
concentration;	   and	   C)	   permeability	   index	   show	   significant	   attenuation	   in	   p55KO	  
animals.	  (N=4-­‐6	  per	  group;	  ***	  P<0.001	  **	  P<0.01)	  
Figure' 3.5'Measures' of' lung' oedema' forma/on' –' A)' Wet' weight/dry' weight;' B)'
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3.4.7 Inflammatory	  consequences	  of	  TNF	  receptor	  signalling	  in	  acid	  aspiration.	  
Acid	  aspiration	  has	  been	  shown	  to	  be	  dependant	  on	  IL-­‐8	  (88)	  and	  neutrophils	  (260).	  
Given	   the	  ability	  of	  TNF	   to	   induce	   IL-­‐8	  production	   (265)	   in	   the	   lung	  and	  ultimately	  
promoting	   neutrophil	   recruitment,	   it	   was	   hypothesised	   that	   each	   TNF	   receptor	  
induced	   different	   degrees	   of	   inflammation	   within	   the	   lung.	   In	   particular,	   the	  
protection	  conferred	  through	  p55	  TNFR	  deletion	  could	  be	  secondary	  to	  reduced	  TNF	  
driven	   inflammatory	   signalling	   within	   the	   lung.	   Hence,	   soluble	   levels	   of	  
cytokines/chemokines	   (figure	   3.6)	   as	   well	   as	   lung	   leukocytes	   (figure	   3.7)	   were	  
measured.	  
Inflammatory	  cytokines/chemokines.	  	  
It	  was	  first	  confirmed	  that	  TNF	  was	  upregulated	  within	  the	  alveolar	  space	  to	  similar	  
levels	  between	  all	   the	  strains.	  The	  fact	  that	  there	  was	  TNF	  present	  at	  similar	   levels	  
supported	   the	   view	   that	   differences	   in	   TNF	   bioavailability	   did	   not	   account	   for	   the	  
physiological	  differences	  observed	  between	  the	  groups	  i.e.	  lower	  levels	  of	  bioactive	  
TNF	   accounting	   for	   protection	   in	   p55KO	   strains,	   and	   vice	   versa	   for	   p75KO/DKO	  
animals.	  When	  BALF	  was	  analysed	  at	  this	  3-­‐hour	  time	  point	  for	  neutrophil/monocyte	  
chemoattractants	  including	  MIP-­‐2/KC	  (mouse	  IL-­‐8	  analogues)	  and	  MCP-­‐1,	  there	  were	  
no	   differences	   found	  between	   knockout	   groups.	   Interestingly,	   IL-­‐6	   levels	  were	   not	  
attenuated	  in	  p55KO	  animals	  but	  showed	  a	  strong	  tendency	  to	  be	  higher	   in	  p75KO	  
injured	   animals	   as	   compared	   to	   WT	   injured	   controls	   (P=0.068,	   Mann-­‐Whitney	   U-­‐
test).	  There	  were	  no	  differences	  seen	  between	  acid	  injured	  p55KO	  and	  WT	  animals.	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Figure	  3.6.	  Differences	  in	  alveolar	  cytokines/chemokines	  between	  strains	  after	  acid	  
aspiration	  
Acid	  aspiration	  leads	  to	  a	  significant	  increase	  in	  alveolar	  levels	  of	  cytokines	  (TNF	  and	  
IL-­‐6)	  and	  chemokines	  (KC,	  MIP-­‐2	  and	  MCP-­‐1).	  This	  increase	  occurs	  in	  WT,	  p55KO	  and	  
p75KO	  groups	   to	  a	   similar	  degree.	  There	   is	   a	   tendency	   for	  p75KO	  group	   to	  have	  a	  








































































































































Figure' 3.6' Acid" aspira+on" leads" to" a"
signiﬁcant" increase" in" alveolar" levels" of"
c y tok i ne s" ( TNF" and" I L = 6 )" and"
chemokines"(KC,"MIP=2"and"MCP=1)."This"
increase" occurs" in" WT," p55KO" and"
p75KO"groups"to"a"similar"degree."There"
is"a"tendency"for"p75KO"group"to"have"a"




Differential	  roles	  for	  TNF	  receptors	  in	  experimental	  ARDS	  
	   129	  
Pulmonary	  leukocyte	  recruitment	  	  
Analysis	  of	   lavage	  cell	  numbers	  using	  haemocytometric	   cell	   counting	  at	   the	  end	  of	  
the	  3	  hour	  protocol	  showed	  no	  significant	  neutrophil	  proportions	  within	  the	  alveolar	  
space	  in	  any	  of	  the	  groups	  tested	  (%	  neutrophils	  among	  BALF	  cells	  -­‐	  WT	  Saline	  1±0%;	  
WT	  acid	  3.3±1.7%;	  p55KO	  4.1±2.4%;	  p75KO	  0.3±0.4%;	  DKO	  0.3±0.3%).	  	  
	  
Hence,	   it	   was	   likely	   that	   within	   this	   early	   time-­‐frame	   leukocytes	   had	   not	   fully	  
migrated	  into	  the	  alveolar	  space	  and	  may	  have	  been	  present	  either	  adhered	  to	  lung	  
endothelium	  within	  the	  vasculature,	  or	  were	  within	  the	  lung	  interstitium,	  and	  hence	  
not	   retrievable	   through	   lung	   lavage.	   This	   prompted	   the	   evaluation	   of	   analysis	   of	  
leukocyte	   sequestration	   to	   the	   whole	   lung	   using	   flow	   cytometry.	   Whole	   lung	  
homogenate	  was	   gated	   using	   the	   gating	   strategy	   shown	   in	   figure	   3.7.	   Neutrophils	  
and	   monocytes	   were	   first	   gated	   in	   lung	   cell	   suspensions	   as	   CD45+CD11b+NK1.1-­‐	  
events	  (R1	  +	  R2).	  Subsequently,	  neutrophils	  were	  identified	  as	  Ly-­‐6CintermediateLy-­‐6Ghi	  
(R3),	  whereas	   inflammatory	  monocytes	  were	   identified	   as	   Ly-­‐6ChiLy-­‐6Glo	   (R4).	   	  We	  
have	  previously	  showed	  that	  following	  the	  cell	  fixation	  procedure	  (using	  IC	  fixative)	  
that	   the	  Gr-­‐1	   antibody	   (clone	  RB6-­‐8C5)	   only	   recognizes	   the	   Ly-­‐6G	  epitope	  on	   cells	  
(241).	   	  Thus	  the	  staining	  with	  this	  antibody	  here	  are	  defined	  as	  Ly-­‐6Ghi,	  rather	  than	  
Gr-­‐1hi.	   As	   expected,	   at	   three	   hours	   there	   were	   significant	   increases	   in	   lung-­‐
sequestered	   neutrophils	   and	   inflammatory	   (Ly-­‐6Chi)	   monocytes	   in	   WT	   animals.	  
However,	   consistent	  with	   the	  chemokine	  data,	  no	  differences	  between	  p55KO	  and	  
WT	   strains	   were	   seen.	   Very	   interestingly	   the	   p75KO	   animals	   showed	   significantly	  
more	  leukocyte	  infiltration.	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Figure	   3.7.	   Differences	   in	   lung	   leukocyte	   numbers	   between	   strains	   after	   acid	  
aspiration	  
Lung	  sequestered	  neutrophils	  and	  inflammatory	  monocytes	  were	  counted	  using	  flow	  
cytometry	  on	  single	  cell	  suspension	  produced	  by	  mechanical	  disruption	  of	  the	  right	  
lung.	   Leukocytes	   were	   gated	   as	   CD45	   positive	   (R1).	   Myeloid	   cells	   	   (R2)	   were	  
identified	  as	  CD11b+	  and	  NK1.1-­‐	   (to	  exclude	  NK	  cell	  populations).	  Neutrophils	  were	  
identified	  as	  Ly-­‐6Ghi	  (R3).	  Inflammatory	  monocytes	  were	  identified	  as	  Ly-­‐6Glo	  and	  Ly-­‐
6chi	   subset	   (R4).	  Acid	   aspiration	   leads	   to	   a	   significant	   increase	   in	   lung	   sequestered	  
neutrophils	   and	   inflammatory	   monocytes	   in	   all	   groups.	   The	   p55KO	   group	   shows	  
similar	  levels	  to	  WT	  animals.	  In	  contrast	  the	  p75KO	  group	  shows	  significantly	  higher	  
levels	  of	  sequestered	  leukocytes	  as	  compared	  to	  WT	  animals.	  (N=5-­‐7	  per	  group;	  ***	  
P<0.001	  **	  P<0.01	  *	  P<0.05)	  
	  
3.4.8 Histology	  
Histological	   analysis	   (figure	   3.8)	   supported	   the	   flow	   cytometric	   evaluation.	   No	  
differences	  were	  present	   in	  terms	  of	   leukocyte	   infiltration	  between	  WT	  and	  p55KO	  
animals.	   However,	   p75KO	   lung	   sections	   showed	   substantial	   leukocyte	   infiltration.	  



























































































Figure' 3.7' Lung" sequestered" neutrophils" and" inﬂammatory" monocytes" were"
counted" using" ﬂow" cytometry" on" single" cell" suspension" produced" by" mechanical"
disr pKon"of"th "right" lung."Leukocytes"were"gated"as"CD45"posiKve"(R1)."Myeloid"
cells" " (R2)"were" idenKﬁed"as"CD11b+"and"NK1.19" (to"exclude"NK"cell"populaKons)."
Neutrophils"were"idenKﬁed"as"Ly96G"very"high"(R3)."Inﬂammatory"monocytes"were"
idenKﬁed" as" Ly96G" low" and" Ly96c" high" subset" (R4).' Acid" aspiraKon" leads" to" a"
signiﬁcant"increase"in"lung"sequestered"neutrophils"and"inﬂammatory"monocytes"in"
all" groups." The" p55KO" group" shows" similar" levels" to"WT" animals." In" contrast" the"
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lower	  extent	  of	  alveolar	  wall	   thickening,	   intra-­‐alveolar	  proteinaceous	  material,	  and	  
alveolar	  oedema	  as	  compared	  with	  WT	  animals.	  
	  
	  
Figure	  3.8.	  Lung	  histology	  after	  acid	  aspiration	  
H&E-­‐stained	   sections	   (original	  magnification	   x200)	   of	  WT	   and	   p55KO	   animals	   at	   3	  
hours	  after	  acid	  instillation.	  Acid	  instillation	  induces	  significant	  increases	  in	  alveolar	  
wall	   thickening,	   intra-­‐alveolar	   proteinaceous	  material,	   and	   alveolar	   oedema	   in	  WT	  
animals.	   These	   parameters	   representing	   alveolar	   capillary	   barrier	   breakdown	   are	  
reduced	  in	  p55KO	  animals,	  whereas	  leukocyte	  infiltration	  is	  present	  in	  all	  strains	  and	  
to	  a	  greater	  extent	  in	  p75KO	  animals.	  Scale	  bar	  represents	  50μm.	  
	  
3.4.9 TNF	  receptor	  shedding	  and	  expression	  in	  blood	  monocytes	  and	  neutrophils	  
Acid	   aspiration	   led	   to	   a	   significant	   increase	   in	   soluble	   TNF	   receptor	   levels	   in	   the	  
alveolar	   space	   as	   compared	   to	   saline	   controls	   (Figure	   3.9	   A).	   Consistent	   with	  
previous	   data	   from	   our	   laboratory,	   the	   levels	   of	   soluble	   TNF	   receptors	   correlated	  
well	  with	  alveolar	  protein	  concentration	  suggesting	  leak	  into	  the	  alveolar	  space	  from	  
Uninjured)WT) Acid)ins/lled)WT)
Acid)ins/lled)p55KO) Acid)ins/lled)p75KO)
Figure' 3.8' H&E$stained, sec.ons, (original, magniﬁca.on, x200), of, WT, and, p55KO,
animals, at, 3, hours, aDer, acid, ins.lla.on., Acid, ins.lla.on, induces, signiﬁcant,
increases, in, alveolar, wall, thickening,, intra$alveolar, proteinaceous, material,, and,
alveolar, oedema, in,WT, animals., These, parameters, represen.ng, alveolar, capillary,
barrier,breakdown,are,reduced,in,p55KO,animals,,whereas,leukocyte,inﬁltra.on,is,
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the	   vascular	   compartment	   (Figure	   3.9	   B).	   Hence,	   TNF	   receptor	   expression	   was	  
analysed	  on	  blood	  monocytes	  and	  neutrophils	  (potential	  sources	  of	  these	  receptors)	  
to	  ensure	  a)	   that	   the	  phenotype	  of	   the	  strains	  matched	   their	   respective	  genotype,	  
and	  b)	  that	   levels	  of	  expression	  of	  the	  non-­‐deleted	  TNF	  receptor	   in	  the	  p55KO	  and	  
p75KO	  strains	  were	  equivocal	  to	  WT	  animals	  expressing	  both	  receptors.	  Figure	  3.10	  
confirms	   the	   strain	   phenotypes	   match	   the	   genotypes.	   It	   also	   shows	   that	   the	   cell	  
surface	   expressions	  of	   the	  non-­‐depleted	   TNF	   receptors	   in	   the	   genetically	  modified	  
strains	  are	  similar	  to	  WT	  animals.	  Hence,	  differences	  in	  the	  levels	  of	  shed	  soluble	  TNF	  
receptor	   and/or	   increased	   compensatory	   TNF	   signalling	   through	   an	   overexpressed	  
non-­‐depleted	  receptor	  do	  not	  explain	  the	  physiological	  effects	  seen.	  
	  
Figure	  3.9.	  Soluble	  TNF	  receptor	  levels	  in	  alveolar	  lavage	  after	  acid	  aspiration	  	  
A)	   Acid-­‐induced	   the	   production	   of	   the	   soluble	   forms	   for	   both	   p55	   and	   p75	   TNF	  
receptors.	   (N=5-­‐6	  per	   group;	   ***	  P<0.001).	  B)	   The	   sources	   for	   these	   receptors	   are	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predominantly	  from	  the	  plasma	  compartment	  as	  their	  levels	  shows	  strong	  significant	  
correlations	  with	  the	  extent	  of	  protein	  leak	  (Pearson	  R	  =	  0.995;	  P<0.0001).	  
	  	  
Figure	  3.10.	  Cell	  surface	  TNF	  receptor	  expression	  on	  neutrophils	  and	  monocytes	  in	  
all	  knockout	  strains	  
Given	  that	  the	  likely	  sources	  for	  the	  soluble	  TNF	  receptors	  in	  the	  lavage	  are	  vascular,	  
TNF	   receptor	   expression	  was	  measured	   on	   blood	   leukocytes.	   A)	  Whole	   blood	   (R1)	  
was	   processed	   for	   flow	   cytometric	   assessment.	   First	   CD11b	   positive	   cells	   were	  
divided	   into	   F4/80	   positive	   (R2	   -­‐	   monocytes)	   and	   negative	   (R3	   -­‐	   neutrophils).	  
Neutrophils	  show	  a	  high	  side	  scatter	  as	  a	  consequence	  of	  their	  granular	  composition	  
whereas	  monocytes	  are	  slightly	  larger	  (higher	  forward	  scatter)	  and	  less	  granular.	  B)	  




divided& into& F4/80& posiMve& (R2)& and& negaMve& (R3)& to& produce& two& disMnct& ell&
populaMons&of&neutrophils&and&monocytes.&Neutrophils&show&a&high&side&scaPer&as&a&
consequence&of& their& granular& composiMon&whereas&monocytes& are& slightly& larger&
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The	  levels	  of	  expression	  of	  p75	  on	  p55KO	  and	  vice	  versa	  for	  p75KO	  are	  similar	  to	  WT	  
animals.	   Monocytes	   showed	   a	   higher	   level	   of	   expression	   of	   cell	   surface	   p75	  
receptors	  as	  compared	  to	  neutrophils.	  
	  
	  
3.5 	   Discussion	  
There	  are	  some	  important	  observations	  and	  discussion	  points	  that	  arise	  from	  these	  
physiology	   data	   with	   respect	   to	   the	   way	   in	   which	   oedema	   formation	   occurs	  
immediately	  following	  acid	  aspiration:	  
1 The	  p55	  TNFR	  has	  an	  impact	  on	  indices	  of	  alveolar-­‐capillary	  barrier	  function.	  
2 The	   p55	   TNFR	  mediates	   injury	   independent	   of	   downstream	   pro-­‐inflammatory	  
events.	  
3 The	   p75	   TNFR	   impacts	   upon	   alveolar	   inflammation	   and	   lung	   leukocyte	  
sequestration.	  
4 Finally,	   physiological	   disturbance	   occurs	  well	   before	   leukocyte	   infiltration	   into	  
the	  alveolar	  space.	  
3.5.1 Mechanisms	  of	  oedema	  formation	  after	  acid	  aspiration	  
ARDS	   shows	   sudden	   deteriorations	   in	   gas	   exchange	   as	   a	   result	   of	   acute	   onset	  
alveolar	   oedema.	   This	   is	   particularly	   true	   in	   the	   case	   of	   ARDS	   caused	   by	   gastric	  
aspiration	  in	  which	  oedema	  can	  develop	  within	  hours	  in	  relation	  to	  the	  acidic	  nature	  
of	  these	  contents.	  Although	  the	  signalling	  from	  within	  the	  alveolar	  space	  to	  the	  peri-­‐
capillary	   compartment	   is	   fast	   (39,	   42,	   85),	   leukocyte	   transmigration	   from	   the	  
pulmonary	  microcirculation	   into	   the	   alveolar	   space	   occurs	   from	  4	   hours	   after	   acid	  
aspiration	   (195).	   Kennedy	  and	   colleagues	   showed	   in	   a	  non-­‐ventilated	   rat	  model	  of	  
acid	  aspiration	  that	  the	  injury	  was	  of	  a	  biphasic	  pattern	  of	  injury.	  They	  hypothesised	  
that	   the	   initial	   phase	   (1-­‐2	   hours)	   was	   a	   consequence	   of	   a	   direct	   physicochemical	  
process	   and	   that	   the	   second	   phase	   (2-­‐4	   hours)	   was	   a	   consequence	   of	   an	   acute	  
inflammatory	   response	   (195).	   The	   majority	   of	   studies	   utilising	   the	   acid	   aspiration	  
paradigm	  of	   lung	   injury	  have	   investigated	  the	  second	  stage	  of	  early	  acid	  aspiration	  
events	  (i.e.	  after	  3	  hours	  of	  insult).	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However,	   the	  data	  presented	   in	   figure	  3.1	  shows	  that	  acid	  produces	  an	   immediate	  
and	   sustained	   deterioration	   in	   respiratory	   mechanics	   in	   WT	   animals	   from	   30	  
minutes,	  and	  at	  90	  minutes	  there	  is	  a	  worsening	  of	  the	  Ers,	  which	  likely	  represents	  
the	   true	   development	   of	   alveolar	   oedema.	   Saline	   instillation,	   on	   the	   other	   hand,	  
produces	   the	   same	   initial	   increase	   (at	   30	   minutes)	   but	   leads	   to	   immediate	  
improvements	  by	  60	  minutes.	  The	  cause	  and	  nature	  of	  this	  immediate	  and	  sustained	  
increase	   in	   Ers	   (0-­‐90	  minutes)	   after	   acid	   remains	   unknown	   and	   has	   received	   little	  
attention.	   However,	   it	   is	   imaginable	   that	   the	   alveolar	   instillation	   of	   acid	   induces	  
immediate	   contraction	   of	   smooth	   muscle	   within	   the	   conducting	   airways.	   Mitzner	  
showed	  a	  significant	  contribution	  of	  airways	  calibre	  to	  changes	  in	  compliance	  (1/Ers)	  
by	   adding	  methacholine	   to	   rabbit	   bronchial	   circulation	   (266)	   and	   Ewart	   showed	   a	  
similar	   response	   to	   acetylcholine	   infusion	   in	   mouse	   lungs	   (240).	   An	   alternative	  
explanation	   for	   the	   sudden	   change	   in	   elastance	   could	   be	   an	   early	   surfactant	  
dysfunction	  causing	  increased	  alveolar	  recoil.	  However,	  this	  is	  unlikely	  as	  the	  instilled	  
fluid	   is	   unlikely	   to	   be	   immediately	   delivered	   to	   the	   alveoli	   lining	   fluid,	   making	   a	  
chemical	   reaction	   with	   surfactant	   leading	   to	   its	   dysfunction	   within	   30	   minutes	  
unlikely.	   A	   further	   possibility	   could	   be	   alveolar	   fluid	   clearance	  with	   sustained	   AFC	  
resulting	  in	  improvements	  of	  respiratory	  mechanics	  after	  saline	  instillation.	  Alveolar	  
fluid	   clearance	   is	   performed	  by	   the	   epithelium	  of	   the	   distal	   conducting	   airways	   as	  
well	  as	   the	  alveolus.	  Acid	  aspiration	  has	  been	  shown	  to	   impact	  upon	  alveolar	   fluid	  
clearance	  but	  this	  has	  often	  only	  been	  measured	  at	  much	  later	  time-­‐points	  i.e.	  after	  
4	  hours	  (71,	  255).	  	  
3.5.2 The	  TNF	  double	  edged	  sword	  –	  p55	  versus	  p75	  signalling	  
TNF	  has	  been	  implicated	  in	  sepsis	  induced	  ARDS	  since	  it	  was	  first	  discovered	  to	  have	  
the	   same	  molecular	   structure	  as	   cachectin	  by	  Beutler	  and	  Cerami	   in	  1985	   (140).	  A	  
number	   of	   studies	   have	   demonstrated	   an	   involvement	   of	   TNF	   in	   mediating	   acid	  
aspiration-­‐induced	   lung	   injury.	   Davidson	   et	   al	   (197)	   showed	   decreased	   albumin	  
permeability	   index,	   lung	   myeloperoxidase	   activity	   (leukocyte	   infiltration)	   and	  
improved	   PaO2/FiO2	   after	   treatment	  with	   intra-­‐tracheal	   anti-­‐TNF	   antisera,	   in	   a	   rat	  
model	  of	  acid	  aspiration.	   	  Other	  groups	  have	   identified	  a	  role	   for	  TNF	   in	  mediating	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systemic	   injury	   following	   acid	   (196).	   However,	   in	   these	   model	   systems	   simply	  
blocking	  the	  activity	  of	  TNF	  does	  not	  fully	  prevent	  the	  lung	  injury.	  	  
	  
In	   contrast,	   in	   our	   experiments,	   animals	   with	   the	   specific	   deletion	   of	   the	   p55	  
receptor	   showed	   near	   complete	   abrogation	   of	   lung	   injury	   in	   oxygenation	   and	  
respiratory	  mechanics.	  Additionally,	  animals	  with	  no	  TNF/TNF	  receptor	  signalling	  (i.e.	  
DKO)	  have	  a	  similar,	  if	  not	  greater	  injury	  (with	  respect	  to	  respiratory	  mechanics)	  than	  
WT	   animals.	   The	   physiological	   data	   support	   previous	   data	   from	   our	   laboratory	  
showing	   protection	   (in	   respiratory	   mechanics,	   lung	   wet/dry	   weights,	   alveolar-­‐
capillary	  barrier	  permeability,	  and	  survival)	  with	  p55	  TNFR	  blockade	  through	  genetic	  
and	  pharmacological	  approaches	   in	  mice	  exposed	   to	  ventilator	   induced	   lung	   injury	  
(224,	  252).	  	  
	  
The	   protective	   effect	   of	   p55	   deletion	   in	   acid	   aspiration	   could	   not	   be	   explained	   by	  
differences	   in	   available	   soluble	   TNF.	   Any	   difference	   in	   TNF	   bioavailability	   was	  
important	  to	  exclude	  for	  two	  reasons.	  Firstly,	  p55	  TNFR	  activation	  can	  induce	  NFκB	  
transcription	  and	  induce	  TNF	  production	  and	  therefore	  its	  absence	  could	  reduce	  TNF	  
upregulation	  in	  the	  alveolar	  space.	  Secondly,	  soluble	  TNF	  receptors	  are	  found	  in	  the	  
alveolar	   space	   after	   acid	   aspiration	   and	   hence,	   could	   quench	   TNF,	   inducing	  
significant	  alterations	   in	  TNF	  bioavailability	  between	  the	  experimental	  groups	  (150,	  
267).	  Soluble	  receptor	   levels	  were	  not	  measured	  in	  the	   lavage	  of	  knockout	  animals	  
as	   the	   roles	   and	   relative	   contributions	   of	   each	   soluble	   TNF	   receptor	   (soluble	   p55	  
versus	   soluble	   75)	   is	   uncertain	   and	  not	  within	   the	   scope	  of	   this	  work.	   Indeed,	   our	  
laboratory	  has	   shown	   that	   pulmonary	   inflammation	   induces	   the	   release	  of	   soluble	  
p75	  TNFR	  from	  alveolar	  macrophages,	  whereas	  models	  showing	  significant	  alveolar	  
epithelial	   permeability	   and	   pulmonary	   oedema	   lead	   to	   the	   upregulation	   of	   both	  
soluble	   p55	   and	   soluble	   p75	   TNFRs	   in	   the	   alveolar	   space,	   as	   a	   consequence	   of	  
leakage	  from	  the	  plasma	  (248).	  The	  correlation	  between	  protein	  and	  receptor	  levels	  
in	   WT	   animals	   exposed	   to	   acid	   aspiration	   confirms	   the	   latter	   and	   hence,	   makes	  
interpretation	   of	   alveolar	   soluble	   receptor	   levels	   difficult.	   Importantly,	   no	  
differences	  between	  soluble	  TNF	  levels	  existed	  between	  experimental	  groups.	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By	  contrast,	  the	  p75	  TNFR	  seems	  to	  have	  a	  minimal	  role	  in	  oedema	  formation	  given	  
that	   the	   p75KO	   strain	   showed	   similar	   degrees	   of	   alveolar	   capillary	   barrier	  
dysfunction	   (wet/dry	   weight	   and	   permeability)	   to	   WT	   animals.	   Within	   these	  
experiments	   in	  acid	  aspiration	   (as	  well	   as	   those	   from	   the	  VILI	  model	   above	   (224)),	  
the	  conclusion	  that	  p75	  TNFR	  signalling	  may	  be	  protective	  is	  based	  substantially	  on	  
the	   significant	   exacerbation	   of	   respiratory	   mechanics	   in	   p75KO	   mice	   over	   WT.	  
However,	  as	  the	  model	  was	  designed	  to	  induce	  a	  substantial	  amount	  of	  injury	  in	  WT	  
mice,	   it	  was	   inherently	   easier	   to	  detect	   attenuation	  of	   injury	   than	  exacerbation	  of	  
injury	   in	   most	   parameters.	   Hence,	   it	   remained	   uncertain	   as	   to	   how	   p75	   TNFR	  
deletion	  transduces	  changes	  in	  physiological	  responses	  such	  as	  Ers,	  PIP	  and	  Rrs.	  One	  
possible	  explanation	  may	  come	  from	  the	  p75KO	  group	  having	  greater	  inflammatory	  
responses	   with	   respect	   to	   the	   macrophage-­‐derived	   cytokine	   IL-­‐6	   and	  
neutrophil/monocyte	  recruitment.	  	  
	  
Peschon	  and	  colleagues	  developed	  the	  genetic	  strains	  used	  in	  our	  work	  by	  inserting	  
neomycin	   cassettes	   within	   the	   encoding	   genetic	   sequence	   of	   the	   TNF	   receptors	  
(220).	  Using	  these	  knockout	  strains,	  Peschon	  et	  al	  was	  the	  first	  to	  suggest	  divergent	  
physiological	  roles	  for	  the	  TNF	  receptors	  in	  models	  of	  sepsis	  and	  lung	  inflammation.	  
Their	   data	   showed	   that	   p75KO	   mice	   continued	   to	   be	   susceptible	   to	   septic	   shock	  
whereas	  p55KO	  mice	  showed	  protection.	  It	  was	  not	  until	  the	  development	  of	  these	  
knockout	  strains	  that	  the	  precise	  effects	  of	  TNF	  signalling	  through	  its	  receptors	  could	  
be	   elucidated.	   Studies	   prior	   to	   this	   utilised	   agonist	   and	   antagonist	   antibodies	  with	  
variable	  affinities	  and	  effects.	  More	  recent	  studies	  utilising	  these	  strains	  have	  found	  
divergent	   roles	   for	   the	   TNF	   receptors	   in	   a	   variety	   of	  models	   including	  myocardial	  
infarction	   (223),	  septic	  shock	   (221),	   retinal	   ischaemia	   (162),	  cardiac	   transplantation	  
(222),	  acute	  kidney	  rejection	  (268),	  and	  VILI	  (224).	  However,	  the	  mechanisms	  remain	  
obscure.	   Interestingly,	   all	   these	   studies	   describing	   such	   opposing	   effects	   of	   the	  
individual	   TNF	   receptors,	   irrespective	   of	   the	   model	   being	   tested,	   draw	   the	   same	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3.5.3 TNF	  receptor	  expression	  in	  lung	  cells	  
To	   begin	   to	   dissect	   this	   differential	   effect	   of	   the	   two	   receptors	   for	   TNF,	   it	   is	  
important	  to	  discuss	  the	  receptor	  expression	  on	  different	  cells	  within	  the	  lung.	  There	  
is	   continuing	   debate	   as	   to	   the	   cell	   specific	   expression	   of	   TNF	   receptors	  within	   the	  
lung.	   Liu	   et	   al	   used	   flow	   cytometry	   to	   show	   that	   epithelial	   cells	   (MLE-­‐Kd)	   and	   rat	  
primary	   type	   2	   AECs	   express	   both	   p55	   and	   p75	   TNFRs	   and	   that	   cell	   surface	  
expression	   of	   the	   p75	   TNFR	   is	   lower	   than	   p55	   TNFR	   (269).	   Ermert	   and	   colleagues	  
showed	  using	   immunolocalisation	   that	  alveolar	   septa	  have	  undetectable	  p55	  TNFR	  
and	  weak	  p75	  TNFR	  expression	  in	  rat	  and	  human	  lungs	  (270).	  This	  study	  also	  found	  
moderate	   localisation	   of	   both	   receptors	   on	   alveolar	   macrophages.	   It	   has	   been	  
recently	  shown	  by	  our	   laboratory	  using	  flow	  cytometry	  that	  pulmonary	  endothelial	  
cells	  have	  greater	  expression	  of	  the	  p55	  TNFR	  compared	  to	  the	  p75	  TNFR	  and	  that	  
the	   p55	   TNFR	   plays	   a	   dominant	   role	   in	   TNF-­‐mediated	   pulmonary	   microvascular	  
dysfunction	   (201).	   Dorr	   et	   al	   showed	   that	   alveolar	   macrophages	   have	   higher	   p75	  
TNFR	  surface	  expression	  than	  p55	  TNFR	  expression.	  Of	  note,	  this	  study	  showed	  that	  
in	  direct	  inflammatory	  insults,	  depletion	  of	  alveolar	  macrophages	  leads	  to	  a	  reduced	  
amount	   of	   alveolar	   soluble	   p75	   TNFR,	   suggesting	   this	   cell	   type	   contributes	  
significantly	   to	   the	  effects	  mediated	  by	  soluble	  p75	  TNFR	   (248).	  The	  evidence	   thus	  
far	   is	   weighted	   towards	   ubiquitous	   expression	   of	   TNF	   receptors	   in	   the	   pulmonary	  
endothelium,	   alveolar	   epithelium	   and	   alveolar	   macrophages	   but	   with	   p55	   TNFR	  
being	  highly	  expressed	  on	  lung	  parenchyma	  and	  p75	  TNFR	  being	  highly	  expressed	  on	  
leukocytes.	  	  
	  
These	   data	   are	   most	   easily	   explained	   by	   oedema	   formation	   occurring	   specifically	  
through	  signalling	  via	  the	  p55	  TNFR.	  Furthermore,	   in	   light	  of	   the	  possible	  opposing	  
protective	   effect	   conveyed	   by	   the	   p75	   TNFR,	   it	   was	   important	   to	   confirm	   that	   no	  
differences	   existed	   in	   surface	   expression	   of	   TNF	   receptors	   between	   uninjured	  
knockout	   and	  WT	   strains	   (i.e.	   p75	   receptor	   expression	   in	   p55KO	   animals;	   and	   p55	  
receptor	  expression	  in	  p75KO	  animals	  are	  the	  same	  as	  expression	  of	  both	  receptors	  
in	   WT	   animals).	   To	   do	   so,	   TNF	   receptor	   expression	   in	   blood	   neutrophils	   and	  
monocytes	   was	   measured.	   Although	   this	   expression	   was	   not	   comprehensively	  
examined	   in	   all	   cell	   types,	   the	  data	   suggests	   that	  overexpression	  of	   the	  undeleted	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receptor	  does	  not	  account	   for	  any	  physiological	  differences	  observed.	   In	  summary,	  
precisely	  which	  TNF	  receptor	  signalling	  predominates	   in	  any	  given	  scenario	   is	   likely	  
to	  be	  a	  complicated	  situation	  governed	  by	  the	  tissue	  specific	  expression	  level	  of	  each	  
receptor	   (as	   previously	   discussed),	   which	   may	   be	   upregulated	   at	   the	  
transcriptional/translational	   level,	   or	   downregulated	   by	   the	   action	   of	   sheddases	  
(271,	  272).	  	  
3.5.4 Oedema	  formation	  occurs	  through	  the	  p55	  TNF	  receptor	  and	  independent	  
of	  pro-­‐inflammatory	  effects	  	  
Ligation	   of	   the	   p55	   TNFR	   by	   TNF	   has	   two	   broad	   consequences	   with	   respect	   to	  
signalling	  events.	  The	  first	  is	  the	  formation	  of	  complex	  I	  on	  the	  cell	  surface	  leading	  to	  
the	   activation	   of	   MAPK-­‐induced	   gene	   transcription	   through	   the	   activation	   of	   the	  
transcription	   factor	   NFκB.	   These	   signalling	   pathways	   drive	   the	   ‘pro-­‐inflammatory’	  
consequences	   of	   TNF	   ligand	   leading	   to	   cytokine/chemokine	   upregulation,	  
endothelial	   cell	   adhesion	   molecule	   expression,	   and	   leukocyte	   transmigration.	   The	  
alternative	  event	  that	  can	  occur	  as	  a	  consequence	  of	  TNF	  binding	  to	  the	  p55	  TNFR	  is	  
the	   activation	   of	   ‘death-­‐signalling’	   through	   the	   formation	   of	   complex	   II.	   The	  
physiology	   data	   show	   that	   the	   p55	   TNFR	   plays	   an	   important	   direct	   role,	  
‘independent’	   of	   downstream	   inflammatory	   consequences,	   in	   mediating	   the	  
injurious	  effects	  of	  TNF	  on	  the	  alveolar-­‐capillary	  barrier.	  	  
	  
Given	   this	  overwhelming	  evidence	   for	   the	   role	  of	  p55	  TNFR	   signalling	   in	   leukocyte	  
recruitment	  it	  was	  surprising	  that	  there	  was	  no	  reduction	  in	  inflammation	  within	  the	  
p55KO	  group,	  albeit	  at	  very	  early	  stages	  of	  lung	  injury.	  Furthermore,	  a	  multitude	  of	  
experimental	   studies	   have	   investigated	   the	   roles	   of	   neutrophils	   and	  mononuclear	  
cells	  in	  mediating	  alveolar	  capillary	  barrier	  dysfunction	  in	  acid	  aspiration	  (260,	  273).	  
The	  importance	  of	  p55	  TNFR	  signalling	  in	  early	  leukocyte	  sequestration	  has	  also	  been	  
suggested	  (39,	  85).	  	  
	  
Flow	   cytometric	   analysis	   of	   lungs	   found	   significant	   numbers	   of	   inflammatory	  
leukocytes	   sequestered	   within	   the	   lung	   after	   acid	   aspiration	   but	   these	   had	   not	  
transmigrated	   into	   the	   alveolar	   space.	   Most	   interestingly,	   the	   p55KO	   animals	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showed	  significant	  physiological	  protection	  but	  had	  comparable	  leukocyte	  numbers	  
within	  the	  lung.	  This	  is	  consistent	  with	  the	  study	  by	  our	  laboratory	  looking	  at	  the	  role	  
of	   TNF	   receptors	   in	   VILI	   (224).	   At	   2	   hours	   after	   onset	   of	   high	   stretch	   ventilation,	  
Wilson	   et	   al	   found	   minimal	   alveolar	   neutrophilia	   and	   no	   difference	   in	   lung	  
myeloperoxidase	   activity	   between	  WT	   and	   p55KO	   strains	   exposed	   to	   high	   stretch	  
ventilation,	   despite	   the	   p55KO	   group	   showing	   profound	   physiological	   protection.	  
Finally,	  WT	  animals	  died	  from	  90	  minutes	  producing	  a	  25%	  survival	  rate	  at	  2	  hours,	  
whereas	   p55KO	   mice	   showed	   100%	   survival	   by	   the	   end	   of	   the	   protocol.	   Such	  
profound	   differences	   in	   respiratory	   physiology	   further	   question	   the	   role	   and	  
implication	   of	   neutrophil	   mediated	   inflammation	   driving	   the	   pathogenesis	   of	  
alveolar	  oedema	  early	  in	  ARDS.	  	  
	  
Additionally,	  many	  studies	  also	  show	  that	  physiological	  deterioration	  occurs	  prior	  to	  
significant	   neutrophil	   infiltration	   within	   the	   lung	   suggesting	   that	   the	   neutrophilic	  
infiltration	  may	  be	  a	  consequence	  of,	  as	  opposed	  to,	  the	  mechanism	  for	   injury.	  For	  
instance,	   Matt	   and	   colleagues	   showed	   significant	   elevations	   in	   BALF	   total	   protein	  
levels	  at	  4	  hours	  in	  a	  model	  of	  acid	  aspiration	  but	  minimal	  neutrophil	  infiltration	  into	  
the	   alveolar	   space	   (274).	   	   Additionally,	   oedema	   can	   form	   in	   the	   absence	   of	  
neutrophils,	  for	  instance,	  in	  neutropenic	  patients	  (94,	  275).	  
	  
One	  explanation	   for	   the	  equivalent	  amounts	  of	   ‘inflammation’	  between	  genetically	  
modified	  animals	  could	  be	  explained	  by	  chronic	  compensation	  and	  this	  may	  account	  
for	   the	   non-­‐dependence	   on	   the	   p55	   TNFR	   in	   leukocyte	   sequestration	   in	   p55KO	  
animals.	   Indeed,	   acute	   blockade	   of	   p55,	   by	   Bertok	   et	   al	   (252),	   using	   a	   domain	  
antibody	  shows	  attenuation	  in	  oedema	  as	  well	  as	   inflammation	  in	  a	  two-­‐hit	  mouse	  
model	  of	  endotoxin	  plus	  VILI.	  	  
3.5.5 The	  p75	  TNF	  receptor	  	  –	  a	  potential	  alveolar	  inflammatory	  rheostat	  
The	   p75KO	   animals	   show	   worse	   respiratory	   mechanics	   and	   increased	   leukocyte	  
recruitment	   to	   the	   lung.	   Very	   little	   is	   known	   about	   the	   downstream	   intracellular	  
signalling	  and	   functional	  consequences	  of	  p75	  TNFR	   ligation	   (in	  comparison	   to	  p55	  
TNFR	  ligation).	  The	  p75	  TNFR	  pathway	  has	  been	  thought	  to	  play	  the	  role	  of	  “ligand	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passing”	  exacerbating	  p55	  TNFR	  signalling	  (152).	   If	  this	  were	  the	  case	  in	  these	  data	  
one	  would	  expect	  a	  protective	  effect	  in	  the	  p75KO	  group.	  Additionally,	  as	  discussed,	  
the	  p75	  TNFR	  plays	   a	   role	   in	   sequestering	  excess	   TNF	   through	   its	   soluble	   receptor	  
form.	   A	   significant	   proportion	   of	   alveolar	   soluble	   p75	   TNFR	   comes	   from	   shedding	  
from	   the	   cell	   surface	   of	   alveolar	   macrophages	   given	   that	   their	   depletion	   (by	  
clodronate	   liposomes)	   significantly	   attenuates	   soluble	   p75	   levels	   in	   endotoxin	  
induced	   lung	   inflammation	   (248).	  While	  one	  explanation	   for	   this	  protective	   role	  of	  
p75	  TNFR	   could	  be	   that	   this	   ‘quenching’	   effect	  on	  TNF	   ligand	   is	   important	   to	   limit	  
signalling	   through	   the	   ‘injurious’	  p55	  TNFR,	   this	  does	  not	  adequately	  explain	   these	  
data.	  If	  the	  p75	  TNFR	  simply	  had	  such	  a	  modulating	  role,	  then	  the	  ‘double	  knockout’	  
(DKO)	   animals	   should	   show	   some	  protection,	  which	  was	  not	   the	   case.	   In	   contrast,	  
the	   increased	   injury	   in	  DKO	  animals	   suggests	   that	  p75	  TNFR	  signalling	  per	   se	   likely	  
induces	  some	  protective	  effect.	  	  
	  
Interestingly,	   the	   study	   performed	   by	   Peschon	   and	   colleagues	   also	   showed	   that	  
neutrophil	   trafficking	   into	   the	   lung	   was	   increased	   in	   p75KO	   animals.	   Increased	  
activation	  of	  the	  lung	  endothelium	  in	  p75KO	  strains	  does	  not	  explain	  the	  increased	  
recruitment	   of	   leukocytes.	   Bertok	   et	   al	   that	   showed	   that	   lung	   endothelial	   cell	  
adhesion	   molecule	   (CAM)	   upregulation	   (VCAM-­‐1,	   E-­‐selectin,	   ICAM-­‐1)	   during	  
intravenous	   TNF	   injection	   was	   dependant	   predominantly	   on	   the	   p55	   TNFR.	  
Furthermore,	  Bertok	  showed	  that	   the	   lung	  endothelium	  has	  a	  higher	  expression	  of	  
the	  p55	  TNFR	  versus	  the	  p75	  TNFR	  and,	  within	  2	  hours	  of	  intravenous	  LPS	  challenge,	  
the	  p55	  TNFR	  is	  shed	  whereas	  the	  p75	  TNFR	  remains	  stable	  (201).	  	  
	  
In	  addition,	  the	  consequences	  of	  p75	  TNFR	  activation	  may	  be	  different	  depending	  on	  
the	  specific	  cell	  type	  on	  which	  it	   is	  activated	  and	  hence,	   its	  role	  within	  the	  alveolar	  
space	   may	   be	   very	   different	   to	   that	   on	   the	   endothelium.	   In	   direct	   forms	   of	   lung	  
injury,	   alveolar	   macrophages	   have	   been	   shown	   to	   release	   TNF	   and	   induce	   the	  
intrapulmonary	  activation	  of	  NFκB,	  leading	  to	  cytokine/chemokine	  elaboration,	  with	  
subsequent	   leukocyte	   recruitment	   into	   the	   lung	   (81,	   276,	   277).	   The	   p75	   TNFR	   is	  
highly	   expressed	   on	   alveolar	   macrophages	   (248,	   278).	   TGFβ	   has	   been	   shown	   to	  
upregulate	   p75	   TNFR	   expression	   on	   peritoneal	   macrophages	   and	   TNF	   signalling	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through	   the	   p75	   TNFR	   has	   been	   shown	   to	   induce	   tolerogenic	   anti-­‐inflammatory	  
properties	   in	   these	   macrophages	   (279).	   Hence,	   It	   is	   possible	   that	   the	   p75	   TNFR	  
inhibits	  the	  release	  of	  pro-­‐inflammatory	  mediators	  from	  alveolar	  macrophages.	  This	  
would	   explain	   the	   tendency	   for	   increased	   IL-­‐6	   production	   in	   p75KO	   as	   compared	  
with	   WT	   animals	   (figure	   3.6).	   It	   is	   possible	   that	   the	   p75	   TNFR	   makes	   alveolar	  
macrophages	  tolerant	  to	  any	  overwhelming	  insult,	  such	  as	  acid	  aspiration,	  delivered	  
to	  the	  alveolar	  space.	  
	  
Furthermore,	   the	   proliferation	   and	   function	   of	   CD4+CD25+	   T-­‐regulatory	   cells,	   that	  
have	  recently	  been	  shown	  to	  promote	  resolution	  of	  lung	  injury	  (98),	  is	  mediated	  by	  
p75	   TNFR	   ligation	   (280).	   This	   receptor	   has	   been	   shown	   to	   induce	  maximally	   anti-­‐
inflammatory	   suppressive	   effect	   of	   this	   subset	   of	   regulatory	   T-­‐cells	   (281).	   	   Finally,	  
p75	  TNFR	  mediated	  gene	   transcription	   leads	   to	   the	  expression	  of	  genes	  coding	   for	  
anti-­‐inflammatory	   molecules	   such	   as	   adrenomedullin,	   GM-­‐CSF	   and	   IL-­‐10	   in	   brain	  
microglia	  in	  response	  to	  various	  inflammatory	  stimuli	  (282).	  
	  
Intratracheal	   instillation	   of	   TNF	   has	   been	   shown	   to	   induce	   airway	  
hyperresponsiveness	  through	  a	  receptor	  dependant	  manner.	  A	  possible	  explanation	  
between	   the	   increased	   respiratory	   resistance	   and	   inflammation	   seen	   in	   p75KO	  
animals	   may	   be	   provided	   by	   a	   study	   investigating	   airway	   hyperresponsiveness	   to	  
methacholine	  in	  mouse	  model	  of	  airway	  inflammation	  (283).	  This	  study	  by	  Kanehiro	  
et	  al	   showed	  that	  TNF	   is	  upregulated	   in	  an	  ovalbumin	  model	  of	  allergy	  and	  signals	  
specifically	  through	  the	  p75	  TNFR	  on	  γδ	  T-­‐cells	  to	  downregulate	  airway	  inflammation	  
and	  hyperresponsiveness.	  Hence,	   investigation	   into	  p75	  TNFR	  activation	  within	   the	  
bronchial	   walls	   and	   alveolar	   spaces	   in	   direct	   forms	   of	   ARDS	   could	   be	   a	   potential	  
important	  therapeutic	  strategy	  to	  prevent	  the	  overzealous	  inflammation,	  and	  reduce	  
the	  derangements	  in	  respiratory	  mechanics	  that	  occurs	  in	  ARDS.	  
	  
3.6 	   Concluding	  remarks	  
Despite	   extensive	   research	   over	   the	   span	   of	  what	   is	   now	   nearly	   30	   years,	   no	   TNF	  
based	   biological	   therapies	   have	   been	   found	   to	   treat	   ARDS	   whereas	   chronic	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conditions	   such	  as	   rheumatoid	   arthritis	   and	  Crohn’s	  disease	  have	   found	   successful	  
clinical	   translation.	  Unfortunately,	   therapeutic	   strategies	   in	   critical	   illness	   to	   target	  
the	   deleterious	   effects	   of	   TNF	   have	   been	   non-­‐specific	   and	   prematurely	   conducted	  
with	   the	  absence	  of	  mechanistic	   insights.	  For	   instance,	  many	  compounds	   targeting	  
TNF	  quench	  the	  total	  activity	  of	  TNF	  –	   ‘good	  and	  bad’	  –	  as	  opposed	  to	  the	  specific	  
signalling	   pathways	   that	   lead	   to	   its	   ‘toxic’	   effects.	   The	   possibility	   that	   the	   two	  
receptors	   for	   TNF	   could	   have	   very	   different	   functionalities	   remained	   ignored	   until	  
very	  recently.	  Overall,	   the	  physiological	  data	   in	   this	  clinically	   relevant	  experimental	  
model	   of	   ARDS	   suggests	   that	   global	   blockade	   is	   unlikely	   to	   have	   a	   positive	  
therapeutic	   effect	   (as	   DKO	   strains	   remained	   injured),	   whereas	  more	   sophisticated	  
therapeutic	  blockade	  of	   the	  p55	  TNFR	  at	   the	  endothelial/epithelial	   junction	  and/or	  
enhancement	  of	  the	  p75	  TNFR	  (possibly	  on	  alveolar	  macrophages/monocytes)	  may	  
prove	  beneficial.	  	  
	  
In	  view	  of	  the	  significant	  protection	  conveyed	  by	  p55	  TNFR	  deletion	  the	  remainder	  of	  
this	   thesis	   now	   focuses	   on	   this	   receptor.	   Furthermore,	   this	   receptor	   is	   potentially	  
amenable	   to	   therapeutic	   blockade	  using	   a	  novel	   p55	   targeted	  domain	   antibody	   as	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4 Activation	  of	  alveolar	  epithelial	  p55	  TNF	  receptor	  death	  
signalling	  in	  acid-­‐induced	  lung	  injury	  
	  
Abstract	  
TNF	   has	   consistently	   been	   implicated	   as	   the	   quintessential	   pro-­‐inflammatory	  
cytokine.	  However,	  chapter	  3	  showed	  that	  the	  effects	  of	  p55	  and	  p75	  TNFR	  signalling	  
seem	  very	  diverse,	  even	  opposing.	  Furthermore,	  downstream,	  cellular	  or	  molecular	  
inflammatory	  events	  could	  not	  explain	  the	  protection	  observed	  from	  acid	  aspiration	  
in	   p55KO	   animals.	   Hence,	   I	   hypothesised	   that	   an	   alternative	   p55	   TNFR	   signalling	  
pathway	  may	  explain	  how	  it	  mediates	  pulmonary	  oedema	  formation.	  	  
	  
The	  major	  difference	  between	  the	  p55	  and	  p75	  TNFRs	  is	  the	  ability	  of	  the	  p55	  TNFR	  
to	  signal	  through	  its	  intra-­‐cytoplasmic	  death	  domain,	  and	  hence	  this	  extrinsic	  ‘death	  
signalling’	  pathway	  was	  investigated.	  The	  activity	  of	  a	  cysteine	  protease	  (caspase-­‐8)	  
involved	   in	   activation	   of	   the	   death	   domain	   (and	   formation	   of	   the	   death	   signalling	  
inducing	  signalling	  complex)	  was	  measured	  as	  an	   index	  of	  p55	  TNFR	  death	  domain	  
activation.	  Indeed,	  lungs	  from	  p55KO	  animals	  were	  found	  to	  have	  significantly	  lower	  
levels	  of	  caspase-­‐8	  activation	  and	   in	  WT	  animals	   this	  activation	  occurred	  within	  90	  
minutes	  of	  acid	  instillation.	  Interestingly,	  in	  injured	  WT	  animals	  only	  1-­‐2%	  of	  alveolar	  
cells	   showed	   signs	   of	   late	   stage	   apoptosis	   (positive	   TUNEL	   staining)	   after	   3	   hours,	  
despite	  significant	  caspase-­‐8	  activation	  and	   in	   the	  presence	  of	   severe	  physiological	  
dysfunction.	  
	  
	  A	   soluble	   marker	   of	   epithelial	   injury	   called	   receptor	   for	   advanced	   glycation	   end-­‐
products	   (RAGE)	   was	   measured	   and	   found	   to	   be	   reduced	   in	   p55KO	   animals,	  
implicating	  an	   injurious	  effect	  of	   the	  p55	  TNFR	  on	  the	  alveolar	  epithelium.	  A	  novel	  
flow	  cytometry	  based	  caspase-­‐8	  assay	  was	  developed	   to	  determine	   that	  p55	  TNFR	  
mediated	  caspase-­‐8	  activation	  occurred	  specifically	  in	  type	  1	  AECs.	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Multiple	   studies	   have	   implicated	   the	   importance	   of	   the	   alveolar	   epithelium	   as	   an	  
integral	   layer	  preventing	  the	  formation	  of	  pulmonary	  oedema.	  Data	   in	  this	  chapter	  
shows	   that	   p55	   TNFR	   mediated	   caspase-­‐8	   activation	   occurs	   within	   the	   type	   1	  
epithelium	  prior	   to	   completed	   cell	   death.	   This	   implicates	   the	  activation	  of	   the	  p55	  
TNFR	   death	   domain	   and	   signalling	   through	   caspase-­‐8	   as	   the	  mechanism	   by	  which	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4.1 	   Introduction	  
	  
ARDS	  is	  primarily	  characterised	  by	  a	  disruption	   in	  alveolar-­‐capillary	  barrier	  function	  
with	  increased	  endothelial	  and	  epithelial	  permeability,	  ultimately	  leading	  to	  flooding	  
of	   the	   alveolar	   space.	  Although	   the	   capillary	   endothelium	  prevents	  high	  molecular	  
weight	  proteins	  and	  plasma	  to	   leak	   into	  the	   interstitium,	  the	  alveolar	  epithelium	  is	  
an	   essential	   layer	   that	   has	   to	   be	  breached	   for	   alveolar	   oedema	   to	  develop.	   In	   the	  
1970’s,	   Schneeberger	   et	   al	   showed	   that	   bidirectional	  movement	   of	   low	  molecular	  
weight	   proteins	   (such	   as	  HRP)	   is	   restricted	   by	   the	   zona	   occludens	   junctions	   found	  
between	  alveolar	  epithelial	  cells	   (284-­‐286).	  Gorin	  and	  Stewart	  showed	  in	  a	  seminal	  
study	  that	  the	  alveolar	  epithelial	  layer	  provides	  the	  greatest	  resistance	  (greater	  than	  
92%)	  to	  the	  flux	  of	  proteins	  from	  the	  circulation	  to	  the	  alveolar	  space	  (38).	  The	  lung	  
epithelium	  also	   has	   a	   dual	   role	   in	   not	   only	   preventing	   oedema	   formation	  but	   also	  
actively	   clearing	   it	   from	   the	   alveolar	   space.	   Firstly,	   the	   tight	   junctions	   that	   bind	  
epithelial	  cells	  together	  prevent	  fluid	  from	  entering	  the	  alveolar	  space.	  Secondly,	  the	  
alveolar	   epithelium	   is	   a	   crucial	   controller	  of	   the	  water	   content	   and	   constitution	  of	  
alveolar	   lining	   fluid.	  This	   function	   is	  performed	   through	   the	  net	  active	   transport	  of	  
sodium	  out	   of	   the	   alveolar	   space	   into	   the	   interstitial	   space	   and	   hence	   creating	   an	  
electrochemical	  gradient	  for	  water	  absorption.	  This	  specific	  function	  of	  the	  alveolar	  
epithelium	   known	   as	   alveolar	   fluid	   clearance	   (AFC)	   is	   crucial	   for	   the	   resolution	   of	  
alveolar	  oedema	  during	  lung	  injury	  states	  (69).	  	  
	  
Chapter	  3	  showed	  that	  pulmonary	  oedema	  development	  during	  the	  early	  phase	  of	  
acid	   aspiration	  was	  mediated	   specifically	   through	   the	   p55	   TNFR,	   and	   not	   the	   p75	  
TNFR.	  Surprisingly,	  there	  remained	  significantly	  high	  levels	  of	  lung	  inflammation	  (to	  a	  
similar	   level	   as	   WT	   animals)	   in	   p55KO	   animals.	   Hence,	   the	   data	   shows	   two	  
fundamental	  aspects	  of	  TNF-­‐induced	  alveolar-­‐capillary	  barrier	  dysfunction.	  Firstly,	  it	  
is	  independent	  of	  p55	  TNFR	  pro-­‐inflammatory	  signalling,	  and	  secondly,	  that	  it	  occurs	  
through	   non-­‐neutrophil	   mediated	   mechanisms	   (given	   that	   injury	   occurred	   early	  
when	  no	  alveolar	  neutrophilia	  was	  present).	  In	  addition,	  the	  significant	  maintenance	  
of	   barrier	   function	   in	   p55KO	   animals	   turned	   the	   attention	   for	   subsequent	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experiments	   towards	   the	   alveolar	   epithelium,	   which	   as	   discussed	   has	   been	  
suggested	   to	   be	   the	  most	   important	   defence	   against	   the	   exudative	   phase	   of	   lung	  
injury	  (43,	  44,	  46,	  287).	  	  
	  
The	  mechanism	  through	  which	  epithelial	  injury	  is	  induced	  in	  ARDS	  remains	  obscure	  
although	  more	   recently	   has	   been	   shown	   to	   occur	   through	   apoptosis	   mechanisms	  
(288).	   However,	   the	   majority	   of	   these	   studies	   have	   focussed	   at	   much	   later	   time-­‐
points	   (>6	   hours)	   compared	   to	   the	   physiological	   dysfunction	   seen	   in	   our	  model	   of	  
acid	   aspiration	   (60-­‐120	   minutes).	   Unlike	   the	   p75	   TNFR,	   the	   p55	   TNFR	   has	   an	  
intracytoplasmic	  death	  domain	  and	  is	  a	  member	  of	  the	  death	  receptor	  family	  along	  
with	  5	  other	  receptors	   including	  Fas	  receptor	   (Fas),	  TNF-­‐related	  apoptosis	   inducing	  
ligand	  (TRAIL)	   -­‐1	  and	  -­‐2,	  death	  receptor	   (DR)	   -­‐5,	  and	  -­‐6.	  Much	  of	  the	   literature	  has	  
focussed	   on	   mechanisms	   through	   which	   the	   Fas	   ligand/Fas	   interactions	   have	  
contributed	   to	   epithelial	   injury	   (56,	   57,	   59,	   289-­‐295)	   and	   TRAIL	   has	   also	   been	  
associated	  in	  influenza	  virus	  induced	  lung	  inflammation	  (66).	  	  
	  
Ligation	   of	   the	   p55	   TNFR	   leads	   to	   the	   recruitment	   of	   a	   number	   of	   death	   domain	  
proteins	   with	   the	   activation	   of	   caspase-­‐8	   through	   the	   formation	   of	   a	   cytoplasmic	  
death	   inducing	   signalling	   complex	   (DISC).	   Importantly,	   the	   p75	   TNFR	   has	   no	  
capability	   of	   directly	   activating	   caspase-­‐8,	   as	   it	   does	   not	   possess	   a	   death	   domain.	  
There	  is	  a	  paucity	  of	   literature	  investigating	  TNF-­‐induced	  apoptosis	   in	  lung	  injury	  in	  
comparison	   to	   the	   pro-­‐inflammatory	   effects	   of	   the	   cytokine,	   namely,	   pulmonary	  
capillary	  endothelial	  activation	  with	  subsequent	  recruitment	  and	  activation	  of	  blood-­‐
derived	  leucocytes	  (201,	  252,	  296-­‐303).	  The	  p55	  TNFR	  has	  been	  shown	  very	  recently	  
to	   mediate	   injury	   through	   apoptosis	   in	   radiation-­‐induced	   lung	   toxicity	   (62),	   chest	  
trauma-­‐induced	  lung	  injury	  (65),	  renal	  ischaemia	  induced	  lung	  injury	  (64),	  and	  febrile	  
endotoxin-­‐induced	  lung	  injury	  (63,	  304).	  Over	  the	  period	  of	  this	  thesis,	  Maniatis	  et	  al	  
showed	  that	  p55	  TNFR	  can	  induce	  caspase-­‐3	  activation	  in	  acid	  aspiration	  at	  24	  hours	  
in	   addition	   to	   pro-­‐inflammatory	   signalling	   (305).	   Hence,	   in	   view	   of	   increasing	  
evidence	  for	  TNF-­‐induced	  apoptosis	   in	  various	   lung	   injury	  models,	  and	  that	  specific	  
signalling	  through	  the	  p75	  TNFR	  had	  no	  impact	  upon	  the	  physiological	  consequences	  
of	   acid-­‐induced	   lung	   injury,	   all	   subsequent	  experiments	  were	   focussed	   to	  examine	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whether	   the	   injurious	   mechanism	   of	   p55	   TNFR	   signalling	   within	   this	   model	   was	  
mediated	   through	   the	   activation	   of	   the	   extrinsic	   apoptotic	   pathway,	   and	   how	   this	  
induced	  the	  significant	  physiological	  dysfunction	  observed.	  
	  
4.2 Aims	  
The	  significant	  role	  of	  the	  p55	  TNFR	  pathway	  in	  promoting	  alveolar	  oedema	  seemed	  
independent	  to	  its	  downstream	  inflammatory	  consequences.	  Hence,	  the	  alternative	  
p55	  TNFR	  ‘death’	  signalling	  pathway	  was	  hypothesised	  to	  induce	  oedema	  formation.	  
Hence,	   this	   chapter	   seeks	   to	   determine	   1)	   the	   extent,	   and	   2)	   the	   localisation	   of	  
apoptotic	   cell	   signalling	   and	   death	   after	   acid	   aspiration	   and	   determine	   if	   this	   is	  
dependant	  upon	  the	  activation	  of	  the	  p55	  TNFR.	  
	  
4.3 Experimental	  design	  
4.3.1 In	  vivo	  model	  
WT	  and	  p55KO	  underwent	  aspiration	  of	  50μl	  of	  0.15M	  HCl	  followed	  by	  mechanical	  
ventilation	   for	   90	   or	   180	   minutes.	   The	   same	   experimental	   set-­‐up	   was	   used,	   as	  
described	  in	  chapter	  3.	  	  
4.3.2 Analysis	  of	  alveolar	  mediators	  
At	   the	  end	  of	   the	  protocol	   right	   lungs	  either	  underwent	  unilateral	   lavage	   to	  attain	  
BALF,	  and	   left	   lungs	  of	  animals	  were	  snap	   frozen	   in	   liquid	  nitrogen	  and	  stored	  at	   -­‐
80oC	   for	   caspase	   analysis.	   Markers	   of	   epithelial	   and	   endothelial	   injury	   were	  
measured	  in	  BALF	  by	  ELISA.	  
4.3.3 TUNEL	  analysis	  
In	   some	   experiments,	   left	   lungs	   of	   some	   animals	   were	   also	   inflated	   at	   a	  
transpulmonary	   pressure	   of	   15cm	   height	   of	   4%	   paraformaldehyde.	   Lungs	   were	  
subsequently	   processed	   for	   paraffin	   embedding	   and	   sections	   attained	   for	   terminal	  
deoxynucleotidyl	  transferase–mediated	  dUTP	  nick	  end-­‐labeling	  (TUNEL)	  assay	  using	  
the	   TACS	   in	   situ	   Apoptosis	   Detection	   Kit,	   in	   accordance	   with	   manufacturers	  
instructions.	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4.3.4 Measurement	  of	  apoptosis	  signalling	  
Measurement	  of	  caspase	  activity	  in	  lung	  homogenate	  	  
Caspase	   activity	  was	  measured	   in	   lung	  homogenates	   through	   the	  detection	  of	   the	  
cleavage	  of	  a	  specific	  substrate:	  IETD-­‐AFC	  for	  caspase-­‐8,	  and	  LEHD-­‐AFC	  for	  caspase-­‐9.	  
Whilst	  the	  conjugated	  7-­‐amino-­‐4-­‐trifluoromethyl	  coumarin	  (-­‐AFC	  component)	  emits	  
blue	   light	   (λmax	   =	   400nm),	   upon	   cleavage	   by	   the	   relevant	   caspase,	   the	   free	   -­‐AFC	  
emits	   yellow-­‐green	   light	   (λmax	   =	   505nm)	   and	   hence,	   activity	   of	   caspases	   can	   be	  
quantified	   using	   a	   fluorescent	   plate	   reader.	   The	   left	   lung	   was	   snap	   frozen	   and	  
homogenised	   in	   the	   cell	   lysis	   buffer	   provided.	   During	   the	   homogenisation	   process	  
and	  until	  the	  point	  of	  incubation	  with	  the	  substrate	  all	  samples	  were	  kept	  on	  ice	  to	  
minimise	   any	   changes	   to	   caspase-­‐8	   activity.	   The	   homogenate,	   substrate,	   and	  
reaction	  buffer	  were	   incubated	  at	  37oC	  and	   then	   the	   fluorescence	  read	  after	  a	  60-­‐
minute	  incubation.	  
Flow	  cytometric	  localisation	  of	  caspase-­‐8	  activity.	  	  
In	  another	  series	  of	  experiments,	  lungs	  were	  instilled	  and	  incubated	  with	  dispase	  for	  
30	  minutes	  at	  room	  temperature,	  after	  which	  they	  were	  minced	  gently	  and	  washed.	  
They	  were	  subsequently	   incubated	  for	  60	  minutes	  with	  a	  cell	  permeable	  caspase-­‐8	  
probe:	   FAM-­‐IETD-­‐FMK.	   The	   probe	   again	   utilised	   the	   specific	   caspase-­‐8	   substrate	  
sequence	  -­‐	  IETD.	  The	  unfixed	  single	  cell	  suspension	  was	  incubated	  with	  this	  probe	  for	  
60	   minutes	   at	   37oC	   with	   regular	   10-­‐minute	   vortex	   to	   facilitate	   mixing.	   The	   IETD	  
sequence	  is	  cleaved	  by	  active	  caspase-­‐8	  and	  the	  probe	  forms	  a	  permanent	  covalent	  
sulfhydryl	   bond	   with	   the	   active	   caspase-­‐8	   (using	   the	   FMK	   moiety)	   and	   the	   FAM	  
moiety	  allows	   it	   to	  be	  detected	   in	   the	  FITC	  channel	  of	   the	   flow	  cytometer.	  After	  a	  
wash	   step	   the	   cell	  mixture	  was	   incubated	   in	   DMEM/HEPES	   to	   allow	   the	   unbound	  
probe	   to	   freely	   diffuse	   out	   of	   the	   cells.	   After	   this	   step,	   cells	   were	   incubated	  with	  
antibody	   stock	   (to	   identify	   leukocytes,	   pulmonary	   endothelial	   cells,	   and	   type	   1	  
alveolar	  epithelial	  cells)	  to	  allow	  cell	  specific	  detection	  of	  caspase-­‐8	  activation	  within	  
the	  same	  sample.	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4.4 Results	  
4.4.1 Acid	  aspiration	  induces	  epithelial	  injury.	  	  
Acid	  aspiration	  leads	  to	  significant	  barrier	  disruption	  through	  a	  predominant	  impact	  
on	   epithelial	   function	   (37,	   42,	   306,	   307).	   The	   type	   1	   AEC	   determines	   95%	   of	   the	  
alveolar	  cell	  surface	  area.	  The	  receptor	  for	  advanced	  glycation	  end-­‐products	  (RAGE)	  
has	  been	  shown	  to	  be	  a	  specific	  marker	   for	   type	  1	  AECs	   (308).	  Lavage	  RAGE	   levels	  
were	  significantly	  increased	  at	  3	  hours	  in	  WT	  animals	  after	  acid	  aspiration	  (figure	  4.1	  
A).	   In	   contrast	   levels	  were	   significantly	   lower	   in	   the	   p55KO	   strain,	   confirming	   that	  
injury	   to	   type	   1	   AECs	   was	   mediated	   through	   activation	   of	   the	   p55	   TNFR	   death	  
signalling.	  Furthermore,	  an	  endothelial	  marker,	  endocan	  (309),	  was	  also	  found	  to	  be	  
upregulated	  after	  acid	  aspiration	  in	  lavage	  fluid,	  but	  no	  such	  reductions	  were	  seen	  in	  
p55KO	  animals,	  suggesting	  that	  the	  p55	  TNFR	  is	  mediating	  injury	  specifically	  through	  
an	   impact	   upon	   the	   alveolar	   epithelium	   (figure	   4.1	   B).	  We	   hypothesised	   that	   this	  
epithelial	   injury	   was	   mediated	   through	   the	   activation	   of	   p55	   TNFR	   dependant	  
apoptosis	  pathways.	  
	  
Figure	  4.1.	  Epithelial	  and	  endothelial	  markers	  of	  injury	  in	  WT	  and	  p55KO	  strains	  
Levels	  of	  receptor	  for	  advanced	  glycation	  end-­‐products	  (RAGE),	  as	  a	  specific	  marker	  
of	   injury	   to	   type	   1	   AECs,	   was	   upregulated	   at	   3	   hours,	   and	   showed	   substantial	  
attenuation	   in	   p55KO	   animals,	   confirming	   that	   the	   p55	   TNFR	   caspase-­‐8	   activation	  
induced	  epithelial	   injury	   (A).	   In	   contrast,	   levels	   of	   the	   endothelial	  marker	   endocan	  
were	  upregulated	  in	  the	  alveolar	  space	  but	  showed	  no	  difference	  with	  p55	  deletion	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4.4.2 Lung	  oedema	  formation	  is	  not	  explained	  by	  completed	  apoptosis	  of	  
alveolar	  cells	  	  
One	   of	   the	  most	   commonly	   utilised	   assays	   for	   detecting	   apoptosis	   is	   the	   terminal	  
deoxynucleotidyl	   transferase–mediated	   dUTP	   nick	   end-­‐labelling	   (TUNEL)	   assay.	   A	  
histological	   based	   TUNEL	   assay	   was	   used	   to	   detect	   any	   DNA	   fragmentation	   and	  
condensation	  suggestive	  of	  end	  stages	  of	  apoptotic	  cell	  death.	   In	  combination	  with	  
strict	   morphological	   evidence	   i.e.	   DNA	   condensation	   within	   the	   nucleus,	   reliable	  
detection	  of	  apoptosis	  can	  be	  performed.	  The	  TACS	   in	  situ	  Apoptosis	  Detection	  Kit	  
has	  been	  used	  for	  histological	  assessment	  in	  paraffin	  embedded	  lung	  sections	  (310).	  	  
	  
Acid	   aspiration	   produced	   a	   subtle	   but	   detectable	   increase	   in	   TUNEL	   positive	   cell	  
number	  at	  3	  hours,	  compared	  to	  control.	  However,	  this	  was	  in	  the	  order	  of	  less	  than	  
one	  apoptotic	  nucleus	  per	  high	  power	   field,	  out	  of	  an	  average	  80	  nuclei	   that	  were	  
present	  per	  field	  (figure	  4.2).	  When	  DNA	  breaks	  were	  induced	  in	  uninjured	  sections	  
through	   the	   application	   of	   a	   DNAse	   enzyme,	   all	   nuclei	   stained	   DAB	   positive	  
confirming	   that	   the	   protocol	   was	   suitable	   for	   nuclear	   staining	   and	   that	   technical	  
issues	  were	  not	  responsible	  for	  the	  lack	  of	  TUNEL	  staining	  in	  injured	  animals	  (figure	  
4.2	  B).	  It	  was	  difficult	  to	  discern	  the	  specific	  cell	  types	  stained	  positive	  for	  TUNEL	  but	  
one	   criterion	   for	   assessment	   was	   that	   they	   all	   be	   located	   on	   the	   alveolar	   walls.	  
Interestingly,	  p55KO	  animals	  did	  show	  a	  reduced	  apoptotic	  index	  when	  compared	  to	  
WT	  animals	  suggesting	  that	  this	  receptor	  indeed	  plays	  a	  role	  in	  the	  development	  of	  
cell	   death	   during	   lung	   injury	   (figure	   4.2	   D).	   However,	   acid	   aspiration	   at	   3	   hours	  
produced	   a	   significant	   amount	   of	   alveolar	   oedema	   and	   physiological	   dysfunction.	  
These	   data,	   showing	   a	   very	   low	   percentage	   of	   TUNEL	   positive	   cell	   death,	   cannot	  
explain	  such	  physiological	  dysfunction	  and	  injury.	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Figure	  4.2.	  TUNEL	  staining	  at	  3	  hours	  after	  acid	  aspiration	  	  
(A)	   TUNEL	   staining	   of	   lung	   sections	   showed	   undetectable	   staining	   in	   uninjured	  
animals.	   (B)	  The	  addition	  of	  DNAse	  to	   lung	  sections	   (to	  actively	   induce	  DNA	  strand	  
breaks	   as	   a	   positive	   control)	   illustrates	   the	  maximal	   number	   of	   nuclei	   that	   can	   be	  
stained	  (≈80	  TUNEL	  positive	  cells/HPF).	  (C)	  TUNEL	  staining	  in	  sections	  of	  lungs	  taken	  
3	   hours	   after	   acid	   aspiration	   shows	   some	   TUNEL	   positive	   events	   which,	   (D)	   was	  
partially	   reduced	   in	  p55KO	  animals.	   (E)	  However,	  although	  a	  statistically	  significant	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positive	  nuclei	  were	  less	  than	  1	  per	  HPF,	  implying	  minimal	  cell	  death	  despite	  severe	  
physiological	  injury.	  (N=5;	  *	  P<0.05)	  
	  
4.4.3 TNF	  p55	  receptor	  activates	  caspase-­‐8	  ‘death	  signalling’	  in	  lungs	  after	  acid	  
aspiration	  	  
The	   TUNEL	   data	   presented	   a	   significant	   disparity	   between	   the	   levels	   of	  
morphological	  apoptosis	   (i.e.	  1-­‐2%)	  and	  the	  severity	  of	   injury	   that	  was	  apparent	   in	  
WT	  animals	  at	  this	  3-­‐hour	  time-­‐point.	  DNA	  degradation	  as	  shown	  by	  positive	  TUNEL	  
stain	   is	   the	   final	   event	   of	   cell	   death.	   A	   number	   of	   apoptosis	   signalling	   pathways	  
(intrinsic	  and	  extrinsic)	  can	  lead	  to	  the	  stage	  of	  cell	  death	  detected	  by	  TUNEL.	  Hence,	  
to	   determine	   which	   pathway	   of	   death	   signalling	   had	   been	   activated,	   caspase-­‐8	  
(extrinsic)	  and	  caspase-­‐9	  activity	   (intrinsic)	  were	  measured	   in	   lung	  homogenates	  at	  
three	  hours	  after	  acid	  aspiration.	  There	  was	  a	  1.7	  fold	  upregulation	  in	  lung	  caspase-­‐8	  
activity	   in	   the	   WT	   group	   as	   compared	   to	   uninjured	   animals	   (figure	   4.3	   A).	  
Furthermore,	  this	  upregulation	  in	  caspase-­‐8	  activity	  was	  significantly	  reduced	  by	  61%	  
in	   the	  p55KO	  group	  placing	  p55	  TNFR	  as	   the	  major	  death	   receptor	   responsible	   for	  
the	  early	  activation	  of	  caspase-­‐8.	  The	  observation	  that	  cells	  did	  not	  have	  to	  be	  dead	  
for	  physiological	  dysfunction	  to	  occur	  suggested	  that	  the	  p55	  TNFR	  caspase-­‐8	  signal	  
itself	   may	   have	   driven	   the	   downstream	   mechanisms	   leading	   to	   the	   physiological	  
dysfunction.	  	  
4.4.4 Caspase-­‐8	  activation	  occurs	  early	  in	  experimental	  lung	  injury	  
Caspases	  are	  intracellular	  serine	  proteases	  that	  are	  pre-­‐formed.	  Upon	  binding	  of	  TNF	  
to	   the	   p55	   TNFR	   complex	   it	   is	   endocytosed	   within	   minutes	   leading	   to	   the	  
recruitment	   of	   intracellular	   adaptor	   proteins	   (TRADD	   and	   FADD)	   facilitating	   the	  
recruitment	   of	   caspase-­‐8	   (311).	   Indeed,	   caspase-­‐8	   activity	   was	   measured	   at	   90	  
minutes	  given	  that	  significant	  separation	   in	  oxygenation	  and	  respiratory	  mechanics	  
were	   already	   apparent	   at	   this	   time	   between	   WT	   and	   p55KO	   groups	   (figure	   3.3).	  
These	   earlier	   measurements	   found	   caspase-­‐8	   activity	   to	   be	   twice	   as	   high	   at	   90	  
minutes	   in	   comparison	   to	   3	   hours	   in	   WT	   animals	   (figure	   4.3	   B).	   Although	   not	  
measured	  there	  would	  likely	  have	  been	  an	  even	  lower	  extent	  of	  TUNEL	  positive	  cells	  
at	  90	  minutes	  providing	  further	  support	  that	  the	  activation	  of	  death	  signalling	  per	  se	  
could	  have	  induced	  the	  substantial	  physiological	  dysfunction	  observed.	  There	  was	  no	  
Chapter	  4	  
TNF-­‐induced	  death	  signaling	  in	  experimental	  ARDS	  
	   155	  
such	  upregulation	  in	  caspase-­‐9	  activity	  (at	  3	  hours)	  suggesting	  the	  extrinsic	  pathway	  
(mediated	   through	   death	   receptor	   activation)	   and	   not	   the	   intrinsic	   pathway	   had	  
been	  activated	  after	  acid	  aspiration	  (Figure	  4.3	  C).	  
	  
Furthermore,	   at	   this	   earlier	   time	   point	   the	   levels	   of	   neutrophil/monocyte	  
sequestration	  would	  be	  even	  lower,	  further	  substantiating	  that	  the	  signal	  to	  activate	  
caspase-­‐8	  likely	  came	  from	  the	  alveolar	  compartments	  and	  that	  the	  mechanisms	  for	  
oedema	   formation	   were	   independent	   of	   blood	   derived	   leukocytes.	   The	   higher	  
caspase-­‐8	   signal	   and	   the	   separation	   in	   respiratory	   physiology	   between	   WT	   and	  
p55KO	   animals	   prompted	   all	   further	  measurements	   to	   be	   performed	   at	   this	   early	  
time	  point	  of	  90	  minutes.	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Figure	  4.3.	  Caspase-­‐8	  and	  -­‐9	  activity	  in	  lung	  homogenates	  after	  acid	  aspiration	  
Despite	   the	   low	  numbers	  of	   end-­‐stage	   cell	   death	   as	   assessed	  by	   the	  TUNEL	  assay,	  
there	  was	   a	   significant	   activation	   of	   the	   extrinsic	   death	   pathway	   (as	  measured	   by	  
caspase-­‐8	   activity)	   in	  WT	   injured	   animals	   (A).	   This	   increase	   in	   caspase-­‐8	   activation	  
was	   significantly	   attenuated	   (by	   61%)	   in	   p55KO	   animals	   confirming	   that	   the	   p55	  
TNFR	   contributes	   to	   death	   signaling	   activation	   in	   acid	   aspiration.	   Furthermore,	  
caspase-­‐8	   activity	   in	   WT	   animals	   is	   higher	   levels	   at	   the	   earlier	   time-­‐point	   of	   90	  
minutes,	  suggesting	  that	  TNF-­‐induced	  caspase-­‐8	  activation	  is	  an	  early	  phenomenon	  
and	   may	   explain	   the	   early	   physiological	   dysfunction.	   In	   contrast,	   the	   intrinsic	  
pathway	   (as	   measured	   by	   caspase-­‐9)	   remains	   unaffected	   by	   acid	   aspiration	   at	   3	  
hours	  (C).	  	  (N=5;	  *	  P<0.05	  ***	  P<0.001)	  
	  
Figure'4.2!Despite! the! low!numbers!of!end3stage!cell!death!as!assessed!by! the!TUNEL!
assay,!there!was!a!signiﬁcant!ac?va?on!of!the!extrinsic!death!pathway!(as!measured!by!
caspase38!ac?vity)! in!WT! injured!animals! (A).!This! increase! in!caspase38!ac?va?on!was!
signiﬁcantly!aIenuated!(by!61%)!in!p55KO!animals!conﬁrming!that!the!p55!TNF!receptor!
contributes! to! death! signaling! ac?va?on! in! acid! aspira?on.! Furthermore,! caspase38!
ac?vity! in! WT! animals! is! is! higher! levels! at! the! earlier! ?me3point! of! 90! minutes,!
sugges?ng! that! TNF! induced! caspase38! ac?va?on! is! an! early! phenomenon! and! may!
explain! the! early! physiological! dysfunc?on.! In! contrast,! the! intrinsic! pathway! (as!
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4.4.5 Localisation	  of	  caspase-­‐8	  activity	  
To	  gain	  a	  deeper	  understanding	   into	  how	  p55	  TNFR	  /caspase-­‐8	  signalling	  mediated	  
oedema	  formation,	  it	  was	  important	  to	  determine	  the	  exact	  cell	  types	  in	  which	  this	  
caspase-­‐8	  signal	  occurred.	  A	  flow	  cytometric	  caspase-­‐8	  assay	  was	  adopted	  instead	  of	  
a	   histological	   approach	   for	   two	   reasons.	   Firstly,	   flow	   cytometry	   enables	   a	   more	  
quantitative	  assessment	  of	  caspase-­‐8	  activity.	  Secondly,	  through	  the	  use	  of	  multiple	  
antibodies	   (and	   positive	   and	   negative	   gating	   strategies)	   the	   analysis	   of	   caspase-­‐8	  
activation	   in	   various	   cell	   types	   (see	  below)	   could	   be	   identified	   in	   each	   experiment	  
within	  the	  same	  sample.	  	  
	  
Caspase-­‐8	   activity	   in	   the	   WT	   injured	   lungs	   was	   measured	   using	   a	   fluorescent	  
caspase-­‐8	  probe	  (FMK-­‐IETD-­‐FAM).	  The	  caspase-­‐8	  specific	  IETD	  moiety	  is	  conjugated	  
to	   a	   fluorescent	   FAM	  moiety	   and	   an	   FMK	   moiety.	   The	   probe	   is	   lipid	   soluble	   and	  
freely	  permeates	  into	  and	  out	  of	  cells.	  Any	  activated	  caspase-­‐8	  binds	  and	  cleaves	  the	  
IETD	   sequence	   and	   the	   proximity	   of	   the	   compound	   leads	   to	   the	   formation	   of	   a	  
permanent	  covalent	  bond	  between	  the	  active	  caspase-­‐8	  and	  the	  FMK	  moiety.	  After	  
washing	   unbound	   probe	   out	   of	   the	   cell,	   flow	   cytometry	  was	   used	   to	   quantify	   the	  
FAM	   signal	   (in	   the	   FITC	   channel)	   of	   the	   bound	   caspase-­‐8-­‐FMK-­‐IETD-­‐FAM	   complex	  
retained	  within	   the	   cell.	   This	  was	  applied	   to	  unfixed	   cell	   suspensions	   from	  dispase	  
treated	  lungs	  to	  avoid	  the	  loss	  of	  caspase-­‐8	  activity	  through	  formaldehyde	  fixation.	  
Hence,	   lungs	   were	   digested	   in	   a	   standardised	   fashion	   through	   the	   intra-­‐tracheal	  
instillation	   of	   dispase	   as	   previously	   described.	   Furthermore,	   as	   lungs	  were	  minced	  
gently	  the	  lung	  parenchyma	  was	  teased	  away	  from	  the	  main	  bronchi	  to	  enable	  ideal	  
preparation	  of	  distal	  lung	  cells.	  
	  
The	  lung	  cell	  suspension	  was	  subsequently	  incubated	  with	  the	  caspase-­‐8	  probe.	  The	  
probe	   required	   incubation	  at	  37oC	   for	  binding	  and	   removal	  of	  unbound	  dye	   for	  60	  
minutes.	   Every	   other	   stage	   of	   the	   protocol	   was	   performed	   on	   ice	   with	   ice-­‐cold	  
reagents,	   thereby,	  minimising	   alterations	   in	   cellular	   caspase-­‐8	   activity.	   Three	  main	  
cell	   types	   were	   analysed	   –	   alveolar	   epithelium,	   pulmonary	   capillary	   endothelium,	  
and	   leukocytes.	  We	   focussed	   our	   cellular	   localisation	   to	   type	   1	   AECs	   as	   they	   have	  
distinct	   membrane	   bound	   cellular	   identification	   marker	   (EpCAM	   and	   T1-­‐alpha)	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whereas	  type	  2	  cells	  require	  permeabilisation	  for	  detection	  of	  intracellular	  molecules	  
such	  as	  surfactant	  protein	  C.	  This	  permeabilisation	  process	  could	  have	  affected	  the	  
caspase-­‐8	   signal	   and	   promoted	   loss	   of	   intracellular	   molecules	   as	   well	   as	   bound	  
probe.	  Leukocytes	  were	  identified	  as	  CD31-­‐EpCAM-­‐T1alpha-­‐CD45+	  cells,	  endothelium	  
as	  CD45-­‐Epcam-­‐T1alpha-­‐CD31+,	  and	   type	  1	  AECs	  as	  CD45-­‐CD31-­‐EpCAM+T1alpha+	  cell	  
populations.	  The	  gating	  strategy	  is	  shown	  in	  figure	  4.4	  A.	  	  
	  
Caspase-­‐8	  activity	  was	   localised	   specifically	   to	   type	  1	  AECs	  and	   this	   activity	  was	  8-­‐
fold	  higher	   in	   injured	  as	   compared	   to	  uninjured	  animals	   (figure	  4.4	  B).	   In	   contrast,	  
pulmonary	  capillary	  endothelium	  and	  leukocytes	  showed	  a	  10-­‐fold	  and	  40-­‐fold	  lower	  
level	  of	  caspase-­‐8	  activity,	  respectively,	  and	  did	  not	  show	  any	  increase	  during	  injury.	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Figure	   4.4.	   Flow	   cytometric	   analysis	   of	   cell	   specific	   caspase-­‐8	   activity	   after	   acid	  
aspiration	  
Flow	  cytometry	  was	  used	   to	   localise	  and	  quantify	   caspase-­‐8	  activation	   in	   the	   lung.	  
After	   labelling	   with	   the	   FAM-­‐IETD-­‐FMK	   caspase-­‐8	   probe	   and	   relevant	   antibodies,	  
lungs	   were	   analysed	   using	   the	   above	   gating	   strategies	   (A).	   Firstly,	   debris	   was	  
excluded	  using	  forward	  and	  side	  scatter,	  and	  three	  main	  cell	  types	  were	  identified	  –	  
Type	   1	   AECs	   as	   CD45-­‐CD31-­‐EpCAM+T1alpha+;	   endothelial	   cells	   as	   CD45-­‐Epcam-­‐
T1alpha-­‐CD31+;	   and	   leukocytes	   as	   CD31-­‐EpCAM-­‐T1alpha-­‐CD45+.	   Caspase-­‐8	   activity	  
was	  localised	  predominantly	  to	  the	  alveolar	  epithelium,	  and	  this	  cell	  type	  showed	  a	  
8-­‐fold	   increase	   in	  activity	   in	   injured	  animals.	  The	  epithelium	  also	  showed	  a	  10-­‐fold	  
Figure' 4.3' Flow% cytometry% was% used% to% localise% and% quan3fy% casopase68% ac3va3on% in% the% lung.% A=er%
labelling%with%the%FAM6IETD6FMK%caspase68%probe%and%relevant%an3bodies,% lungs%were%analysed%using%the%
above%ga3ng%stratgies%(A).%Firstly,%debris%was%excluded%using%forward%and%side%scaIer,%and%three%main%cell%
types%were% iden3ﬁed% –% Type% 1% AECs% as% CD456CD316EpCAM+T1alpha+;% endothelial% cells% as% CD456EpCAM6
T1alpha6CD31+;% and% le kocytes% as% CD316EpCAM6T1alpha6CD45+.% Casp se68% ac3vity% was% localised%
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higher	   expression	   than	   endothelium	  and	   leukocytes,	   neither	   of	  which	   showed	   any	  
upregulation	  during	  injury.	  (N=6;	  **P<0.01).	  
	  
4.5 Discussion	  	  
Although,	   studies	  have	   implicated	  TNF	   to	   induce	  neutrophil	   sequestration	   in	  ARDS	  
and	   increase	   the	   severity	   of	   injury	   (302,	   312),	   others	   have	   shown	   TNF-­‐induced	  
oedema	   formation	   to	   be	   independent	   of	   neutrophils	   (199).	   Endothelial	   activation	  
and	   subsequent	   neutrophil	   recruitment	   can	   also	   increase	   endothelial/epithelial	  
permeability	   through	   the	   release	   of	   mediators	   such	   as	   serine	   proteases	   (e.g.	  
elastase),	   which	   cleave	   junctional	   adhesion	   molecules	   such	   as	   E-­‐cadherin,	   found	  
between	   endothelial	   cells	   (313-­‐315).	   Our	   work	   demonstrating	   that	   the	   protection	  
induced	  through	  p55	  TNFR	  deletion	  was	  seemingly	  independent	  to	  the	  classical	  pro-­‐
inflammatory	  effects	  of	  TNF	  signalling,	  prompted	  the	  interrogation	  of	  the	  alternative	  
signalling	  pathway,	  that	  of,	  p55	  TNFR	  mediated	  death	  signalling.	  	  
	  
Apoptosis	   of	   the	   endothelium	   and	   epithelium	   has	   been	   heavily	   implicated	   in	   the	  
development	   of	   barrier	   dysfunction	   and	   pulmonary	   oedema	   (56,	   290,	   316-­‐318).	  
Bachofen	   and	   Weibel	   performed	   the	   original	   studies,	   which	   examined	   epithelial	  
integrity	   in	   ARDS,	   and	   showed	   that	   type	   1	   AECs	   of	   post-­‐mortem	   ARDS	   lungs	   had	  
significant	   ultrastructural	   damage	   (319).	   In	   the	   late	   nineties,	   Matute-­‐Bello	   and	  
colleagues	  were	  the	  first	  to	  present	  data	  that	  epithelial	  apoptosis	  mechanisms	  could	  
possibly	  explain	   this	  epithelial	   injury	   (56).	  This	  study	   found	  that	   increased	   levels	  of	  
bioactive	  Fas	  ligand	  in	  the	  alveolar	  space	  of	  ARDS	  patients	  could	  induce	  apoptosis	  of	  
primary	   human	   distal	   lung	   epithelial	   cells.	   Furthermore,	   FasL	   concentration	   was	  
higher	  at	  24	  hours	  in	  those	  patients	  that	  died	  in	  comparison	  to	  survivors.	  	  
4.5.1 Epithelial	  caspase-­‐8	  activation	  dominates	  in	  acid	  aspiration	  
The	   localisation	   of	   caspase-­‐8	   activation	  was	   important	   to	   truly	   dissect	   further	   the	  
mechanisms	  through	  which	  p55	  TNFR	  ligation	  mediated	  injury.	  There	  are	  a	  variety	  of	  
methods	   that	   could	   be	   utilised	   to	   ascertain	   exactly	   where	   caspase	   activation	   was	  
occurring.	  A	  flow	  cytometry	  based	  technique	  was	  developed	  to	  localise	  and	  quantify	  
relative	  caspase-­‐8	  activity	  in	  whole	  lung.	  Although	  other	  publications	  have	  localised	  
TNF-­‐induced	   caspase	   activation	   in	   lung	   using	   histology,	   arguably,	   this	   remains	   a	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substandard	   technique	   due	   to	   the	   close	   apposition	   of	   the	   endothelium	   and	  
epithelium.	  Indeed,	  even	  immunohistochemistry	  using	  two/three	  antibodies	  staining	  
does	  not	  allow	  complete	  differentiation	  within	   the	  alveolar	  wall.	   In	   the	  absence	  of	  
robust	   techniques	   to	   locate	   the	   cell	   specific	   activation	   of	   death	   signalling,	   many	  
studies	   use	   in	   vitro	   experiments	   to	   support	   their	   in	   vivo	   findings	   (320).	   Hence,	  
investigation	  of	  cell	  death	  signalling	  using	  in	  vitro	  methods	  may	  present	  large	  jumps	  
in	  logic	  and	  should	  be	  interpreted	  with	  caution	  given	  that	  cell	  culture	  has	  significant	  
variability	  with	   respect	   to	  viability,	   and	   is	   very	  different	   from	   the	   in	   vivo	   situation.	  
The	  advantage	  of	  whole	  lung	  flow	  cytometry	  through	  labelling	  of	  various	  epitopes	  at	  
the	  same	  time	  allows	  analysis	  of	  multiple	  cell	  types	  (from	  a	  single	  sample)	  through	  
positive	  and	  negative	  gating	  strategies.	  	  
	  
A	   novel	   assay	   was	   developed	   using	   a	   fluorochrome-­‐conjugated	   cell-­‐permeable	  
caspase-­‐8-­‐specific	  inhibitor	  compound	  FAM-­‐IETD-­‐FMK.	  Lungs	  were	  dispase	  digested	  
to	   prepare	   single	   cell	   suspensions	   and	   subsequently	   incubated	  with	   DMEM	   /2.5%	  
HEPES,	  as	  used	  by	  a	  number	  of	   investigators,	   to	  produce	  endothelial	  and	  epithelial	  
primary	   cell	   cultures	   from	   lungs	   (247,	  321).	   This	   technique	  enabled	   the	  analysis	  of	  
caspase-­‐8	   activity	   in	   addition	   to	   its	   localisation,	  which	   is	   significantly	   quenched	  by	  
most	   fixatives	   including	   methanol	   and	   paraformaldehyde.	   This	   advantage	   of	  
measuring	  activity	  (as	  opposed	  to	  presence)	  is	  important	  as	  caspase-­‐8	  can	  induce	  its	  
own	  activation	  when	  present	  in	  high	  local	  concentrations	  (322).	  	  
	  
After	   the	   exclusion	   of	   debris,	   and	   using	   antibodies	   to	   identify	   the	   three	  main	   cell	  
types	   in	   the	   lungs	   (endothelia,	  epithelia,	  and	   leukocytes),	   the	  caspase-­‐8	   signal	  was	  
specifically	  localised	  to	  within	  type	  1	  alveolar	  epithelial	  cells	  (AEC).	  Type	  1	  AECs	  from	  
acid	   instilled	   animals	   showed	   a	   8-­‐fold	   higher	   caspase-­‐8	   activation	   as	   compared	   to	  
uninjured	   animals.	   Furthermore,	   endothelial	   cells	   and	   leukocytes	   showed	   a	   lower	  
caspase-­‐8	   activity	   and	   no	   increase	   with	   acid-­‐induced	   lung	   injury.	   The	   specific	  
localisation	  and	  extremely	  high	  activity	  of	  caspase-­‐8	  to	  type	  1	  AECs	  (as	  opposed	  to	  
endothelial	  cells)	  was	  supported	  by	  the	  reduction	  in	  RAGE	  (a	  specific	  type	  1	  epithelial	  
marker)	  and	  not	  endocan	  (an	  endothelial	  marker)	  in	  p55KO	  animals.	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4.5.2 The	  amount	  of	  completed	  ‘cell	  death’	  in	  clinical	  and	  experimental	  ARDS	  
does	  not	  correlate	  with	  physiological	  derangements	  
The	   low	   level	   of	   TUNEL	   staining	   and	   the	   importance	   of	   early	   proximal	   death	  
signalling	  per	  se	  on	  physiological	  outcomes	  has	  not	  really	  been	  appreciated	   in	   lung	  
injury	   literature.	  The	  TUNEL	  assay	  detects	  cells	  undergoing	  apoptosis	   through	  DNA	  
fragmentation	  and	   involves	   the	   labelling	  of	   the	  broken	  hydroxyl	   (-­‐OH)	  ends	  with	  a	  
biotin-­‐conjugated	   dUTP	   through	   the	   terminal	   deoxynucleatidyl	   transferase	   (TdT)	  
enzyme.	   The	   specificity	   of	   TUNEL	   as	   a	   method	   for	   detecting	   apoptosis	   has	   been	  
under	   debate	   for	   some	   time,	   due	   to	   the	   fact	   that	   necrosis	   also	   leads	   to	   the	  
development	   of	   free	   DNA	   ends	   (323).	   However,	   it	   remains	   a	   widespread	  method	  
amongst	  most	   researchers	   investigating	  apoptosis.	   Furthermore,	   recommendations	  
by	   the	   Nomenclature	   Committee	   on	   Cell	   Death	   in	   2009	   suggested	   that	  
morphological	  signs	  of	  apoptosis,	  such	  as	  classic	  nuclear	  condensation	  into	  discrete	  
bodies	   (called	   ‘apoptotic	   bodies’),	   in	   combination	   with	   staining	   for	   DNA	  
fragmentation	   should	   be	   used	   to	   give	   a	  more	   reliable	   indication	   of	  when	   a	   cell	   is	  
actually	   ‘dead’	   (245).	   Although	   positive	   TUNEL	   staining	   was	   undetectable	   in	  
uninjured	  normal	  lungs,	  blinded	  analysis	  of	  slides	  showed	  only	  1-­‐2%	  of	  nuclei	  within	  
injured	  lungs	  staining	  positive	  for	  TUNEL.	  Although	  this	  TUNEL	  index	  was	  significantly	  
reduced	  in	  p55KO	  animals,	  a	  disparity	  existed	  between	  the	  extent	  of	  injury	  and	  low	  
levels	  of	  TUNEL	  positivity	  in	  WT	  animals.	  Technical	  reasons	  could	  not	  account	  for	  this	  
low	  incidence	  as	  concurrent	  staining	  of	  sections	  exposed	  to	  DNAse	  to	  fragment	  DNA	  
found	  all	  nuclei	  were	  positively	  stained	  (figure	  4.2	  B).	  	  
	  
The	  finding	  of	  such	  a	   low	  incidence	  of	  TUNEL	  positive	  cells	   in	   lungs	  with	  significant	  
injury	   brings	   into	   question	   the	   role	   of	   completed	   cell	   death	   in	   development	   of	  
ALI/ARDS.	  Indeed,	  post	  mortem	  studies	  of	  ARDS	  lungs	  shows	  only	  up	  to	  a	  maximum	  
of	  10%	  of	  apoptotic	  TUNEL	  positive	  cells	  (58).	  The	  removal	  of	  10%	  of	  the	  total	  lung	  
capacity	   of	   normal	   lungs	   should	   not	   lead	   to	   the	   severe	   respiratory	   compromise	  
found	   in	   ARDS.	   Furthermore,	   this	   10%	   will	   likely	   include	   many	   TUNEL	   positive	  
leukocytes.	  Hence,	  an	  alternative	  explanation	  must	  exist	  as	  to	  how	  the	  activation	  of	  
apoptosis	   pathways	   in	   lung	   parenchyma	   would	   result	   in	   the	   physiological	  
derangements	  seen	  in	  ARDS.	  Animal	  investigations	  of	  lung	  injury	  report	  similar	  levels	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of	  TUNEL	  positive	  staining	  to	  the	  level	  we	  present	  (68,	  317)	  but	  at	  even	  later	  time-­‐
points	   of	   lung	   injury.	   Indeed,	   nearly	   all	   animal	   studies	   examining	   the	   effect	   of	   Fas	  
ligation	  shows	  low	  levels	  of	  TUNEL	  positive	  apoptosis	  in	  the	  presence	  of	  greater	  fold	  
increase	   in	   caspase	   activity.	   For	   instance,	   Bem	   and	   colleagues	   utilised	   the	   Fas	  
activating	   antibody	   Jo2	   to	   produce	   a	   specific	   intra-­‐alveolar	   activation	   of	   death	  
signalling	   and	   showed	   less	   than	   1	   TUNEL	   positive	   cell	   per	   high	   power	   field	   at	   24	  
hours	  after	  Fas	  ligation	  despite	  a	  much	  greater	  upregulation	  of	  caspase-­‐3	  activity	  at	  
24	  hours	  (293).	  Furthermore,	  at	  later	  stages	  of	  injury,	  there	  are	  minimal	  numbers	  of	  
TUNEL	  positive	  cells,	  of	  which	  the	  majority	  are	  TUNEL	  positive	  leukocytes	  (318).	  The	  
data	  presented	  in	  this	  chapter	  is	  also	  consistent	  with	  a	  report	  by	  Imai	  et	  al	  looking	  at	  
acid	  aspiration	  with	   injurious	  mechanical	  ventilation	  where	   it	  was	   found	  that	   lungs	  
had	   minimal	   TUNEL	   positive	   events	   despite	   significant	   injury	   (53),	   and	   increased	  
TUNEL	   positivity	   in	   other	   organs	   e.g.	   kidney.	   Interestingly,	   this	   study	   showed	   that	  
acid	  aspiration	  with	  non-­‐injurious	  ventilation	  led	  to	  more	  TUNEL	  positive	  events	  than	  
acid	  aspiration	  with	   injurious	   ventilation,	  which	   seems	   somewhat	   counter	   intuitive	  
given	   the	   latter	   showed	   greater	   physiological	   injury.	   This	   further	   confirms	   a	   poor	  
correlation	  between	  the	  extent	  of	  completed	  cell	  death	  and	  physiological	  lung	  injury.	  	  
	  
One	  explanation	  for	  the	  low	  level	  of	  apoptotic	  cell	  numbers	  (i.e.	  incidence	  of	  TUNEL	  
positivity)	  detected	  could	  be	  a	  balance	  between	  completed	  apoptosis	  and	  clearance	  
of	   apoptotic	   bodies	   (324).	   The	   lack	   of	   TUNEL	   positive	   cells	   in	   our	   experiments	   is	  
primarily	  due	  to	  a	   low	  level	  of	  apoptosis	  (as	  opposed	  to	  high	  clearance)	  for	  several	  
reasons.	  
	  
Firstly,	   if	   the	   clearance	   process	   by	   phagocytes	   occurs	   very	   quickly	   (as	   has	   been	  
shown	   in	   some	   studies	   using	   intra-­‐tracheally	   instilled	   apoptotic	   thymocytes	   (324,	  
325))	   not	   many	   apoptotic	   cells	   will	   actually	   be	   seen.	   This	   would	   therefore	  
underestimate	   the	   amount	   of	   apoptosis	   observed.	   However,	   the	   phagocytosis	   of	  
intratracheally	  instilled	  of	  apoptotic	  bodies	  (such	  as	  apoptotic	  thymocytes)	  (although	  
shown	  to	  occur	  within	  minutes),	  does	  not	  take	  into	  account	  the	  time	  taken	  for	  a	  cell	  
to	   become	   apoptotic	   through	   condensation	   of	   its	   nucleus.	   Indeed,	   induction	   of	  
apoptosis	  in	  vitro	  of	  thymocytes	  can	  take	  over	  12	  hours	  (325).	  Of	  greater	  relevance,	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unpublished	  in	  vitro	  data	  from	  within	  our	  laboratory	  (Dr	  M	  Fletcher,	  PhD	  Thesis)	  has	  
shown	   that	   MLE-­‐12	   cells	   only	   show	   significant	   positive	   staining	   for	   Annexin	   V	   at	  
approximately	   24	   hours	   after	   exposure	   to	   TNF	   and	   cyclohexamide,	   which	   can	   be	  
reversed	  by	  a	  pan-­‐caspase	  inhibitor.	  Hence,	  irreversible	  apoptosis	  potentially	  occurs	  
at	  much	   later	   time-­‐points	   in	  epithelial	   cells	   in	   vitro.	  Our	  work	  has	  examined	  much	  
earlier	  time	  points	  after	  injury	  suggesting	  that	  end-­‐stage	  apoptosis	  had	  not	  yet	  likely	  
occurred.	   Indeed,	  given	  that	  caspase-­‐8	  activation	  was	  still	  detectable	  suggests	  cells	  
were	  still	  in	  the	  early	  signalling	  phases	  of	  apoptosis.	  
	  
Secondly,	   the	   removal	   of	   apoptotic	   epithelial	   cells	   would	   require	   replacement	  
through	  proliferating	  type	  2	  AECs,	  but	  histology	  still	  suggests	  the	  presence	  of	  intact	  
alveoli.	  This	   is	  unlikely	  to	  occur	  within	  such	  an	  acute	  time	  frame	  particularly	   in	  the	  
presence	  of	  an	  intact	  alveolar	  structure.	  In	  comparison,	  chronic	  lung	  diseases	  such	  as	  
emphysema,	  where	  apoptotic	  bodies	  are	  abundant	  show	  significant	  disturbance	   to	  
alveolar	  ultrastructure	  (310).	  
4.5.3 Pro-­‐apoptotic	  “death”	  versus	  inflammatory	  “survival”	  signaling	  
The	  important	  effect	  of	  inflammatory	  signalling	  through	  NFκB	  in	  reducing	  cell	  death	  
could	  also	  explain	  the	   low	  levels	  of	  cell	  death	   in	  the	  presence	  of	  severe	   injury.	  The	  
internalisation	  of	  the	  cell	  surface	  TNF/p55	  TNFR	  complex	  1	   leads	  to	  a	  change	   in	   its	  
assembly	   forming	   complex	   2	   and	   this	   enables	   the	   recruitment	   of	   death	   domain	  
proteins,	   such	   as	   TRADD	   and	   FADD,	   to	   the	   internalised	   complex.	   This	   internalised	  
receptor	  complex	  also	  known	  as	  the	  death	  inducing	  signalling	  complex	  recruits	  and	  
activates	   caspase-­‐8.	   The	   mechanism	   behind	   the	   switch	   that	   determines	   whether	  
signalling	  occurs	   through	  complex	  1	  and	   complex	  2	   is	   still	   unknown	  and	   it	  may	  be	  
likely	  that	  both	  are	  activated	  simultaneously	  and	  that	  the	  importance	  is	  determined	  
through	   regulatory	   proteins	   and	   ubiquitination.	   However,	   it	   is	   known	   that	   the	  
activation	  of	  NFκB	  promotes	  the	  expression	  of	  anti-­‐apoptotic	  proteins	  such	  as	  c-­‐FLIP	  
and	   c-­‐IAP1	   (326,	   327).	   Although	   the	   specific	   activation	   of	   NFκB	   pathways	   or	   anti-­‐
apoptotic	   factors	   are	   not	   specifically	  measured	   –	   neutrophil	   recruitment	   has	   been	  
shown	  to	   relate	   to	  NFκB	   transcription	   in	  acid-­‐induced	   lung	   injury	   (328).	  Given	   this,	  
NFκB	  activation	  leading	  to	  the	  upregulation	  of	  anti-­‐apoptotic	  factors	  may	  explain	  the	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lack	   of	   progression	   to	   cell	   death	   within	   the	   three-­‐hour	   period.	   Interestingly,	  
preliminary	   analysis	   of	   a	   longer-­‐term	   model	   of	   acid	   aspiration	   (as	   described	   in	  
chapter	  6)	  also	  suggests	  minimal	  TUNEL	  positive	  staining	  at	  24	  and	  48	  hours.	  Hence,	  
the	  potential	  sustained	  anti-­‐apoptotic	  effect	  of	  NFκB	  activation	  may	  be	  an	  important	  
therapeutic	  avenue	  for	  investigation.	  	  
	  
Of	   note,	   the	   p75	   TNFR	   has	   no	   death	   domain	   and	   hence,	   cannot	   directly	   activate	  
caspase-­‐8.	  However,	  sole	  signalling	  through	  the	  p75	  TNFR	  in	  p55KO	  animals	  leading	  
to	   the	   transcription	   of	   NFκB	   may	   potentially	   explain	   the	   further	   reduction	   in	   cell	  
death	  within	  this	  strain.	  Hence,	  the	  reduction	  in	  apoptosis	  measurements	  in	  p55KO	  
mice	  may	   indeed	  be	   through	  various	  pathways	  –	  1)	  a	   reduced	  p55	  TNFR	  mediated	  
caspase-­‐8	   signal;	   2)	   an	   increase	   in	   more	   downstream	   inhibitors	   which	   mediate	   a	  
reduced	   caspase-­‐8	   activity;	   3)	   an	   increase	   in	   anti-­‐apoptosis	   signalling	   through	   an	  
intact	  p75	  TNFR.	  The	  latter	  has	  also	  been	  shown	  to	  potentially	  explain	  the	  divergent	  
roles	  for	  these	  receptors	  in	  retinal	  ischaemia	  (162).	  	  
4.5.4 Introducing	  the	  concept	  of	  “apoptotic	  limbo”	  
Overall	  the	  data	  suggests	  a	  concept	  whereby	  death	  signalling	  has	  been	  initiated,	  but	  
cellular	   destruction	   or	   entry	   into	   the	   final	   irreversible	   pathways	   of	   cell	   death	   is	  
prevented	  by	  pro-­‐survival	  signals.	  However,	  despite	  minimal	  cell	  death	  and	  the	  cell	  
potentially	   trying	   to	   survive,	   significant	   physiological	   dysfunction	   remains.	   This	  
concept	   of	   a	   cell,	   despite	   receiving	   overwhelming	   cell	   death	   signals,	   is	   prevented	  
from	   dying	   as	   a	   consequence	   of	   organised	   pro-­‐survival/anti-­‐apoptotic	   signals	   has	  
been	   called	   “apoptosis	   interruptus”	   and	   has	   received	   more	   interest	   in	   cardiology	  
literature.	   It	   was	   first	   shown	   in	   chronic	   heart	   failure	  where	   activated	   caspase-­‐3	   is	  
prevented	   from	   completing	   cell	   death	   through	   the	   upregulation	   of	   inhibitors	   of	  
apoptosis	   such	   as	   X-­‐IAP	   and	   Smac-­‐L	   (329).	   In	   close	   similarity	   to	   our	  work,	   studies	  
performed	   by	   Narula	   et	   al	   in	   acute	   and	   chronic	   heart	   failure	   showed	   that	   organ	  
function	   remained	   compromised	   during	   this	   phase	   of	   “apoptosis	   interruptus”	   and	  
that	   apoptotic	   intermediaries	  may	   result	   in	   cellular	   dysfunction	   (330,	   331).	  Hence,	  
this	   period	   of	   “apoptotic	   limbo”	   where	   the	   lung	   is	   in	   a	   state	   of	   physiological	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dysfunction	   without	   cells	   having	   died	   may	   represent	   a	   therapeutic	   window	   to	  
reverse	  and	  restore	  cellular	  function	  and	  thereby	  regain	  normal	  physiology.	  	  
	  
4.6 Concluding	  remarks	  
This	   chapter	   advances	   our	   knowledge	   on	   the	   specific	   cell	   in	   which	   p55	   TNFR	  
mediated	   caspase-­‐8	   activation	   is	   occurring,	   the	   alveolar	   epithelial	   type	   1	   cell.	   This	  
data	   also	   reveals	   an	   interesting	   phenomenon	   where	   significant	   physiological	  
dysfunction	   is	   seen	   in	   the	   absence	   of	   completed	   apoptosis.	   Hence,	   rather	   than	  
completed	  cell	  death,	   the	  death	  signal	   (i.e.	   caspase-­‐8)	   itself	  or	  downstream	  events	  
may	  have	  directly	  promoted	  oedema	  formation.	  The	  next	  goal	  was	  to	  ascertain	  the	  
causal	   link	   between	   p55	   TNFR/caspase-­‐8	   activation,	   and	   epithelial	   injury.	   In	  
particular,	   to	   determine	   how	   “apoptosis	   limbo”	   may	   impact	   on	   lung	   epithelial	  
function,	   leading	   to	   hypoxaemia	   and	   changes	   to	   respiratory	   mechanics	   –	   both	  
hallmarks	  of	  clinical	  ARDS.	  The	  next	  chapter	  describes	  the	  measurement	  of	  alveolar	  
fluid	   clearance	   as	   a	   clinically	   relevant	   and	   specific	   index	   of	   alveolar	   epithelial	  
function.	  This	  data	  provides	  a	  compelling	  argument	  as	  to	  how	  the	  p55	  TNFR	  death	  
signal	   manifests	   as	   alveolar	   oedema	   and	  may	   represent	   an	   opportunity	   to	   inhibit	  
apoptosis	  signalling,	  prior	  to	  cell	  death,	  and	  restore	  epithelial	  function.	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5 TNF-­‐induced	  death	  signalling	  triggers	  alveolar	  epithelial	  
dysfunction	  in	  acid-­‐induced	  lung	  injury	  
	  
Abstract	  
Maintenance	   of	   alveolar	   epithelial	   integrity	   is	   essential	   to	   the	   prevention	   of	   the	  
pulmonary	  oedema	  formation	   in	  ARDS.	  Furthermore,	  not	  only	  does	   the	  epithelium	  
prevent	  fluid	  permeability	  but	  it	  can	  also	  clear	  fluid	  actively	  from	  the	  alveolar	  space.	  
This	  process	  known	  as	  alveolar	  fluid	  clearance	  (AFC)	  is	  critically	  reduced	  in	  patients	  
with	   ARDS.	   Additionally,	   those	   with	   the	   lowest	   AFC	   show	   a	   higher	   mortality	   and	  
hence,	  AFC	  measurement	  is	  a	  specific	  marker	  of	  alveolar	  epithelial	  function	  and	  has	  
high	   clinical	   relevance.	   The	   previous	   chapter	   showed	   that	   p55	   TNFR	   induced	  
caspase-­‐8	  activation	  was	  localised	  to	  the	  alveolar	  type	  1	  epithelial	  cell.	  The	  data	  also	  
suggest	   that	   physiological	   disturbance	   was	   independent	   of	   completed	   cell	   death.	  
Hence,	  we	  wished	   to	   elucidate	   how	   caspase-­‐8	   activation	   per	   se	   induced	   epithelial	  
dysfunction.	  A	  previously	  characterised	  ex	  vivo	  model	  to	  measure	  AFC	  was	  adapted	  
and	   validated.	   Our	   measurement	   of	   AFC	   rate	   showed	   excellent	   correlations	   with	  
other	   markers	   of	   epithelial	   injury,	   including	   RAGE	   and	   respiratory	   mechanics.	  We	  
examined	   the	   link	   between	   the	   TNF/p55	   TNFR/caspase-­‐8	   axis	   and	   epithelial	  
dysfunction	   by	   using	   three	   different	   experimental	   approaches	   (p55	   TNFR	   genetic	  
knockout,	  pharmacological	  inhibition	  of	  caspase-­‐8,	  and	  depletion	  of	  resident	  alveolar	  
macrophages).	  Collectively,	  the	  measurement	  of	  AFC	  in	  each	  protocol	  supported	  the	  
overall	   conclusion	   that	   TNF-­‐p55	   TNFR-­‐caspase-­‐8	   axis	   is	   a	   crucial	   determinant	   of	  
epithelial	   function.	   In	   particular,	   the	   extent	   to	   which	   caspase-­‐8	   was	   activated	  
showed	   significant	   correlation	   with	   the	   deterioration	   in	   AFC.	   Importantly,	   these	  
approaches	   of	   p55	   TNFR	   genetic	   deletion,	   caspase-­‐8	   inhibition,	   and	   macrophage	  
depletion	   all	   rescued	   AFC	   after	   acid	   aspiration	   and	   showed	   improved	   respiratory	  
physiology.	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5.1 Introduction	  
Alveolar	  fluid	  clearance	  (AFC)	  is	  a	  function	  of	  the	  lungs	  performed	  specifically	  by	  the	  
alveolar	  and	  distal	  bronchial	  epithelium.	  Matthay	  and	  Wiener-­‐Kronish	  showed	  that	  
an	  intact	  epithelium	  was	  essential	  to	  resolve	  alveolar	  oedema	  induced	  by	  increased	  
alveolar	   capillary	   barrier	   permeability	   (46).	   Ware	   and	   Matthay	   showed	   AFC	   is	  
impaired	   in	   over	   50%	  of	   patients	  with	   ARDS	   and	   those	  with	  maintained	  AFC	   have	  
better	  outcomes	  (69).	  The	  ability	  of	  the	  lungs	  to	  clear	  fluid	  is	  determined	  by	  vectorial	  
transport	   of	   sodium	   and	   chloride	   from	   the	   alveoli	   into	   the	   lung	   interstitium.	   This	  
creates	   an	   osmotic	   gradient	   for	  water	   to	   be	   cleared	   from	   the	   airspaces.	   Epithelial	  
sodium	   channel	   (ENaC)	   are	   found	   on	   the	   apical	   surface	   of	   the	   epithelium	   and	  
transport	   sodium	   into	   the	   cell	   through	   a	   transcellular	   gradient	   created	   by	   basal	  
Na+/K+	  ATPase	  pumps	  that	  actively	  extrude	  intracellular	  sodium	  from	  epithelial	  cells	  
into	   the	   interstitium.	  This	  process	   is	   integral	   to	   the	  maintenance	  of	   the	   lung	   lining	  
fluid	  during	  health,	  but	  also	  the	  resolution	  of	  alveolar	  oedema	  in	  pathological	  states	  
such	  as	  high-­‐altitude	  pulmonary	  oedema,	  cardiogenic	  oedema	  and	  ARDS.	  	  
	  
In	   the	   previous	   chapter	   we	   showed	   that	   pulmonary	   oedema	   formation	   and	  
subsequent	   physiological	   deteriorations	   were	   mediated	   through	   the	   activation	   of	  
p55	   TNFR	   signalling.	   This	   was	   found	   to	   be	   an	   immediate	   response	   (within	   90	  
minutes)	   and	   independent	   of	   the	   classical	   pro-­‐inflammatory	   consequences	   of	   p55	  
TNFR	   signalling.	   Instead,	   p55	   TNFR	  mediated	   death	   signalling	   induced	   a	   significant	  
upregulation	   of	   caspase-­‐8	   that	   was	   attenuated	   in	   p55KO	   animals	   and	   localised	   to	  
within	   the	   alveolar	   epithelium.	   The	   extent	   of	   TUNEL	   positive	   cell	   death	   seen	  
amounted	  to	  1-­‐2%	  of	  all	  alveolar	  cells	  and,	  although	  attenuated	   in	  p55KO	  animals,	  
could	  not	  fully	  account	  for	  the	  severity	  of	  injury	  seen	  in	  WT	  animals.	  	  
	  
Hence,	   this	   chapter	   elaborates	   on	   the	   trigger	   and	   downstream	   effect	   of	   this	  
epithelial	   p55	   TNFR	   caspase-­‐8	   signal	   and	   hypothesises	   that	   this	   death	   signal	   is	  
triggered	   by	   alveolar	   macrophages	   and	   directly	   impacts	   upon	   the	   epithelial	  
machinery,	  leading	  to	  impaired	  resolution	  of	  alveolar	  oedema	  through	  alveolar	  fluid	  
clearance.	  Whilst,	  apoptosis	  mechanisms	  have	  been	  shown	  to	  mediate	  injury	  to	  the	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alveolar	   epithelium,	   the	   relationships	   between	   apoptosis	   and	   functional	  
measurements	   of	   the	   epithelium	   (like	   AFC)	   remain	   undetermined.	   This	   is	   link	   is	  
essential	  to	  elucidate,	  particularly	  given	  that	  alveolar	  fluid	  clearance	  when	  impaired	  
influences	  morbidity	  and	  mortality	   in	  patients	  with	  ARDS	  (69).	  Determining	   if,	  why,	  
when	   and	   which	   precise	   apoptotic	   mechanisms	   impair	   epithelial	   function	   should	  
provide	  novel	   links	  between	  well-­‐established	  ARDS	  paradigms.	   In	  particular,	   if	  such	  
causal	   relationships	  are	  established,	  measurement	  of	  clinically	  relevant	  parameters	  




The	  aim	  in	  this	  chapter	  was	  to	  determine	  the	  causal	  link	  between	  the	  TNF/p55	  TNFR	  
/caspase-­‐8	  axis	  and	  deteriorations	  in	  respiratory	  physiology	  with	  respect	  to	  epithelial	  
dysfunction.	  
	  
5.3 Experimental	  design	  
5.3.1 In	  situ	  measurement	  of	  alveolar	  fluid	  clearance	  
Alveolar	  fluid	  clearance	  (AFC)	  rate	  was	  ascertained	  by	  the	  increase	  in	  fluorescence	  of	  
a	   tracheally	   instilled	   non-­‐permeable	   tracer	   (AlexaFluor594-­‐conjugated	   BSA)	   within	  
the	  BALF	  over	  a	  30-­‐minute	  period	  using	  an	  adaptation	  of	  a	  published	  in	  situ	  model	  
(242).	   In	  brief,	  animals	  underwent	  anaesthesia,	  tracheostomy	  and	  low	  tidal	  volume	  
ventilation	  for	  a	  brief	  period	  on	  FiO2	  of	  1.0	  (in	  total	   less	  than	  15	  minutes).	  Animals	  
were	   given	   20	   units	   heparin	   intravenously,	   and	   exsanguinated	   under	   terminal	  
anaesthesia.	  Mice	   subsequently	   underwent	   intra-­‐tracheal	   instillation	  with	   700µl	   of	  
isoosmolar	  5%	  BSA	  (Sigma-­‐Aldrich)	  containing	  50µg/ml	  of	  AlexaFluor	  594-­‐conjugated	  
(AF594)	  BSA	   (Invitrogen).	   Immediately	   after	   instillation	  a	   first	   aliquot	  of	   200µl	  was	  
removed	   as	   a	   t=0	   reference	   sample.	  Mice	  were	   immediately	   placed	   on	   a	   custom-­‐
made	   continuous-­‐positive-­‐airway	   pressure	   (CPAP)	   system	   delivering	   a	   FiO2	   1.0	   at	  
8cmH2O,	   and	   they	  were	  maintained	   at	   36.5-­‐38oC	   throughout	   the	   protocol.	   At	   the	  
end	   of	   the	   30	   minutes,	   a	   surgical	   pneumothorax	   was	   induced	   through	   blunt	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dissection	   of	   the	   diaphragm	   ensuring	   full	   recovery	   of	   remaining	   instillate.	   The	  
fluorescence	  of	  the	  original	  instillate	  (Fi),	  the	  t=0	  (F0)	  and	  the	  t=30	  (F30)	  sample	  was	  
measured	   in	   triplicate.	   The	   distal	   airways	   fluid	   clearance	   over	   30	   minutes	   was	  
determined	  by	  the	  equation:	   [1-­‐(F0/F30)]	  x100	  where	  F0	   is	   the	  fluorescence	  of	  the	  
t=0	  reference	  sample	  and	  F30	  is	  the	  fluorescence	  of	  the	  30-­‐minute	  sample.	  
5.3.2 Caspase-­‐8	  inhibition	  experiments	  
The	   caspase-­‐8	   specific	   inhibitor	   (Z-­‐VAD-­‐IETD)	   again	   utilising	   the	   IETD	   caspase-­‐8	  
specific	   sequence	   was	   used.	   The	   inhibitor	   is	   cleaved	   by	   activated	   caspase-­‐8	   and	  
remains	   bound	   to	   the	   active	   site	   preventing	   further	   caspase	   induced	   caspase	  
activation	   and	  hence	   amplification	   of	   the	   cascade.	   The	   caspase-­‐8	   specific	   inhibitor	  
(4mg/kg)	  was	  administered	  through	  the	  right	  external	  jugular	  vein	  5	  minutes	  prior	  to	  
acid	   instillation.	   The	   inhibitor	   is	   dissolved	   in	   DMSO;	   hence,	   the	   same	   amount	   and	  
concentration	  of	  DMSO	  was	  used	  as	  the	  vehicle	  control.	  After	  90	  minutes,	  AFC	  was	  
measured,	   as	   described	   earlier.	   Subsequently,	   right	   lungs	   were	   used	   for	   flow	  
cytometric	   assessment	   of	   leukocyte	   infiltration	   and	   the	   left	   lungs	   for	   caspase-­‐8	  
activity	  assay.	  
5.3.3 Alveolar	  macrophage	  depletion	  
At	  48	  hours	  prior	  to	  acid	  instillation	  mice	  underwent	  laryngoscopy	  under	  anaesthesia	  
as	   previously	   described.	   Subsequently,	   75ul	   of	   clodronate	   or	   PBS	   containing	  
liposomes	  were	  instilled	  to	  deplete	  resident	  alveolar	  macrophages.	  
	  
5.4 Results	  
5.4.1 Validation	  of	  in	  situ	  alveolar	  fluid	  clearance	  measurement	  
A	   number	   of	  models	   have	   been	   developed	   to	  measure	   AFC	   rates	   in	   rodents.	   The	  
most	  common	  method	  utilised	  has	  been	  the	  in	  situ	  method	  described	  by	  Garat	  and	  
colleagues	   (242).	   The	   majority	   of	   clinical	   and	   experimental	   set-­‐ups	   calculate	   AFC	  
through	   the	   intra-­‐tracheal	   instillation	   of	   a	   labelled	   marker	   in	   the	   alveolar	   space.	  
Ideally	   this	  marker	   should	   be	   impermeable	   and	   remain	   in	   the	   alveolar	   space	   such	  
that	   as	   water	   is	   absorbed	   from	   the	   instillate	   through	   intact	   AFC	  mechanisms,	   the	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proportional	   increase	   in	   the	   alveolar	   concentration	   of	   this	  marker	   represents	   AFC	  
rate.	  
	  
The	   Alexafluor594-­‐conjugated	   BSA	   was	   the	   marker	   used	   for	   these	   studies	   as	   it	  
showed	  a	  linear	  relationship	  between	  protein	  concentration	  and	  fluorescence	  (figure	  
5.1	  A).	  Hence,	  over	   the	  30-­‐minute	  AFC	  measurement	  period,	  as	  water	   is	   absorbed	  
from	  the	  lungs,	  there	  is	  an	  increase	  in	   instillate	  protein	  concentration	  from	  0	  to	  30	  
minutes,	   which	   is	   similarly	   measured	   as	   a	   proportional	   increase	   in	   fluorescence.	  
Hence,	  this	  marker	  was	  ideal	  for	  the	  measurement	  of	  AFC.	  The	  marker	  concentration	  
chosen	  was	   50μg/ml	   dissolved	   in	   a	   solution	  made	   isotonic	   to	   plasma	   through	   the	  
addition	  of	  BSA	  at	  5%	  final	  concentration,	  and	  made	  isoosmotic	  to	  mouse	  plasma	  at	  
332mmosol/L	  (332)	  through	  the	  addition	  of	  NaCl.	  
	  
To	  ascertain	  if	  the	  measurements	  derived	  from	  this	  in	  situ	  system	  truly	  reflected	  AFC	  
rate,	   expressed	  as	  %	  AFC	  over	  30	  min,	   a	   variety	  of	   compounds	  known	   to	  enhance	  
and	   inhibit	  AFC	  were	   introduced	   into	   the	   instillate	   (242,	  333)	   (figure	  5.1	  B).	   In	   the	  
absence	   of	   any	   compound,	   basal	   AFC	  was	   11.5%/30min.	  When	   these	   experiments	  
(figure	  5.1	  C)	  were	  performed	  with	  the	  sodium	  channel	  inhibitor	  amiloride	  (at	  2mM	  
concentration)	  within	   the	   instillate,	   there	  was	  a	  47%	   inhibition	  of	  AFC.	  Conversely,	  
instillation	   with	   isoproterenol	   (at	   2mM	   concentration)	   produced	   a	   48%	  
enhancement	  of	  AFC.	  Furthermore,	   isoproterenol	  continued	   to	  augment	  AFC	  at	  60	  
minutes	   suggesting	   that	   AFC	   remained	   stable	   in	   this	   ex-­‐vivo	   experimental	   set-­‐up,	  
reaching	  a	  maximal	  rate	  of	  approximately	  30%/hour.	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Figure	   5.1.	   Development	   and	   validation	   of	   in	   situ	  measurement	   of	   alveolar	   fluid	  
clearance	  
AlexaFluor-­‐594	   conjugated	   BSA	   shows	   a	   linear	   relationship	   between	   fluorescence	  
and	  protein	  concentration	  making	   it	   ideal	   for	   calculating	  AFC	   (A).	  Basal	  AFC	   rate	   is	  
11.7%	  in	  the	  first	  30	  minutes	  and	  decreases	  to	  7.6%	  over	  the	  following	  30	  minutes.	  
The	  maximal	  augmentation	  of	  AFC	  that	  could	  be	  achieved	  by	  isoproterenol	  (2mM)	  is	  
approximately	   30%/hour	   (B).	   Isoproterenol	   shows	   a	   48%	   enhancement	   and	  
amiloride	   produces	   a	   47%	   inhibition	   of	   AFC	   at	   30	   minutes	   validating	   the	   AFC	  
measurement	  technique	  (C).	  (N=4-­‐5	  per	  group;	  **P<0.01)	  
	  
	  
We	  found	  that	  there	  were	  strong	  correlations	  between	  AFC	  and	  mouse	  body	  weight	  
as	  well	  as	  lung	  dry	  weight.	  The	  same	  volume	  of	  instillate	  was	  instilled	  in	  all	  animals	  
and	   hence	   the	   larger	   the	   animal,	   the	   greater	   the	   lung	   size/surface	   area	   for	   fluid	  
reabsorption,	   the	  greater	  proportion	  of	  700μl	   fluid	  cleared,	  and	   therefore	  a	  higher	  
AFC	   (figure	   5.2	   A	   and	   B).	   Taking	   this	   into	   account,	   there	   were	   no	   differences	   in	  
Figur '5.1'AlexaFluor*594.conjugated.BSA.shows.a.
linear. rela;onship. between. ﬂuorescence. and.
protein. concentra;on. making. it. ideal. for.
calcula;ng.AFC. (A)..Basal.AFC. rate. is. 11.7%. in. the.
ﬁrst. 30. minutes. and. decreases. to. 7.6%. over. the.
following. 30. minutes.. Maximal. augmenta;on. of.
AFC.by.isoproterenol.(2mM).is.approximately.30%/
hour. compared. to. 19.3%/hour. without. drug. (B)..
Isoproterenol. shows. a. 48%. enhancement. and.
amiloride. produces. a. 47%. inhibi;on. of. AFC. at. 30.
minutes. valida;ng. the. AFC. measurement.
technique.(C)..(N=4*5.per.group;.**P<0.01).
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uninjured	   AFC	   between	   age	   and	   weight	   matched	   WT	   and	   knockout	   strains,	  
suggesting	   baseline	   differences	  would	   not	   account	   for	   any	   future	   differences	   seen	  
(figure	  5.2	  C).	  In	  these	  validation	  experiments,	  we	  used	  animals	  of	  various	  different	  
weights/ages.	  All	   further	  measurements	  of	  AFC	  were	  performed	   in	  10-­‐12	  week	  old	  
mice	  weighing	  approximately	  25g	  to	  minimise	  this	  effect	  of	  body	  weight/lung	  size	  on	  
AFC.	  
	  
Figure	  5.2.	  Animal	  size	  and	  strain	  differences	  in	  AFC	  measurement	  
AFC	   shows	   strong	   correlations	   with	   mouse	   body	   weight	   (A	   -­‐	   Pearson	   r	   =	   0.637;	  
P<0.001)	   and	   lung	   dry	   weight	   (B	   -­‐	   Pearson	   r	   =	   0.633;	   P<0.001).	   There	   were	   no	  
differences	   in	  baseline	  AFC	  measurements	  between	  weight	  matched	   (30g)	  WT	  and	  
p55KO,	  p75KO	  or	  DKO	  strains	  (C).	  N=6-­‐8	  per	  group	  
	  
F igu re' 5 .2' AFC$ shows$ s t rong$
correla1ons$with$mouse$body$weight$(A$
9$ Pearson$ r$ =$ 0.637;$ P<0.001)$ and$ lung$
dry$ weight$ (B$ 9$ Pearson$ r$ =$ 0.633;$
P<0.001).$ There$were$no$diﬀerences$ in$
baseline$ AFC$ measurements$ between$
weight$matched$(30g)$WT$and$p55/p75$
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5.4.2 Measurement	  of	  in	  situ	  AFC	  during	  injury.	  	  
It	  was	   important	   to	  ensure	   that	   loss	  of	  alveolar	  barrier	   integrity	   in	   injured	  animals	  
did	  not	   influence	  AFC	  measurements.	   Firstly,	   the	  dilution	  of	   the	   initial	   instillate	  by	  
pre-­‐existing	   alveolar	   oedema	   in	   injured	   groups	   would	   tend	   to	   decrease	   apparent	  
AFC.	   This	   was	  minimised	   by	   the	   initial	   lavage	   procedure	   to	   retrieve	   a	   t=0	   sample	  
which	  had	  been	  already	  mixed	  with	  the	  alveolar	  milieu.	  	  
	  
Secondly,	   on	   going	   fluid	   leak	   into	   the	   alveolar	   space	   (from	   the	   vascular	  
compartments)	   may	   have	   diluted	   the	   dye	   in	   the	   alveolar	   compartment.	   This	   was	  
minimised	  through	  effective	  exsanguination	  of	  the	  lungs	  through	  the	  transection	  of	  
the	   IVC	   and	   aorta,	   followed	   by	   the	   introduction	   of	   a	   pneumothorax	   and	   three	  
recruitment	  manoeuvres	  of	  30cmH2O	  to	  empty	  West’s	  zone	  2	  and	  3.	  However,	  to	  be	  
certain	   that	   these	  procedures	  minimised	   the	  potential	   for	   leak	   from	  the	   remaining	  
blood/plasma	   into	   the	   alveolar	   space,	   an	   AlexaFluor-­‐488	   conjugated	   BSA	   dye	  was	  
injected	  intravenously	  (5	  minutes	  before	  the	  end	  of	  the	  protocol)	  and	  the	  extent	  of	  
leak	   into	   the	   alveolar	   space	   over	   the	   30-­‐minute	   AFC	   measurement	   period	   was	  
ascertained	   in	   uninjured	   and	   injured	   animals	   (N=2-­‐3).	   Again	   minimal	   leak	   (of	  
intravenously	   injected	  AlexaFluor-­‐488	   conjugated	  BSA)	   into	   the	  alveolar	   space	  was	  
observed	  (less	  than	  0.2%	  of	  the	  plasma	  fluorescence).	  	  
	  
Thirdly,	   there	   may	   have	   been	   loss	   of	   the	   intratracheal	   protein	   tracer	   into	   the	  
interstitial	   compartment	   leading	   to	  an	  underestimation	  of	  AFC.	  To	  ensure	   that	   the	  
majority	  of	  tracer	  was	  indeed	  recovered,	  5	  separate	  alveolar	  flushes	  (with	  1ml	  NaCl)	  
were	   performed.	   This	   produced	   an	   exponential	   washout	   of	   the	   intratracheally	  
instilled	  AlexaFluor594-­‐conjugated	  BSA	  and	  this	  left	  less	  than	  1%	  of	  total	  instilled	  dye	  
in	   the	   lung	   homogenate	   implying	   minimal	   loss	   of	   alveolar	   dye	   into	   the	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5.4.3 AFC	  deteriorates	  acutely	  after	  acid	  aspiration	  and	  correlates	  with	  markers	  
of	  alveolar	  epithelial	  injury.	  
The	   above	   validation	   confirmed	   that	   this	   method	   could	   be	   applied	   to	   the	   acid	  
aspiration	  injury	  model.	  AFC	  was	  measured	  at	  90	  minutes	  after	  acid	  aspiration,	  given	  
that	   caspase-­‐8	   activation	  was	   highest	   and	   significant	   differences	   in	   the	   physiology	  
between	  WT	  and	  p55KO	  animals	  were	  already	  apparent	  at	  this	  early	  time-­‐point.	  Acid	  
instillation	  led	  to	  a	  reduction	  in	  AFC	  from	  10.95±0.97%	  (mean±SD	  AFC	  of	  uninjured	  
group)	   to	   5.55±2.13%	   (mean±SD	   AFC	   of	   WT	   acid	   group).	   There	   were	   strong	  
correlations	  between	  AFC	  and	  RAGE	  levels,	  and	  AFC	  and	  Ers	  in	  uninjured	  animals	  and	  
WT	  animals	  exposed	  to	  acid	  aspiration	  confirming	  further	  that	  the	  measurement	  of	  
AFC	   gave	   a	   true	   indication	   of	   injury	   to	   the	   alveolar	   epithelium,	   and	   that	  




Figure	  5.3.	  Correlations	  between	  AFC	  and	  other	  markers	  of	  epithelial	  dysfunction	  
Deteriorations	   in	  AFC	   induced	  by	  acid	   instillation	  correlate	   strongly	  with	  measured	  
changes	  in	  respiratory	  system	  elastance	  (A	  -­‐	  Pearson	  r	  =	  -­‐0.942;	  P<0.0001)	  and	  levels	  
of	   soluble	   BALF	   RAGE	   (B	   -­‐	   Pearson	   r	   =	   -­‐0.901;	   P	   <0.0001)	   confirming	   robust	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5.4.4 The	  p55	  TNF	  receptor	  triggers	  the	  early	  disturbance	  of	  alveolar	  fluid	  
clearance	  in	  experimental	  ARDS	  
The	  work	  so	  far	  showed	  that	  the	  p55	  TNFR	  is	  activated	  early	  at	  90	  minutes	  after	  acid	  
aspiration	  leading	  to	  caspase-­‐8	  activation	  localised	  to	  type	  1	  alveolar	  epithelial	  cells.	  
In	  comparison	  to	  the	  49%	  downregulation	  of	  AFC	   in	  WT	  animals,	   the	  p55KO	  group	  
showed	  only	   a	   27%	   reduction	   (figure	   5.4	  A).	   Furthermore,	   p55KO	   animals	   showed	  
significant	   reductions	   in	   BALF	   alveolar	   RAGE	   level	   at	   90	  minutes	   providing	   further	  
suggestion	  that	  epithelial	  injury	  was	  reduced	  (figure	  5.4	  B).	  	  
	  
To	  confirm	  that	  this	  was	  a	  p55	  TNFR	  specific	  phenomenon	  AFC	  was	  also	  measured	  in	  
acid	   instilled	   p75KO	   animals.	   There	   was	   substantial	   epithelial	   injury	   in	   the	   p75KO	  
strain	  with	   increased	  RAGE	  and	  reduced	  AFC	  (to	  similar	   levels	  as	  WT	  animals).	  This	  
confirmed	  our	  notion	   that	   the	  p55	  TNFR	  was	   the	  predominant	  pathway	  mediating	  
the	   TNF	   signal	   that	   leads	   to	   epithelial	   dysfunction.	   Indeed,	   when	   all	   groups	   are	  
analysed	  together,	  AFC	  continues	  to	  correlate	  strongly	  with	  alveolar	  RAGE	  levels	  and	  
Ers	  confirming	  that	  epithelial	  dysfunction	  accounted	  for	  differences	  between	  p55KO	  
and	  other	  groups	  (figure	  5.4	  C	  and	  D).	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Figure	   5.4.	  Differences	   in	  AFC	  between	  WT	  and	   TNFR	   knockout	   strains	   after	   acid	  
aspiration	  
Acid	   instillation	   in	  WT	  animals	   induces	   a	   significant	   49%	  deterioration	   in	  AFC.	   This	  
deterioration	  is	  attenuated	  in	  p55KO	  group	  implicating	  TNF	  death	  signalling	  through	  
the	   p55	   TNFR	   in	   the	   development	   of	   epithelial	   dysfunction	   (A).	   The	   p75KO	   group	  
remains	   injured	  confirming	  TNF	  mediated	  effects	  are	   independent	  of	  this	  receptor.	  
Levels	  of	  BALF	  RAGE	  are	  significantly	   lower	   in	  the	  p55KO	  strains	  further	  confirming	  
lower	   epithelial	   injury	   (B).	   The	  data	   from	   the	   knockout	   strains	   follow	   the	  previous	  
relationship	  between	  AFC	  and	  changes	  in	  respiratory	  system	  elastance	  (C	  -­‐	  Pearson	  r	  
=	   -­‐0.871;	  P<0.0001)	  and	  BALF	  RAGE	   	   (D	   -­‐	  Pearson	  r	  =	   -­‐0.886;	  P<0.0001).	  N=6-­‐8	  per	  








































































































































Death	  signalling	  triggers	  alveolar	  epithelial	  dysfunction	  
	   178	  
5.4.5 Caspase-­‐8	  activity	  leads	  to	  epithelial	  dysfunction.	  
To	   elucidate	   the	   causal	   link	   between	   the	   activation	   of	   caspase-­‐8	   and	   alveolar	  
epithelial	   dysfunction,	   a	   cell	   permeable	   caspase-­‐8	   specific	   inhibitor	   compound	   (Z-­‐
VAD-­‐IETD)	   was	   administered	   prior	   to	   acid	   instillation.	   This	   was	   given	   through	   the	  
external	   jugular	   vein	   and	   hence,	   as	   directly	   as	   possible,	   into	   the	   pulmonary	  
circulation.	   After	   90	  minutes	  we	  measured	   parameters	   of	   lung	   injury	   and	   alveolar	  
fluid	   clearance	   and	   it	   was	   found	   that	   the	   instillation	   of	   vehicle	   produced	   similar	  
deteriorations	   in	  PaO2/FiO2	  ratio	  and	  AFC	  as	  compared	  to	  WT	  acid	   instilled	  animals	  
(without	   vehicle).	   Administration	   of	   the	   caspase-­‐8	   inhibitor	   compound	   showed	   a	  
striking	  improvement	  in	  PaO2/FiO2	  ratio	  and	  alveolar	  fluid	  clearance	  measurements	  
(figure	  5.5	  A	  and	  B).	  	  
	  
To	  ensure	  that	  the	  inhibitor	  did	  indeed	  reduce	  caspase-­‐8	  activity	  we	  measured	  it	  in	  
the	  lung	  homogenate	  and	  found	  that	  the	  dose	  administered	  led	  to	  a	  26%	  reduction	  
in	   activity	   (figure	   5.5	   C).	   Even	   more	   interestingly,	   there	   was	   a	   significant	   inverse	  
correlation	  between	  the	  extent	  of	  caspase-­‐8	  activation	  (or	  inhibition,	  as	  in	  this	  case)	  
and	  alveolar	  fluid	  clearance	  ability	  within	  these	  animals	  (figure	  5.5	  D).	  Hence,	  these	  
inhibition	  experiments	   suggest	   that	   the	  downstream	  effects	  of	  caspase-­‐8	  signalling	  
have	  a	  specific	  and	  direct	  impact	  upon	  the	  alveolar	  fluid	  clearance	  machinery	  within	  
the	   distal	   lung	   and	   alveolar	   epithelium.	   This	   protective	   effect	   was	   seemingly	  
independent	  to	  lung	  leukocyte	  recruitment	  (figure	  5.5	  E).	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Figure	  5.5.	  Protective	  effect	  on	  respiratory	  physiology	  by	  caspase-­‐8	  inhibition	  	  
Acid	   instillation	   leads	   to	   deteriorations	   in	   oxygenation	   (A)	   and	   AFC	   (B)	   in	   vehicle	  
treated	   WT	   controls,	   which	   is	   rescued	   by	   the	   caspase-­‐8	   inhibitor	   Z-­‐VAD-­‐IETD.	  
Caspase-­‐8	   activity	   is	   marginally	   reduced	   in	   inhibitor	   treated	   animals	   (C)	   but	   the	  
extent	  of	   caspase-­‐8	  activation	   (or	   inhibition)	   shows	  strong	   inverse	  correlation	  with	  
AFC	  (D)	  (n=16,	  Pearson	  r	  =	  -­‐0.843;	  P<0.0001).	  This	  protection	  remains	   independent	  
of	   lung	   sequestered	   leukocytes	   as	   similar	   levels	   of	   lung	   neutrophil	   and	  monocyte	  
Figure' 5.5' Acid% ins(ll ( n% leads% to% deteriora(ons% in%
oxygena(on% (A)% and% AFC% (B)% in% vehicle% treated% WT%
controls,%which%is%rescued%by%the%caspase@8%inhibitor%Z@
VAD@IETD.% Caspse@8% ac(vity% is% marginally% reduced% in%
inhibitor% treated% animals% (C)% but% the% extent% of%
caspase@8% ac(va(o % (or% inhibi(on)% shows% strong%
inverse% correla(on% with% AFC% (D)% (n=16,% Pearson% r% =%
@0.843;%P<0.0001).%this%protec(on%remains%independent%
of%lung%sequestered%leukocytes%as%similar%levels%of%lung%
neutrophil% and% monocyte% numbers% were% present%
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numbers	  were	  present	  between	  vehicle	  and	  inhibitor	  treated	  groups	  (E).	  N=5-­‐6	  per	  
group;	  *	  P<0.05;	  **P<0.01;	  ***	  P<0.001	  
	  
5.4.6 Early	  epithelial	  death	  signalling	  is	  dependant	  on	  resident	  alveolar	  
macrophage	  derived	  TNF	  
It	   has	   been	   shown	   previously	   that	   depletion	   of	   alveolar	  macrophages	   conveyed	   a	  
protective	   effect	   after	   acid	   aspiration	   (83).	   Hence,	   resident	   alveolar	   macrophages	  
could	  have	  been	  the	  trigger	  for	  the	  upstream	  release	  of	  TNF	  leading	  to	  the	  injurious	  
effect	  through	  the	  p55	  TNFR.	  A	  90%	  depletion	  of	  the	  resident	  alveolar	  macrophage	  
population	   was	   achieved	   through	   the	   intra-­‐tracheal	   administration	   of	   clodronate	  
containing	   liposomes	  (48	  hours	  prior	  to	  acid	   instillation).	  This	  depletion	  (figure	  5.6)	  
was	  confirmed	  by	  cell	  counts	  determined	  through	  flow	  cytometric	  analysis	  of	  whole	  
lung	   single	   cell	   suspensions.	   Intra-­‐tracheal	   administration	   only	   depleted	   resident	  
alveolar	   macrophages,	   which	   were	   defined	   as	   CD45+CD11b-­‐CD11c+F4/80+	   (R3	   in	  
figure	   5.6).	   Other	   cell	   types	   such	   as	   dendritic	   cells	   and	   systemic	   leukocyte	  
populations	  were	  unaffected	   (for	   their	   specific	  phenotypes	  please	   refer	   to	   chapter	  
7).	  
	  
Macrophage	  depletion	  produced	  significant	  improvements	  in	  oxygenation	  as	  well	  as	  
respiratory	  system	  elastance	  (Ers)	  even	  within	  90	  minutes	  of	  acid	  aspiration	  (figure	  
5.7	  A	  and	  B).	  This	  was	  also	  independent	  of	  leukocyte	  infiltration	  (figure	  5.7	  C	  and	  D).	  
Flow	   cytometric	   analysis	   of	   right	   lungs	   showed	   significantly	   increased	   numbers	   of	  
neutrophils	  as	  a	  result	  of	  clodronate	  instillation,	  which	  increased	  significantly	  further	  
on	   acid	   aspiration.	   Despite	   physiological	   protection,	   the	   clodronate+acid	   group	  
showed	   even	   greater	   neutrophil	   infiltration	   and	   similar	   inflammatory	   monocyte	  
infiltration.	   This	   data	   is	   consistent	   with	   the	   leukocyte	   infiltration	   observed	   in	   the	  
genetic	  knockout	  animals.	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Figure	  5.6.	  Flow	  cytometric	  evaluation	  of	  resident	  alveolar	  macrophage	  depletion	  
by	  intratracheal	  clodronate	  administration	  
Resident	   alveolar	   macrophages	   were	   identified	   in	   right	   lung	   homogenate	   as	  
CD45posCD11bnegCD11cposF4/80pos.	  Intra-­‐tracheal	  instillation	  of	  clodronate	  liposomes	  
induced	   a	   90%	   reduction	   in	   the	   total	   resident	   macrophage	   population	   without	  
inducing	   depletion	   in	   other	   lung	   resident	   cells	   such	   as	   CD11bpos	   and	   CD11bneg	  
dendritic	  cells,	  or	  systemic	  leukocytes.	  N=5	  per	  group;	  ***	  P<0.001	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Figure	   5.7.	   Protective	   effects	   on	   respiratory	   physiology	   through	   alveolar	  
macrophage	  depletion	  
Depletion	   of	   resident	   alveolar	   macrophages	   protected	   against	   acid-­‐induced	   lung	  
injury	   with	   improved	   oxygenation	   (A)	   and	   lower	   respiratory	   system	   elastance	   (B).	  
Clodronate	   liposomes	   alone	   induced	   a	   small	   increase	   in	   lung	   neutrophil	  
sequestration	   (C)	   but	   overall	   acid	   aspiration	   induced	   significant	   numbers	   of	   lung	  
neutrophils	  and	  monocytes	  (D)	  in	  both	  PBS	  and	  clodronate	  liposome	  instilled	  groups	  
suggesting	   resident	   macrophages	   drive	   acid-­‐induced	   lung	   injury	   independent	   to	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In	  view	  of	  the	  apparent	  dissociation	  with	  leukocyte	  infiltration,	  it	  was	  hypothesised	  
that	   macrophage	   depletion	   seemingly	   led	   to	   a	   similar	   impact	   upon	   the	   alveolar	  
epithelium	   through	   a	   reduction	   in	   TNF-­‐mediated	   signalling.	   Indeed,	   macrophage	  
depletion	  led	  to	  a	  significant	  reduction	  in	  alveolar	  soluble	  TNF	  levels	  at	  90	  minutes,	  
which	   corresponded	  with	   a	   reduced	   caspase-­‐8	   activation	   in	   the	   lung	  homogenate,	  
which	   as	   shown	   previously	   is	   confined	  within	   alveolar	   epithelial	   cells	   (figure	   5.8	   A	  
and	  B).	  Finally,	  the	  reduced	  activation	  of	  TNF-­‐p55	  TNFR-­‐caspase-­‐8	  signalling	  resulting	  
from	  macrophage	   depletion	   produced	  marked	   improvements	   in	   alveolar	   epithelial	  
injury,	   as	  measured	   by	   BALF	   RAGE,	   as	  well	   as	   function,	   as	  measured	   through	   AFC	  
(figure	  5.8	  C	  and	  D).	  The	  measurement	  of	  AFC	  and	  RAGE	  continued	  to	  show	  strong	  
correlations	   suggesting	   robust	   measurement	   of	   epithelial	   function	   (figure	   5.8	   E).	  
Once	   again	  within	   this	   set	   of	   experiments,	   the	   AFC	   correlated	  with	   lung	   epithelial	  
caspase-­‐8	  activation,	  confirming	   that	  TNF-­‐induced	  caspase-­‐8	  activation	  determined	  
epithelial	  injury	  and	  function	  (figure	  5.8	  F).	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Figure	  5.8.	  The	  protective	  effects	  of	  alveolar	  macrophage	  depletion	  are	  mediated	  
through	  a	  reduction	  in	  TNF-­‐induced	  epithelial	  dysfunction	  
Resident	   alveolar	   macrophages	   were	   the	   predominant	   producers	   of	   TNF	   at	   90	  
minutes	   after	   acid	   aspiration	   and	   the	   reduction	   in	   their	   numbers	   significantly	  
reduced	  the	  alveolar	  expression	  of	  soluble	  TNF	  (A).	  Furthermore,	  caspase-­‐8	  activity	  
was	  significantly	  reduced	  presumably	  secondary	  to	  reduced	  p55	  TNFR	  induced	  death	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epithelial	   injury	   as	   measured	   by	   BALF	   RAGE	   (C)	   and	   improved	   AFC	   (D).	   There	  
remained	  a	  strong	  correlation	  between	  AFC	  and	  BALF	  RAGE	  (E;	  n	  =	  17;	  Pearson	  r	  =	  -­‐
0.845;	   p<0.0001;	   uninjured	   data	   points	   are	   the	   same	   as	   in	   figures	   5.4	   and	   5.5)	  
confirming	   a	   robust	   measurement	   of	   alveolar	   epithelial	   injury.	   Finally,	   caspase-­‐8	  
activation	  showed	  a	  strong	  inverse	  correlation	  to	  AFC	  (F;	  n	  =	  17;	  Pearson	  r	  =	  -­‐0.894;	  
p<0.0001;	   uninjured	   data	   points	   are	   the	   same	   as	   in	   figures	   5.4	   and	   5.5),	   further	  
corroborating	   findings	   from	   the	   caspase-­‐8	   inhibition	   studies	   that	   caspase-­‐8	   is	   a	  
critical	   component	   involved	   in	   mediating	   the	   early	   disturbance	   in	   AFC.	   N=5-­‐6	   per	  
group	  *P<0.05;	  **P<0.01;	  ***	  P<0.001	  
	  
5.4.7 Alternative	  mechanisms	  of	  caspase-­‐8	  activation	  
Although	  depletion	  of	  resident	  alveolar	  macrophages	  led	  to	  a	  significant	  reduction	  in	  
soluble	  TNF	  levels	  in	  BALF	  (figure	  5.8	  A),	  it	  only	  induced	  a	  68%	  reduction	  in	  caspase-­‐8	  
activation	   at	   90	   minutes.	   Furthermore,	   genetic	   deletion	   of	   the	   p55	   TNFR	   only	  
conveyed	  a	  61%	  reduction	  in	  caspase-­‐8	  activity	  at	  3	  hours.	  This	  incomplete	  reduction	  
suggested	   the	   presence	   of	   alternative	   mechanisms	   of	   death	   receptor	   activation.	  
These	   include	   mechanisms	   independent	   to	   alveolar	   macrophages,	   and	   soluble	  
TNF/p55	  TNFR	  interactions.	  	  
	  
There	   is	   substantial	   evidence	   implicating	   the	   involvement	   of	   the	   FasL/Fas	   death	  
receptor	   axis	   in	   ARDS	   and	   soluble	   FasL	   is	   upregulated	   in	   the	   BALF	   during	  
experimental	   and	   clinical	   studies	   (56,	   57,	   59,	   290,	   292).	   At	   90	   minutes	   after	   acid	  
aspiration,	   unlike	   soluble	   TNF	   (as	   seen	   in	   figure	   5.8	   A),	   there	   was	   no	   detectable	  
upregulation	   of	   soluble	   FasL	   in	   BALF	   of	   WT	   animals.	   However,	   there	   remained	   a	  
possibility	  that	  those	  non-­‐depleted	  alveolar	  macrophages	  (approximately	  10%)	  could	  
contribute	   to	   death	   receptor	   activation	   through	   signalling	   via	   membrane	   bound	  
death	  ligands	  (mTNF	  or	  mFasL),	  and	  hence	  contribute	  to	  caspase-­‐8	  signalling	  within	  
the	   epithelium.	   Hence,	   we	   examined	   expression	   of	   mFasL	   and	   mTNF	   on	   resident	  
alveolar	   macrophages.	   Furthermore	   other	   leukocytes	   such	   as	   blood	   derived	  
neutrophils	  and	   inflammatory	  monocytes	  could	  also	  contribute	  through	  membrane	  
ligands	   or	   the	   shedding	   of	   soluble	   ligands.	   As	   expected,	   at	   90	   minutes,	   alveolar	  
macrophages	   expressed	   mFasL	   and	   mTNF	   on	   their	   cell	   surface	   (figure	   5.9	   A).	  
However,	  lung	  sequestered	  neutrophils	  and	  inflammatory	  monocytes	  also	  expressed	  
mTNF	   and	   mFasL	   (figure	   5.9	   B	   and	   C).	   No	   differences	   in	   expression	   were	   seen	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between	  uninjured	  and	  injured	  animals.	  Hence,	  membrane	  associated	  death	  ligands	  
and	   other	   leukocytes	   such	   as	   neutrophils	   and	   monocytes	   could	   potentially	  
contribute	   to	   epithelial	   death	   signalling	   at	   this	   time-­‐point.	   This	   requires	   further	  
exploration.	  	  
	  
The	  story	  becomes	  more	   interesting	  at	  3	  hours	  after	  acid	  aspiration	  at	  which	  point	  
there	  is	  a	  significant	  upregulation	  of	  BALF	  soluble	  FasL	  (Figure	  5.10	  A).	  No	  differences	  
are	   seen	   between	   WT	   and	   p55KO	   groups.	   This	   upregulation	   of	   soluble	   FasL	   at	   3	  
hours	  possibly	  accounts	   for	  the	   incomplete	  reduction	   in	  caspase-­‐8	  activation	  (60%)	  
in	  p55KO	  strain	  at	  3	  hours.	  In	  addition,	  at	  three	  hours,	  there	  were	  strong	  correlations	  
between	   soluble	   FasL	   in	   the	   alveolar	   space	   with	   the	   amount	   of	   neutrophil	   and	  
monocyte	   sequestration	   to	   the	   lung.	   This	   supports	   the	   notion	   that	   blood	   derived	  
leukocytes	   could	  act	  as	   sources	   for	   soluble	  Fas	   ligand	  during	   later	  phases	  of	   injury	  
(figure	   5.10	   B	   and	   C).	   The	   cell	   surface	   expression	   of	   FasL	   at	   3	   hours	   on	   these	  
leukocytes	   remains	   to	   be	   studied	   and	   future	   work	   investigating	   the	   relationship	  
between	  neutrophils/monocytes	  and	  FasL	  release	  may	  shed	  interesting	  light	  into	  this	  
phenomenon	  of	  exudative	   leukocyte	   induced	  epithelial	  death	  signalling	  and	  how	   it	  
may	  influence	  disturbances	  in	  AFC.	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Figure	   5.9.	   Cell	   surface	   expression	   of	   death	   ligands	   TNF	   and	   FasL	   on	   alveolar	  
macrophages,	   neutrophils	   and	   inflammatory	   monocytes	   in	   naïve	   and	   injured	  
animals	  	  
TNF	   and	   FasL	   was	   expressed	   on	   the	   cell	   surface	   of	   lung	   resident	   alveolar	  
macrophages	   (A),	   lung	   sequestered	   neutrophils	   (B)	   and	   lung	   sequestered	   Ly6Chi	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animals.	  Expression	  is	  derived	  after	  subtraction	  of	  isotype	  control	  expression	  values.	  




Figure	  5.10.	  Correlations	  in	  alveolar	  FasL	  levels	  with	  leukocyte	  sequestration	  to	  the	  
lung	  
Soluble	   Fas	   ligand	   was	   upregulated	   in	   the	   alveolar	   space	   at	   3	   hours	   after	   acid	  
aspiration	   to	  a	   similar	  extent	   in	  both	  WT	  and	  p55KO	  animals	   (A).	   Levels	  of	   soluble	  
BALF	  showed	  strong	  positive	  correlations	   to	   lung	  neutrophil	   (B	  –	  Pearson	   r	  =	  0.83;	  
P<0.01)	   and	  monocyte	   (C	   –	   Pearson	   r	   =	   0.89;	   P<0.001)	   sequestration	   to	   the	   lung.	  
N=5-­‐8	  per	  group;	  *	  P<0.05	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5.5 Discussion	  
5.5.1 Alveolar	  fluid	  clearance	  –	  conceptual	  discussions	  
It	   is	  well	  established	  that	  a	  number	  of	  species,	   including	  bovid,	  canine,	   rodent	  and	  
man,	   actively	   clear	   alveolar	   liquid	   through	   a	   process	   known	   as	   alveolar	   fluid	  
clearance	   (69,	   70,	   242,	   334-­‐339)	   and	   that	   this	   is	   performed	   specifically	   by	   the	  
alveolar	   epithelium.	   The	   majority	   of	   investigations	   have	   focussed	   on	   stimulating	  
alveolar	   fluid	   clearance	   (AFC)	   through	  beta-­‐adrenoceptor	   agonists	   that	   function	   to	  
increase	  intracellular	  cAMP	  levels	  which	  in	  turn	  induce	  1)	  an	  increased	  channel	  open	  
probability	   and	  2)	   an	   increased	   surface	  expression	   (from	  cytoplasmic	   stores	  within	  
the	   endoplasmic	   reticulum)	   of	   ENaC,	   CFTR,	   and	  Na+/K+	  ATPase	   ion	   channels	   (340).	  
Whilst	   there	   has	   been	   extensive	   progress	   in	   the	   elucidation	   of	   mechanisms	   that	  
enhance	  AFC	  through	  beta-­‐agonists,	  the	  clinical	  translation	  has	  faltered	  through	  the	  
failure	  of	  large	  clinical	  trials	  of	  intravenous	  and	  inhaled	  beta	  agonists	  (73,	  75-­‐77,	  341,	  
342).	   A	   reason	   for	   this	   failure	   may	   be	   the	   fact	   that	   AFC	   can	   be	   enhanced	   in	  
mild/moderate	   ARDS	   but	   deteriorates	   significantly	   in	   severe	   ARDS	   (340),	   and	   that	  
the	   severity	   of	   ARDS	   was	   high	   in	   patients	   recruited	   to	   such	   trials.	   The	   rational	  
explanation	   being	   that	   in	   mild/moderate	   ARDS	   there	   is	   sufficient	   functional	  
epithelium	   remaining	   for	   intrinsic	  mechanisms	   to	   be	   enhanced	  whereas,	   in	   severe	  
ARDS	   the	   severity	   of	   epithelial	   injury	   leads	   to	   the	   inability	   of	   exogenously	  
administered	  agents	  to	  enhance	  AFC.	  	  
	  
This	  measurement	   of	   AFC	   gives	   a	   specific	   indication	   into	   the	   state	   of	   the	   alveolar	  
epithelium	  and	  no	  other	  parameter	   is	  as	  specific	  and	  so	  clinically	  relevant	  (46,	  69).	  
Measurements	  of	  basal	  AFC	  rate	  have	  varied	  significantly	  between	  investigators	  and	  
may	  be	  due	  to	  a	  number	  of	  technical	  factors	  including	  the	  specific	  type	  of	  set-­‐up	  (in	  
situ	   flooded	  model	   (242),	   ex	   vivo	   isolated	  perfused	  model	   (217),	   in	   vivo	  ventilated	  
model	   (333))	  as	  well	  as	   the	  precise	  probes/instillate	  used	  for	  measurement.	  The	   in	  
situ	  measurement	   of	   AFC	   using	   AlexaFluor594	   in	   C57BL6	   strain	   of	  mice	   showed	   a	  
basal	   AFC	   rate	   of	   11.7%	   over	   the	   first	   30	   minutes	   and	   7.6%	   over	   the	   second	   30	  
minutes	  confirming	  that	  the	  measurement	  over	  longer	  periods	  may	  be	  less	  accurate.	  
Studies	  by	  Fukuda	  et	  al	  suggest	  that	  the	  fast	  accumulation	  of	  interstitial	  fluid	  volume	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in	   such	  a	  non-­‐perfused	   system	   limits	  AFC	  measurements	   in	   the	   in	   situ	   set-­‐up,	   and	  
furthermore	  may	  promote	  the	  re-­‐flooding	  of	  the	  alveolar	  space	  leading	  to	  a	  plateau	  
in	  AFC	  measurements	  (333).	  	  
5.5.2 RAGE,	  the	  epithelium,	  and	  apoptosis	  
After	   90	   minutes	   of	   acid	   aspiration	   there	   was	   a	   50%	   reduction	   in	   AFC	   and	   this	  
reduction	   correlated	   strongly	  with	   the	  upregulation	  of	  RAGE	   in	   the	  alveolar	   space.	  
RAGE	  has	  been	  established	  as	  a	  marker	  of	  type	  1	  AEC	  injury	  (308,	  343)	  and	  increased	  
volumes	  and	  proton	  concentrations	  of	  acid	  aspiration	  lead	  to	  incremental	  increases	  
in	  BALF	  soluble	  RAGE	  at	  4	  hours	  (308,	  344).	  Su	  et	  al	  also	  showed	  that	  RAGE	  fails	  to	  be	  
upregulated	   in	   indirect	   forms	   of	   lung	   injury	   implying	   that	   epithelial	   injury	   is	   an	  
important	   determinant	   of	   RAGE	   release	   (344).	   This	   thesis	   also	   confirms	   that	   BALF	  
RAGE	  levels	  (regardless	  of	  animal	  group)	  inversely	  correlate	  with	  AFC	  at	  90	  minutes	  
providing	   strong	   evidence	   that	   the	   measured	   AFC	   is	   a	   robust	   marker	   of	   alveolar	  
epithelial	  function	  during	  injury.	  Briot	  et	  al	  found	  a	  weaker	  but	  significant	  correlation	  
between	   BALF	   RAGE	   and	   AFC	   in	   studies	   using	   isolated	   perfused	   human	   lungs,	  
indicating	   its	   clinical	   relevance	   in	   this	   setting	   (345).	   RAGE	   is	   expressed	   as	   a	  
transmembrane	  protein	  on	  the	  basal	  surface	  of	  epithelial	  cells	  and	  is	  thought	  to	  play	  
a	  role	  in	  tethering	  the	  epithelium	  to	  the	  basement	  membrane	  (346).	  Work	  from	  our	  
laboratory	   has	   shown	   a	   dramatic	   increase	   in	   alveolar	   RAGE	   only	   when	   oedema	  
manifests	  in	  a	  model	  of	  VILI	  (239).	  Furthermore,	  Uchida	  showed	  that	  levels	  of	  RAGE	  
are	   far	   greater	   in	   the	   BALF	   than	   plasma	   during	   pulmonary	   oedema	   suggesting	   a	  
pulmonary	   source	   for	   this	   molecule	   (308).	   Hence,	   through	   as	   yet	   unknown	  
mechanisms,	  in	  the	  presence	  of	  significant	  epithelial	  permeability,	  membrane	  bound	  
RAGE	   is	   cleaved	   and	   its	   soluble	   form	   is	   released	   from	   the	   cell	   surface	   and	  
accumulates	  in	  the	  alveolar	  space.	  	  
5.5.3 TNF,	  the	  epithelium	  and	  apoptosis	  
TNF	  has	  been	  shown	  to	  have	  opposing	  impacts	  upon	  AFC,	  with	  receptor-­‐dependent	  
pathways	   leading	   to	   a	   deterioration	   in	   AFC	   (216)	   and	   receptor-­‐independent	  
pathways	   inducing	   an	   augmentation	   (through	   the	   lectin-­‐type	   domain	   of	   the	   TNF	  
molecule	   (206))	   (215,	   218).	   Rezaiguia	   et	   al	   showed	   that	   upregulation	   of	   AFC	   in	   a	  
model	  of	  pseudomonas	  aeroginosa	  pneumonia	  was	  TNF-­‐dependant	  (193).	  Borjesson	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et	  al	  also	  showed	  that	  an	  upregulation	  in	  AFC	  in	  a	  model	  of	  ischaemia-­‐reperfusion	  of	  
the	  gut	  was	  blocked	  by	  a	  monoclonal	  antibody	  to	  TNF	  (203).	  Braun	  and	  colleagues	  
showed	   that	   the	  application	  of	   TNF	   into	  an	   in	   vivo	   ventilated	   system	   reduced	  AFC	  
and	  that	  blockade	  of	  the	  receptor-­‐binding	  domain	  of	  TNF	  (by	  soluble	  TNFR1)	  allowed	  
TNF’s	   lectin	  domain	   to	  augment	  AFC	   (216).	  This	   study	  concluded	   that	   the	   receptor	  
dependant	   downregulation	   of	   AFC	   by	   TNF	   could	   partially	   be	   due	   to	   infiltrating	  
neutrophils	   increasing	   inflammatory	   signalling	   of	   TNF	   through	   the	   p55	   TNFR.	  
However,	   no	   measurements	   of	   death	   signalling	   have	   ever	   been	   performed	   in	   all	  
studies	  linking	  TNF	  with	  AFC.	  
	  
The	  data	  presented	  in	  this	  chapter	  provides	  crucial	  evidence	  that	  p55	  TNFR	  induced	  
caspase-­‐8	   activation	   is	   a	   major	   determinant	   of	   the	   receptor	   dependant	  
downregulation	  of	  AFC	  during	  injury.	  This	  is	  particularly	  evident	  given	  that	  p55	  TNFR	  
genetic	   depletion,	   caspase-­‐8	   inhibition	   and	   alveolar	  macrophage	   depletion	   studies	  
all	  showed	  a	  significant	  correlation	  between	  AFC	  and	  the	  extent	  to	  which	  caspase-­‐8	  
is	  activated	  (or	  inhibited)	  within	  the	  mouse	  lung.	  These	  data	  support	  a	  dominant	  in	  
vivo	   role	   for	  TNF	   receptor	  dependent	  effects	   in	   reducing	  AFC	  during	   severe	   injury,	  
and	  this	  outweighs	  the	  ligand’s	  intrinsic	  ability	  to	  promote	  AFC.	  	  
	  
The	   receptor	   independent	   mediated	   augmentation	   of	   AFC	   mediated	   through	   the	  
lectin-­‐like	  domain	  and	  the	  LTip	  peptide	  (a	  synthetic	  compound	  mimicking	  the	  lectin-­‐
like	   domain	   of	   TNF	   (218,	   219,	   347-­‐349))	   is	   thought	   to	   be	   due	   an	   upregulation	   of	  
intrinsic	   epithelial	   ENaC	   activity/expression.	   Hence,	   in	   line	   with	   the	   previous	  
discussions	  for	  the	  failure	  of	  beta-­‐agonist	  treatments,	  the	  clinical	  application	  of	  the	  
LTip	   peptide	   to	   promote	   fluid	   clearance	   during	   states	   of	   severe	   injury	   may	   be	  
inappropriate	   given	   that	   the	   epithelium	   may	   not	   be	   in	   a	   state	   to	   increase	   AFC	  
through	   the	   ENaC	   upregulation.	   In	   contrast,	   it	   may	   be	   more	   valuable	   to	   block	  
caspase-­‐8	   activation	   and	   prevent	   deterioration	   in	   epithelial	   AFC	   machinery	   as	  
opposed	  to	  apply	  futile	  therapeutic	  strategies	  akin	  to	  “flogging	  a	  dead	  horse”.	  	  
	  
Finally,	  although	  AFC	  is	  an	  important	  determinant	  within	  these	  data,	  the	  significant	  
physiological	   protection	  observed	   in	   the	  p55KO	  animals	   from	   the	  beginning	  of	   the	  
Chapter	  5	  
Death	  signalling	  triggers	  alveolar	  epithelial	  dysfunction	  
	   192	  
acid	   aspiration	   protocol,	   may	   not	   be	   completely	   attributable	   to	   only	   a	   2-­‐fold	  
improvement	  in	  AFC	  capacity.	  But,	  when	  this	  effect	  is	  synergistically	  combined	  with	  
the	   2-­‐fold	   improvement	   in	   permeability;	   the	   2.6	   fold	   greater	   increase	   in	  
extravascular	  lung	  water	  in	  WT	  animals	  as	  compared	  to	  p55KO	  animals	  can	  be	  more	  
easily	   assimilated.	   This	   provides	   further	   argument	   against	   sole	   therapies	   (beta	  
agonists	   and	   LTip)	   enhancing	  AFC	   given	   that	   these	  will	   have	  minimal	   impact	   upon	  
permeability.	  Within	   this	   study	   AFC	  was	   used,	   as	   it	   is	   very	   specific	   to	   AECs	   and	   a	  
provides	   an	   excellent	   representation	   of	   AEC	   function.	   However,	   it	   is	   crucial	   to	  
appreciate	   that	   AEC	   function	   as	   a	   whole,	   not	   just	   AFC	   (figure	   5.5	   A)	   but	   also	  
permeability	  (figure	  3.5	  C),	  is	  impaired	  by	  p55	  TNFR	  induced	  death	  signalling	  in	  this	  
model.	   Hence,	   targeting	   death	   receptor	   signalling,	   which	   impacts	   upon	   both	  
permeability	  and	  lung	  liquid	  clearance,	  provides	  a	  compelling	  two-­‐pronged	  approach	  
to	  alveolar	  oedema	  formation	  and	  resolution.	  Furthermore,	  the	  application	  of	  beta-­‐
agonists/LTip	  peptide	  to	  enhance	  AFC	  in	  an	  alveolar	  epithelium	  already	  rescued	  from	  
“apoptotic	  limbo”	  through	  the	  initial	  treatment	  with	  p55	  TNF	  receptor	  DAb	  may	  be	  
the	   ideal	   approach.	   However,	   the	   question	   as	   to	   how	   TNF-­‐induced	   caspase-­‐8	  
activation	   mediates	   this	   epithelial	   dysfunction	   (permeability	   and	   AFC)	   remains	  
unanswered.	  	  
5.5.4 Caspase-­‐8,	  the	  epithelium,	  and	  “apoptotic	  limbo”	  
The	   absence	   of	   significant	   cell	   death	   during	   the	   early	   phase	   of	   injury	   and	   the	  
significant	   protection	   from	   caspase-­‐8	   inhibition	   suggests	   that	   physiological	  
dysfunction	  can	  be	  attributed	  directly	  to	  death	  signalling	  per	  se.	  This	  is	  the	  first	  data	  
linking	   the	   activation	   of	   proximal	   extrinsic	   death	   receptor	   signalling	   in	   alveolar	  
epithelium,	   specifically	   caspase-­‐8	   activation,	   to	   its	   dysfunction.	   Although	   the	  
apoptosis	  of	  alveolar	  epithelial	  cells	  has	  been	   implicated	   in	  a	  number	  of	  models	  of	  
ARDS,	  definitive	  mechanisms	  as	  to	  how	  apoptosis	  affects	  the	  physiology	  of	  the	  lung	  
have	  not	  been	  investigated.	  In	  addition,	  the	  majority	  of	  ARDS	  literature	  has	  assumed	  
that	   alveolar	   cells	   simply	   die,	   creating	   ‘cracks	   in	   the	   dam’,	   which	   lead	   to	   alveolar	  
flooding.	   Whilst	   permeability	   has	   been	   used	   as	   a	   global	   marker	   of	  
endothelial/epithelial	   injury	   in	   lung	   apoptosis	   literature,	   this	   is	   the	   first	   study	   to	  
implicate	  alveolar	  fluid	  clearance.	  At	  three	  hours	  less	  than	  1%	  of	  cells	  are	  apoptotic	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and,	  although	  TUNEL	  staining	  was	  not	  performed	  at	  90	  minutes,	  it	  is	  likely	  to	  be	  even	  
lower.	  The	  caspase-­‐8	  inhibition	  studies	  show	  that	  even	  a	  26%	  reduction	  in	  caspase-­‐8	  
activation	   produces	   a	   significant	   improvement	   in	   AFC.	   The	   strong	   correlation	  
between	   caspase-­‐8	   and	  AFC	   in	   both	   the	  pharmacological	   inhibition,	   as	  well	   as	   the	  
macrophage	   depletion	   studies,	   suggests	   the	   downstream	   effects	   of	   caspase-­‐8	  
directly	  influence	  AFC	  mechanisms,	  without	  progressing	  to	  cell	  death.	  	  
	  
As	  introduced	  in	  the	  previous	  chapter,	  the	  impact	  of	  apoptotic	  intermediaries	  during	  
“apoptosis	   interruptus”	  has	  received	  more	  attention	   in	  the	  field	  of	  heart	   failure,	   in	  
particular	  in	  terminally	  differentiated	  cells	  such	  as	  cardiomyocytes.	  In	  the	  case	  of	  the	  
heart,	   Communal	   et	   al	   showed	   that	   Caspase-­‐3	   activation	   is	   able	   to	   directly	   target	  
alpha-­‐actin,	   alpha-­‐actinin	   and	   troponin	   T	   leading	   to	   a	   state	   of	   cardiomyocyte	  
contractile	  dysfunction	  in	  the	  absence	  of	  nuclear	  fragmentation,	  the	  classic	  prequel	  
to	  the	  final	  demise	  of	  a	  cell	   (350).	  Hence,	  despite	  the	  presence	  of	  nuclear	   integrity	  
there	   is	   breakdown	   of	   cytosolic	   components	   leading	   to	   cellular	   dysfunction	   and	  
organ	  failure.	  In	  this	  case,	  left	  ventricular	  systolic	  failure	  may	  be	  equivalent	  to	  AFC	  in	  
the	   lung.	  We	  did	  not	  measure	  caspase-­‐3	  specifically,	  as	  a	  number	  of	  pathways	  can	  
induce	  its	  activation	  including	  the	  intrinsic	  pathway.	  However,	  the	  measurement	  of	  
caspase-­‐8	  shows	  that	  apoptotic	  signalling	  as	  a	  result	  of	  death	  receptor	  activation	  has	  
occurred	  and	  the	  absence	  of	  TUNEL	  tells	  us	  that	  DNA	  fragmentation	  is	  low.	  However,	  
alveolar	   fluid	   clearance	   (a	   functional	   correlate	   in	   the	   lung	   as	   is	   myocardial	  
contractility	   within	   the	   heart)	   is	   impaired	   and	   can	   be	   rescued	   through	   caspase-­‐8	  
inhibition.	   Hence,	   caspase-­‐8	   signalling	   itself	   leads	   to	   the	   downstream	   effects	   that	  
induce	  deteriorations	   in	   epithelial	   function,	   namely	  permeability	   and	  alveolar	   fluid	  
clearance.	  Although	  this	  requires	  further	  investigation,	  there	  is	   increasing	  literature	  
potentially	   explaining	   how	   caspase	   activation	   can	   directly	   influence	   epithelial	  
permeability	  and	  alveolar	  fluid	  clearance	  and	  these	  are	  now	  discussed.	  	  
5.5.5 Alveolar	  epithelial	  bioenergetics	  failure	  
The	   thin	   stretched	   position	   taken	   up	   by	   the	   type	   1	   alveolar	   cell	   producing	   the	  
rounded	   shape	   of	   the	   alveolus,	   whilst	   aided	   by	   pulmonary	   surfactant,	   is	   likely	   to	  
utilise	   significant	   amounts	   of	   ATP,	   whilst	   maintaining	   actin-­‐myosin	   cytoskeletal	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structure	  and	  tight	  junctional	  regulation	  (351).	  Loss	  of	  this	  shape	  and	  dysregulation	  
leads	  to	  breaks	  within	  the	  barrier	  promoting	  permeability	  oedema.	  Furthermore,	  the	  
active	  nature	  of	  alveolar	  fluid	  clearance	  is	  suggested	  by	  the	  Na+/K+	  ATPase	  channel	  
consuming	  nearly	  40%	  of	  all	  ATP	  within	  cells	  (352).	  In	  fact,	  the	  Na+/K+	  ATPase	  moves	  
three	   Na+	   ions	   out	   of	   the	   cell	   and	   two	   K+	   ions	   into	   the	   cell	   per	   ATP	   molecule	  
consumed.	   Islam	   et	   al	   recently	   showed	   that	  mitochondrial	   transfer	   occurred	   from	  
mesenchymal	  stem	  cells	   to	   the	  alveolar	  epithelium	  restoring	  ATP	   levels	   in	   the	   lung	  
and	  barrier	  function	  in	  an	  LPS	  model	  of	  lung	  injury	  (134).	  The	  presence	  of	  oxygen	  in	  
the	   alveolar	   space	   and	   diffusion	   across	   the	   alveolar-­‐capillary	   barrier	   provides	   a	  
constant	  source	  of	  oxygen,	  which,	  unlike	  other	  tissue	  beds,	  is	  independent	  of	  blood	  
flow	   but	   dependant	   on	   diffusion	   distance	   and	   FiO2.	   Whilst	   there	   is	   significant	  
knowledge	   on	   the	   impact	   of	   hypoxia	   on	   the	   pulmonary	   capillary	   endothelium	   and	  
pulmonary	   circulation,	   e.g.	   hypoxic	   pulmonary	   vasoconstriction	   (352)	   and	  hypoxia-­‐
inducible	   factor	  mediated	   gene	   regulation	   (353),	   there	   is	   a	   paucity	  of	   data	   for	   the	  
impact	  upon	  the	  alveolar	  epithelium,	  in	  particular,	  during	  times	  of	  increased	  demand	  
such	   as	   when	   the	   alveolus	   is	   flooded.	   Indeed,	   high	   altitude	   pulmonary	   oedema	  
(HAPE),	  a	  condition	  characterised	  by	   life-­‐threatening	  pulmonary	  oedema	  on	  ascent	  
impairs	   nasal	   ENaC	   activity,	   a	   surrogate	   for	   alveolar	   ENaC	   activity	   (354).	  
Furthermore,	   salmeterol	   decreases	   the	   incidence	   of	  HAPE	   suggesting	   that	   alveolar	  
fluid	  clearance	  mechanisms	  are	  impaired	  in	  hypoxic	  conditions.	  
	  
Bioenergetics	   is	   intimately	   linked	   to	   apoptosis.	   Not	   only	   can	   apoptosis	   proceed	  
through	   the	   intrinsic	   pathway	   and	   lead	   to	   mitochondrial/bioenergetic	   failure	   but	  
paradoxically,	   ATP	   production	   is	   required	   for	   cell	   demise	   through	   apoptosis.	  
Caspase-­‐8	   is	  a	  central	  controller	  between	  death	  receptor	  activation	  of	  the	  extrinsic	  
pathway	   to	   the	  activation	  of	   the	   intrinsic	  pathway.	   If	   there	   is	  enough	  activation	  of	  
caspase-­‐3	  by	  caspase-­‐8	  then	  there	  will	  be	  direct	  activation	  of	  effector	  caspases.	  This	  
is	   known	   as	   type	   1	   extrinsic	   apoptosis.	   If	   there	   is	   slower	   assembly	   of	   the	   death	  
inducing	  signalling	  complex	  (DISC)	  then	  the	  activation	  of	  caspase-­‐8	  is	  slower.	  Hence,	  
in	   order	   to	   amplify	   the	   initial	   death	   signal	   caspase-­‐8	   localises	   to	   the	   outer	  
mitochondrial	  membrane	   (355),	   leading	   to	   the	   formation	  of	  a	  complex	  with	  BID	   to	  
induce	  mitochondrial	  outer	  membrane	  permeabilisation	  (MOMP)	  and	  the	  activation	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of	   the	   intrinsic	   pathway,	   to	   aid	   in	   cellular	   demise	   through	   caspase-­‐3	   activation.	  
Although	   we	   did	   not	   observe	   an	   increase	   in	   activation	   of	   caspase-­‐9	   between	  
uninjured	   and	   acid	   injured	   animals,	   it	   is	   conceivable	   that	   caspase-­‐8	   activation	  was	  
compartmentalised	  to	  the	  mitochondria	  leading	  to	  mitochondrial	  dysfunction	  and	  a	  
low	  energy	  state,	   in	  the	  absence	  of	  caspase-­‐9	  activation.	  The	  disturbance	   in	  supply	  
and	  demand	  of	  ATP	  may	  be	  the	  impediment	  to	  active	  sodium	  transport	  manifesting	  
as	  reduced	  alveolar	  fluid	  clearance.	  	  
5.5.6 Alveolar	  epithelial	  cytoskeletal	  dysregulation	  
An	   alternative	   explanation	   could	   come	   from	   a	   number	   of	   studies	   that	   have	  
investigated	   the	   impact	  of	  apoptosis	  on	  cytoskeletal	   regulation	  of	   the	  cell.	   Indeed,	  
these	   downstream	   consequences,	   for	   example,	   the	   cleavage	   of	   the	   Rho	   GTPase	  
effector,	   ROCK1,	   by	   caspase-­‐3	   induces	   the	   phosphorylation	   of	   myosin	   light	   chain	  
kinase,	   which	   has	   been	   shown	   to	   induce	   dynamic	   cell	   membrane	   blebbing	   (356).	  
Bouvry	   and	   colleagues	   found	   that	   hypoxia	   could	   induce	   alveolar	   epithelial	  
cytoskeletal	  changes	  similar	  to	  those	  seen	  during	  apoptosis	  (357).	  These	  included	  a	  
disruption	  of	  actin,	  and	  cleavage	  of	  alpha-­‐spectrin,	  an	  anchor	  between	  cell	   surface	  
proteins	  and	  the	  cytoskeleton.	  These	  effects	  subsequently	  reduced	  ENaC	  expression	  
and	   transport.	   Most	   interestingly,	   these	   modifications	   in	   cytoskeletal	   and	  
submembrane	  organisation	  recovered	  on	  application	  of	  a	  pan-­‐caspase	  inhibitor.	  This	  
suggests	  that	  the	  impact	  of	  death	  signalling	  on	  the	  intracellular	  cytoskeletal	  scaffold	  
directly	   influences	   sodium	   transport	   through	   effects	   on	   ion	   channel	   expression.	  
These	  effects	  may	  be	  secondary	  to	  reduced	  trafficking	  of	  channel	  subunits	  between	  
cytoskeletal-­‐localised	  and	  membrane-­‐associated	  forms.	  Furthermore	  effects	  on	  tight	  
junctional	   regulation	   as	   a	   result	   of	   intracellular	   cytoskeletal	   disruption	   could	  
potentially	   account	   for	   the	   increased	   permeability	   associated	   with	   p55	   TNFR	  
mediated	  pulmonary	  oedema.	  These	  mechanisms	  require	  further	  exploration.	  
5.5.7 The	  epithelial	  death	  signal	  is	  initiated	  by	  alveolar	  macrophages…	  
The	  early	  events	  of	  acid	  aspiration	  are	  thought	  to	  be	  secondary	  to	  a	  physicochemical	  
process	   (1-­‐2	   hours)	   and	   the	   later	   events	   (3-­‐6	   hours)	   to	   be	   partially	   mediated	   by	  
neutrophils	   (88,	   195,	   196,	   358).	   Undoubtedly,	   a	   chemical	   reaction	   may	   occur	  
between	  acid	  and	  surfactant	  leading	  to	  oxidised	  phospholipids	  as	  has	  been	  shown	  in	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a	   number	   of	   studies	   (359-­‐361).	   However,	   it	   remains	   difficult	   to	   place	   a	  
physicochemical	   disturbance	   as	   the	  main	  mechanism	   of	   oedema	   formation	   in	   this	  
model,	   in	  particular,	  given	  that	  p55	  TNF	  receptor	  deletion,	  caspase-­‐8	  inhibition	  and	  
macrophage	   depletion,	   all	   abrogated	   injury	   with	   similar	   success.	   Indeed,	   such	   a	  
reaction	  is	  likely	  to	  be	  much	  more	  upstream	  in	  this	  process	  occurring	  within	  minutes,	  
before	  the	  upregulation	  of	  any	  inflammatory	  molecular	  mediator	  (such	  as	  TNF	  from	  
macrophages).	  
	  
Our	   data	   suggests	   that	   this	   physiological	   deterioration	   within	   1-­‐2	   hours	   to	   be	  
secondary	   to	   deteriorations	   in	   epithelial	   function	   as	   opposed	   to	   a	   direct	  
consequence	   of	   a	   physicochemical	   reaction.	   Hence,	   it	   may	   be	   that	   given	   the	  
importance	  of	  the	  epithelium	  in	  surfactant	  production	  (albeit	  type	  II	  cells,	  which	  are	  
difficult	   to	   study	   in	   vivo)	   that	   TNF/p55/caspase-­‐8	   death	   signalling	   will	   also	   have	  
downstream	   effects	   on	   surfactant	   production.	   One	   explanation	   may	   come	   from	  
studies	  that	  have	  shown	  that	  TNF	  signalling	  reduces	  surfactant	  turnover	  and	  hence,	  
p55	  TNFR	  deletion	  may	  improve	  the	  recovery	  from	  early	  surfactant	  dysfunction	  (362-­‐
365).	  Furthermore,	  macrophage	  depletion	  with	  clodronate	  has	  also	  been	  shown	  to	  
increase	  surfactant	  pool	  size	  in	  rats	  and	  hence,	  may	  confer	  some	  protection	  through	  
this	  pathway	  (366).	  	  
	  
The	   reduction	   in	   caspase-­‐8	   by	   macrophage	   depletion	   nearly	   approximates	   the	  
reduction	  achieved	  through	  p55	  TNFR	  deletion	  (68%	  versus	  61%,	  respectively).	  This	  
suggests	   that	   macrophage	   derived	   TNF	   mediates	   nearly	   all	   of	   this	   effect.	  
Macrophage	   depletion	   studies	   may	   not	   have	   achieved	   complete	   reductions	   for	  
several	   reasons	   that	   include	   incomplete	   depletion	   (i.e.	   10%	   of	   macrophages	  
remained	   intact	   in	   the	   lung);	   2)	   an	   effect	   of	   clodronate	   pre-­‐treatment	   (i.e.	  
clodronate	   induces	   apoptosis	   in	   macrophages	   which	   may	   leave	   a	   residual	   signal	  
within	   the	   lung).	   Beck-­‐Schimmer	   and	   colleagues	   depleted	   macrophages	   using	  
clodronate	   liposomes	   and	   found	   at	   6	   hours	   after	   acid	   aspiration	   there	   was	  
attenuated	  upregulation	  of	  mRNA	  for	  a	  number	  of	  inflammatory	  mediators	  including	  
TNF,	   ICAM-­‐1,	  MCP-­‐1,	   and	  MIP-­‐2	   (83).	  Our	   study	   found	  a	   reduction	   in	   soluble	   TNF,	  
although	  we	  did	  not	  measure	  other	  inflammatory	  mediators,	  as	  they	  were	  not	  being	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specifically	  studied.	  Beck-­‐Schimmer	  et	  al	  also	  showed	  reductions	  in	  MPO	  activity	  and	  
BALF	  cell	  number,	  however,	  our	  findings	  show	  no	  differences	  in	  the	  lung	  recruitment	  
of	   neutrophils	   or	   inflammatory	   monocytes,	   despite	   the	   acute	   reduction	   in	   TNF	  
production.	   Indeed,	   epithelial	   cells	   have	   been	   shown	   to	   produce	   a	   number	   of	  
chemokines	   including	  MIP-­‐2/KC	   and	  MCP-­‐1	   (265,	   294,	   367,	   368).	   	   The	   clodronate	  
treated	   group	   exposed	   to	   acid	   aspiration	   showed	   a	   tendency	   for	   increased	   lung	  
neutrophil	  sequestration	  despite	  improved	  physiology	  and	  reduced	  epithelial	  injury.	  
This	   increase	  may	  be	  accounted	   for	  by	  a	  mild	  alveolar	  neutrophilia	   induced	  by	   the	  
instillation	  of	  clodronate	  liposomes,	  48	  hours	  earlier,	  as	  has	  been	  described	  by	  other	  
investigators	  (293).	  	  
5.5.8 The	  epithelial	  death	  signal	  may	  be	  perpetuated	  by	  neutrophils…	  
Given	   that	  macrophage	   depletion	   and	   p55	   TNFR	   deletion	   conveyed	   only	   a	   partial	  
reduction	   in	   caspase-­‐8	   (60-­‐70%),	   it	   was	   important	   to	   exclude	   if	   other	   death	  
ligand/receptor	   interactions	   could	   account	   for	   the	   remaining	   40%.	   In	   accordance	  
with	   published	   literature	   we	   investigated	   FasL/Fas	   system	   that	   has	   been	   heavily	  
implicated	  in	  ARDS.	  Alveolar	  soluble	  Fas	  ligand	  was	  only	  detected	  at	  3	  hours	  and	  not	  
at	  90	  minutes,	  suggesting	  a	  minimal	  role	  for	  the	  soluble	  form	  at	  this	  early	  time-­‐point.	  
However,	  flow	  cytometry	  shows	  Fas	  ligand	  and	  TNF	  expression	  on	  the	  cell	  surface	  of	  
alveolar	  macrophages,	  as	  well	  as	  blood	  derived	  monocytes	  and	  neutrophils.	  Hence,	  
despite	  the	  significant	  reductions	  in	  soluble	  TNF	  and	  the	  absence	  of	  soluble	  FasL	  at	  
90	  minutes,	   the	   incomplete	  attenuation	  of	   caspase-­‐8	  activation	  seen	   in	  clodronate	  
treated	   animals	   could	   be	   explained	   through	   membrane	   expressed	   death	   ligands	  
activating	   respective	   epithelial	   death	   receptors.	   Given	   that	   macrophage	   depletion	  
showed	   a	   similar	   (and	   not	   significantly	   greater	   reduction)	   in	   caspase-­‐8	   activity	   (as	  
compared	  to	  p55KO	  animals),	  this	  was	  unlikely	  to	  be	  a	  macrophage-­‐derived	  source.	  
Indeed,	  by	  90	  minutes	  there	  were	  significant	  numbers	  of	  neutrophils	  and	  monocytes	  
sequestered	  within	  the	  lung	  parenchyma.	  Hence,	  it	  is	  possible	  that	  these	  interstitial	  
and	  vascular	  adhered	   leukocytes	  could	  be	  promoting	  the	  remainder	  of	  the	  caspase	  
activation	   through	   basal	   epithelial	   cell	  membrane	   interactions.	   Further	   analysis	   at	  
three	  hours	  showed	  strong	  correlations	  between	  lung	  neutrophil/monocyte	  number	  
and	  alveolar	  soluble	  Fas	  ligand	  concentrations	  in	  the	  BALF	  supporting	  the	  notion	  that	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blood	   derived	   leukocytes	   could	   also	   determine	   the	   activation	   of	   caspase-­‐8,	   taking	  
the	  ‘baton’	  from	  the	  alveolar	  macrophage.	  	  
	  
With	   respect	   to	   the	   FasL/Fas	   axis	  most	   studies	  have	   investigated	   later	   time	  points	  
(>4-­‐6	  hours),	  and	  a	  number	  of	  investigations	  have	  shown	  neutrophils	  and	  monocytes	  
to	  be	  a	  source	  of	  soluble	  FasL	  (318,	  369-­‐372).	  Liles	  and	  colleagues	  were	  the	  first	  to	  
show	   that	   neutrophils	   expressed	   FasL	   and	   Fas	   on	   their	   cell	   surface	   and	   this	  
determined	  their	  short	  half-­‐life	  through	  constitutive	  apoptosis	   (372).	  However,	   this	  
study	   also	   concluded	   that	   neutrophils	   could	   release	   FasL	   from	   their	   cell	   surface.	  
Serrao	  et	  al	  found	  that	  FasL	  from	  neutrophils	  undergoing	  apoptosis	  can	  also	  release	  
FasL	   inducing	   caspase	   activation	   in	   primary	   alveolar	   epithelial	   cells	   (369).	   Mizuta	  
found	  that	  monocytes	  could	  perform	  similar	  acts	  in	  vitro	  (371).	  Kitamura	  found	  that	  
FasL	  expression	  was	   limited	   to	  macrophage	   like	  cells	   in	   the	  alveolar	   space	  and	  Fas	  
was	   present	   on	   neutrophils	   and	   on	   alveolar	   cell	   walls,	   suggesting	   that	   FasL	   from	  
macrophage-­‐like	   cells	   induced	   activation	   of	   epithelial	   death	   signals	   in	   a	   model	   of	  
endotoxin	  induced	  lung	  injury	  (318).	  Finally,	  Folkesson	  et	  al	  showed	  that	  lung	  injury	  
after	   acid	   aspiration	   is	   mediated	   by	   IL-­‐8	   dependant	   neutrophil	   incursion	   into	   the	  
alveolar	   space	   and	   that	   anti-­‐IL-­‐8	  monoclonal	   antibody	   treatment	   given	   5	  minutes	  
before	  or	  1	  hour	  after	  acid	  aspiration	  prevented	  lung	  injury	  and	  improved	  mortality	  
(88).	  A	  follow-­‐up	  study	  by	  Modelska	  and	  colleagues	  showed	  in	  the	  same	  model	  that	  
pre-­‐treatment	   with	   the	   same	   anti-­‐IL-­‐8	   antibody	   also	   rescued	   fluid	   clearance	   at	   4	  
hours	  after	  injury	  (255).	  These	  data	  in	  combination	  provide	  a	  strong	  rationale	  for	  the	  
investigation	  of	  blood-­‐derived	   leukocyte	  driving	  caspase-­‐8	  mediated	  derangements	  
in	  AFC	  at	  later	  stages	  of	  lung	  injury.	  In	  particular,	  this	  suggests	  that	  there	  is	  a	  cellular	  
handover	   for	   death	   receptor	   activation,	   with	   early	   signalling	   being	   dependant	   on	  
alveolar	  macrophage	  derived	  TNF	  and	   later	   signalling	  possibly	  being	  dependant	  on	  
additional	   neutrophil/monocyte	   derived	   death	   ligands.	   Indeed,	   the	   constant	  
leukocyte	  infiltrate	  found	  in	  the	  alveolar	  space	  of	  non-­‐resolving	  ARDS	  lungs	  suggests	  
that	  they	  may	  have	  a	  role	  in	  a	  perpetuating	  state	  of	  death	  signalling,	  prolonging	  this	  
“apoptotic	  limbo”	  within	  the	  alveolar	  epithelium.	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Soon	  after	  the	  publication	  of	  our	  current	  work	   investigating	  the	  effect	  of	  early	  TNF	  
death	   signalling	   on	   AFC	   (373),	   Herrero	   et	   al	   found	   similar	   effects	   induced	   by	   the	  
instillation	  of	  human	  soluble	  FasL	  in	  mice	  (374).	  This	  study	  reports	  that	  alveolar	  fluid	  
clearance	  is	  attenuated	  16	  hours	  after	  the	  instillation	  of	  human	  soluble	  FasL	  and	  that	  
this	  effect	  was	  ameliorated	  through	  the	  administration	  of	  a	  pan-­‐caspase	  inhibitor	  (Z-­‐
VAD-­‐FMK).	  They	  also	  report	  a	  low	  frequency	  of	  TUNEL	  positive	  cell	  death	  and	  imply	  
that	   Fas	   induced	   death	   signalling	   may	   also	   induce	   alveolar	   epithelial	   dysfunction.	  
One	  limitation	  of	  many	  studies	  investigating	  the	  role	  of	  the	  FasL/Fas	  axis	  is	  that	  they	  
utilise	   the	   instillation	   of	   either	   soluble	   Fas	   ligand	   or	   a	   Fas	   receptor	   activating	  
antibody	  (anti-­‐Jo2).	  Hence,	  the	  mechanisms	  focus	  specifically	  on	  lung	  injury	  induced	  
by	  a	  specific	  receptor	  over-­‐activation	  inherently	  producing	  biased	  conclusions.	  This	  is	  
similar	   to	   injury	   induced	   by	   endotoxin,	   which	   investigates	   only	   TLR-­‐4	   mediated	  
downstream	  events,	  which	  are	  predominantly	  inflammatory	  in	  nature.	  Whilst	  these	  
models	  using	  single	  pathway	  overstimulation	  are	  useful,	  it	  is	  important	  to	  investigate	  
the	   pathophysiological	   impact	   of	   death	   signalling	   initiated	   by	   a	   more	   clinically	  
relevant	   insult	   that	   is	   also	   mediated	   through	   numerous	   pathways	   (TLR,	   death	  
receptor,	  chemokine	  etc).	  Acid-­‐induced	  lung	  injury	  remains	  such	  a	  model.	  
	  
5.6 Concluding	  remarks	  
The	   data	   presented	   in	   the	   previous	   three	   chapters	   show	   that	   acid-­‐induced	   lung	  
injury	   is	   triggered	   by	   alveolar	   macrophage	   derived	   TNF	   which	   induces	   caspase-­‐8	  
activation	  specifically	   in	  epithelial	   cells	   through	   its	  p55	  TNFR.	  The	  activation	  of	   the	  
death	   signalling,	   as	   opposed	   to	   TNF	   pro-­‐inflammatory	   signalling,	   in	   the	   first	   two	  
hours	   of	   aspiration,	   leads	   to	   a	   dysregulation	   in	   the	   ability	   of	   the	  
endothelial/epithelial	   barrier	   to	   prevent	   oedema,	   as	   well	   as,	   the	   epithelium	   to	  
resolve	  oedema	  through	  alveolar	  fluid	  clearance.	  The	  absence	  of	  cell	  death	  at	  early	  
time	   points,	   and	   data	   showing	   that	   caspase-­‐8	   specific	   inhibition	   ameliorates	   lung	  
injury,	  suggests	  that	  caspase-­‐8	  itself	  is	  a	  critical	  regulator	  of	  epithelial	  function.	  The	  
precise	   mechanism	   through	   which	   caspase-­‐8	   mediates	   this	   impact	   remains	  
unknown.	   Interestingly,	   at	   3	   hours	   FasL/Fas	   axis	   may	   also	   be	   activated	   in	  
consequence	  to	  blood	  derived	  leukocytes.	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The	  effect	  of	  both	  TNF	  and	  Fas	  mediated	  death	  signalling	  has	  now	  been	  shown	  to	  be	  
an	  important	  determinant	  of	  epithelial	  function,	  both	  here	  and	  by	  a	  number	  of	  other	  
laboratories	  (59,	  65,	  294,	  374-­‐379).	  However,	  it	  is	  also	  well	  established	  that	  the	  p55	  
TNFR	   and	   Fas	   receptors	   are	   also	   integral	   to	   leukocyte	   apoptosis	   and	   the	   timely	  
removal	  of	  leukocytes	  through	  apoptosis	  is	   integral	  to	  the	  resolution	  of	  lung	  injury.	  
In	   particular,	   the	   elucidation	   of	   death	   signalling	   and	   its	   effects	   on	   various	   cells	   is	  
crucial	   to	   fully	   explore	   the	   potential	   benefits	   of	   anti-­‐apoptotic	   therapies	   e.g.	  
potentiating	   AFC;	   but	   also	   their	   potential	   harmful	   effects	   i.e.	   increasing	   leukocyte	  
lifespan	  and	  preventing	  resolution	  of	  inflammation	  and	  injury.	  Hence,	  a	  future	  goal	  is	  
to	   investigate	   the	   relevance	   and	   interactions	   of	   TNF,	   Fas	   and	   other	   death	   ligand	  
induced	   activation	   of	   caspase-­‐8	   in	   a	  more	   clinically	   relevant	   longer-­‐term	  model	   of	  
lung	  injury.	  	  
	  
Such	   a	  model	   should	   allow	   further	  mechanistic	   dissection	   of	   the	   consequences	   of	  
death	   signalling,	   thereby	   improving	   translation	   and	   application	   of	   focussed	  
therapies.	   However,	   no	   such	   ideal	   model	   exists	   and	   the	   remainder	   of	   the	   thesis	  
discusses	   the	   development	   of	   a	   longer	   term	   resolving	   model	   of	   acid	   aspiration	  
extending	  the	  investigation	  of	  death	  signalling	  to	  later,	  and	  arguably,	  more	  clinically	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The	   development	   of	   animal	   models	   to	   recapitulate	   clinically	   relevant	  
pathophysiological	  processes	  that	  drive	  ARDS	  is	  crucial	  to	  find	  novel	  paradigms	  and	  
targets,	   as	   well	   as	   testing	   potential	   therapies.	   The	   previous	   sections	   of	   the	   thesis	  
have	  described	  the	  role	  of	  p55	  TNFR	  mediated	  death	  signalling	  in	  the	  early	  phase	  of	  
acid-­‐induced	  lung	   injury.	  Most	  patients	  with	  ARDS,	  however,	  present	  at	  much	  later	  
time	   points	   and	   therefore,	   any	   therapy	   against	   such	   a	   pleiotropic	   ligand/receptor	  
interaction	  should	  be	  validated	  during	  later	  phases	  of	  injury	  progression.	  Most	  late-­‐
phase	   models	   of	   ARDS	   show	   minimal	   physiological	   injury	   with	   respect	   to	   clinical	  
correlates	  of	  respiratory	  function	  such	  as	  oxygenation	  and	  respiratory	  mechanics.	  	  
	  
To	   facilitate	   the	   investigation	   of	   TNF	   receptors	   and	   death	   signalling	   into	   the	   later	  
phases	  of	  ARDS,	  my	  aim	  was	  to	  establish	  and	  characterise	  a	  model	  of	  acid-­‐induced	  
lung	   injury	   that	   produced	   significant	   physiological	   dysfunction	   whilst	   allowing	  
investigation	  into	  the	  inflammatory,	  as	  well	  as,	  reparative/resolution	  phases	  of	  injury	  
and	   inflammation.	  The	  model	  described	  within	  this	  chapter	  shows	  an	   injurious	  and	  
pro-­‐inflammatory	   phase	   over	   2	   days	   followed	  by	   a	   reparative	   and	   resolving	   phase	  
over	  7-­‐8	  days.	  The	  model	  encompasses	  all	  of	   the	   recommendations	  described	   in	  a	  
recent	  American	  Thoracic	  Society	  workshop	   (192)	  detailing	   the	   requirements	  of	  an	  
optimal	   model	   of	   ARDS.	   It	   shows	   significant	   deteriorations	   in	   lung	   physiology	  
(respiratory	  mechanics	  and	  gas	  exchange),	  endothelial	  and	  epithelial	   injury	  (protein	  
permeability	   and	   alveolar	   fluid	   clearance)	   and	   inflammation	   (soluble	   and	   cellular	  
mediators).	   Most	   notably,	   there	   is	   resolution	   of	   all	   of	   these	   parameters	   enabling	  
investigation	  into	  mechanisms	  that	  promote	  resolution	  of	  lung	  inflammation,	  as	  well	  
as	  lung	  repair	  through	  fibrosis.	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6.1 Introduction	  
The	  acute	  respiratory	  distress	  syndrome	  (ARDS)	  remains	  a	  major	  cause	  of	  morbidity	  
and	  mortality	  in	  the	  intensive	  care	  unit.	  Despite	  decades	  of	  research	  there	  remains	  a	  
significant	  deficit	   in	  the	  knowledge	  of	  mechanisms	  through	  which	  such	  severe	   lung	  
failure	   manifests.	   The	   starkest	   evidence	   for	   this	   is	   the	   absence	   of	   biological	  
treatments	  available	   to	   treat	   this	  devastating	  condition.	  This	   is	  partially	  due	  to	   the	  
poor	   clinical	   translatability	   of	   pre-­‐clinical	   models	   of	   ARDS,	   in	   that	   none	   truly	  
recapitulate	  all	  of	  the	  complex	  pathophysiological	  features	  of	  this	  devastating	  clinical	  
condition.	  
	  
A	   number	   of	   recent	   publications	   have	   highlighted	   the	   importance	   of	   pre-­‐clinical	  
modelling	   of	   acute	   lung	   injury.	   In	   particular,	   an	   excellent	   and	   thorough	   review	   by	  
Matute-­‐Bello	   et	   al	   (37)	   describing	   the	   various	   animal	   models	   that	   are	   currently	  
available.	  This	  review	  classified	  each	  model	  into	  those	  that	  impact	  upon	  the	  capillary	  
endothelium,	   the	  alveolar	  epithelium,	  or	  both;	  and	  has	   contributed	   significantly	   to	  
discussions	  as	  to	  how	  best	  to	  model	  and	  examine	  experimental	  lung	  injury.	  This	  was	  
subsequently	  followed	  up	  by	  the	  publication	  of	  an	  American	  Thoracic	  Society	  (ATS)	  
workshop	   report	   (192)	   produced	   by	   the	   ALI	   research	   community	   providing	   clear	  
guidance	   as	   to	   what	   an	   animal	   model	   of	   ARDS	   should	   feature	   and	   measure,	   in	  
particular,	  the	  limitations	  of	  some	  of	  the	  current	  models.	  Furthermore,	  these	  reports	  
have	   highlighted	   the	   importance	   of	   understanding	   the	   setting	   in	   which	   a	   specific	  
model	  is	  utilised	  and	  the	  cautious	  interpretation	  of	  data	  emanating	  from	  any	  model.	  
An	   ideal	  animal	  model	  should	  produce	  all	  of	  the	  pathophysiological	   features	  of	  the	  
human	   condition,	   which	   are	   listed	   in	   table	   6.1	   (adapted	   from	   Matute-­‐Bello	   et	   al	  
(37)).	   The	   acid	   aspiration	  model	   has	   been	   shown	   to	   replicate	   the	   entire	   range	   of	  
features	   described	   and	   is	   regarded	   as	   the	  most	   clinically	   relevant	  model	   of	   direct	  
ARDS	   in	  view	  of	  an	   immediate	  clinical	  correlate	   (253).	  Acid	  aspiration	  models	  have	  
been	  well	  established	   to	   investigate	   the	  acute	   injurious	   responses	   i.e.	   less	   than	  48	  
hours,	  however,	  their	  usefulness	  has	  been	  limited	  by	  either	  the	  need	  for	  mechanical	  
ventilation	   (which	   limits	   the	   model	   to	   4-­‐6	   hours)	   (259,	   380),	   or	   a	   high	   mortality	  
requiring	  the	  use	  of	  unilateral	  pulmonary	  instillation	  (381,	  382).	  The	  former	  removes	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the	   possibility	   for	   investigation	   into	   the	   later	   phases	   of	   experimental	   ALI	   (given	  
difficulties	   in	   maintaining	   a	   stable	   experimental	   system	   for	   long	   term	   rodent	  
mechanical	  ventilation),	  and	   the	   latter,	  arguably,	  does	  not	   fulfil	   the	  criteria	   for	   the	  
clinical	   ARDS	   i.e.	   an	   acute	   onset	   of	   severe	   hypoxaemia,	   with	   bilateral	   alveolar	  
infiltration.	  Hence,	   as	   a	   result	   of	   the	   high	  mortality,	   tight	  windows	   of	   acid	   dosing,	  
and	   potential	   requirement	   of	   equipment	   for	   rodent	   ventilation,	   only	   3%	   of	   the	  
literature	  utilise	  this	  highly	  relevant	  model	  (37).	  There	  is	  no	  currently	  available	  acid	  
aspiration	   model	   that	   truly	   recapitulates	   the	   later	   phases	   of	   ARDS.	   Hence,	   this	  
chapter	   describes	   the	   development	   of	   an	   acid-­‐induced	   lung	   injury	   model	   that	  
captures	  all	  of	  the	  above	  pathophysiological	  features	  of	  clinical	  ALI,	  with	  respect	  to	  
injury	  and	  inflammation,	  but	  also	  its	  temporal	  profile	  with	  repair	  and	  resolution.	  The	  
model	  should	  allow	  investigation	  into	  the	  complex	  interactions	  between	  the	  various	  
cellular	  and	  molecular	  mediators	  implicated	  in	  ARDS,	  as	  well	  as,	  produce	  changes	  to	  
clinically	  relevant	  physiological	  indices	  of	  lung	  injury,	  such	  as	  respiratory	  mechanics,	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Clinical	  features	   Acute	  onset	  	  
Diffuse	  bilateral	  alveolar	  injury	  	  
Acute	  exudative	  phase	  
Repair	  with	  fibrosis	  
Physiological	  changes	   V/Q	  abnormalities	  
Severe	  hypoxemia	  
Decreased	  compliance/increased	  elastance	  
Impaired	  alveolar	  fluid	  clearance	  
Biological	  changes	   Increased	  endothelial	  and	  epithelial	  permeability	  
Increased	  alveolar	  cytokine	  concentrations	  
Intra-­‐alveolar	  Coagulation	  abnormalities	  
Pathological	  changes	   Neutrophilic	  alveolar	  infiltrate	  
Intra-­‐alveolar	  fibrin	  and	  hyaline	  membrane	  deposition	  
Injury	  of	  the	  alveolar	  epithelium	  	  
	  
Table	  6.1.	  Pathophysiological	  features	  of	  human	  ALI	  
(adapted	  from	  Matute-­‐Bello	  et	  al	  (37).	  	  
	  
6.2 Aims	  
The	  specific	  aims	  of	  this	  chapter	  was	  to:	  
1. Develop	   a	   reproducible	  model	   of	   acid-­‐induced	   lung	   injury	   to	   enable	   future	  
investigation	  into	  the	  role	  of	  the	  death	  receptor	  signalling	  during	  later	  phases	  
of	  injury,	  inflammation,	  and	  recovery	  in	  acid	  aspiration.	  
2. Characterise	  the	  model	  with	  respect	  to	  relevant	  features	  and	  measurements	  
of	  lung	  injury,	  as	  suggested	  by	  the	  ATS	  workshop	  report	  (192).	  
	  
6.3 Experimental	  Design	  
6.3.1 Intra-­‐tracheal	  instillation	  technique	  
C57BL6	  mice	  were	  anaesthetised	  and	  vertically	  suspended	  on	  a	  custom	  made	  stand	  
as	  described	  previously.	  A	  non-­‐thermal	  light	  source	  was	  used	  to	  transilluminate	  the	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trachea.	  Subsequently,	  a	  blunt	  curved	  tooth	  forceps	  was	  used	  to	  displace	  the	  tongue	  
out	  of	   the	  oral	   cavity.	  A	   second	  blunt	   tooth	   forceps	  was	  very	  gently	   introduced	   to	  
retract	   the	   jaw	   posteriorly	   away	   from	   the	   upper	   palate.	   The	   tip	   of	   this	   second	  
forceps	  was	  at	  the	  level	  of	  the	  epiglottis	  within	  the	  vallecula.	  The	  outward	  recoil	  of	  
the	  forceps	  maintained	  an	  open	  oropharnyx	  enabling	  the	  tongue	  to	  be	  released	  and	  
allowing	  the	  use	  of	  the	  other	  forceps	  to	  introduce	  a	  bevelled	  polyethylene	  catheter	  
to	  1	   cm	  below	   the	  vocal	   cords.	   This	   ensured	   complete	   intra-­‐tracheal	   instillation	  of	  
any	  substance	  –	  hydrochloric	  acid	  in	  this	  case.	  
6.3.2 Provision	  of	  high	  dependency	  care	  
After	  instillation,	  mice	  were	  maintained	  in	  a	  vertical	  position	  for	  one	  minute.	  During	  
preliminary	   experiments	   there	   was	   an	   unacceptably	   high	   immediate	   mortality	  
(between	   10	   and	   30	   minutes	   after	   acid	   instillation).	   This	   was	   too	   soon	   to	   be	   a	  
consequence	   of	   the	   development	   of	   ALI	   (as	   a	   result	   of	   acid	   instillation)	   but	  was	   a	  
likely	   consequence	   from	   the	   significant	   respiratory	   depression/distress	   and	  
laryngospasm	   induced	   by	   a	   combination	   of	   general	   anaesthesia	   and	   intratracheal	  
fluid	   instillation.	   Occasionally,	   a	   low	   incidence	   is	   also	   observed	   during	   saline	   and	  
endotoxin	   instillation.	  To	  facilitate	  the	  survival	  of	  mice	  for	  experimentation	  to	   later	  
time-­‐points	  and	  overcome	  this	  early	  mortality	  a	  high	  dependency	  recovery	  chamber	  
was	  developed.	  This	  recovery	  unit	  (photo	  2.3)	  provided	  warming,	  removal	  of	  carbon	  
dioxide,	   and	   humidification.	   Mice	   were	   initially	   placed	   in	   an	   oxygen-­‐enriched	  
environment	   (FiO2	  1.0)	  with	  a	   gradual	   reduction	   in	   FiO2	   to	  0.21	  over	  4	  hours.	   This	  
period	  ensured	  recovery	  from	  anaesthesia	  with	  spontaneous	  movement	  having	  been	  
regained.	  On	  placement	  into	  this	  recovery	  chamber,	  mice	  were	  rotated	  from	  supine	  
to	  left	  lateral	  to	  right	  lateral	  to	  prone,	  ensuring	  an	  even	  distribution	  of	  the	  instillate	  
within	  the	  lungs.	  This	  protocol	  overcame	  the	  initial	  observed	  mortality	  and	  allowed	  
all	  animals	  to	  survive	  and	  be	  investigated	  at	  later	  time	  points.	  
6.3.3 Measurement	  of	  physiology	  changes	  
At	  various	  hours/days	  after	  acid	  instillation,	  measurement	  of	  lung	  injury	  with	  respect	  
to	   respiratory	   physiology	   and	   respiratory	   inflammation	  were	  made	  under	   terminal	  
anaesthesia.	  Firstly,	  animals	  were	  weighed	   to	  obtain	  a	  generic	  estimation	  of	   injury	  
severity.	   Anaesthetised	   mice	   underwent	   tracheostomy	   and	   insertion	   of	   carotid	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arterial	  line	  as	  previously	  described.	  They	  were	  subsequently	  placed	  on	  a	  pulmonary	  
ventilation	   system	   and	   ventilated	  with	   8ml/kg	   tidal	   volume	  with	   a	   FiO2	   of	   1.0	   (as	  
described	  in	  the	  acute	  model	  of	  acid	  aspiration).	  The	  original	  (pre-­‐injury)	  weight	  was	  
used	   for	  estimation	  of	   tidal	   volumes.	  Animals	  were	  placed	  on	   the	   system	  within	  5	  
minutes	  of	  anaesthesia	  and	  a	  recruitment	  manoeuvre	  (30cmH2O	  for	  5	  seconds)	  was	  
performed	  in	  order	  to	  standardise	  the	  volume	  history	  of	  the	  lungs.	  After	  this	   initial	  
recruitment	   manoeuvre,	   the	   animal	   was	   ventilated	   for	   a	   30-­‐minute	   period	   (tidal	  
volume	  8-­‐9ml/kg,	  PEEP	  2.5-­‐3.0cmH2O,	  RR	  120bpm,	  FiO2	  1.0).	   Throughout	   these	  30	  
minutes,	  respiratory	  mechanics	  were	  measured	  every	  5	  minutes.	  Arterial	  blood	  gas	  
analysis	   was	   performed	   at	   the	   end	   of	   this	   30-­‐minute	   period	   of	   ventilation.	   Some	  
animals	  underwent	  insertion	  of	  an	  external	  jugular	  vein	  (EJV)	  catheter	  through	  which	  
AlexaFluor	   594-­‐conjugated	   albumin	   was	   injected	   (immediately	   after	   pulmonary	  
recruitment)	  for	  calculation	  of	  permeability	  index	  as	  previously	  described.	  
6.3.4 Assessment	  of	  pulmonary	  inflammation	  
After	   the	   30-­‐minute	   ventilation	   period,	   mice	   were	   sacrificed	   and	   underwent	  
bronchoalveolar	   lavage	   with	   750µl	   of	   saline.	   Eppendorfs	   containing	   BAL	   samples	  
were	   centrifuged	   at	   1500rpm	   for	   5	   minutes.	   Levels	   of	   BALF	   cytokines	   and	  
chemokines	  within	  the	  supernatant	  were	  quantified	  using	  ELISA	  kits	  (R&D	  Systems).	  
BALF	  cell	  counts	  were	  obtained	  using	  haemocytometry	  and	  differential	  cytology.	  	  
6.3.5 Histological	  lung	  injury	  assessment	  
In	   a	   separate	   series	   of	   experiments,	   animals	   underwent	   acid	   aspiration	   for	  
histopathological	   examination.	   Both	   lungs	   were	   examined	   macroscopically	   for	  
bilateral	  injury.	  Left	  lungs	  of	  animals	  were	  also	  inflated	  at	  a	  transpulmonary	  pressure	  
of	   15cm	   height	   of	   4%	   paraformaldehyde.	   Lungs	   were	   subsequently	   processed	   for	  
paraffin	   embedding	   and	   sections	   attained	   for	   H&E	   staining.	   Furthermore,	   lung	  
sections	   were	   stained	   with	   Masson’s	   Trichrome	   stain	   for	   collagen	   deposition	   and	  
identification	  of	  lung	  fibrosis.	  
6.3.6 Quantification	  of	  alveolar	  epithelial	  dysfunction	  
In	   a	   separate	   series	   of	   experiments,	   anaesthetised	  mice	   underwent	   tracheostomy	  
and	   were	   ventilated	   for	   a	   short	   period.	   During	   this	   period	   animals	   underwent	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cannulation	  of	   the	  EJV	   for	  administration	  of	  20iu	  heparin.	  Mice	  were	  subsequently	  
exsanguinated	   under	   terminal	   anaesthesia	   through	   ligation	   of	   the	   right	   and	   left	  
internal	   carotid	   arteries,	   external	   jugular	   veins,	   as	   well	   as,	   the	   internal	   jugular	  
vein/aorta	  at	  the	  level	  of	  the	  aortic	  bifurcation.	  Subsequently,	  the	  lungs	  underwent	  a	  
standardised	   recruitment	  manoeuvre	  of	  30cmH2O	  and	  were	   instilled	  with	  700µl	  of	  
isoosmolar	  5%	  BSA	  (Sigma-­‐Aldrich)	  containing	  50µg/ml	  of	  AlexaFluor	  594-­‐conjugated	  
(AF594)	   BSA	   (Invitrogen),	   for	   measurement	   of	   alveolar	   fluid	   clearance	   over	   a	   30-­‐
minute	  period	  using	  the	  in	  situ	  model	  previously	  described.	  	  
	  
6.4 	  Results	  
6.4.1 Physiological	  injury	  induced	  by	  acid	  aspiration	  
Acid	  aspiration	  is	  a	  well-­‐established	  paradigm	  for	  experimental	  lung	  injury,	  however,	  
longer-­‐term	   models	   have	   been	   limited	   by	   a	   high	   mortality,	   and	   hence,	   animals	  
undergo	   unilateral	   instillation	   of	   acid	   (382,	   383).	   Hence,	   the	   aim	   for	   the	   initial	  
characterisation	   was	   to	   develop	   a	   model	   leading	   to	   severe	   injury	   but	   enabling	  
animals	   to	   survive	   the	   immediate	   instillation	   period	   and	   be	   investigated	   at	   later	  
stages	   of	   oedema	   progression	   and	   resolution,	   without	   the	   need	   for	   mechanical	  
ventilation.	  	  
	  
Similar	  to	  the	  acute	  model,	   there	  was	  a	  very	  narrow	  range	  for	  the	  development	  of	  
significant	   injury	   in	   the	   absence	   of	   excessive	   mortality.	   Initial	   experiments	   to	  
determine	   the	   severity	   of	   injury	   used	   instillate	   of	   various	   volumes	   and	   pH.	  
Respiratory	  elastance	   (measured	   immediately	  after	   recruitment,	  hence,	  accounting	  
for	   possible	   variations	   from	   the	   effects	   of	   general	   anaesthesia	   and	   surgical	  
preparation)	   and	   BALF	   protein	   (to	   assess	   alveolar	   capillary	   permeability)	   were	  
measured	  at	  24	  hours	  to	  ascertain	  the	  volume	  and	  pH	  required	  to	  attain	  a	  moderate	  
physiological	   insult.	  A	  higher	  volume	  of	   instillate	  enabled	  better	  delivery	  of	  acid	  as	  
assessed	  visually	  through	  Evans	  blue	  dye	  instillation.	  As	  can	  be	  seen	  in	  figure	  6.1	  A	  
and	   B,	   75µl	   0.1M	   HCl	   induced	   significant	   increases	   in	   Ers	   and	   BALF	   protein	   at	   24	  
hours.	   Interestingly,	   this	   instillate	   (75	   µl	   of	   0.1M)	   contained	   the	   same	   number	   of	  
protons	  as	  the	  ventilated	  acute	  acid	  model	   (i.e.	  50µl	  of	  0.15M).	   It	   is	   likely	  that	  this	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longer	  term	  model	  required	  a	  greater	  volume	  because	  acid	  was	  instilled	  through	  the	  
orotracheal	   route	   followed	   by	   spontaneous	   ventilation,	   whereas	   the	   acute	   model	  
involved	   acid	   delivery	   through	   a	   tracheotomy	   followed	   by	   positive	   pressure	  
ventilation.	  The	  latter	  being	  more	  efficient	  and	  hence,	  explaining	  the	  requirement	  of	  
a	  lower	  volume.	  
6.4.2 Weight	  loss.	  	  
Acid	   aspiration	   produced	   significant	   weight	   loss,	   proportional	   to	   the	   dose	   of	   acid	  
instilled.	   Figure	   6.1	   C	   shows	   75µl	   of	   0.1M	   HCl	   produces	   a	   maximum	   reduction	   in	  
body	   weight	   of	   15%,	   as	   compared	   with	   10%	   induced	   by	   the	   50µl	   instillation.	  
Additionally,	   this	  weight	   loss	  was	  more	  protracted	   in	   the	  75µl	  as	   compared	   to	   the	  
50µl-­‐instilled	  group.	  This	  most	  likely	  reflects	  a	  greater	  severity	  of	  illness	  in	  the	  higher	  
volume	   group.	   Interestingly,	   after	   these	   adjustments	   to	   optimise	   the	   injury	   and	  
recovery,	  animals	  survived	  despite	  significant	  injury,	  and	  between	  days	  3	  to	  10	  there	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Figure	  6.1.	  Development	  and	  refinement	  of	  the	  resolving	  model	  of	  acid	  aspiration	  
A	  dose	   titration	  performed	  by	   instillation	  of	  varying	  molarities	  of	  hydrochloric	  acid	  
showed	   that	  75μl	  of	  0.1M	  produced	  a	  2.5	   fold	   increase	   in	  Ers	   (A)	  and	  a	   significant	  
increase	   in	   alveolar	   capillary	   permeability	   as	   measured	   by	   BALF	   protein	   (B).	  
Furthermore,	  this	  increased	  volume	  produced	  a	  significant	  15%	  reduction	  in	  mouse	  
body	  weight	  at	  48	  hours	  despite	  this	  group	  receiving	  an	   intraperitoneal	  500μl	   fluid	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6.4.3 Respiratory	  mechanics.	  	  
Lung	  mechanics	  were	  measured	  after	  rigorously	  standardising	  for	  the	  volume	  history	  
of	  the	  lung	  through	  the	  application	  of	  a	  recruitment	  manoeuvre	  followed	  by	  a	  short	  
period	  of	  anaesthesia.	  This	  was	  important	  as	  the	  impact	  of	  anaesthesia	  and	  surgery	  
on	   mouse	   lungs	   (with	   and	   without	   injury)	   induces	   pulmonary	   atelectasis,	   which	  
would	  effect	  any	  measurements	  of	  respiratory	  mechanics.	  Animals	  during	  days	  1	  and	  
2	  of	   injury	   show	  an	   increase	   in	   Ers	   compared	   to	  non-­‐injured	  animals	   and	   those	  at	  
days	  5	  and	  10	  post-­‐injury	  (figure	  6.2	  A	  and	  B).	  This	  could	  be	  explained	  by	  either	  the	  
presence	  of	   pulmonary	  oedema	  as	  well	   as	   an	   increased	  propensity	   for	   atelectasis.	  
The	   atelectasis	   component	   is	   represented	   by	   the	   significant	   increase	   in	   elastance	  
between	  the	  initial	  recruitment	  (green	  line)	  and	  the	  end	  of	  the	  30-­‐minute	  period	  of	  
ventilation.	   This	   atelectasis	   component	  was	   especially	  marked	   in	   first	   2	   days	   after	  
acid	  aspiration.	  	  
6.4.4 Oxygenation.	  	  
Arterial	  blood	  gases	  were	  taken	  at	  the	  end	  of	  the	  30-­‐minute	  period	  of	  ventilation	  to	  
obtain	   a	   true	   reflection	   of	   the	   impact	   of	   injury	   and	   not	   anaesthesia/recruitment.	  
Similar	  to	  the	  ventilated	  model,	  there	  was	  an	  immediate	  deterioration	  in	  PaO2/FiO2	  
ratio	  at	  3	  hours	  post	  acid	  instillation	  in	  this	  longer-­‐term	  model	  of	  acid	  aspiration.	  This	  
remained	  below	  200	   in	   the	   first	   24	   hours	   (satisfying	  moderate	  ARDS	   criteria)	  with	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Figure	   6.2.	   Changes	   in	   respiratory	   mechanics	   and	   oxygenation	   during	   resolving	  
acid	  aspiration	  
	  (A)	  At	  24	  and	  48	  hours	  after	  acid	  instillation,	  mice	  show	  an	  increase	  propensity	  for	  
alveolar	  collapse	  as	  demonstrated	  by	  the	  30-­‐minute	  ventilation	  time	  courses.	  Green	  
lines	  represent	  recruitment	  manoeuvres.	  (B)	  Respiratory	  system	  elastance	  also	  peaks	  
at	  days	  1	  and	  2	  with	  significant	  improvements	  by	  day	  3.	  (C)	  Oxygenation	  deteriorates	  
immediately	   at	   3	  hours	   and	   then	   recovers	  over	  10	  days.	  N=3-­‐5/each	   time	  point.	   *	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6.4.5 Indices	  of	  lung	  oedema	  –	  permeability	  and	  clearance	  
These	  changes	  in	  oxygenation	  are	  most	  likely	  a	  consequence	  of	  1)	  alveolar-­‐capillary	  
barrier	   dysfunction	   with	   ensuing	   pulmonary	   oedema;	   2)	   ventilation/perfusion	  
mismatch;	   and	   3)	   alveolar	   atelectasis.	   Lavage	   protein	   concentration,	   a	   marker	   of	  
alveolar	   capillary	  barrier	  permeability,	   showed	  a	   significant	   increase	   in	   the	   first	   24	  
hours	  after	  injury	  followed	  by	  a	  gradual	  improvement	  to	  uninjured	  levels	  by	  day	  10	  
(Figure	  6.3	  A).	  At	   later	  time-­‐points	  the	  presence	  of	  BAL	  protein	  may	  not	  accurately	  
represent	   alveolar-­‐capillary	   barrier	   permeability	   given	   that	   the	   alveolar	   epithelium	  
can	   also	   actively	   clear	   fluid	   as	   well	   as	   protein	   (384).	   Hence,	   we	   measured	  
permeability	   index	   in	   animals	   at	   these	   time-­‐points	   through	   the	   intravenous	  
instillation	   of	   AF-­‐594	   labelled	   albumin	   during	   the	   30-­‐minute	   ventilation	   period.	  
Interestingly	  during	  the	  first	  48	  hours,	  increases	  in	  permeability	  index	  matched	  BALF	  
protein	  showing	  marked	   increases.	  However,	  unlike	   the	  BALF	  protein,	  permeability	  
index	   did	   not	   return	   to	   baseline	   values	   by	   day	   10	   and	   remained	   elevated	   (non	  
significant)	  from	  day	  3	  onwards	  (Figure	  6.3	  B).	  This	  confirmed	  the	  notion	  that	  BALF	  
protein	   may	   not	   be	   a	   good	   reflection	   of	   alveolar	   capillary	   barrier	   permeability	   at	  
later	  time	  points	  given	  that	  the	  majority	  of	  proteins	  likely	  translocate	  in	  the	  first	  48	  
hours	   of	   injury	   and	   that	   the	   complete	   resolution	   of	   lavage	   protein	   levels	   likely	  
reflects	  a	  combination	  of	   improved	  barrier	  permeability	  and	  increased	  clearance	  of	  
protein	  from	  the	  alveolar	  space.	  Lung	  wet/dry	  weight	  ratios	  showed	  a	  near	  doubling	  
of	  water	  content	  in	  the	  lungs	  (up	  to	  7.2	  g	  H2O	  per	  gram	  of	  dry	  lung).	  This	  returned	  to	  
baseline	   levels	   by	   day	   10	   (4.5	   g	   H2O	   per	   gram	   of	   dry	   lung)	   (Figure	   6.3	   C).	   Hence,	  
despite	   a	   persistent	   derangement	   in	   permeability	   index,	   lung	   water	   had	   indeed	  
returned	   to	   normal.	   Figure	   6.4	   shows	   the	   macroscopic	   appearance	   of	   uninjured	  
lungs	  and	  lungs	  at	  day	  2	  and	  10	  after	  acid	  aspiration.	  Injured	  animals	  at	  day	  2	  show	  a	  
bilateral	   injury	  with	   significant	   lung	  discolouration	  as	   a	   result	   of	   haemorrhage	  and	  
oedema	  formation.	  The	  lungs	  of	  animals	  at	  day	  10	  after	  acid	  aspiration	  look	  similar	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Figure	  6.3.	  Changes	   in	  alveolar	  capillary	  barrier	  dysfunction	  during	   resolving	  acid	  
aspiration	  
Mice	  show	  significant	   increases	   in	  epithelial	  and	  endothelial	  permeability	  as	  shown	  
by	   increased	   BALF	   protein	   (A)	   and	   increased	   permeability	   index	   (B)	   at	   24	   hours.	  
There	  is	  a	  doubling	  of	  lung	  water	  content	  at	  24	  hours	  with	  subsequent	  reduction	  (C).	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Figure	   6.4.	   Changes	   in	   macroscopic	   appearance	   of	   lungs	   during	   resolving	   acid	  
aspiration	  
Gross	  macroscopic	  appearance	  of	  normal	  uninjured	  mouse	  lungs	  (top)	  and	  lungs	  of	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6.4.6 Epithelial	  injury	  and	  recovery.	  	  
The	   previous	   chapters	   have	   showed	   that	   early	   derangements	   in	   permeability	   and	  
epithelial	   fluid	   clearance	   influenced	   the	  development	  of	   alveolar	  oedema	  over	   the	  
first	  3	  hours	  of	  acid-­‐induced	  lung	  injury.	  Alveolar	  fluid	  clearance	  rate	  was	  measured	  
to	  ascertain	  if	  epithelial	  dysfunction	  was	  present	  during	  later	  stages	  of	  injury	  (i.e.	  2-­‐3	  
days),	   and	   whether	   resolution	   of	   epithelial	   injury	   was	   also	   apparent	   from	   day	   3	  
onwards.	   In	   addition	   to	   alveolar	   fluid	   clearance	   being	   significantly	   reduced	  
immediately	  after	  lung	  injury	  induction	  (within	  90	  minutes),	  there	  continues	  to	  be	  a	  
42%	  reduction	  on	  day	  2,	  after	  which,	   the	   fluid	  clearance	   rate	   is	   re-­‐established	  and	  
recovers	  (figure	  6.5	  A).	  This	  recovery	  leads	  to	  a	  15.5%	  increase	  in	  AFC	  rate	  on	  days	  5	  
and	  10	  as	  compared	  to	  baseline.	  This	  may	  explain	  the	  normal	  wet/dry	  weight	  despite	  
increased	  permeability	  index	  on	  day	  10.	  	  
	  
Soluble	  RAGE	  was	  detectable	  within	  90	  minutes	  of	  acid	  aspiration	  but	  reduce	  after	  
this	  early	  peak	  (figure	  6.5	  B).	  RAGE	  levels	  follow	  a	  similar	  trend	  to	  other	  BALF	  soluble	  
mediators	   and	   return	   to	   near	   baseline	   by	   day	   5.	   There	   were	   strong	   correlations	  
between	   RAGE,	   AFC,	   and	   PaO2/FiO2	   ratio	   suggesting	   these	   parameters	   robustly	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Figure	   6.5.	   Changes	   in	   epithelial	   dysfunction	   and	   injury	   during	   resolving	   acid	  
aspiration	  
AFC	  also	  deteriorates	  within	  3	  hours	  and	  remains	  low	  for	  the	  first	  48	  hours	  (A)	  and	  
dramatically	  recovers	  on	  day	  3.	  There	  is	  a	  significant	  upregulation	  of	  soluble	  RAGE	  in	  
the	  alveolar	  space	  at	  24	  hours	  (B).	  There	  are	  strong	  relationships	  between	  markers	  
of	   epithelial	   injury,	   epithelial	   dysfunction	   and	   arterial	   oxygenation.	   Levels	   of	   BALF	  
RAGE	  inversely	  correlate	  with	  AFC	  (C	  -­‐	  Pearson	  R	  =	  -­‐0.7339;	  P<0.0001);	  AFC	  strongly	  
correlates	  with	  oxygenation	  (D	  -­‐	  Pearson	  R	  =	  0.697;	  P<0.001);	  and	  PF	  ratio	  inversely	  
correlates	  with	  BALF	  RAGE	   (E	   -­‐	  Pearson	  R	  =	   -­‐0.71;	  P<0.01).	  N=3-­‐6/each	   time	  point.	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6.4.7 Characterisation	  of	  alveolar	  inflammation	  and	  resolution	  
Differential	   cytology	   of	   BAL	   showed	   significant	   changes	   in	   the	   alveolar	   content	   of	  
leukocytes	   (figure	  6.6).	  Figure	  6.7	  also	  shows	  the	  representative	  photomicrographs	  
of	   BAL	   cytology	   at	   various	   phases	   after	   acid	   aspiration.	   In	   uninjured	   animals,	   the	  
major	  leukocyte	  population	  is	  the	  alveolar	  macrophage	  and	  constitutes	  over	  95%	  of	  
all	   alveolar	   cells.	   Acid	   aspiration	   induces	   a	   severe	   neutrophil	   alveolitis,	   peaking	   at	  
day	   2,	   and	   disappearing	   very	   rapidly	   by	   day	   3.	   On	   day	   3	   there	   was	   a	   significant	  
increase	  in	  the	  number	  of	  apoptotic	  neutrophils	  many	  of	  which	  were	  in	  the	  process	  
of	  efferocytosis	  by	  macrophages	  (figure	  6.7).	  Additionally,	  there	  is	  an	  increase	  in	  the	  
myeloid	  cell	  population	   (macrophages	  and	  monocytes)	  at	  day	  2	  although	  relatively	  
much	  lower	  and	  overshadowed	  by	  the	  neutrophil	  response.	  The	  increase	  in	  alveolar	  
macrophage	   and	   monocyte	   populations	   likely	   reflects	   an	   exudative	   macrophage	  
population	  with	  the	  total	  alveolar	  macrophage	  population	  being	  expanded	  through	  
replenishment	   from	   blood	   monocyte	   populations.	   This	   recruited	   pool	   may	   be	  
involved	   in	   the	   removal	   of	   apoptotic	   bodies	   and	   help	   clear	   the	   debris	   to	   facilitate	  
resolution	  within	  the	  alveolar	  space.	  Furthermore,	  there	  were	  increases,	  from	  day	  3	  
onwards,	  of	  a	  lymphocyte	  population	  that	  accounts	  for	  nearly	  15%	  of	  all	  leukocytes	  
by	   day	   10.	   Lung	   homogenate	   myeloperoxidase	   activity	   (figure	   6.6	   C)	   shows	   a	  
significant	  rise,	  as	  expected,	  at	  24	  hours	  with	  a	  subsequent	  decline	  at	  48	  hours.	  This	  
initial	   peak	   corresponds	   well	   with	   the	   neutrophil	   influx	   into	   the	   alveolar	   space.	  
However,	  MPO	   activity	   in	   this	   set	   of	   experiments	   continued	   to	   increase	   after	   this	  
initial	  reduction	  at	  day	  2	  reaching	  significantly	  higher	  levels	  by	  day	  10.	  	  
	  
There	  was	  an	  increase	  in	  inflammatory	  cytokine	  production	  with	  day	  2	  showing	  the	  
highest	  levels	  of	  TNF	  and	  IL-­‐6.	  In	  addition,	  BALF	  levels	  of	  MIP-­‐2	  and	  KC	  (mouse	  IL-­‐8	  
analogues),	  which	  drive	  neutrophil	  chemotaxis	  and	  infiltration	  into	  the	  alveolus	  also	  
peak	  at	  day	  2	  but	  effectively,	  disappear	  by	  day	  3.	  The	  cessation	  of	  pro-­‐inflammatory	  
mediator	   production	   and	   their	   catabolism	   is	   strongly	   suggestive	   of	   a	   shift	   in	   the	  
alveolar	   milieu	   from	   a	   highly	   pro-­‐inflammatory	   into	   an	   anti-­‐inflammatory/pro-­‐
resolving	  state	  (figure	  6.8).	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Figure	  6.6.	  Changes	  in	  alveolar	  leukocyte	  types	  and	  numbers	  during	  resolving	  acid	  
aspiration	  
Analysis	  of	   alveolar	   leukocyte	  proportion	   (A)	  and	  number	   (B)	   in	   the	  alveolar	   space	  
showed	   significantly	   increased	   neutrophil	   influx	   peaking	   at	   48	   hours	   post	   acid	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aspiration.	  Concomitantly	  there	  is	  an	  increase	  in	  monocyte/macrophage	  cell	  number	  
in	  the	  alveolar	  space.	  Interestingly,	  myeloperoxidase	  (MPO)	  activity	  increases	  in	  the	  
first	  24	  hours	  but	  then	  declines	  at	  day	  2.	  It	  then	  continues	  to	  increase	  up	  to	  day	  10.	  





Figure	  6.7.	  Changes	  in	  alveolar	  cytology	  during	  resolving	  acid	  aspiration	  
Photomicrographs	   show	   significant	   changes	   in	   alveolar	   cytology	   with	   increasing	  
neutrophilia	   in	   the	   first	   48	   hours.	   By	   day	   3	   there	   is	   a	   dramatic	   reduction	   with	  
increased	   number	   of	   apoptotic	   neutrophils	   (inset),	   many	   of	   which	   have	   been	  
efferocytosed	   by	   alveolar	   macrophages.	   Over	   days	   3	   and	   10	   there	   is	   increasing	  
proportion	   of	   lymphocytes	   and	  monocytic	   cells	   infiltrating	   into	   the	   alveolar	   space	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Figure	   6.8.	   Changes	   in	   alveolar	   cytokines/chemokines	   during	   resolving	   acid	  
aspiration	  
Analysis	  of	  alveolar	  cytokines	  -­‐	  TNF	  (A)	  and	  IL-­‐6	  (B);	  and	  chemokines	  -­‐	  MIP-­‐2	  (C)	  and	  
KC	   (D)	   during	   the	   time	   course	   of	   injury	   shows	   significant	   increases	   in	   the	   first	   48	  
hours	   which	   decline	   on	   day	   3.	   N=3-­‐6/each	   time	   point.	   ***	   P<0.001	   **	   P<0.01	   *	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6.4.8 Lung	  injury	  scoring	  
We	  evaluated	  histological	   injury	  using	   recently	  published	  guidelines	   recommended	  
by	  the	  ATS	  workshop	  report	  on	  animal	  modelling	  of	  ARDS	  (192).	  We	  found	  that	  there	  
were	  significant	  changes	  to	  the	  lung	  parenchyma	  and	  cellular	  infiltration	  in	  the	  lung	  
at	  various	  time-­‐points	  after	  injury	  (figure	  6.9).	  During	  the	  injurious	  phases	  there	  are	  
significant	   increases	   in	   lung	   haemorrhage	   and	   fluid	   in	   the	   alveolar	   space	   (red	  
arrows).	  There	  is	  significant	  disruption	  to	  the	  walls	  of	  the	  alveoli	  with	  thickening	  and	  
multiple	  hyaline	  membranes	  being	  present	  on	  the	   inner	  surface	   (green	  arrows).	  As	  
shown	   previously	   through	   lavage	   cytology	   there	   is	   a	   significant	   rise	   in	   alveolar	  
neutrophils	   (white	   arrows).	   However,	   there	   are	   also	   significant	   numbers	   of	  
interstitial	   neutrophils	   (yellow	   arrows).	   After	   this	   dramatic	   change	   in	   alveolar	  
structure	   there	   appears	   to	   be	   resolution	   through	   the	   removal	   of	   neutrophil	  
infiltrates	   as	   well	   as	   alveolar	   debris.	   This	   clearance	   process	   is	   associated	   with	   a	  
steady	  increase	  (between	  days	  2	  and	  5)	  in	  alveolar	  and	  interstitial	  mononuclear	  cells	  	  
(blue	  arrows).	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Figure	  6.9.	  Histological	  analysis	  of	  resolving	  acid	  aspiration	  
Representative	   haematoxylin	   and	   eosin	   (H&E)-­‐stained	   sections	   of	   uninjured	   and	  
injured	  animals	  at	  all	  time-­‐points	  after	  acid	  aspiration	  (A).	  There	  is	  greater	  cellularity	  
consisting	   mainly	   of	   alveolar	   (white	   arrows)	   and	   interstitial	   (yellow	   arrows)	  
neutrophils	   on	   days	   1	   and	   2	   with	   more	   areas	   of	   atelectasis	   as	   well	   as	   increased	  
alveolar	   disruption	   with	   hyaline	   membranes	   (green	   arrowheads),	   proteinaceous	  
debris	  and	  haemorrhage	  (red	  arrowheads).	  With	  increasing	  time	  there	  is	  a	  shift	  from	  
a	  neutrophilic	   to	  a	  predominantly	  mononuclear	   infiltrate	   (blue	  arrows).	  Lung	   injury	  
scoring	   shows	   a	   significant	   injury	   on	   days	   1	   and	   2	   with	   a	   reduction	   from	   day	   3	  
onwards.	   Lung	   injury	   was	   assessed	   on	   a	   scale	   of	   0–2	   for	   each	   of	   the	   following	  
criteria:	  i)	  neutrophils	  in	  the	  alveolar	  space,	  ii)	  neutrophils	  in	  the	  interstitial	  space,	  iii)	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alveolar	   septal	   thickening.	   N=3-­‐4/each	   time	   point.	   ***	   P<0.001	   **	   P<0.01	   versus	  
uninjured	  
	  
6.4.9 Resolution	  through	  fibrosis	  
To	   ascertain	   if	   the	   resolution	   of	   physiology	   manifest	   as	   complete	   histological	  
recovery	   or	   through	   a	   fibrotic	   repair	   mechanism,	   lung	   sections	   were	   stained	   for	  
collagen	  deposition	  with	  Masson’s	  Trichrome	  stain.	  There	  was	  significantly	  increased	  
collagen	   deposition	   (figure	   6.10	   -­‐	   blue	   staining	   and	   blue	   arrows)	   as	   early	   as	   day	   2	  
after	   acid	   aspiration.	   Sections	   showed	   a	   peri-­‐bronchial	   cellular	   infiltration	   (red	  
arrows)	   with	   marked	   thickening	   of	   bronchiolar	   walls	   (green	   arrows).	   There	   were	  
multiple	   fibrotic	   foci	   (white	  arrows)	  visible	  by	  day	  10	  suggesting	   significant	   fibrosis	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Figure	  6.10.	  Analysis	  of	  fibrosis	  during	  resolution	  of	  acid	  aspiration	  
Representative	  Masson’s	  trichrome	  stained	  sections	  in	  the	  absence	  of	  injury,	  during	  
the	  peak	  of	   injury,	   and	  after	   the	   resolution	  of	   injury	   from	  acid	  aspiration.	  There	   is	  
cellular	   infiltration	   focussed	   in	   the	   peribronchiolar	   regions	   (red	   arrows)	   with	  
increasing	   thickness	   of	   bronchiolar	   walls	   (green	   arrows)	   as	   a	   result	   of	   increased	  
collagen	  deposition	  (blue	  arrows),	  which	   is	  already	  apparent	  as	  early	  as	  day	  2,	  and	  
increases	  over	  the	  course	  of	  the	  injury.	  This	  is	  particularly	  apparent	  at	  day	  10,	  which	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6.5 	  Discussion	  
Animal	   models	   of	   lung	   injury	   have	   significantly	   advanced	   our	   knowledge	   and	  
understanding	   into	   the	   pathophysiology	   of	   ARDS.	   Furthermore,	   they	   test	   the	  
application	   of	   preclinical	   therapeutics	   prior	   to	   application	   in	   humans.	   One	   of	   the	  
major	   advantages	   of	   rodent	   models	   of	   disease	   is	   the	   potential	   application	   of	  
genetically	  engineered	  knockout	  strains	  to	  elucidate	  the	   impact	  of	  specific	  proteins	  
and	   signalling	   pathways	   in	   disease	   pathobiology,	   such	   as	   those	   used	   in	   previous	  
chapters	  of	   this	   thesis.	  Furthermore,	   the	  abundance	  of	  experimental	   reagents	   (e.g.	  
antibodies)	   in	  mouse	   species	  makes	   small	   animal	  modelling	  of	   disease	  essential	   in	  
the	   translational	   pathway	   from	   target	   discovery	   to	   clinical	   application.	   Currently	  
there	  are	  no	  targeted	  pharmacological	   treatments	  available	   for	  ARDS	  and	  all	  drugs	  
that	  have	  been	  applied	  in	  the	  preclinical	  setting	  have	  failed	  in	  clinical	  trials.	  One	  of	  
the	  reasons	  for	  this	  is	  the	  poor	  recapitulation	  of	  clinical	  entities	  such	  as	  ARDS,	  with	  
respect	   to	   not	   only	   pathophysiology	   but	   also	   temporal	   profile,	   in	   the	   currently	  
available	  preclinical	  animal	  models.	  This	  has	  been	  highlighted	  recently	  by	  two	  major	  
publications	   in	   the	   lung	   injury	   literature.	  The	  first	   is	  a	   review	  by	  Matute-­‐Bello	  et	  al	  
(37)	  and	  the	  second,	  guidelines	  from	  an	  ATS	  workshop	  as	  to	  the	  features	  required	  to	  
optimally	  model	  ARDS	  (192).	  Overall,	  no	  current	  clinical	  animal	  model	  replicates	  the	  
complexities	  of	  ARDS	  in	  terms	  of	  severity,	  pathobiology,	  temporal	  profile	  and	  clinical	  
relevance.	  
6.5.1 Pitfalls	  in	  animal	  models	  of	  ARDS	  
There	  are	  currently	  many	  models	  of	  ARDS	  that	  capture	  specific	  aspects	  of	  the	  clinical	  
entity.	   For	   instance,	   endotoxin	   instillation	   produces	   significant	   inflammation	   as	  
evidenced	  by	  a	  massive	  infiltration	  of	  neutrophils	  into	  the	  alveolar	  space.	  However,	  
this	   is	  not	  preceded	  or	   followed	  by	  a	  significant	   increase	   in	   lung	  extravascular	   lung	  
water	   (43).	   Bleomycin	   induced	   lung	   injury	   leads	   to	   increased	   inflammation	   but	   is	  
followed	   by	   a	  massive	   fibrotic	   reaction	   and	   hence,	   it	   represents	   the	  major	  model	  
used	  to	   investigate	   lung	  fibrosis	   (385).	  Other	  models	  such	  as	   intravenous	  oleic	  acid	  
produce	  overwhelming	   injury	  but	  do	  not	  allow	  the	   investigation	  of	   later	  phases,	   in	  
particular	  resolution.	  The	  aim	  of	  this	  chapter	  was	  to	  develop	  a	  model	  that	  allowed	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the	  investigation	  of	  not	  only	  the	  injurious	  and	  inflammatory	  phases	  of	  ARDS,	  but	  also	  
the	  resolution	  and	  recovery	  phases	  from	  a	  highly	  injured	  physiological	  baseline.	  
6.5.2 Acid	  aspiration	  –	  a	  truly	  translational	  model	  
The	   acid	   aspiration	   paradigm	   has	   been	   regarded	   as	   one	   of	   the	   most	   clinically	  
relevant	  models	  of	  ARDS	  as	  it	  mimics	  aspiration	  pneumonitis	  in	  humans	  (also	  known	  
as	  Mendelson’s	  syndrome	  (194)).	  However,	  human	  aspiration	  consists	  of	  more	  than	  
simply	   hydrochloric	   acid	   but	   also	   a	   variety	   of	   other	   insults	   including	   food	   and	  
bacterial	   particulate	   matter.	   Each	   of	   these	   elements	   has	   been	   shown	   to	   enhance	  
injury	   in	  rodents	   (197,	  386-­‐388).	   In	  spite	  of	  this,	   there	   is	  no	  other	  model	  that	  truly	  
replicates	  a	  human	  cause	  and	  produces	  as	  many	  relevant	  features	  of	  human	  ARDS	  in	  
mice.	  
	  
The	   acid	   aspiration	  model	   has	  been	  mainly	   utilised	   in	   association	  with	   a	   period	  of	  
mechanical	   ventilation	   as	   shown	   earlier	   in	   the	   acute	   3-­‐hour	  model.	   However,	   this	  
does	  not	  allow	  for	  investigations	  into	  the	  later	  phases	  of	  illness	  due	  to	  limitations	  in	  
providing	  prolonged	  mechanical	  ventilation	  in	  rodents.	  A	  major	  hurdle	  is	  the	  narrow	  
window	   for	   dosing	   acid	   (37)	   –	   too	   much	   leading	   to	   overwhelming	   injury	   and	  
unacceptably	   high	   mortality,	   and	   too	   little	   failing	   to	   produce	   sufficient	   injury	   for	  
investigation.	   This	   is	   confirmed	   by	   the	   initial	   dose-­‐titration	   experiments.	   Hence,	  
those	  models	  that	  have	  used	  the	  acid	  aspiration	  paradigm	  to	  investigate	  later	  time-­‐
points	   of	   acute	   lung	   injury	   have	   compromised	   on	   mortality	   with	   a	   lower	   level	   of	  
injury	   by	   using	   a	   smaller	   dose	   of	   acid	   (pH	   and	   volume)	   or	   through	   unilateral	  
instillation	  (191,	  381,	  382).	  Arguably,	  these	  protocols	  do	  not	  reproduce	  the	  severity	  
or	  the	  bilateral	   injury	  necessary	  for	  defining	  ARDS.	  The	  high	  mortality	  and	  need	  for	  
techniques	   to	   provide	  mechanical	   ventilation	  may	   explain	  why	   the	   acid	   aspiration	  
model	  is	  only	  utilised	  in	  3%	  of	  ARDS	  literature	  (37)	  despite	  being	  cited	  as	  one	  of	  the	  
most	  clinically	  relevant	  models	  (187,	  253).	  	  
	  
The	   model	   described	   in	   this	   chapter	   incorporates	   simple	   technical	   aspects	   of	  
everyday	   clinical	   intensive	   care	  practice	   that	   cumulatively	   improve	   the	   recovery	  of	  
animals	  during	  the	  immediate	  aspiration	  phase.	  This	  starts	  from	  the	  beginning	  of	  the	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protocol	  where	  a	  fluid	  bolus	  is	  administered	  during	  anaesthesia	  to	  prevent	  excessive	  
weight	   loss	   and	   haemodynamic	   compromise.	   Subsequently,	   careful	   airway	  
manipulation	   enables	   a	   grade	   2	   “Levine	   and	  McCormack”	   view	   of	   the	   vocal	   cords	  
allowing	   the	   careful	   insertion	  of	   a	   catheter	   to	   facilitate	   acid	   instillation	   (see	  photo	  
2.2).	  The	  subsequent	  care	  of	  animals	  in	  a	  custom	  made	  recovery	  box	  (see	  photo	  2.3)	  
providing	  humidification,	  warming,	  and	  oxygen	  therapy	  reduced	  the	  early	  immediate	  
mortality	  to	  zero.	  This	  early	  mortality	  was	  likely	  secondary	  to	  severe	  bronchospasm	  
and	  upper	  airway	  oedema	  given	  that	  sternal	  recession	  was	  visually	  apparent	  in	  those	  
animals	   that	  died	  during	  model	  development.	  Despite	   the	   initial	   fluid	   resuscitation	  
there	  was	  a	  significant	  reduction	  in	  weight	  over	  the	  first	  2	  days	  after	  acid	  aspiration.	  
In	  previous	  studies	  within	  our	  group	  using	  a	  similar	  instillation	  technique,	  endotoxin	  
(without	  the	  initial	  fluid	  bolus)	  produced	  only	  a	  2%	  weight	  loss	  at	  24	  hours	  (389),	  in	  
comparison	  to	  8%	  in	  this	  model.	  The	  difference	  between	  50ul	  and	  75ul	  volumes	  of	  
0.1M	  acids	  likely	  represents	  different	  severities	  and	  progression	  of	  illness.	  
6.5.3 Respiratory	  physiology	  attains	  ARDS	  criteria	  
The	  current	  model	  achieves	  clinical	  ARDS	  criteria	  within	  24	  hours	  of	  insult.	  There	  is	  
an	   acute	   onset	   of	   hypoxaemia	   (reaching	   a	   PaO2/FiO2	   of	   200),	   and	   as	   can	   be	   seen	  
from	   the	  macroscopic	   lung	   images	   (figure	   6.4)	   there	   is	   considerable	   bilateral	   lung	  
oedema.	  Furthermore,	  there	  were	  significant	  deteriorations	  in	  respiratory	  mechanics	  
and	  gas	  exchange.	  Many	  investigators	  ignore	  the	  need	  for	  robust	  standardisation	  of	  
lung	  physiology,	  particularly	  in	  rodents.	  As	  a	  consequence	  of	  their	  high	  thoracic	  wall	  
and	  respiratory	  compliance,	  anaesthesia	  and	  surgical	  preparation	  inevitably	  induces	  
alveolar	   collapse.	   Hence,	   in	   the	   current	   experiments,	   respiratory	   mechanics	   and	  
arterial	   oxygenation	   were	   measured	   after	   rigorous	   standardisation	   of	   the	   volume	  
history	   of	   mouse	   lungs	   using	   a	   recruitment	   manoeuvre	   followed	   by	   a	   30	   minute	  
period	   of	   low	   tidal	   volume	   ventilation.	   This	   enabled	   any	   confounding	   factors	  
between	   animals	   (at	   different	   time-­‐points	   and	   different	   severities	   of	   injury)	   to	   be	  
standardised.	  We	  have	  recently	  shown	  that	  the	  measurement	  of	   lung	  mechanics	   in	  
mice	   significantly	   depends	   on	   how	   they	   are	   manipulated	   during	   any	   mechanical	  
ventilation	   protocol.	   For	   instance,	   mice	   ventilated	   at	   10ml/kg	   without	   regular	  
recruitment	   manoeuvres	   show	   a	   gradual	   decrease	   in	   lung	   compliance	   due	   to	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atelectasis,	  as	  compared	  to	  mice	  ventilated	  at	  10ml/kg	  but	  with	  regular	  30	  minutes	  
recruitment	  manoeuvres	   (239).	   In	   this	  acid	  model,	   there	   is	  a	   tendency	   for	  alveolar	  
collapse	  (as	  determined	  by	  substantial	  reduction	   in	   lung	  elastance	  after	  application	  
of	  the	  first	  recruitment	  manoeuvre	  as	  seen	  in	  figure	  6.2	  A)	  especially	  on	  days	  1	  and	  
2.	  Hence,	  the	  changes	  in	  respiratory	  mechanics	  are	  a	  reflection	  of	  not	  only	  alveolar	  
oedema	   formation	   but	   also	   alveolar	   atelectasis.	   The	   changes	   in	   BALF	   protein	   and	  
lung	  wet/dry	  weight	  ratio	  confirm	  the	  significant	  increase	  in	  alveolar	  capillary	  barrier	  
permeability	  and	  impact	  upon	  the	  alveolar	  epithelium.	  
6.5.4 Alveolar	  epithelial	  dysfunction	  and	  recovery	  in	  later	  phases	  of	  ARDS	  
The	   importance	   of	   the	   alveolar	   epithelium	   in	   lung	   injury	   pathogenesis	   has	   formed	  
the	  basis	  of	  the	  thesis	  thus	  far.	  Even	  within	  this	  longer	  model	  we	  found	  that	  alveolar	  
fluid	   clearance	   deteriorated	   within	   3	   hours	   of	   acid	   aspiration	   and	   showed	   a	   42%	  
reduction	   at	   48	   hours.	   In	   comparison	   with	   the	   3-­‐hour	   acute	   acid	   model,	   this	  
reduction	   in	  AFC	  seemed	   less,	  potentially	  suggesting	  a	   lower	  severity	  of	   injury	  as	  a	  
result	  of	  differences	  in	  the	  instillation	  technique	  (i.e.	  [orotracheal	  and	  spontaneous	  
ventilation]	   versus	   [tracheostomy	   and	   mechanical	   ventilation]).	   Whilst	   acid	  
aspiration	  models	  have	  been	  shown	   to	   induce	  deteriorations	   in	  AFC	   (71,	  255),	   this	  
model	  shows	  (for	  the	  first	   time)	  a	  recovery	   in	  AFC	  from	  day	  3	  onwards,	  suggesting	  
that	  there	  is	  restoration	  and	  repair	  of	  the	  alveolar	  epithelium.	  This	  stark	  recovery	  in	  
alveolar	   fluid	  clearance	  occurs	  between	  days	  2	  and	  3	  and	  coincides	  with	  a	  marked	  
reduction	   in	   cytokines	   and	   neutrophil	   migration	   into	   the	   alveolar	   space.	   Hence,	  
these	   data	   support	   the	   hypothesis	   that	   the	   later	   deteriorations	   in	   AFC	   may	   be	  
secondary	  to	  signals	  (such	  as	  death	  ligands)	  emanating	  from	  recruited	  leukocytes	  (as	  
discussed	  in	  section	  5.5.8).	  Future	  investigation	  examining	  the	  relationship	  between	  
caspase-­‐8	   activation	   and	   AFC	   at	   later	   time-­‐points	   as	   well	   as	   other	   mediators	  
maintaining	   the	   deterioration	   in	   AFC	   will	   provide	   interesting	   insights	   into	   this	  
important	  pathophysiological	  phenomenon.	  Finally,	  AFC	  seems	  to	  increase	  up	  to	  day	  
10	  achieving	  an	  18%	  increase	  compared	  to	  baseline	  AFC	  using	  this	  system.	  This	  may	  
account	   for	   the	   normal	   wet/dry	   weight	   ratio	   in	   the	   presence	   of	   increase	  
permeability.	  The	  mechanisms	  that	  lead	  to	  this	  sudden	  improvement	  in	  AFC	  remain	  
undetermined	  and	  remain	  the	  subject	  for	  future	  work.	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6.5.5 DAMPen	  the	  RAGE	  
RAGE	   is	   a	   multi-­‐ligand	   transmembrane	   protein	   that	   functions	   as	   a	   pattern	  
recognition	   receptor.	  RAGE	  has	  been	  advocated	  as	   a	   specific	   biomarker	   for	   type	  1	  
alveolar	  epithelial	  dysfunction	   in	  experimental	  and	  human	  models	  of	  disease	   (344,	  
345,	  390).	  It	  is	  a	  member	  of	  the	  immunoglobulin	  superfamily	  and	  is	  highly	  expressed	  
in	  lung	  tissue	  and	  is	  localised	  to	  the	  basal	  surface	  of	  type	  1	  alveolar	  epithelial	  cells.	  It	  
recognises	   a	   large	   number	   of	   ligands	   including	   a	   number	   of	   damage-­‐associated	  
molecular	   patterns,	   ranging	   from	   advanced	   glycation	   end-­‐products,	   amyloid	   beta-­‐
peptides,	   high-­‐mobility	   group	   box-­‐1	   (HMGB-­‐1)	   protein	   and	   S100	   proteins.	   The	  
activation	  of	  membrane	  bound	  RAGE	  leads	  to	  the	  activation	  of	  MAP	  kinase	  pathway	  
leading	   to	  NFκB	  activation	   (391,	   392).	   There	   is	   increasing	   recognition	   that	  RAGE	   is	  
important	  in	  the	  detection	  of	  sterile	  damage	  by	  sensing	  danger	  signals	  (e.g.	  HMGB-­‐1)	  
released	  in	  response	  to	  cellular	  stress	  and	  cell	  death	  (12).	  
	  	  
RAGE	  was	  utilised	  in	  this	  thesis	  as	  a	  marker	  of	  epithelial	  injury	  as	  has	  been	  shown	  by	  
a	  number	  of	  investigators.	  Uchida	  et	  al	  (308)	  showed	  that	  as	  severity	  of	  acid-­‐induced	  
lung	  injury	  increased	  (increasing	  acid	  normality)	  the	  concentration	  of	  alveolar	  RAGE	  
also	   increased	   in	   a	   dose-­‐dependant	   manner.	   Furthermore,	   this	   effect	   was	  
reproduced	   as	   the	   volume	   of	   acid	   was	   increased	   suggesting	   that	   the	   amount	   of	  
protons	  instilled	  is	  the	  important	  determinant	  of	  injury	  in	  this	  model.	  No	  RAGE	  was	  
detected	  in	  the	  serum	  (consistent	  with	  unreported	  findings	  from	  our	  group)	  of	  these	  
animals	   suggesting	   a	   pulmonary	   source.	   In	   the	   same	   study,	   they	   also	   found	   that	  
RAGE	  was	  increased	  during	  permeability	  pulmonary	  oedema	  with	  greater	   increases	  
in	   those	   with	   ALI/ARDS	   as	   opposed	   to	   hydrostatic	   permeability	   oedema.	   Hence,	  
these	  data	  suggest	  that	  the	  source	  of	  RAGE	  is	  indeed	  the	  lung	  and	  during	  injury	  it	  is	  
released	  into	  the	  alveolar	  space.	  Although,	  there	  have	  been	  many	  studies	  examining	  
the	   expression	   of	   membrane	   bound	   RAGE,	   the	   consensus	   at	   present	   is	   that	   it	   is	  
expressed	   predominantly	   by	   type	   1	   AECs	   although	   expression	  may	   be	   inducible	   in	  
primary	  human	  lung	  microvascular	  endothelial	  cells	  (393,	  394).	  	  
	  
The	  systemic	  administration	  of	  soluble	  RAGE	  significantly	  attenuated	  lung	  injury	  in	  a	  
model	   of	   endotoxin	   induced	   lung	   injury	   and	  may	   contribute	   to	   the	   suppression	  of	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excessive	   inflammatory	   responses	   (395).	   Briot	   et	   al	   utilised	   an	   isolated	   perfused	  
human	   lung	  model	   to	   show	   that	   alveolar	   RAGE	   showed	   an	   inverse	   relationship	   to	  
alveolar	   fluid	   clearance.	   In	   contrast,	   perfusate	   RAGE	   showed	   no	   significant	  
association.	   In	  both	  our	   short	   (figure	  5.3)	  and	   long-­‐term	  model	   (figure	  6.5)	  of	  acid	  
aspiration	  used	  in	  this	  thesis	  there	  were	  significant	  inverse	  correlations	  between	  AFC	  
and	   alveolar	   RAGE	   confirming	   that	   both	   were	   robust	   markers	   of	   epithelial	  
dysfunction	  at	  all	  stages	  of	  lung	  injury.	  	  
	  
However,	   the	  question	  remains	   in	  this	   longer-­‐term	  model	  as	  to	  what	  soluble	  RAGE	  
signifies	  at	  later	  time	  points.	  RAGE	  is	  shed	  within	  90	  minutes	  of	  acid	  instillation	  and	  
hence,	  the	  pattern	  seen	  within	  this	  model	  suggests	  that	  RAGE	  could	  be	  an	  indicator	  
for	   epithelial	   barrier	   permeability,	   whereas	   BAL	   protein	   is	   a	   marker	   of	   combined	  
endothelial	   and	   epithelial	   permeability.	   This	   may	   hold	   true	   given	   that	   protein	  
originates	  from	  the	  plasma	  compartment	  but	  RAGE	  is	  thought	  to	  be	  integral	  to	  the	  
binding	  of	  the	  epithelium	  to	  the	  basement	  membrane	  of	  the	   lung	  (396)	  and	  hence	  
any	   damage	   may	   promote	   disruption	   and	   facilitate	   alveolar	   flooding	   with	   the	  
“washing	  in”	  of	  RAGE	  into	  the	  alveolar	  space.	  Furthermore,	  the	  proteolytic	  shedding	  
of	  RAGE	  (by	  MMP-­‐3	  and	  -­‐13)	  into	  its	  soluble	  form	  (397)	  may	  dampen	  inflammatory	  
responses	   by	   acting	   as	   a	   decoy	   receptor	   reducing	   the	   extent	   to	   which	   damage	  
associated	  molecular	  patterns	  (DAMPs	  -­‐	  such	  as	  HMGB-­‐1)	  can	  promote	  inflammation	  
and	  the	  extent	  to	  which	  membrane	  RAGE	  can	  signal	  NFκB	  activation.	  The	  application	  
of	   this	   resolving	   model	   of	   acid	   aspiration	   to	   investigate	   RAGE	   biology	   would	  
potentially	  provide	  interesting	  avenues	  into	  the	  roles	  of	  this	  interesting	  molecule	  in	  
acute	  sterile	  lung	  injury	  and	  inflammation.	  	  
	  
It	   has	   recently	   been	   shown	   the	   down	   regulation	   of	   cellular	   expressed	   RAGE	   also	  
promotes	  the	  development	  of	  fibrosis	  in	  patients	  with	  interstitial	  pulmonary	  fibrosis.	  
This	  was	  also	  shown	  to	  be	  the	  case	  in	  mice	  injured	  with	  bleomycin	  and	  the	  authors	  
suggested	  this	  to	  involve	  a	  mechanism	  involving	  a	  dysregulation	  in	  AEC	  cell	  adhesion,	  
migration	  and	  proliferation	  (398).	  Given	  the	  substantial	  epithelial	   injury	  seen	  in	  the	  
resolving	  acid	  model	  as	  well	  as	  the	  progression	  to	  fibrosis,	  this	  model	  may	  be	  ideal	  to	  
investigate	  this	  association	  of	  RAGE	  with	  fibroproliferation.	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6.5.6 Resolution	  of	  inflammation	  is	  integral	  to	  physiological	  resolution	  
The	  role	  of	  inflammation	  during	  various	  phases	  of	  ARDS	  is	  a	  relatively	  obscure	  entity.	  
Whilst	  depletion	  of	  neutrophils	  and	  monocytes	  has	  attenuated	  ARDS	  in	  experimental	  
models	  (89,	  399-­‐402),	  ARDS	  continues	  to	  occur	  during	  neutropenia	  in	  patients	  with	  
haematological	   failure	   (91-­‐94).	  Hence,	   rather	   than	  targeting	  these	  cells	  which	  have	  
major	  roles	   in	  fighting	  bacterial	   infection,	   it	  may	  be	  more	  efficacious	  to	  target	  pro-­‐
resolving	  mechanisms	   to	  potentiate	   repair	  of	   the	   lung.	   Indeed,	   critical	   illness	   in	   its	  
entirety	   may	   be	   seen	   primarily	   as	   a	   non-­‐resolving	   state	   of	   inflammation.	   In	   the	  
introduction,	   we	   discussed	   the	   mechanisms	   behind	   resolution	   and	   recovery	   in	  
critical	  illness	  many	  of	  which	  are	  recapitulated	  within	  this	  model.	  
	  
The	   first	   step	   towards	   resolution	   and	   recovery	   is	   the	   removal	   of	   any	   stimulus.	   An	  
advantage	  of	  the	  instillation	  of	  acid	  is	  that	  it	  provides	  a	  defined	  time	  zero.	  The	  acid	  is	  
likely	   to	   be	   buffered	   relatively	   quickly	   either	   within	   the	   alveolar	   space	   or	   in	   the	  
blood.	  In	  contrast,	  the	  larger	  doses	  of	  endotoxin	  may	  remain	  within	  the	  respiratory	  
system	   for	   longer	   and	   contribute	   to	   a	   sustained	   TLR-­‐4	   activation.	  Hence,	   although	  
time	  zero	  is	  known,	  the	  activation	  kinetic	  in	  the	  endotoxin	  model	  is	  likely	  to	  be	  more	  
prolonged.	  Furthermore,	  and	  most	  importantly,	  unlike	  any	  of	  the	  endotoxin	  models	  
(intravenous	  or	   inhaled)	   there	   is	   significant	  physiological	  dysfunction	   recapitulating	  
the	   picture	   of	   clinical	   ARDS.	   This	   facilitates	   much	   needed	   investigation	   into	   the	  
mechanisms	   through	   which	   inflammation	   can	   promote	   and	   resolve	   physiological	  
derangement	  (e.g.	  hypoxaemia,	  respiratory	  compliance,	  and	  AFC)	  during	  lung	  injury.	  
In	   contrast,	   most	   investigators	   struggle	   to	   produce	   the	   same	   physiological	  
dysfunction	   with	   other	   ARDS	   models,	   and	   hence,	   although	   resolution	   of	   lung	  
inflammation	   can	   be	   investigated	   well,	   resolution	   of	   lung	   injury	   and	   physiology	  
cannot.	  In	  fact,	  only	  models	  using	  extremely	  large	  doses	  of	  intravenous	  endotoxin,	  or	  
oleic	   acid	   model	   produce	   any	   pulmonary	   oedema	   in	   mice	   (37).	   In	   general,	   the	  
endothelial	  and	  epithelial	  surfaces	  of	  the	  lung	  are	  quite	  resistant	  to	  endotoxin	  (43).	  	  
Indeed,	  the	  lack	  of	  mortality	  during	  days	  1–2	  (when	  injury	  peaked)	  may	  be	  specific	  to	  
the	  acid	  model,	  which	  showed	  minimal	  haemodynamic	  compromise.	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The	   lavage	   cellular	   profile	   shows	   a	   shift	   from	   a	   neutrophilic	   alveolitis	   to	   a	   more	  
mononuclear	   alveolitis	   -­‐	   another	   recommended	   workshop	   feature	   for	   an	  
inflammatory	   response	   (192).	   The	   loss	   of	   neutrophils	   from	   day	   2	   onwards	   is	   a	  
necessary	  feature	  for	  the	  resolution	  of	  inflammation.	  This	  reduction	  is	  likely	  to	  occur	  
through	   apoptosis	   followed	   by	   subsequent	   efferocytosis	   by	  macrophages.	   Indeed,	  
during	  day	  3	   there	  are	  an	  abundant	  number	  of	  apoptotic	  bodies	  visible	  within	   the	  
cytoplasm	   of	   mononuclear	   cells	   on	   BAL	   cytology	   (figure	   6.7).	   This	   apoptosis	   and	  
efferocytosis	   of	   neutrophils	   is	   an	   integral	   step	   to	   signal	   the	   beginning	   of	  
inflammatory	   resolution.	   The	   ingestion	   of	   apoptotic	   cell	   bodies	   by	   activated	  
monocytes	   leads	  to	  a	  change	   in	   their	  phenotype	  and	  a	  reduced	  production	  of	  pro-­‐
inflammatory	  cytokines	  and	  an	  increased	  production	  of	  anti-­‐inflammatory	  cytokines	  
(129,	  403).	  	  
	  
It	   is	   interesting	   that	   the	   resolution	   of	   inflammation	   comprising	   the	   loss	   of	  
neutrophils	  (likely	  through	  apoptosis);	  their	  ingestion	  by	  macrophages;	  the	  reduction	  
in	  TNF/IL-­‐6	  production	   should	   coincide	   so	  well	  with	   the	   resolution	  of	  physiological	  
injury	   (such	   as	   oxygenation	   and	   AFC).	   Indeed,	   this	   supports	   the	   notion	   that	  
inflammatory	   leukocytes	   perpetuate	   lung	   injury	   but	   it	   is	   also	   evident	   that	  
functionally	   pro-­‐resolving	   leukocytes	   may	   be	   recruited	   to	   the	   lung.	   This	   switch	  
between	   pro-­‐inflammatory	   and	   pro-­‐resolving	   phenotypes	   of	   leukocytes	   already	  
within	  the	  lung	  is	  likely	  to	  be	  of	  paramount	  importance	  and	  one,	  which	  malfunctions	  
in	   ARDS.	   Indeed,	   the	   BAL	   cytology	   shows	   increases	   in	   lymphocyte	   proportion	  
accounting	   for	  up	   to	  15%	  of	  all	   leukocytes	   in	   the	  alveolar	   space	  at	  10	  days.	  This	   is	  
consistent	   with	   recent	   data	   from	   D’Alessio	   et	   al	   suggesting	   the	   importance	   of	   T-­‐
regulatory	   cell	   populations	   in	   the	   resolution	   of	   endotoxin	   mediated	   lung	  
inflammation	  (98).	  	  
	  	  
An	   interesting	  observation	   is	   that	  during	   the	   first	  48	  hours	  a	   significant	  number	  of	  
neutrophils	  remain	  within	  the	  interstitial	  space	  (as	  assessed	  by	  the	  histological	  lung	  
injury	   score).	   Indeed,	   this	   raise	   questions	   as	   to	   the	   robustness	   of	   using	   alveolar	  
cytology	  counts	  to	  measure	  neutrophil	   influx.	  Of	  further	   interest	   is	  the	   increases	   in	  
lung	  homogenate	  MPO	  activity	  after	  day	  3	  even	  after	  alveolar	  neutrophils	  have	  been	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removed.	  This	  potentially	  suggests	  that	  interstitial	  populations	  or	  mononuclear	  cells	  
may	   be	   contributing	   to	   this	   MPO	   activity.	   Hence,	   a	   technique	   to	   investigate	   the	  
interstitial	  space	  of	  the	  lungs	  may	  be	  of	  significant	  interest.	  Such	  a	  technique	  would	  
also	  be	  of	  significant	  value	  for	  other	  resident	  and	  itinerant	  cell	  populations	  (such	  as	  
dendritic	   cells,	   interstitial	   macrophages,	   and	   lymphocytes)	   within	   the	   interstitial	  
compartment.	  The	   functions	  and	   roles	  of	   these	   interstitial	   cell	   types	  have	   received	  
little	  attention	  in	  ARDS	  research	  and	  will	  be	  the	  focus	  of	  chapter	  7.	  
6.5.7 Resolution	  through	  pulmonary	  fibrosis	  
If	  patients	  survive	  the	  acute	  exudative	  phase	  of	  ARDS	  they	  either	  progress	  to	  repair	  
normally	  or	   in	  a	  significant	  proportion	  proceed	   into	  the	  fibro-­‐proliferative	  phase	  of	  
the	  syndrome.	  In	  fact,	  Papazian	  et	  al	  performed	  open-­‐lung	  biopsies	  on	  100	  patients	  
after	   7	   days	   of	   fulfilling	   ARDS	   criteria	   and	   found	   53%	  of	   patients	   had	   a	   significant	  
fibrotic	   component	   (404).	   Whilst	   the	   fibroproliferative	   phase	   of	   ARDS	   has	   been	  
predominantly	   discussed	   to	   occur	   after	   the	   exudative	   phase,	   in	   fact,	   a	   number	   of	  
studies	   in	   man	   has	   shown	   the	   deposition	   of	   extracellular	   matrix	   during	   the	   early	  
stages	  of	  ARDS,	   in	  particular,	   those	  caused	  by	  direct	   insults.	  Marshall	  et	  al	  showed	  
that	   BAL	   from	   patients	   between	   1	   and	   7	   days	   of	   ARDS	   diagnosis	   was	   able	   to	  
stimulate	   ex	   vivo	   lung	   fibroblast	   proliferation	   (405).	   Armstrong	   et	   al	   showed	   that	  
markers	  of	  collagen	  turnover	  are	  elevated	  within	  48	  hours	  of	  ARDS	  suggesting	  that	  
the	   fibroproliferative	   phases	   commences	   earlier	   than	   previously	   perceived	   (406).	  
Pugin	   et	   al	   found	   collagen	   synthesis	   occurring	   on	   the	   first	   day	   of	   intubation	   in	  
association	  with	  the	  production	  of	  pro-­‐inflammatory	  cytokines	  (407).	  Indeed,	  type	  1	  
collagen	   mRNA	   increases	   within	   2	   hours	   of	   cardiopulmonary	   bypass	   (a	   common	  
cause	  of	  ARDS)	  and	  is	  dependant	  on	  resident	  fibroblasts	  (408).	  There	  are	  increased	  
numbers	   of	   myofibroblasts	   and	   procollagen	   type	   1	   producing	   cells	   during	   the	  
exudative	   phase	   of	   ARDS	   (409).	   Furthermore,	   TGF-­‐beta,	   a	   mediator	   heavily	  
implicated	   in	   various	   forms	   of	   lung	   fibrosis,	   is	   also	   upregulated	   on	   day	   3	   of	   ARDS	  
(410-­‐412).	  	  
	  
The	   factors	   that	   determine	   the	   development	   of	   fibrosis	   in	   ARDS	   remain	   unknown	  
and	   very	   few	   animal	  models	   allow	   investigation	   of	   this	   during	   a	   clinically	   relevant	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interval	   (385,	   413).	   Bleomycin	   is	   the	   most	   commonly	   used	   model	   to	   investigate	  
mechanisms	   of	   fibrosis	   but	   fibrosis	   takes	   3-­‐4	  weeks	   to	   develop,	   and	   the	  model	   is	  
questioned	   for	   its	   clinical	   relevance.	  Within	   this	   acid	  model	   there	   is	   thickening	   of	  
bronchioles	  through	  the	  deposition	  of	  peribronchial	  collagen	  as	  early	  as	  day	  2,	  and	  
this	  progresses	  to	  the	  development	  of	  alveolar	  fibrosis	  and	  peribronchial	  fibrotic	  foci	  
by	  day	  10.	  Indeed,	  the	  fibrotic	  component	  may	  explain	  why	  lung	  elastance	  had	  not	  
normalised	  by	   day	   10,	   continuing	   to	   show	  a	   significant	   16%	   increase	   compared	   to	  
normal.	   Hence,	   this	   model	   provides	   a	   temporal	   profile	   of	   ARDS	   fibroproliferation	  
that	  is	  closer	  to	  the	  human	  condition.	  In	  addition,	  it	  will	  be	  interesting	  to	  investigate	  
the	   impact	  of	  secondary	   insults	  on	  fibrosis,	   in	  particular,	   infectious	  and	  mechanical	  
ventilatory	   insults	  both	  of	  which	  are	  pro-­‐fibrotic	   in	   clinical	   and	  experimental	  ARDS	  
(404,	  414).	  	  
	  
6.6 Concluding	  remarks	  
A	   model	   of	   experimental	   ARDS	   has	   been	   developed	   utilising	   the	   intratracheal	  
instillation	   of	   hydrochloric	   acid.	   This	   model	   facilitates	   the	   investigation	   into	   the	  
cellular	  and	  molecular	  factors	  that	  determine	  both	  early	  injurious	  and	  late	  resolving	  
phases	   of	   lung	   injury.	   Unlike	  most	   models	   this	   resolving	   acid	  model	   recapitulates	  
many	   of	   the	   physiological	   derangements	   found	   in	   ARDS	   including	   abnormalities	   in	  
gas	   exchange,	   respiratory	   mechanics	   and	   alveolar	   fluid	   clearance.	   Hence,	   there	   is	  
injury	   to	   the	   pulmonary	   capillary	   endothelium	   and	   alveolar	   epithelium,	   with	  
subsequent	  repair	  through	  fibrosis.	  This	  model	  reproduces	  the	  temporal	  profile	  and	  
illness	  severity	  found	  in	  clinical	  ARDS	  and	  combining	  it	  with	  other	  clinically	  relevant	  
insults	  such	  as	  ventilation	  and	  infection	  will	   truly	  recapitulate	  the	  path	  followed	  by	  
patients	  suffering	  with	  ARDS	  on	  the	  ICU.	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7 Compartmental	  analysis	  of	  leukocytes	  in	  healthy	  and	  
injured	  mouse	  lungs	  
	  
Abstract	  
The	  analysis	  of	  leukocyte	  functions	  during	  the	  injurious	  and	  resolving	  phases	  of	  lung	  
injury	   is	   crucial	   to	   gain	   further	   understanding	   of	   the	   roles	   for	   resident	   as	   well	   as	  
itinerant	   cells	   during	   health	   and	   injury.	   Chapters	   3,4	   and	   5	   showed	   that	   resident	  
alveolar	  macrophages	  trigger	  alveolar	  epithelial	  dysfunction	  through	  the	  elaboration	  
of	  TNF.	  This	  occurs	  very	  early	  at	  90	  minutes	  after	  insult.	  The	  last	  chapter	  shows	  that	  
neutrophils	   and	   monocytes	   migrate	   into	   the	   lung	   and	   remarkably	   that	   these	  
migrated	  cells	  disappear	  between	  days	  2	  and	  3.	  This	  disappearance	  coincides	  with	  a	  
loss	   of	   inflammatory	   cytokines	   (including	   TNF)	   and	   also	   the	   improvement	   in	   lung	  
oedema	   and	   physiology	   (respiratory	   mechanics,	   permeability	   and	   alveolar	   fluid	  
clearance).	   Furthermore,	   histology	   shows	   a	   considerable	   number	   of	   neutrophils	  
within	   the	   interstitial	   space.	   Hence,	   I	   developed	   and	   validated	   a	   technique	   to	  
investigate	   the	   compartmental	   location	   of	   leukocytes	   within	   mouse	   lungs	   during	  
health	  and	  after	  injury	  i.e.	  acid	  aspiration.	  Various	  leukocytes	  were	  characterised	  in	  
the	   alveolar,	   interstitial	   and	   vascular	   spaces	   within	   the	   lung.	   Furthermore,	   during	  
injury	  and	  resolution	  there	  were	  significant	  changes	   in	   leukocyte	  type	  and	  function	  
in	  between	  compartments	  and	  time-­‐points.	  This	  chapter	  points	  to	  the	  usefulness	  of	  
this	   technique	   to	   examine	   the	   roles	   of	   each	   leukocyte	   depending	   on	   where	   it	   is	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7.1 Introduction	  
Leukocytes	   have	   been	   consistently	   implicated	   in	   the	   pathogenesis	   of	   ALI/ARDS,	  
however,	  there	  remains	  a	  gap	  in	  our	  understanding	  as	  to	  how	  they	  contribute	  to	  or	  
are	   dysregulated	   in	   ALI/ARDS.	   Furthermore,	   the	   mechanisms	   linking	   leukocyte-­‐
mediated	  inflammation	  and	  alveolar-­‐capillary	  barrier	  dysfunction	  in	  ARDS	  is	  far	  from	  
clear.	  ARDS	  develops	  in	  patients	  with	  severe	  neutropenia	  and	  marrow	  failure	  (91-­‐94)	  
suggesting	   that	   other	   non-­‐leukocyte	   mediated	   mechanisms	   also	   play	   a	   significant	  
role,	   but	   recovery	   from	   neutropenia	   can	   also	   lead	   to	   ARDS	   in	   patients	   with	  
haematological	   malignancy	   (95).	   Hence,	   the	   roles	   of	   leukocytes	   are	   likely	   to	   be	  
dependant	  on	  the	  context	  to	  which	  they	  are	  recruited	  to	  the	  lung	  and	  influenced	  by	  
extrinsic	  factors.	  
	  
Although	  neutrophils	  are	  crucial	  in	  the	  first	  step	  against	  injury	  and	  infection,	  there	  is	  
accumulating	   evidence	   that	   monocytic	   cell	   populations	   significantly	   influence	   the	  
progression	  of	   injury,	   inflammation,	  as	  well	  as,	  resolution	  during	  experimental	   lung	  
injury.	   For	   instance,	   work	   within	   our	   laboratory	   has	   shown	   that	   bone	   marrow	  
derived	   inflammatory	   monocytes	   marginate	   to	   the	   lung	   microvasculature	   and	  
promote	  pulmonary	   oedema	   and	   endothelial	   dysfunction	  within	   the	   hours	   of	   lung	  
injury	   induction	   (241,	   399,	   415).	  Others	   have	   shown	   that	  monocytes	   promote	   on-­‐
going	   neutrophil	   recruitment	   to	   the	   lung	   (97)	   after	   endotoxin	   challenge.	   Finally,	   a	  
number	  of	  investigators	  have	  shown	  that	  myeloid	  cells	  can	  also	  attenuate	  lung	  injury	  
and	  promote	  its	  resolution	  (112,	  246,	  416).	  The	  early	  chapters	  of	  this	  thesis	  showed	  
that	   resident	   alveolar	   macrophages	   play	   a	   significant	   role	   in	   promoting	   early	  
epithelial	   dysfunction	   through	   death	   receptor	   activation.	   The	   prolonged	  model	   of	  
experimental	   acid-­‐induced	   lung	   injury	   described	   in	   the	   previous	   chapter	   enables	  
investigation	  into	  later	  phases	  of	  injury,	  in	  particular,	  the	  determinants	  of	  resolution	  
of	  this	   injury.	  Currently,	   intratracheal	  endotoxin	   is	  the	  most	  commonly	  used	  model	  
to	   investigate	   pulmonary	   inflammation	   and	   its	   resolution,	   however	   as	   discussed	  
previously,	   it	   does	   not	   induce	   sufficient	   amounts	   of	   alveolar	   oedema	   to	   allow	  
investigation	  into	  how	  these	  inflammatory	  processes	  may	  promote	  alveolar-­‐capillary	  
barrier	   disruption.	   Interestingly,	   our	   acid	  model	   shows	   significant	   alveolar	  oedema	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with	  a	  reduced	  alveolar	  fluid	  clearance	  in	  the	  first	  2	  days	  after	  acid	   instillation	  that	  
dramatically	  improves	  once	  leukocytes	  (in	  particular,	  neutrophils)	  have	  disappeared.	  
Furthermore,	   there	   is	   an	   increase	   in	   the	   number	   of	   exudative	   myeloid	   cells	   and	  
lymphocytes	   over	   the	   course	   of	   injury	   and	   these	   cells	  may	  promote	   resolution,	   as	  
has	  been	  shown	  in	  a	  number	  of	  other	  models	  (98,	  100).	  	  
	  
This	   chapter	   focuses	   on	   the	   development	   of	   a	   novel	   flow	   cytometry	   protocol	   to	  
phenotype	   resident	   leukocyte	   subtypes	   during	   normal	   physiology,	   as	   well	   as,	  
itinerant	   cells	   during	   injury	   and	   resolution	   within	   this	   model	   of	   lung	   injury.	   The	  
techniques	   utilised	   thus	   far	   to	   investigate	   leukocyte	   infiltration	   into	   the	   lung	   have	  
relied	  on	  histological	  examination	  and	  whole	   lung	   flow	  cytometry	  and	  hence,	  have	  
been	  quite	   non-­‐specific.	   For	   instance,	   histology	  may	   allow	  differentiation	  between	  
interstitial	   and	   alveolar	   cells,	   but	   differences	   between	   vascular	   and	   interstitial	  
components	   remains	   difficult,	   and	   artefacts	   during	   processing	   may	   influence	   the	  
data	   obtained.	   Furthermore,	   different	   leukocyte	   subtypes	   can	   often	   be	   difficult	   to	  
distinguish.	  	  
	  
Flow	  cytometry	   is	   a	  powerful	   tool	   to	  elucidate	   the	   complex	   cellular	   and	  molecular	  
phenotype	   as	   well	   as	   function	   of	   leukocytes	   within	   the	   lung.	   However,	   flow	  
cytometric	   analyses	   are	   often	   based	   on	   comparisons	   between	   lavage	   versus	   lung	  
homogenate.	   Unfortunately,	   it	   is	   likely	   that	   many	   intra-­‐alveolar	   cells	   still	   remain	  
within	   the	   lung	   after	   lavage,	   and	   hence,	   does	   not	   allow	   a	   complete	   and	   accurate	  
assessment	   of	   cell	   localisation	   (intra-­‐alveolar	   vs	   interstitial/intravascular)	   or	  
quantification.	  Furthermore,	  flushing	  the	  vasculature	  of	  the	  lung	  leaves	  behind	  cells	  
that	  are	  marginated	  to	  the	  endothelium	  of	  the	  lung	  (237),	  making	  the	  differentiation	  
between	  interstitial	  and	  intravascular	  spaces	  very	  difficult	  by	  flow	  cytometry.	  Finally,	  
it	   is	   likely	  that	  cells	  within	  the	   interstitium	  play	  a	  crucial	  role	  and	  hence	  have	  been	  
ignored	  in	  the	  majority	  of	  literature	  often	  requiring	  expensive	  tools	  such	  as	  intravital	  
microscopy	  to	  investigate	  them	  further	  (238,	  417-­‐420).	  	  
	  
A	  major	  advantage	  with	  the	  lung,	  unlike	  solid	  organs,	   is	  the	  access	  to	  both	  sides	  of	  
the	   endothelial-­‐tissue	   interface.	   This	   enables	   the	   application	   of	   intratracheal	   and	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intravenous	   labels	   to	  positively	   identify	  alveolar	  and	   intravenous	  cells	  and	  crucially	  
identify	  (through	  negative	  gating)	  the	  interstitial	  cell	  population.	  With	  this	  in	  mind	  I	  
set	   out	   to	   establish	   and	   validate	   a	   flow	   cytometry	   technique	   to	   enable	   the	  
identification	   of	   the	   leukocyte	   subsets	   in	   the	   various	   lung	   compartments	   allowing	  
investigation	  into	  their	  number,	  localisation,	  phenotype,	  and	  function	  in	  healthy	  and	  
injured	  mouse	  lungs.	  	  
	  
7.2 Aims	  
1) Develop	   a	   method	   to	   enable	   distinction	   between	   leukocytes	   in	   the	   three	  
compartments	  within	  the	  lung	  –	  vascular,	  interstitial	  and	  alveolar.	  
2) Characterise	  the	  various	  leukocyte	  subsets	  within	  the	  lung	  compartments.	  
3) Attain	  a	  preliminary	  characterisation	  of	  the	  changes	  that	  occur	  during	  injury	  
and	  resolution.	  
	  
7.3 Experimental	  Design	  
7.3.1 In	  vivo	  protocols	  
Anaesthetised	   WT	   mice	   underwent	   instillation	   of	   hydrochloric	   acid	   as	   previously	  
described	   in	   the	   resolution	   model.	   At	   various	   time-­‐points	   after	   injury,	   animals	  
underwent	  tracheostomy	  and	  right	  external	  jugular	  vein	  cannulation	  through	  which	  
2μg	   of	   a	   PE	   anti-­‐CD45	   antibody	   (diluted	   in	   100μl	   sterile	   PBS)	  was	   injected.	   At	   the	  
same	   time,	   animals	   underwent	   systemic	   anticoagulation	   and	   five	   minutes	   after	  
injection	  of	   the	   antibody	   animals	  were	   exsanguinated	  under	   terminal	   anaesthesia.	  
The	  thoracic	  cavity	  was	  exposed	  through	  a	  midline	  sternotomy	  and	  the	  lungs	  gently	  
teased	   from	   their	   pleural	   adhesions.	   Subsequently,	   5-­‐0	   silk	   sutures	   were	   placed	  
carefully	   around	   the	   right	   and	   left	   main	   bronchi.	   One	   or	   both	   lungs	   underwent	  
instillation	   with	   0.5ml	   or	   1ml	   sterile	   PBS	   containing	   2μg	   of	   a	   PE-­‐Cy7	   anti-­‐CD45	  
antibody,	  respectively.	  The	  bronchial	   ties	  were	  tightened	  and	   lungs	  were	  removed.	  
Whole	  blood	  was	  also	  attained	  for	  analysis	  via	  the	  external	   jugular	  venous	  cannula	  
and/or	  cardiac	  puncture.	  The	  PE-­‐	  and	  PE-­‐Cy7	  anti-­‐CD45	  antibodies	  were	  of	  the	  same	  
clone	  and	  hence,	  bound	  to	  the	  same	  epitope	  of	  the	  CD45	  molecule.	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7.3.2 Flow	  cytometric	  processing.	  
Each	  lung	  was	  placed	  in	  separate	  orange	  MACS	  tubes	  containing	  2mls	  of	  IC	  fixation	  
buffer.	   They	   then	   underwent	   standardised	   disruption	   using	   the	   MACS	  
homogenisation.	   Ice-­‐cold	   flow	   cytometry	   wash	   buffer	   (20ml)	   was	   added	   to	   the	  
homogenate	  and	  the	  tube	  placed	  on	  ice.	  Subsequently,	  the	  homogenate	  was	  filtered	  
through	  a	  40μm	   filter	  and	  washed	   through	  with	  20ml	  of	   ice-­‐cold	  wash	  buffer.	  The	  
single	   cell	   suspension	   was	   centrifuged	   at	   2000rpm	   for	   5	   minutes	   at	   4oC.	   After	  
discarding	  the	  supernatant	  the	  cell	  pellet	  was	  reconstituted	  in	  500μl	  of	  FWB.	  	  	  
7.4 Results	  
7.4.1 Characterisation	  of	  myeloid	  populations	  in	  the	  uninjured	  mouse	  lung	  using	  
standard	  in	  vitro	  antibody	  incubation	  
We	   used	   antibodies	   against	   CD45,	   CD11c,	   and	   CD11b	   to	   separate	   the	   various	  
myeloid	  cell	  populations	  in	  lungs	  of	  uninjured	  mice.	  Gating	  on	  CD45	  positive	  events	  
(figure	  7.1	  A)	  found	  four	  distinct	  populations	  of	  leukocytes	  (R1	  –	  R4;	  figure	  7.1	  B),	  as	  
characterised	  by	  CD11c	  and	  CD11b.	  	  
CD11c+	  alveolar	  macrophage	  and	  dendritic	  cell	  populations	  
The	  CD11c+	  population	  (R1+R2	  in	  figure	  7.1B)	  contained	  three	  populations	  of	  cells	  on	  
the	  basis	  of	  their	  expression	  of	  CD11b	  and	  MHCII	  (figure	  7.1	  C).	  One	  population	  are	  
CD11b	  and	  MHCII	  both	  negative	  (P1	  in	  the	  dot	  plot),	  and	  considered	  to	  be	  resident	  
alveolar	  macrophages.	  These	  cells	  are	  also	  CD103	  negative,	  with	  strong	  expression	  of	  
F4/80	  and	  SiglecF	   (red	   line	   in	   the	  histogram),	   and	  are	  highly	  auto	   fluorescent.	   The	  
next	  two	  groups	  of	  cells	  (P2	  and	  P3)	  show	  high	  expression	  of	  MHCII	  and	  hence	  are	  
most	   likely	   to	   be	   antigen	   presenting	   cells	   i.e.	   conventional	   dendritic	   cells	   (cDCs).	  
Either	  CD11b	  or	  CD103	  expression	  distinguishes	  between	  these	  two	  populations,	  i.e.	  
CD11b-­‐CD103+	   DC	   (P2	   and	   blue	   line)	   and	   CD11b+CD103-­‐	   DC	   (P3	   and	   green	   line).	  
CD103	   is	   a	   receptor	   E-­‐cadherin	   and	   is	   involved	   in	   the	   process	   through	  which	   DCs	  
extend	   dendrites	   through	   the	   epithelial	   layer	   to	   sample	   the	   alveolus.	   Both	   cDC	  
populations	   were	   negative	   expressers	   of	   F4/80	   and	   SiglecF,	   which	   are	   both	  
macrophage	  markers.	  These	  cDC	  phenotypes	  are	  consistent	  with	  data	  showing	  that	  
the	   CD11b-­‐CD103+	   are	   localised	   under	   the	   alveolar	   and	   bronchial	   epithelium	   and	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extrude	   dendrites	   into	   the	   alveolar	   space	   or	   bronchial	   lumen.	   These	   are	   called	  
‘epithelial’	  cDCs.	  The	  CD11b+CD103-­‐	  have	  been	  localised	  to	  the	  walls	  of	  bronchioles	  
and	  are	  called	  ‘lamina	  propria’	  cDCs	  (421).	  
CD11b+CD11c-­‐	  monocyte/neutrophil	  populations	  
The	   CD11c-­‐	   population	   seems	   to	   have	   two	   cell	   populations,	   CD11b	   positive	   and	  
negative	   (R3	   and	   R4,	   respectively,	   in	   figure	   7.1B).	   As	   CD11b	   is	   an	   integrin	   found	  
predominantly	   on	   neutrophils	   and	  mononuclear	   cells,	   CD11c-­‐CD11b+	   cells	   (R3)	   are	  
likely	  to	  be	  monocyte/neutrophil	  populations	  with	  CD11c-­‐CD11b-­‐	  cells	  (R4)	   likely	  to	  
represent	  the	  non-­‐myeloid	  cells	  e.g.	  lymphocytes.	  R3	  was	  then	  analysed	  using	  Ly-­‐6G	  
and	  Ly-­‐6C	  (figure	  7.1D)	  –	  classic	  differentiation	  markers	  of	  neutrophil	  and	  monocyte	  
subsets	   in	  mice	   (422).	  As	  mentioned	  previously	   the	  cell-­‐fixation	  procedure	  used	   to	  
prepare	   the	   lung	   cell	   suspension	   led	   to	   a	  denaturation	  of	   the	  Gr-­‐1	   epitope	   (which	  
consists	  of	  Ly-­‐6C/Ly-­‐6G)	  on	  monocyte	  populations	  and	  the	  loss	  of	  recognition	  of	  the	  
Gr-­‐1hi	  monocyte	  populations	   (241).	  However,	   the	  use	  of	   a	   Ly-­‐6C	   antibody	   enabled	  
their	   identification	   with	   Ly-­‐6Chi	   and	   Ly-­‐6Clo	   being	   equivalent	   to	  
classical/inflammatory	  and	  non-­‐classical/resident	  subsets,	   respectively	   (422).	  When	  
whole	   lung	  cell	   suspension	  was	  gated	  on	  CD45+CD11c-­‐CD11b+	  population,	  and	  then	  
analysed	   for	   Ly6G	   and	   Ly6C	   expression,	   there	   were	   five	   further	   populations	  
distinguished	  (P4	  to	  P8	  in	  figure	  7.1	  D).	  P4	  are	  neutrophils	  as	  they	  express	  high	  levels	  
of	   Ly-­‐6G.	   P5	   are	   likely	   to	   be	   eosinophils	   as	   they	   are	   Ly-­‐6CinterLy-­‐6Ginter,	   and	   also	  
founded	  to	  be,	  F4/80	  positive	  with	  high	  side	  scatter	  (as	  a	  result	  of	  their	  granularity)	  
(423).	  P6-­‐8	  are	  monocytes	  with	  two	  main	  subtypes	  –	  the	  non-­‐classical/resident	  (P6)	  
or	   classical/inflammatory	   (P8)	   subsets	   with	   low	   to	   high	   expression	   of	   Ly-­‐6C,	  
respectively.	   There	   is	   also	   an	   intermediate	   population	   (P7)	   likely	   to	   represent	  
monocytes	   undergoing	   a	   stage	   of	   conversion	   between	   classical	   and	   non-­‐classical	  
forms.	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Figure	   7.1.	   Flow	   cytometric	   analysis	   of	   naïve	   mouse	   lungs	   (without	   in	   vivo	  
labelling)	  
Whole	   lung	   single	   cell	   suspension	   underwent	   in	   vitro	   incubation	   with	   relevant	  
antibody	  combinations	  to	  determine	  the	  populations	  of	  myeloid	  cells	  present.	  A)	  The	  
gating	   strategy	   defined	   all	   leukocytes,	   which	   were	   positively	   stained	   with	   CD45	  
antibody	   (G1).	  B)	  CD45	  positive	   events	  were	   analysed	  with	  CD11c	   and	  CD11b	   and	  
four	  distinct	  cell	  populations	  were	  defined	  (R1	  –	  R4).	  C)	  Cells	  positive	  for	  CD11c	  (R1	  
and	  R2)	  were	  comprised	  of	  three	  populations	  –	  resident	  alveolar	  macrophages	  (P1),	  
CD103+	   dendritic	   cells	   (P2),	   and	   CD103-­‐	   dendritic	   cells	   (P3).	   Each	   of	   these	   also	  
showed	   distinct	   cell	   surface	   markers	   with	   both	   dendritic	   cells	   being	   positive	   for	  
MHCII	   and	   resident	   alveolar	  macrophages	   being	   positive	   for	   F4/80	   and	   SiglecF.	  D)	  
Events	  negative	  for	  CD11c	  and	  positive	  for	  CD11b	  (R3)	  were	  characterised	  using	  Ly-­‐
6C	  and	  Ly-­‐6G.	  This	  R3	  population	  was	  comprised	  of	  3	  main	  cell	   types	   -­‐	  neutrophils	  
(P4),	  eosinophils	  (P5),	  and	  monocyte	  subsets	  (P6-­‐P8,	  depending	  on	  Ly-­‐6C	  staining).	  
	  
Figure' 7.1' Whole& lung& single& cell& suspension& underwent& in& vitro& incuba5on& with& relevant& an5body&
combina5ons& to& determine& the& popula5ons& of& myeloid& cells& present.&A)# The& ga5ng& strategy& deﬁned& all&
leukocytes&which&were&posi5vely&stained&with&CD45&an5body&(G1)&.&B)#CD45&posi5ve&events&were&analysed&
with&CD11b&and&CD11c&and&four&dis5nct&cell&popula5ons&were&deﬁned&(R1&–&R4).&C)#Cells&posi5ve&for&CD11c&
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7.4.2 Validation	  of	  in	  vivo	  staining	  of	  alveolar	  and	  vascular	  compartments	  
The	  strategy	  described	  above	  only	  analyses	  whole	  lung	  homogenate	  using	  an	  in	  vitro	  
incubation	  with	  the	  antibodies	  and	  hence,	  does	  not	  allow	  localisation	  of	  cell	  types	  to	  
a	   particular	   compartment	   within	   the	   lung.	   To	   investigate	   the	   compartmental	  
localisation	   of	   leukocytes,	   lungs	   were	   sequentially	   labelled	   ‘in	   vivo’	   through	  
administration	   of	   an	   intravenous	   (PE-­‐conjugated)	   and	   intratracheal	   (PE-­‐Cy7	  
conjugated)	   anti-­‐CD45	   antibody	   (figure	   7.2).	   Firstly,	   in	   the	   absence	   of	   intravenous	  
and	  intratracheal	  labelling	  of	  the	  lung,	  all	  events	  were	  negative	  in	  the	  PE	  and	  PE-­‐Cy7	  
channels	  (Plot	  A	  –	  gate	  R1).	  The	  intravenous	  administration	  of	  a	  PE-­‐conjugated	  anti-­‐
CD45	   antibody	   produced	   a	   clearly	   separate	   population	   (Plot	   B	   –	   gate	   R3)	   of	   CD45	  
positive	   cells	   located	   in	   the	   vascular	   compartment	   leaving	   behind	   a	   population	  
containing	  all	  of	  the	  unlabelled	  non-­‐vascular	  events	  (Plot	  B	  –	  gate	  R2).	  	  
	  
Subsequent	   ‘in	   vitro’	   labelling	   (after	   intravenous	   injection)	   of	   the	  whole	   single	   cell	  
suspension	   (to	   label	   all	   leukocytes)	   using	   a	   PE-­‐Cy7-­‐conjugated	   CD45	   antibody	  
(against	  the	  same	  epitope	  of	  the	  CD45	  molecule	  as	  the	  intravenous	  antibody)	  leads	  
to	  a	  clear	  shift	  upwards	  of	  all	  CD45	  positive	  cells	  along	  the	  y-­‐axis	  i.e.	  PE-­‐Cy7	  positive.	  
Over	   98%	  of	   the	   vascular	   labelled	   (intravenous	   PE	   CD45	   positive	   events)	   (R3)	   also	  
labelled	  positive	  to	  this	   in	  vitro	  PE-­‐Cy7	  CD45	  antibody	  (R5),	  suggesting	  that	  despite	  
the	  high	  dose,	  the	  intravenous	  antibody	  does	  not	  saturate	  the	  CD45	  epitope.	  This	  co-­‐
labelling	   step	   with	   the	   in	   vitro	   PE-­‐Cy7	   anti-­‐CD45	   antibody,	   also	   brought	   out	   a	  
population	   of	   leukocytes	   (R4)	   from	   the	   PE	   negative	   “non-­‐vascular”	   gate	   (R2),	  
consisting	  theoretically	  of	  all	  alveolar	  and	  interstitial	  leukocytes,	  not	  accessed	  by	  the	  
intravenous	  CD45	  antibody.	  	  
	  
Instillation	  of	  a	  PE-­‐Cy7	  conjugated	  CD45	  antibody	  into	  the	  airways	  showed	  that	  non-­‐
vascular	  cells	  can	  be	   further	  divided	   into	  two	  cell	  populations.	   	  Cells	  stained	  highly	  
positive	   for	   intratracheal	   CD45	   (R6)	   are	   likely	   to	   be	   mainly	   resident	   alveolar	  
macrophages.	  The	  population	  remaining	  behind	  (R7)	  that	  has	  a	  relatively	  ‘negative’	  
MFI	  in	  intratracheal	  CD45	  axis,	  is	  likely	  to	  contain	  interstitial	  leukocytes	  (as	  well	  as	  all	  
other	  CD45	  negative	  lung	  parenchymal	  cells).	  These	  populations	  were	  not	  accessible	  
to	   either	   the	   intratracheal	   or	   intravenous	   administered	   CD45	   antibodies.	   Of	   note,	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the	   cells	   labelled	   positively	   with	   the	   PE-­‐CD45	   intravascular	   antibody	   (i.e.	   vascular	  
leukocytes	  in	  R8)	  show	  a	  similar	  MFI	  to	  interstitial	  leukocytes	  (in	  R7)	  with	  respect	  to	  
the	  intratracheal	  CD45	  label.	  	  
	  
The	  alveolar	  population	  (R6)	  shows	  an	  extremely	  high	  MFI	  in	  the	  intratracheal	  CD45	  
axis.	  Of	  note,	  the	  interstitial	  population	  (R7)	  shows	  a	  wide	  distribution	  in	  MFI	  in	  the	  
PE-­‐Cy7	  channel	   (y-­‐axis),	  although	  much	   lower	  than	  the	  alveolar	  R6	  population.	  The	  
R7	  events	  with	  a	  relatively	  higher	  MFI	  cannot	  be	  explained	  by	  direct	  in	  vivo	  labelling	  
(i.e.	   leak	  of	  the	  alveolar	  antibody	  into	  the	  interstitial	  compartment)	  given	  that	  they	  
have	  the	  same	  MFI	  as	  vascular-­‐labelled	  cells	  (R8).	  One	  would	  expect	  a	  higher	  staining	  
of	   the	   interstitial	   population	   as	   compared	   to	   the	   vascular	   population	   by	   the	  
intratracheal	  instilled	  antibody.	  However,	  one	  consideration	  should	  be	  the	  potential	  
for	   indirect	   “in	   vitro”	   labelling	   by	   excess	   PE-­‐Cy7	   CD45	   antibody	   during	   the	   lung	  
homogenisation	   process	   prior	   to	   the	   first	   wash.	   This	   was	   minimised	   (as	   much	   as	  
possible)	  by	  diluting	  the	  homogenised	  sample	  immediately	  in	  20mls	  FWB	  during	  the	  
first	   wash	   step.	   Despite	   this	   potential	   processing	   artefact,	   there	   remains	   a	   clear	  
separation	  (in	  the	  order	  of	  one	  log	  fold)	  between	  the	  lowest	  MFI	  of	  the	  alveolar	  (R6)	  
and	   highest	  MFI	   of	   the	   interstitial	   (R7)	   population	   allowing	   robust	   separation.	   R9	  
represents	   the	   theoretical	   population	   that	   would	   occur	   if	   bidirectional	   leak	   of	  
antibody	  occurred.	  This	  was	  less	  than	  0.3%	  of	  total	  lung	  events.	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Figure	  7.2.	  Development	  of	  in	  vivo	  labelling	  protocol	  
The	  absence	  of	  antibodies	  shows	  a	  clear	  negative	  population	  (R1)	  of	  cells	  when	  lung	  
single	  cell	   suspension	   is	  analysed	  with	   the	  PE	   (x-­‐axis)	  and	  PE-­‐Cy7	   (y-­‐axis)	   channels.	  
The	   in	   vivo	   injection	   of	   a	   PE	   conjugated	   CD45	   antibody	   leads	   to	   a	   clear	   shift	  
rightward	  of	  a	  population	  (R2)	  found	  in	  the	  vasculature	  of	  the	  lung	  leaving	  a	  region	  
containing	  all	  non-­‐vascular	  events	  (R3).	  The	  labelling	  of	  the	  lung	  suspension	  in	  vitro	  
with	   a	   PE-­‐Cy7	   conjugated	   CD45	   antibody	   leads	   to	   an	   upward	   shift	   of	   leukocyte	  
populations.	  Of	  note	  nearly	  all	  of	  the	   intravenously	   labelled	   leukocytes	  (>98%)	  also	  
stain	   positive	   for	   the	   in	   vitro	   CD45	   antibody	   (R5).	   Additionally,	   two	   CD45	   positive	  
populations	  (R4)	  of	  cells	  emerge	  from	  the	  PE	  negative	  group	  (R2).	  These	  are	  likely	  to	  
be	  the	  alveolar	  and	  interstitial	  populations.	  When	  the	  same	  PE-­‐Cy7	  conjugated	  CD45	  
antibody	   is	   instilled	   intratracheally	  one	  population	   is	   labelled	  strongly	  positive	   (R6)	  
whereas	  the	  other	  remains	  relatively	  negative	  (R7).	  This	  positive	  population	  is	  likely	  
to	   be	   alveolar	   leukocytes	   (R6)	   exposed	   to	   the	   inratracheal	   CD45	   anitibody.	   The	  
remaining	  dual	  negative	  region	  (i.e.	  R7	  -­‐	  negative	  for	  both	  iv	  and	  it	  labelling)	  contains	  
all	   non-­‐vascular	   and	   non-­‐alveolar	   events	   and	   hence	   contains	   any	   interstitial	  
leukocyte	  population	  (as	  well	  as	  other	  lung	  parenchymal	  cells)	  (R7).	  The	  vascular	  (R8)	  
subset	  remains	  relatively	  negative	  for	  the	  intratracheal	  antibody	  compared	  to	  the	  R6	  
population.	   The	   number	   of	   events	   found	   in	   R9,	   representing	   the	   extent	   of	  
bidirectional	  leak	  of	  antibody,	  is	  less	  than	  0.3%	  of	  the	  total	  population.	  This	  confirms	  
Figure'7.2'The$abse ce$ f$an,bodies$shows$a$clear$nega,ve$p ula,on$(R1)$of$cells$when$lung$single$cell$
suspension$ is$ analysed$ with$ the$ PE$ (x?axis)$ and$ PE?Cy7$ (y?axis)$ channels.$ The$ in$ vivo$ injec,on$ of$ a$ PE$
conjugated$CD45$an,body$leads$to$a$clear$shiG$rightward$of$a$popula,on$(R2)$found$in$the$vasculature$of$
the$ lung$ leaving$ a$ non?vascular$ regions$ (R3).$ The$ labeling$ of$ the$ lung$ suspension$ in$ vitro$with$ a$ PE?Cy7$
conjug ted$ CD45$ an,body$ leads$ to$ an$ upward$ shiG$ of$ leucocyte$ popula,ons.$ Of$ note$ all$ of$ the$
intravenously$ labeled$ leucocytes$also$ stain$posi,ve$ for$ the$ex$vivo$CD45$an,body$ (R5).$Addi,onally,$ two$
popula,ons$of$cells$emerge$from$the$PE$nega,ve$group$which$also$express$CD45$(R4).$These$are$likely$to$be$
the$ alveolar$ or$ inters,,al$ popula,ons.$ When$ the$ same$ PE?Cy7$ conjugated$ CD45$ an,body$ is$ ins,lled$
intratracheally$one$popula,on$is$ labeled$strongly$posi,ve$(R6)$whereas$the$other$remains$unlabeled$(R7).$
This$posi,ve$popula,on$is$likely$to$be$alveol r$leuc cytes$(R6)$an $the$ ther$(which$is$nega,ve$for$both$iv$
and$it$labeling)$is$likely$to$be$inters,,al$(R7).$The$vascular$(R8)$subset$remain$nega,ve$for$the$intratracheal$
an,body.$The$number$of$events$ found$ in$R9,$ represen,ng$the$extent$of$bidirec,onal$ leak$of$an,body,$ is$
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that	  the	  in	  vivo	  labelling	  enables	  separation	  of	  events	  into	  alveolar,	   interstitial,	  and	  
vascular	  compartments.	  
	  
7.4.3 Resident	  alveolar	  macrophage	  and	  dendritic	  cell	  populations	  validate	  the	  
distinction	  between	  the	  alveolar	  and	  interstitial	  compartments	  of	  the	  lung	  
This	   in	   vivo	   labelling	   strategy	  was	   further	   validated	   by	   confirming	   the	   presence	   of	  
expected	   leukocyte	   phenotypes	   in	   the	   three	   compartments	   of	   the	   normal	   mouse	  
lung:	  
	  
1. PE-­‐Cy7	   CD45	   positive	   alveolar	   compartment	   (R6)	   should	   contain	  
predominantly	  resident	  alveolar	  macrophages.	  
2. Unlabelled	   interstitial	   compartment	   (R7)	   should	   harbour	   the	   dendritic	   cell	  
populations.	  
3. PE	  CD45	   positive	   vascular	   compartment	   (R8)	   should	   contain	   predominantly	  
monocytes	  and	  neutrophils	  
	  
Alveolar	   macrophages	   (P1	   in	   figure	   7.1	   C),	   as	   their	   name	   suggests,	   have	   been	  
established	   to	   be	   located	   predominantly	   in	   the	   alveolar	   space	   (424).	   The	   two	  
dendritic	   cell	   populations	   (P2	   and	   P3	   in	   figure	   7.1	   C)	   have	   been	   previously	  
characterised	   in	   mice	   and	   their	   predominant	   localisation	   is	   within	   the	   interstitial	  
space	  (425,	  426).	  Hence,	  the	  next	  step	  was	  to	  validate	  if	  this	  in	  vivo	  staining	  strategy	  
could	   distinguish	   between	   cells	   located	   in	   the	   alveolar	   space	   (resident	   alveolar	  
macrophage	  population	  -­‐	  P1)	  and	  those	  located	  within	  the	  interstitium	  (dendritic	  cell	  
populations	  -­‐	  P2	  and	  P3).	  	  
	  
Analysis	  of	  the	  intratracheally	  labelled	  alveolar	  population	  (i.e.	  PE-­‐Cy7	  CD45+	  and	  PE-­‐
CD45-­‐;	  blue	  gate	  in	  Figure	  7.3	  A)	  revealed	  that	  CD11c+CD11b-­‐	  population	  accounted	  
for	  over	  95%	  of	  total	  alveolar	  events	  (A1	  in	  figure	  7.3	  B).	  This	  population	  were	  also	  
highly	  autofluorescent,	  MHCII-­‐	  and	  CD103-­‐,	  and	  F4/80+	  and	  SiglecF+,	  identifying	  them	  
as	   resident	   alveolar	   macrophages,	   consistent	   with	   our	   previous	   experiments	   and	  
previous	  literature	  (112,	  423,	  427,	  428).	  The	  remaining	  5%	  of	  leukocytes	  within	  the	  
alveolar	   space	   consisted	   of	   CD11c+CD11b-­‐MHCII+CD103+	   (3%)	   and	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CD11c+CD11b+MHCII+CD103-­‐	   (0.5%)	   likely	   to	   be	   conventional	   DC	   populations,	   and	  
CD11c+CD11b+Ly-­‐6G+	   neutrophils	   (1%).	   There	   were	   also	   events	   that	   were	   CD11b-­‐
CD11c-­‐	  and	  these	  may	  represent	  a	  small	  lymphocyte	  population	  or	  plasmacytoid	  DCs	  
(known	   to	  be	   low	  expressers	  of	  CD11c,	  CD11b-­‐	  and	  MHCII+	   (425,	  426,	  429))	  within	  
the	  alveolar	  space.	  
	  	  
Within	   the	   interstitial	   compartment	   (i.e.	   double	   negative	   for	   PE-­‐CD45	   and	   PECy7-­‐
CD45;	  green	  gate	  in	  figure	  7.3	  A)	  there	  were	  three	  populations	  of	  cells	  that	  could	  be	  
characterised	  using	  CD11c	  and	  CD11b	  (figure	  7.3	  -­‐	  I1,	  I2,	  and	  I3).	  CD11c+	  populations	  
I1	   and	   I2	   are	   both	   interstitial	   dendritic	   cell	   populations	   given	   the	   extremely	   high	  
expression	   of	   MHCII.	   Again,	   both	   DC	   populations	   could	   be	   distinguished	   by	  
differences	  in	  the	  surface	  expression	  of	  CD11b	  and	  CD103.	  Population	  I1	  are	  CD11b-­‐
CD103+	   whereas	   population	   I2	   are	   CD11b+CD103-­‐.	   Furthermore,	   these	   DC	  
populations	   differ	   from	   resident	   alveolar	   macrophage	   populations	   with	   I1	   and	   I2	  
being	   negative	   for	   F4/80	   and	   SiglecF.	   The	   third	   population	   (I3),	   which	   are	   CD11c	  
negative	   and	   CD11b	   positive,	   are	   discussed	   in	   the	   next	   section	   covering	   the	  
distinction	  between	  interstitial	  and	  vascular	  compartments.	  Of	  note,	  in	  the	  uninjured	  
mouse	   lung	   there	  were	   no	   CD11c	   positive	   cells	   in	   the	   vascular	   compartment	   (red	  
gate	  in	  figure	  7.3	  A).	  	  
	  
In	  summary,	  the	   intratracheal	   labelling	  strategy	  positively	  and	  specifically	   identifies	  
alveolar	  macrophages	  whilst	   leaving	   interstitial	   cell	  populations	   (mainly	   comprising	  
dendritic	   cells)	   unstained.	   Hence,	   allowing	   distinction	   between	   alveolar	   and	  
interstitial	  cell	  types.	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Figure	  7.3.	  In	  vivo	  labelling	  protocol	  enables	  separation	  of	  alveolar	  and	  interstitial	  
compartments	  of	  the	  naïve	  mouse	  lung	  
A)	   In	   vivo	   labelling	   and	   gating	   strategy	   to	   enable	   separation	   of	   the	   three	  
compartments	   of	   the	   lung.	   B)	   The	   intratracheal	   CD45	   antibody	   labels	   only	   the	  
resident	   alveolar	   macrophage	   population	   (A1;	   red	   gate)	   that	   is	   MHCII-­‐,	   CD103-­‐,	  
F4/80+	   and	   SiglecF+.	   The	   interstitial	   compartment,	   as	   defined	   by	   those	   events	   not	  
labelled	   by	   the	   intratracheal	   (PE-­‐Cy7	   CD45)	   and	   intravenous	   (PE	   CD45)	   antibody,	  
shows	  two	  populations	  of	  dendritic	  cells	  that	  are	  CD11c+	  and	  MHCII+.	  One	  population	  
is	  CD11b-­‐CD103+	  (I1;	  blue	  gate)	  and	  the	  second	  CD11b+CD103-­‐	  (I2;	  green	  gate).	  The	  
































































































MHC#II## CD103# F4/80# SiglecF#
MHC#II## CD103# F4/80# SiglecF#
I3#























Compartmental	  analysis	  of	  leukocytes	  in	  mouse	  lungs	  
	   248	  
7.4.4 MHCII	  expression	  on	  interstitial	  and	  vascular	  monocyte	  populations	  
validates	  the	  distinction	  between	  interstitial	  and	  vascular	  compartments	  of	  
the	  lung	  
The	  in	  vivo	  labelling	  technique	  detected	  no	  CD11c-­‐CD11b+	  events	  within	  the	  alveolar	  
space	   (figure	   7.4	   –	   Alveolar	   Compartment).	   All	   of	   CD11c-­‐CD11b+	   events	   (in	   the	  
uninjured	  mouse	   lung)	   are	   in	   the	   interstitial	   or	   vascular	   compartments	   and	   these	  
contain	  predominantly	  monocytes	  and	  neutrophils	  (figure	  7.4).	  	  
	  
Interestingly,	   within	   the	   interstitial	   compartment	   (figure	   7.4),	   the	   CD11c-­‐CD11b+	  
leukocytes	   (I3)	  consisted	  of	  a	  small	  proportion	  of	  neutrophils	   (approx.	  5-­‐10%;	   I3-­‐1)	  
and	   a	   predominant	   population	   of	   Ly6Clo	   monocytes	   (approx.	   90-­‐95%;	   I3-­‐2).	   In	  
contrast,	   the	  vascular	  compartment	  showed	  greater	  proportion	  of	  neutrophils	   (V1;	  
25%)	   as	  well	   as	   a	  more	   varied	   proportion	   of	  monocyte	   subsets:	   Ly6Clo	   (V3;	   25%);	  
Ly6Cinter	   (V4;	   15%);	   and	   Ly6Chi	   subset	   (V5;	   30%).	   Additionally,	   there	   were	   a	   high	  
proportion	  of	  eosinophils	   (V2;	  5%),	  which	  were	   localised	   solely	  within	   the	  vascular	  
compartment.	  	  
	  
Most	  striking	  was	  the	  difference	  in	  MHCII	  expression	  of	  Ly6Clo	  monocyte	  populations	  
between	   the	   interstitial	   and	   vascular	   compartments,	   with	   the	   interstitial	   Ly6Clo	  
monocytes	   showing	   a	   100-­‐fold	   higher	   expression	   of	   MHCII	   compared	   to	   their	  
vascular	   counterparts	   (figure	  7.4).	  Hence,	   there	   are	   two	  different	   Ly6Clo	  monocyte	  
populations	   within	   the	   mouse	   lung	   with	   distinct	   phenotypes	   separated	   by	   the	  
capillary	   endothelium.	   These	   differences	   in	  MHCII	   expression	   suggest	   a	   functional	  
diversity	  with	  different	  antigen	  presenting	  capabilities	  between	  these	  two	  monocyte	  
populations.	   I	   have	   called	   this	   MHCII	   high	   population	   an	   interstitial	   ‘monocyte’	  
population,	  as	  opposed	  to	  a	  ‘macrophage’	  population	  as	  it	  does	  not	  express	  CD11c.	  
This	   clear	   separation	   in	   phenotype	   between	   interstitial	   and	   vascular	   Ly6Clo	  
monocytes	  confirms	  minimal	  leak	  of	  intravenous	  antibody	  into	  the	  interstitial	  space	  
in	  the	  uninjured	  lung,	  further	  supporting	  the	  case	  that	  the	  in	  vivo	  labelling	  protocol	  
allows	   robust	   differentiation	   between	   cells	   within	   the	   vascular	   and	   interstitial	  
compartments	  of	  the	  lung.	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Figure	   7.4.	   In	   vivo	   labelling	   enables	   separation	   of	   the	   interstitial	   and	   vascular	  
compartments	  of	  the	  naïve	  mouse	  lung	  	  
There	   are	   no	   CD11c-­‐CD11b+	   events	   in	   the	   alveolar	   space.	   The	   interstitium	   has	   a	  
CD11c-­‐CD11b+	  population	  and	  this	  consists	  of	  Ly-­‐6Ghi	  neutrophils	  (I1;	  5-­‐10%)	  and	  of	  
Ly-­‐6Clo	   monocytes	   (I2;	   90-­‐95%).	   The	   vascular	   space	   consists	   of	   a	   much	   larger	  
population	   of	   CD11c-­‐CD11b+	   events	   that	   show	   a	   wider	   distribution	   in	   cell	   type:	  
neutrophils	  (V1;	  25%),	  eosinophils	  (V2;	  5%),	  and	  Ly-­‐6Clo/inter/hi	  monocytes	  (V3;	  25%	  /	  
V4;	   15%	   /	   V5;	   30%,	   respectively).	   The	   interstitial	   Ly-­‐6Clo	   monocytes	   have	   a	  
significantly	   higher	   MHCII	   expression	   compared	   to	   the	   vascular	   Ly-­‐6Clo	   monocyte	  
population.	   This	   confirms	   that	   the	   intravenous	   CD45	   antibody	   allows	   separation	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7.4.5 Phenotypic	  and	  compartmental	  characterisation	  of	  myeloid	  subsets	  in	  the	  
naïve	  mouse	  lung	  
Overall	  the	  following	  table	  summarises	  the	  phenotypes	  of	  myeloid	  cells	  identified	  in	  
the	  naive	  mouse	  lung	  during	  these	  experiments.	  
	  
Cell	  Type	   Location	   CD11c	   CD11b	   MHCII	   CD103	   F4/80	   SiglecF	   Ly-­‐6C	   CD86	   AF	  
Resident	  Alveolar	  
Macrophage	  
Alveolar	   +++	   -­‐	   -­‐	   -­‐	   +++	   +++	   +++	   +	   +++	  
Epithelial	  cDC	   Interstitium	   +++	   -­‐	   +++	   +++	   -­‐	   -­‐	   -­‐	   +++	   -­‐	  
Lamina	  Propria	  cDC	   Interstitium	   +++	   +++	   +++	   -­‐	   +	   -­‐	   -­‐	   +	   -­‐	  
Interstitial	  
monocyte/macrophage	  
Interstitium	   -­‐	   ++	   +++	   -­‐	   +	   -­‐	   -­‐	   +++	   -­‐	  
Classical	  ‘inflammatory’	  
Monocyte	  
Vascular	   -­‐	   ++	   +/-­‐	   -­‐	   +	   -­‐	   +++	   ?	   -­‐	  
Non-­‐classical	  ‘resident’	  
monocyte	  
Vascular	   -­‐	   ++	   -­‐	   -­‐	   +	   -­‐	   -­‐	   ?	   -­‐	  
Eosinophil	   Vascular	   -­‐	   ++	   -­‐	   -­‐	   +	   ?	   ++	   ?	   +++	  
Neutrophil	   Vascular	   -­‐	   ++	   -­‐	   -­‐	   -­‐	   -­‐	   ++	   ?	   +	  
	  
+++/++/+	  high/intermediate/low;	  -­‐	  negative;	  ?	  not	  tested;	  AF	  auto	  fluorescence	  
cDC	  –	  conventional	  dendritic	  cell	  
	  
	  
Table	  7.1.	  The	  phenotypic	  characteristics	  of	  myeloid	  cell	  populations	   in	   the	  naïve	  
mouse	  lung	  	  
	  
7.4.6 A	  preliminary	  examination	  of	  leukocyte	  kinetics	  during	  experimental	  acid-­‐
induced	  lung	  injury	  
Observations	  into	  the	  flux	  of	  leukocytes	  through	  the	  various	  compartments	  of	  lungs	  
at	  various	  stages	  of	   lung	  injury	  are	  crucial	  to	  gain	  a	  better	  understanding	  into	  their	  
roles.	   The	   methods	   described	   above	   were	   applied	   to	   the	   acid	   aspiration	   model	  
described	   in	   chapter	   6	   to	   gain	   a	   preliminary	   insight	   into	   the	   effectiveness	   of	   this	  
labelling	   technique	  during	   injury.	  Animals	  underwent	   in	   vivo	   labelling	  on	  days	  1,	   2	  
and	  4	  after	  acid	  aspiration.	  These	  time-­‐points	  were	  predicted	  to	  best	  show	  influx	  of	  
leukocytes	   and	   efflux/loss	   of	   leukocytes	   during	   inflammation	   and	   resolution	   of	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injury.	   Figure	   7.5	   A	   shows	   representative	   flow	   cytometry	   plots	   for	   the	  
compartmental	   gating	   strategy	   as	   discussed	   previously	   in	   the	   uninjured	   mouse	  
(figure	  7.2	  D).	  The	  numbers	  of	  dual	  positive	  (i.e.	  PE+PE-­‐Cy7+)	  events,	  representing	  the	  
extent	   of	   bidirectional	   leak	   of	   antibodies	   during	   the	   protocol	   across	   the	   alveolar	  
capillary	   barrier,	   remain	   relatively	   unchanged	   (at	   <0.5%)	   between	   uninjured	   and	  
injured	   animals	   even	   during	   significant	   barrier	   disruption	   on	   days	   1	   and	   2.	   Hence,	  
this	   allowed	   good	   separation	   and	   consistent	   gating	   of	   the	   three	   compartments	  
between	  the	  various	  stages	  of	  injury.	  	  
	  
Figure	  7.5	  B	  shows	  the	  CD11c	  and	  CD11b	  characteristics	  of	  CD45	  positive	  cells	  in	  the	  
various	   compartments	   of	   the	   lungs	   during	   injury.	   In	   the	   uninjured	   lung	   there	   are	  
minimal	  numbers	  of	  CD11c+	  cells	  in	  the	  vascular	  space.	  There	  is	  an	  overall	  increase	  in	  
CD11b+	   cells	   in	   the	   vascular	   compartment	   throughout	   the	   course	   of	   injury.	   In	  
particular	   there	   is	   an	   increase	   on	   day	   1	   in	   CD11c+CD11b+	   cells,	   representing	  
neutrophils,	   as	   these	   events	   are	   also	   Ly-­‐6Ghi.	   In	   contrast,	   there	   is	   a	   reduction	   in	  
CD11c-­‐CD11b+	   cells	  on	  day	  1	  with	   substantial	   recovery	   from	  day	  2	  onwards.	  These	  
events	  represent	  blood	  monocytes.	  	  
	  
The	   interstitial	   and	   alveolar	   compartments	   also	   show	   an	   influx	   of	   CD11b	   positive	  
cells	   from	   day	   1	   onwards,	   suggestive	   of	   the	   recruitment	   of	   these	   exudative	  
leukocytes	   i.e.	   blood	  derived	  monocytes	   and	  neutrophils.	   Interestingly,	  monocytes	  
seem	  to	  become	  increasingly	  CD11c	  positive	  as	  they	  transition	  from	  the	  vascular	  to	  
interstitial	   to	   alveolar	   compartments.	   Further	   quantification	   of	   this	   is	   discussed	   in	  
section	  7.4.11.	  	  
	  
The	  following	  sections	  shall	  now	  discuss,	  in	  more	  detail,	  the	  changes	  in	  kinetics	  and	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Figure	  7.5.	  Changes	  in	  myeloid	  cell	  type	  in	  lung	  compartments	  after	  acid	  aspiration	  
A)	   In	  vivo	   labelling	  of	   lungs	   shows	  good	  separation	  between	  compartments	  during	  
injury	   suggesting	   minimal	   leak	   of	   antibodies	   across	   the	   alveolar	   capillary	   barrier	  
during	   the	   in	   vivo	   incubation	   period.	   B)	   Changes	   in	   CD11b	   and	   CD11c	   plots	   over	  
injury	  (days	  0-­‐2)	  and	  resolution	  (day	  4).	  There	  is	  an	  increase	  in	  CD11b	  positive	  event	  
throughout	  the	  course	  of	  injury	  with	  these	  events	  being	  more	  CD11c+	  in	  the	  alveolar	  
space.	  
	  
7.4.7 Changes	  in	  resident	  alveolar	  macrophages	  during	  the	  acute	  phase	  of	  lung	  
injury	  
Resident	   alveolar	   macrophages	   are	   CD45+CD11c+CD11b-­‐F4/80+	   events.	   Using	   this	  
gating	   strategy,	   we	   found	   approximately	   1.5±0.3	   million	   resident	   alveolar	  
macrophages	  in	  the	  right	  lung	  of	  uninjured	  mice	  (figure	  7.6	  A).	  At	  24	  hours	  after	  acid	  
aspiration	   there	   was	   a	   significant	   3-­‐fold	   decline	   in	   resident	   alveolar	   macrophage	  
numbers	   within	   the	   alveolar	   space.	   This	   was	   restored	   to	   normal	   levels	   at	   day	   2.	  
Figure'7.5'
Figure' 7.5' A)' In' vivo' labeling' of' lungs' shows' good' separa:on' between' compartments' during' injury'
sugges:ng'minimal' leak' of' an:bodies' across' the' alveolar' capillary' barrier' during' the' in' vivo' incuba:on'
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Interestingly,	   there	  was	  a	   significant	   rise	  of	   a	   cell	   population	  within	   the	   interstitial	  
compartment	   showing	   essentially	   the	   same	   phenotype	   as	   resident	   alveolar	  
macrophage	   (from	   2.5%	   to	   27.6%	   of	   total	   CD45+CD11c+CD11b-­‐F4/80+	  cells).	   These	  
cells	   are	   also	   SiglecF+,	   highly	   autofluorescent,	   with	   a	   low	   expression	   of	  MHCII	   (as	  
compared	  to	  CD11b-­‐	  dendritic	  cells	  which	  would	  have	  been	  the	  most	  likely	  potential	  
contaminant),	  consistent	  with	  the	  phenotype	  of	  alveolar	  macrophages.	  	  This	  finding	  
suggests	  that	  some	  alveolar	  macrophages	  may	  have	  moved	  into	  the	  space	  within	  the	  
alveoli	  that	  is	  not	  easily	  accessible	  by	  the	  intratracheally	  administered	  antibody	  (e.g.	  
embedded	  in	  cell	  clumps	  or	  debris),	  or	  that	  they	  have	  mobilised	  out	  of	  the	  alveolar	  
space	  into	  the	  lung	  interstitium.	  If	  they	  are	  shown	  to	  move	  beyond	  the	  interstitium	  
e.g.	  to	  nearby	  lymph	  nodes	  then	  this	  would	  potentially	  explain	  their	  disappearance	  
at	  day	  1.	  	  
	  
A	  technical	  consideration	  for	  this	  interstitial	  localisation	  of	  alveolar	  macrophages	  on	  
day	  1	  could	  also	  be	  due	  to	  a	  reduced	  labelling	  by	  the	  alveolar	  PE-­‐Cy7	  CD45	  antibody	  
from	  poor	  distribution	  or	  significant	  pulmonary	  oedema	  present	  at	  this	  24-­‐hour	  time	  
point.	  However,	  this	  remains	  unlikely	  because	  levels	  of	  oedema	  between	  days	  1	  and	  
2	   are	   comparable,	   but	   only	   animals	   on	   day	   1	   show	   this	   reduction	   in	  macrophage	  
number	  and	  change	  to	  an	  interstitial	  distribution.	  Furthermore,	  there	  is	  a	  significant	  
increase	   in	   MHCII	   expression	   of	   alveolar	   macrophages	   at	   day	   1,	   suggesting	   an	  
increased	  activation	  state	  (figure	  7.6	  B)	  and	  potential	  for	  antigen	  presentation.	  	  
7.4.8 Reductions	  in	  dendritic	  cell	  numbers	  from	  the	  onset	  of	  lung	  injury	  
The	   majority	   of	   CD103+	   cDCs	   in	   the	   uninjured	   mouse	   lung	   are	   predominantly	  
interstitial	   in	   nature	   (over	   90%	   in	   the	   uninjured	   mouse	   lung	   using	   this	   labelling	  
strategy).	   Acid	   aspiration	   leads	   to	   a	   significant	   decline	   in	   this	   interstitial	   located	  
CD103+	  cDC	  populations	  within	  24	  hours	  of	  injury	  (figure	  7.6	  C).	  Unlike	  the	  resident	  
alveolar	   macrophage	   population,	   which	   is	   repopulated	   at	   day	   2,	   this	   CD103+	   cDC	  
population	  remains	  low	  in	  number	  even	  at	  4	  days	  after	  acid	  aspiration.	  Furthermore,	  
this	  population	  already	  expresses	   a	  high	   level	  of	  MHCII	   and	  no	   significant	   changes	  
were	  observed	   in	   their	  MHCII	  expression.	  Changes	   in	  CD11c+CD11b+	  dendritic	   cells	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remained	  difficult	   to	   investigate	   given	   the	   dramatic	   increase	   in	   other	   CD11b+	   cells	  
during	  injury	  and	  hence,	  were	  hidden	  from	  potential	  analysis.	  
	  
	  
Figure	   7.6.	   Changes	   in	   resident	   alveolar	  macrophage	   and	   dendritic	   cell	   numbers	  
during	  lung	  injury	  
A)	   There	   is	   a	   marked	   reduction	   in	   the	   resident	   alveolar	   macrophage	   population	  
(gated	  as	  CD45+CD11c+CD11b-­‐F4/80+	  events)	  on	  day	  1	  after	  injury.	  This	  is	  replenished	  
on	  day	  2	  back	  to	  normal	  levels.	  There	  is	  also	  a	  significant	  increase	  in	  the	  number	  of	  
interstitial	  macrophages	   on	  day	   1	   suggesting	   a	   possibility	   that	   they	   are	   capable	   of	  
migration	  out	  of	   the	   alveolar	   space.	  B)	   There	   is	   an	   increased	  MHCII	   expression	  on	  
both	   alveolar	   and	   interstitial	   macrophages	   on	   day	   2	   suggesting	   increased	   antigen	  
presentation	   capability.	   C)	   There	   is	   a	   marked	   reduction	   in	   the	   interstitial	  
CD45+CD11c+CD11b-­‐CD103+	   ‘epithelial’	   dendritic	   cell	   population	   from	   day	   1	   after	  
injury.	  This	  remains	  low	  even	  at	  day	  4.	  	  N=3-­‐5.	  ♯P<0.05	  versus	  uninjured	  in	  alveolar	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7.4.9 The	  pulmonary	  sequestration	  of	  blood	  derived	  myeloid	  cells	  
There	   are	   two	   phases	   of	   neutrophil	   and	  monocyte	   infiltration	   observed	   after	   acid	  
aspiration.	   Flow	   cytometric	   quantification	   of	   whole	   lung	   homogenate	   during	  
experiments	  using	   the	  acute	  ventilated	  model	   shows	  4	  million	  neutrophils	   and	  6.5	  
million	  monocytes	   sequestered	   to	   the	   right	   lung	  during	   the	   first	  3	  hours	  after	  acid	  
aspiration	   (figure	  3.7).	   In	   vivo	   labelling	  experiments	  were	  not	  performed	  at	   this	  3-­‐
hour	   time	   point	   and	   hence	   the	   precise	   localisation	   of	   leukocytes	   in	   the	   very	   early	  
phase	   of	   acid-­‐induced	   lung	   injury	   remains	   unknown.	   However,	   when	   total	   lung	  
leukocytes	  are	   counted	   in	   this	   longer-­‐term	  model	   this	   initial	   infiltration	  disappears	  
by	  day	  1	  (the	  assumption	  being	  that	  a	  similar	  level	  of	  acute	  infiltration	  is	  also	  present	  
in	   this	   longer-­‐term	  model).	   This	   is	   followed	   by	   a	   second	   phase	   of	   neutrophil	   and	  
monocyte	  sequestration	  on	  day	  2	  (figure	  7.7	  A).	  In	  vivo	  labelling	  shows	  a	  significant	  
influx	   of	   neutrophils	   and	  monocytes	   into	   interstitial	   and	   alveolar	   spaces	   on	   day	   2.	  
This	  influx	  is	  also	  transient,	  declining	  in	  all	  compartments	  by	  day	  4,	  and	  is	  consistent	  
with	  the	  profile	  observed	  during	  BAL	  cytology	  in	  chapter	  6	  (figure	  6.7).	  	  
	  
The	  numbers	  of	  neutrophils	  and	  monocytes	  in	  the	  vascular	  space	  remains	  relatively	  
constant	  but	  quantification	  of	   vascular	   compartment	  may	  be	   subject	   to	   variability.	  
This	   variability	   is	   dependent	   on	   the	   consistency	   of	   exsanguination	   (i.e.	   anti-­‐
coagulation,	  transection	  of	  major	  vessels,	  and	  three	  recruitment	  manoeuvres)	  of	  the	  
lungs	   between	   animals.	   The	   addition	   of	   a	   pulmonary	   vascular	   flushing	   step	   or	   an	  
isolated	  perfused	  lung	  apparatus	  should	  enable	  more	  accurate	  determination	  of	  the	  
vascular	  compartment	   i.e.	   leukocytes	  that	  are	  marginated	  and	  adhered	  to	  the	   lung	  
endothelium.	  To	  gain	  some	  insight	  into	  the	  quantities	  of	  neutrophils	  and	  monocytes	  
in	   the	   blood,	   whole	   blood	   was	   sampled	   and	   analysed.	   This	   showed	   a	   significant	  
blood	   neutrophilia	   (increased	   neutrophil	   count)	   and	   conversely	   a	   monocytopenia	  
(reduced	  monocyte	  count)	  on	  day	  1	  (figure	  7.7	  B	  and	  D,	  respectively).	  	  
Neutrophil	  kinetics	  during	  lung	  injury	  
There	  is	  an	  increase	  in	  blood	  neutrophils	  on	  day	  1	  (figure	  7.7	  B).	  The	  second	  influx	  of	  
leukocytes	   into	   the	   right	   lung	   constitutes	   3	   million	   neutrophils	   (figure	   7.7	   C).	  
Interestingly,	   there	   seems	   to	   be	   an	   equal	   distribution	   of	   neutrophils	   between	   the	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alveolar	   and	   interstitial	   compartments.	   The	   increasing	  blood	  neutrophilia	  on	  day	  1	  
could	  contribute	  to	  the	  significant	  rise	  in	  interstitial	  and	  alveolar	  neutrophils	  within	  
the	  lung	  on	  day	  2,	  although	  this	  requires	  further	  exploration.	  On	  day	  2,	  preliminary	  
data	   (N=2)	  suggests	   that	  over	  25%	  of	  all	  alveolar	   located	  neutrophils	   stain	  positive	  
for	  annexin	  V	  (figure	  7.8),	  suggesting	  that	  apoptosis	  is	  the	  major	  mechanism	  for	  the	  
decline	  in	  neutrophil	  numbers	  by	  day	  4,	  by	  which	  time	  the	  distribution	  returns	  to	  a	  
similar	   state	   as	   seen	   in	   naïve	   lungs.	   Many	   of	   these	   neutrophils	   are	   undergoing	  
normal	  apoptosis	  given	  they	  are	  negative	  for	  propidium	  iodide	  (a	  marker	  of	  delayed	  
apoptosis/necrosis).	  
Monocyte	  kinetics	  during	  lung	  injury	  
Interestingly,	   in	   contrast	   to	   neutrophil	   number	   at	   24	   hours	   after	   injury,	   there	   is	   a	  
stark	   reduction	   in	   blood	   monocyte	   number	   (figure	   7.7	   D).	   However,	   similar	   to	  
neutrophils,	   at	   48	   hours	   there	   is	   a	   pronounced	   expansion	   of	   monocyte	   numbers	  
within	  the	  interstitial	  and	  alveolar	  spaces	  of	  lungs	  after	  acid	  aspiration	  (figure	  7.7	  E).	  
This	  expansion	  disappears	  by	  day	  4	  and	  is	  associated	  with	  concomitant	  restoration	  of	  
monocyte	   numbers	   within	   the	   blood.	   Interestingly,	   this	   influx	   of	   blood	   derived	  
mononuclear	   cells	   coincides	   with	   the	   normalisation/replenishment	   of	   the	   alveolar	  
macrophage	  populations	  (day	  2	  in	  figure	  7.6	  A).	  	  
	  
Figure	   7.9	   shows	   representative	   flow	   plots	   for	   mononuclear	   and	   neutrophil	  
infiltration	   into	   the	  three	  compartments	  of	   the	   lung.	   In	   the	  naïve	  uninjured	  mouse	  
lung,	  the	  alveolar	  space	  shows	  no	  monocytes	  and	  minimal	  neutrophils	  (figure	  7.9	  B;	  
orange	  arrow),	   and	   the	   interstitial	   space	  only	   contains	   the	   Ly-­‐6CloMHCII+	   subset	  of	  
interstitial	  monocytes	  (figure	  7.9	  B;	  black	  arrow).	  However,	  as	  injury	  progresses,	  on	  
day	  1	  there	  are	  the	  expected	  infiltrations	  of	  neutrophils	  (figure	  7.9	  B;	  red	  arrows)	  in	  
the	  interstitial	  and	  alveolar	  spaces,	  as	  described.	  However,	  in	  addition	  on	  day	  2	  there	  
is	  an	  expansion	  of	   the	  Ly-­‐6Chi	  “classical/inflammatory”	   subset	  of	  monocytes	   (figure	  
7.9	   B;	   green	   arrow)	   that	   disappear	   by	   day	   4.	   These	   likely	   derive	   from	   the	   blood,	  
which	  shows	  a	  loss	  of	  this	  cell	  type	  on	  the	  previous	  day	  (figure	  7.9	  B;	  purple	  arrow).	  
Additionally,	  on	  day	  4	  there	  is	  an	  increasing	  infiltration	  of	  Ly-­‐6Cintermediate	  monocytes	  
in	  the	  alveolar	  space	  (figure	  7.9;	  blue	  arrow).	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Overall,	   on	   day	   2	   there	   are	   over	   3	  million	  monocytes	   in	   each	   of	   the	   alveolar	   and	  
interstitial	  spaces	  (accounting	  for	  6	  million	  infiltrated	  into	  the	  lung)	  (figure	  7.10	  A).	  In	  
the	   interstitial	   space	   these	   consist	   of	   40%	   Ly-­‐6Clo,	   40%	   Ly-­‐6cintermediate	   and	   20%	   Ly-­‐
6Chi.	   The	   alveolar	   compartment	   contains	   mainly	   Ly-­‐6cintermediate	   (70%)	   with	   the	  
remainder	   being	   Ly-­‐6Clo.	  Of	   note,	   resident	   alveolar	  macrophages	   also	   exhibit	   a	   Ly-­‐
6cintermediate	   phenotype.	   Hence,	   these	   data	   support	   the	   notion	   that	   exudative	  
monocytes	  could	  serve	  to	  replenish	  the	  resident	  alveolar	  macrophage	  population	  by	  
taking	  on	  a	  Ly-­‐6cintermediate	  phenotype.	  All	   infiltrating	  monocyte	  populations	   (on	  day	  
2)	   also	   show	   increasing	   CD11c	   expression	   as	   they	   move	   into	   the	   alveolar	   space	  
consistent	  with	  a	  change	  from	  a	  monocyte	  to	  a	  macrophage	  phenotype	  (figure	  7.10	  
B).	   However,	   they	   do	   not	   express	   high	   levels	   of	   F4/80	   or	   lose	   significant	   CD11b	  
expression	  to	  completely	  adopt	  the	  resident	  alveolar	  macrophage	  phenotype.	  	  
	  
On	  day	  2	  there	  is	  also	  a	  significant	  proportion	  of	  Ly-­‐6Clo	  monocytes	  in	  both	  alveolar	  
and	  interstitial	  compartments	  of	  the	   lung	  (blue	  bars	   in	  figure	  7.10	  A).	   Interestingly,	  
they	   show	  an	   increase	   in	   their	  MHCII	   expression	   from	   the	   vascular	   to	   the	  alveolar	  
compartments	  (figure	  7.10	  C).	  The	  variations	  in	  MHCII	  expression	  suggest	  functional	  
differences	  of	  these	  cells	  depending	  on	  the	  compartment	  in	  which	  they	  are	  localised,	  
potentially,	   showing	   more	   antigen	   presenting	   capabilities/requirements	   in	   the	  
alveolar	   space.	   Importantly,	   the	   infiltrating	   Ly-­‐6Cintermediate	   and	   Ly-­‐6Chi	   monocytes	  
show	  a	  much	  lower	  expression	  of	  MHCII	  (two	  log	  fold	  lower).	  Moreover,	  this	  CD11c	  
and	  MHCII	  data	  also	  confirms	  that	  this	  technique	  is	  able	  to	  discern	  differences	  in	  cell	  
surface	   marker	   expression	   within	   similar	   cells	   that	   are	   present	   in	   different	  
compartments	   of	   the	   lung.	   The	   function	   and	   eventually	   fate	   of	   these	   exudative	  
monocytes	  requires	  further	  elucidation	  using	  experimental	  protocols	  that	  may	  allow	  
blood-­‐derived	  monocytes	   to	  be	   tracked	   into	   the	   lung	  e.g.	  5-­‐bromo-­‐2’-­‐deoxyuridine	  
(BrDU)	  pulse	  labelling	  of	  bone	  marrow	  progenitors	  as	  has	  been	  done	  in	  a	  number	  of	  
recent	  publications	  (389,	  430).	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Figure	  7.7.	  Changes	   in	  neutrophil	   and	  monocytes	  numbers	   in	   lung	   compartments	  
and	  blood	  during	  lung	  injury	  
A)	  There	  are	  two	  phases	  of	  neutrophil/monocyte	  infiltration	  into	  the	  lungs	  after	  acid	  
aspiration.	  The	  first	  occurs	  as	  early	  as	  3	  hours	  (as	  derived	  from	  the	  acute	  ventilated	  
model)	  and	  the	  second	  at	  2	  days.	  (B)	  There	  is	  a	  blood	  neutrophilia	  on	  day	  1	  and	  (C)	  
an	  increase	  in	  interstitial	  and	  alveolar	  infiltration	  on	  day	  2.	  Over	  half	  of	  all	  infiltrated	  
neutrophils	   remain	   in	   the	   interstitial	   compartment	   on	   day	   2.	   (D)	   Blood	  monocyte	  
levels	   reduce	   at	   day	   1	   but	   (E)	   their	   influx	   into	   the	   lungs	   shows	   a	   similar	   trend	   to	  
neutrophils,	   increasing	   in	   the	   alveolar	   and	   interstitial	   compartments	   on	   day	   2.	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day	  2.	  N=3-­‐7;	  *P<0.05;	  ♯P<0.01	  versus	  uninjured	  and	  day	  1	  in	  alveolar	  compartment;	  
**P<0.01	  versus	  uninjured	  and	  day	  1	  in	  interstitial	  compartment.	  
	  
	  
Figure	  7.8.	  A	  preliminary	  analysis	  of	  neutrophil	  apoptosis	  during	  lung	  injury	  
A)	   Gating	   strategy	   for	   Annexin	   V	   and	   propidium	   iodide	   labelling	   of	   neutrophils	  
obtained	  through	  alveolar	  lavage	  on	  on	  day	  2	  after	  acid	  aspiration.	  Plot	  on	  left	  side	  
shows	   unstained	   control	   showing	   all	   events	   are	   in	   R1	   quadrant.	   On	   labelling	  with	  
Annexin	  V	  and	  propidium	  iodide	  there	  is	  an	  increase	  in	  the	  number	  of	  events	  in	  the	  
R2	   quadrant.	   These	   are	   events	   undergoing	   apoptosis	   and	   displaying	  
phosphatydlserine	   on	   their	   outer	   surface	   for	   annexin	   V	   to	   bind.	   B)	   Over	   25%	   of	  
neutrophils	   are	   undergoing	   apoptosis	   on	   day	   2	   suggesting	   on-­‐going	   resolution	   of	  
inflammation.	   Of	   note	   there	   are	   no	   events	   showing	   delayed	   apoptosis	   (R3)	   or	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phosphatydlserine'on'their'outer'surface'for'annexin'V'to'bind.'B)'Over'25%'of'neutrophils'are'undergoing'
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Figure	  7.9.	  Kinetics	  of	  CD11b	  positive	  events	  during	  lung	  injury	  
A)	  There	  is	  an	  increase	  in	  the	  number	  of	  CD11b	  positive	  events	  (black	  gates)	  during	  
the	   course	   of	   lung	   injury.	   B)	   The	   alveolar	   and	   interstitial	   compartments	   show	   an	  
increase	   in	   neutrophils	   on	  day	   1	   (red	   arrows).	   The	   interstitial	   compartment	   shows	  
infiltration	   of	   Ly-­‐6Chi	   monocytes	   on	   day	   2	   (green	   arrow).	   These	   are	   most	   likely	  
derived	   from	   the	   blood,	   which	   shows	   a	   reduction	   in	   Ly-­‐6Chi	   monocytes	   on	   the	  
preceding	   day	   1	   (purple	   arrow).	   The	   infiltration	   of	   Ly-­‐6Chi	   monocytes	   into	   the	  
interstitial	   space	   is	   followed,	   on	   day	   4,	   by	   a	   marked	   increase	   in	   Ly-­‐6Cintermediate	  
monocytes	   in	   the	   alveolar	   compartment	   (blue	   arrow).	   The	   vascular	   compartment	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Figure	   7.10.	   Increasing	   expression	   of	   cell	   surface	   CD11c	   and	   MHCII	   during	  
monocyte	  transmigration	  
A)	  Monocyte	  influx	  on	  day	  2	  predominates	  over	  neutrophil	  influx	  in	  both	  the	  alveolar	  
and	   interstitial	   compartments	   of	   the	   lungs.	   The	   interstitial	   compartment	   shows	   a	  
increase	   in	  all	  monocyte	  subtypes	  on	  day	  2.	   In	  contrast,	   the	  alveolar	  compartment	  
consists	   predominantly	   of	   Ly-­‐6Cintermediate	   monocytes.	   B)	   On	   day	   2,	   all	   subsets	   of	  
monocytes	   show	  an	   increase	   in	  CD11c	  expression	   as	   they	   traverse	   the	  endothelial	  
and	   epithelial	   layers.	   The	   increase	   in	   Ly-­‐6Cintermediate	   subpopulations	   and	   the	  
increased	   CD11c	   expression	   suggests	   a	   conversion	   from	   a	   monocyte	   to	   a	  
macrophage	  phenotype;	  N=3;	  P<0.001	  by	  2-­‐way	  ANOVA	  (repeated	  measures)	  across	  
compartments	   C)	   On	   day	   2,	   there	   is	   an	   increasing	   expression	   of	  MHCII	   on	   Ly-­‐6Clo	  
monocytes	   from	   the	   vascular	   to	   the	   alveolar	   compartment.	  N=3;	   P<0.05	   across	   all	  
groups	  by	  1-­‐way	  ANOVA;	  *P<0.05	  versus	  vascular	  compartment.	  
	  
7.4.10 CD4	  T-­‐cell	  infiltration	  during	  resolution	  of	  lung	  injury	  
The	  changes	  in	  MHCII	  expression	  in	  the	  various	  compartments	  imply	  a	  role	  for	  a	  T-­‐
cell	   response	   as	   a	   crucial	   component	   to	   inflammation	   in	   lung	   injury	   as	   has	   been	  
suggested	  by	  a	  number	  of	  authors	  (98,	  431).	  In	  view	  of	  this	  increasing	  expression	  of	  
Figure'7.10'
Figure' 7.10'A)'Monocy3c' inﬂux' on' day' 2' predominates' over' neutrophil' inﬂux' in' both' the' alveolar' and'
inters33al' compartments' of' the' lungs.' The' inters33al' compartment' shows' a' signiﬁcant' increase' in' all'
monocyte' subtypes' on' day' 2.' In' contrast,' the' alveolar' compartment' consists' predominantly' of' Ly6C'
intermediate'monocytes.'B)'on'day'2,'all' subsets'of'monocytes'show'an' increase' in'CD11c'expression'as'
they'traverse'the'endothelial'and'epithelial' layers.'The' increase' in'Ly6C' intermediate'subpopula3ons'and'
the'increased'CD11c'expression'suggests'a'conversion'from'a'monocyte'to'a'm croph ge'phenotype;'N=3;'
P<0.001'by'2Rway'ANOVA' (repeated'measures)' across' compartments'C)'On'day'2,' there' is' an' increasing'
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MHCII	   on	  monocytes	   as	   they	   traverse	   from	   the	   vascular	   to	   interstitial	   to	   alveolar	  
compartments	   (figure	  7.10	  C),	   and	  also	   the	   increased	  expression	  at	  24	  hours	   after	  
injury	  on	  alveolar	  macrophages	   (figure	  7.6	  B),	  we	  sought	   to	  detect	  changes	   in	  CD4	  
helper	   T-­‐cell	   infiltration	   into	   the	   lung,	   given	   that	   MHCII	   is	   the	   exclusive	   co-­‐
stimulatory	  molecule	  to	  CD4	  T-­‐cells	  (432).	  Hence,	  the	  numbers	  of	  CD45+CD11b-­‐CD4+	  
T-­‐cells	  with	  low	  side	  scatter	  were	  quantified	  (figure	  7.11	  A).	  As	  expected	  there	  were	  
minimal	   numbers	   of	   T-­‐cells	   in	   the	   alveolar	   compartment	   in	   the	   naïve	  mouse	   lung,	  
with	   over	   90%	   of	   all	   CD45+CD11b-­‐CD4+	   T-­‐cells	   being	   present	   in	   the	   interstitial	  
compartment	  at	  any	  time.	  	  
	   	  
The	  response	  to	  injury	  showed	  a	  decline	  in	  the	  number	  of	  interstitial	  T-­‐cells	  at	  day	  1	  
(figure	  7.11	  B;	  green	  bars).	  At	  day	  2	  there	  is	  a	  marked	  increase	  in	  CD4	  T-­‐cells	  in	  both	  
interstitial	   (green	  bars)	  and	  alveolar	   (blue	  bars)	  compartments.	  Over	  20%	  of	  T-­‐cells	  
are	   present	   in	   the	   alveolar	   space	   during	   day	   2.	   The	   overall	   number	   of	   T-­‐cells	  
decreases	  by	  day	  4	  in	  both	  alveolar	  and	  interstitial	  compartment	  (effectively	  back	  to	  
naïve	  levels).	  The	  proportion	  of	  T-­‐cells	   located	  in	  the	  alveolar	  versus	  the	  interstitial	  
compartment	  also	  decreases	  at	  day	  4	  (with	  now	  only	  13%	  in	  the	  alveolar	  space).	  It	  is	  
important	   to	  note	   that	   lungs	  were	  harvested	  by	   transecting	   the	  bronchi	  distally	   to	  
avoid	   T	   cell	   contamination	   in	   the	   sample	   from	   hilar	   lymph	   nodes.	   This	   was	  
standardised	  in	  all	  animals.	  Even	  if	  this	  technical	  consideration	  could	  have	  influenced	  
these	  data	  it	  would	  have	  done	  so	  only	  in	  the	  interstitial	  compartment	  (not	  exposed	  
to	   the	   in	   vivo	   intratracheal	   PE-­‐Cy7	   CD45	   antibody).	   Hence,	   the	   changes	   in	   the	  
alveolar	  compartment	  truly	  reflect	  changes	  in	  CD4	  T-­‐cell	  numbers	  in	  response	  to	  acid	  
aspiration.	   Of	   interest,	   the	   doubling	   in	   T-­‐cell	   infiltration	   (within	   the	   alveolar	   and	  
interstitial	  spaces)	  at	  day	  2	  occurs	  at	  the	  time	  when	  resolution	  of	  physiological	  injury	  
and	  inflammation	  begins	  and	  at	  a	  point	  when	  the	  second	  phase	  of	  monocyte	  influx	  
peaks	  in	  this	  model.	  The	  next	  step	  will	  be	  to	  examine	  the	  maximally	  suppressive	  anti-­‐
inflammatory/pro-­‐resolution	   subset	   of	   these	   cells	   –	   the	   CD25+FoxP3+	   population	  
(280,	  281,	  433-­‐435).	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Figure	  7.11.	  Interstitial	  T-­‐cell	  infiltration	  during	  lung	  injury	  resolution	  
A)	  T-­‐helper	  cells	  were	  gated	  as	  CD45+CD11b-­‐CD4+	  events.	  B)	  In	  lung	  tissue	  from	  the	  
uninjured	  mouse	   the	  majority	  of	   T	   cells	   are	   in	   the	   interstitial	   compartment	   (green	  
bars).	   The	   alveolar	   space	   contains	   a	   negligible	   number.	   As	   injury	   progresses	   the	  
interstitial	   population	   initially	   declines	   substantially	   on	   day	   1	   followed	   by	   a	  
substantial	   increase	   on	   day	   2.	   By	   day	   4	   there	   is	   a	   reduction	   in	   the	   populations	  
suggesting	  a	  rapid	  fluctuations	   in	  CD4	  positive	  T-­‐cell	  responses	  during	  the	   injurious	  
and	   reparative	   phases	   of	   lung	   injury.	   N=3-­‐5;	   ♯P<0.05	   Day	   1	   versus	   Day	   2	   alveolar	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7.5 Discussion	  
This	  model	   of	   acid	   aspiration	   incorporates	   all	   of	   the	   important	   pathophysiological	  
features	   of	   ARDS	   as	   suggested	   by	   the	   ATS	   workshop	   report	   in	   experimental	  
modelling	  ARDS	  (192).	  Leukocytes	  have	  been	  implicated	  in	  the	  pathogenesis	  of	  acid	  
aspiration	  since	  the	  first	  description	  of	  Mendelson’s	  syndrome	  (194,	  436).	  However,	  
elucidating	   how	   leukocytes	   mediate	   the	   physiological	   dysfunction,	   in	   particular	  
hypoxaemia	   that	   determines	   clinical	   management	   (e.g.	   intubation	   or	  
implementation	   of	   extracorporeal	   oxygenation)	   remains	   unknown	   and	   ill	   defined.	  
This	  is	  partly,	  as	  discussed	  previously,	  due	  to	  the	  lack	  of	  pre-­‐clinical	  models	  that	  truly	  
recapitulate	  the	  clinical	  picture.	  	  
	  
In	  chapters	  3,	  4	  and	  5,	  I	  have	  described	  how	  the	  acute	  phase	  of	  acid-­‐induced	  alveolar	  
oedema	   formation	   is	   determined	  by	   the	  production	  of	   inflammatory	  mediators,	   in	  
particular	  TNF,	  by	  alveolar	  macrophages	  which	  ultimately	  promotes	  epithelial	  barrier	  
dysfunction	  and	  deteriorations	   in	  alveolar	   fluid	  clearance	   through	   the	  activation	  of	  
p55	   TNF	   receptor	   mediated	   caspase-­‐8	   signalling.	   This	   effect	   is	   seemingly	  
independent	  of	  inflammatory	  mediators	  given	  that	  p55	  TNFR	  deficient	  animals	  have	  
similar	   lung	   leukocyte	   counts	   and	   that	   the	   physiological	   effects	   occur	   within	   90	  
minutes	  of	  acid	  aspiration,	  far	  before	  substantial	  alveolar	  leukocyte	  infiltration.	  
	  
However,	   given	   the	   extensive	   evidence	   for	   the	   involvement	   of	   leukocytes	   in	   acid	  
aspiration	   and	  more	   broadly	   in	   ARDS	   it	  was	   important	   to	   establish	   the	   kinetics	   of	  
leukocyte	   infiltration	   into	  the	   lungs	  within	  this	  model.	   In	  particular,	   the	  correlation	  
between	   lung	  neutrophil/monocyte	   infiltration	   (at	  3	  hours)	  and	  Fas	   ligand	   levels	   in	  
the	  alveolar	  space	  (figure	  5.10)	  potentially	  suggests	  that	  the	  delivery	  of	  death	  ligands	  
(by	   blood	   derived	   leukocytes)	   to	   the	   lung	   parenchyma	   could	   sustain	   the	   initial	  
alveolar	   capillary	   barrier	   dysfunction	   and	   pulmonary	   oedema	   formation,	   initially	  
triggered	   by	   alveolar	   macrophage	   derived	   TNF.	   Indeed,	   the	   continued	   increase	   in	  
alveolar	   TNF	   levels	   up	   to	   day	   2,	   in	   association	   with	   leukocyte	   infiltration,	   is	  
consistent	  with	  this	  argument.	  The	  subsequent	  reduction	  at	  day	  3	  (of	  both	  cytokine	  
levels	   and	   leukocyte	   numbers)	   and	   the	   recovery	   of	   alveolar	   epithelial	   function	   (as	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determined	   by	   alveolar	   fluid	   clearance)	   suggest	   that	   molecular	   and	   cellular	  
inflammatory	  mediators	   play	   a	   crucial	   role	   in	   the	   resolution	   and	   recovery	   of	   lung	  
physiology.	  Investigations	  into	  the	  types	  and	  exact	  functions	  of	  itinerant	  leukocytes	  
are	   lacking	   but	   crucial	   to	   understanding	   the	   reasons	   for	   and	   the	   consequences	   of	  
such	  shifts	  in	  inflammatory	  responses.	  This	  chapter	  describes	  a	  technique	  to	  enable	  
a	  more	  thorough	  evaluation	  into	  the	  types	  and	  location	  of	  leukocytes	  within	  the	  lung	  
to	  help	  investigate	  their	  roles	  and	  function,	  but	   importantly,	  their	   interactions	  with	  
parenchymal	  cells.	  
7.5.1 Rationale	  for	  compartmental	  evaluation	  
There	   are	   a	   vast	   variety	   of	   leukocytes	  within	   the	   lung	  with	   each	   having	   known	   or	  
supposed	  roles	  during	  the	  various	  phases	  of	   lung	  injury.	  Flow	  cytometry	  provides	  a	  
powerful	   tool	   to	   elucidate	   the	   phenotype	   and	   functions	   of	   these	   cells	   within	   the	  
tissue.	   Although	   recent	   publications	   have	   presented	   data	   to	   analyse	   leukocyte	  
subsets	   using	   flow	   cytometry	   (423,	   437),	   they	   have	   not	   addressed	   the	   true	  
localisation	  of	  leukocytes	  within	  the	  lung.	  Johnston	  et	  al	  performed	  cardiac	  perfusion	  
and	   lavage	   procedures	   to	   determine	   which	   cells	   were	   present	   within	   the	   lung	  
interstitium	  (437).	  However,	  lung	  lavage,	  in	  our	  hands,	  only	  removes	  approximately	  
10%	   of	   resident	   alveolar	   macrophages	   from	   the	   alveolar	   space	   in	   naïve	   animals.	  
After	   the	   onset	   of	   injury	   the	   recoverability	   of	   alveolar	   macrophages	   is	   likely	   to	  
worsen	   as	   a	   consequence	   of	   the	   macrophages	   becoming	   activated	   and	   more	  
adherent	   to	   the	   underlying	   alveolar	   epithelium,	   a	   concept	   called	   ‘the	  macrophage	  
disappearance	  reaction’	  (82,	  438,	  439).	  Furthermore,	  it	  has	  been	  shown	  that	  cardiac	  
perfusion	  does	  not	  remove	  all	  cells	  from	  the	  pulmonary	  vasculature	  and	  those	  that	  
have	   marginated	   or	   adhered	   to	   the	   lung	   endothelium	   remain	   behind	   and	   play	   a	  
substantial	  role	  in	  the	  propagation	  of	  lung	  injury	  (89,	  237,	  241,	  399,	  415).	  The	  in	  vivo	  
labelling	   protocols	   described	   in	   this	   chapter	   enables	   the	   positive	   ‘real-­‐time’	  
identification	   of	   leukocytes	   within	   the	   vascular	   and	   alveolar	   compartments	   of	   the	  
lungs,	   and	   through	   negative	   gating	   strategies	   the	   identification	   of	   the	   interstitial	  
compartment	   (as	   the	   unstained	   compartment).	   Investigation	   of	   the	   interstitial	  
compartment	   of	   the	   lung	   has	   proven	   elusive.	   This	   is	   partly	   due	   to	   a	   limitation	   in	  
histological	  techniques,	  which	  are	  limited	  to	  identifying	  only	  2	  or	  3	  cellular	  epitopes	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(double	   or	   triple	   immunostaining).	   Hence,	   the	   full	   range	   of	   cells	   cannot	   be	  
characterised.	   Furthermore,	   histology	   is	   subject	   to	   sectioning	   artefact	   and	   is	   only	  
semi-­‐quantitative.	   More	   recently,	   intravital	   microscopy	   has	   facilitated	   further	  
investigation	  of	   this	  compartment	  but	  has	   limitations	  with	  respect	   to	  area	  of	   lungs	  
that	  can	  be	  examined	  (sub-­‐pleural)	  and	  the	  high	  costs	  (418-­‐420).	  The	  advantage	  of	  
the	  in	  vivo	  labelling	  technique	  presented	  here	  is	  that	  it	  offers	  all	  of	  the	  advantages	  of	  
multi	   channel	   flow	   cytometry	   and	   allows	   the	   identification	  of	   numerous	   cell	   types	  
using	  multiple	  markers	  within	  the	  three	  compartments	  of	  the	  mouse	  lung.	  	  
7.5.2 Confounding	  factors	  to	  in	  vivo	  labelling	  strategies	  
It	  is	  important	  at	  this	  stage	  to	  consider	  the	  potential	  confounding	  factors	  that	  would	  
preclude	   the	   ideal	   separation	   of	   lung	   compartments	   e.g.	   the	   use	   of	   negative	  
selection	   and	   potential	   for	   leak	   of	   antibodies	   between	   compartments.	   From	   this	  
perspective,	   the	  use	  of	   negative	   selection	   in	   this	   technique	  would	   always	  more	  or	  
less	   ‘overestimate’	   the	   interstitial	   compartment	   especially	  when	   100%	   labelling	   by	  
intratracheal	   and	   intravascular	   antibody	   has	   not	   occurred.	   On	   the	   other	   hand,	   if	  
intratracheal	  or	   intravenous	  antibodies	   leaked	   in	  vivo	   into	  other	  compartments,	  or	  
they	  are	  not	  properly	  washed/removed	  before	  homogenisation	  and	  cell	  suspension	  
making	  process,	  it	  would	  ‘underestimate’	  the	  interstitial	  compartment.	  
	  
The	  robust	  separation	  of	  alveolar	  and	  vascular	  compartments	  (figure	  7.2)	  suggests	  a	  
high	   proportion	   and	   intensity	   of	   labelling	   by	   the	   in	   vivo	   antibodies.	   However,	   any	  
small	   amount	   of	   leak	   of	   these	   antibodies	   would	   also	   label	   interstitial	   events	   into	  
either	  the	  alveolar	  or	  vascular	  compartments.	  If	  significant	  bidirectional	  leak	  were	  to	  
occur	  then	  these	   interstitial	  events	  would	  be	  positively	   labelled	  by	  both	  antibodies	  
and	  would	  be	  found	  in	  R9	  (figure	  7.2).	  This	  was	  found	  to	  be	  less	  than	  0.3%	  of	  total	  
lung	   events	   and	   this	   proportion	   remained	   unchanged	   throughout	   injury.	  
Furthermore,	   this	   double	   positive	   population	   consisted	   mainly	   of	   CD11b-­‐
CD11c+F4/80+	   events	   i.e.	   resident	   alveolar	  macrophages	   possibly	   due	   to	   their	   high	  
autofluorescence.	   Another	   explanation	   could	   also	   be	   that	   despite	   optimal	  
compensation	   of	   the	   flow	   cytometer,	   a	   small	   amount	   of	   the	   PE-­‐Cy7	   fluorescence	  
may	  have	  drifted	  into	  the	  PE	  channel.	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There	  are	  two	  further	  potential	  contaminants	  that	  could	  lead	  to	  the	  in	  vivo	  antibody	  
labelling	   cells	   in	   different	   compartments.	   These	   are	   those	   that	   could	   occur	   during	  
sample	  processing:	  
1. Intravascular	  antibody	  to	  sample	  
2. Intraalveolar	  antibody	  to	  sample	  
	  
The	  first	  can	  be	  minimised	  by	  flushing	  the	  pulmonary	  vasculature.	  Although	  this	  was	  
not	  performed	  it	  was	  felt	  that	  the	  following	  steps	  would	  have	  minimised	  the	  impact	  
of	  this	  artefact:	  
1. The	   dilution	   of	   the	   intravenous	   administered	   antibody	   into	   the	  
circulating	  volume.	  
2. Animals	   underwent	   systemic	   anticoagulation	   and	   exsanguination	  
prior	  to	  processing,	  minimising	  the	  residual	  volume	  of	  blood	  left	  in	  the	  lung.	  	  
	  
The	   second	   potential	   artefact	   could	   result	   from	   the	   excess	   intratracheally	   instilled	  
PE-­‐Cy7	  antibody	  (present	   in	  the	  alveolar	  spaces	  and	  bronchial	  tree)	  binding	  to	  cells	  
during	   lung	   homogenisation.	   This	  was	   possible	   due	   to	   the	  whole	   lung	   (tied	  with	   a	  
suture	   at	   each	   respective	   bronchus)	   being	   placed	   in	   the	   homogenisation	   tubes.	  
Hence,	   excess	   unbound	   intratracheal	   antibody,	   released	   during	   the	   lung	  
homogenisation	   procedure,	   could	   have	   labelled	   interstitial	   or	   intravascular	   cells	  
within	   the	   cell	   suspension,	   in	   particular	   prior	   to	   the	   first	   wash	   and	   centrifugation	  
when	  the	  antibody	  has	  not	  yet	  been	  removed	  from	  the	  sample.	  This	  excess	  antibody	  
was	  not	  allowed	  to	  drain	  out	  of	  the	  tracheobronchial	  tree	  because	  this	  would	  have	  
allowed	  some	  alveolar	  localised	  cells	  to	  be	  lost	  from	  the	  sample.	  Hence,	  this	  protocol	  
was	   pursued	   to	   allow	   the	  maximum	   retention	   of	   cells	   in	   the	   homogenate	   thereby	  
enabling	   the	  most	   accurate	   determination	   of	   cell	   number.	   However,	   certain	   steps	  
were	  taken	  to	  minimise	  this	  potential	  confounder.	  These	  included:	  
1. Ligation	   of	   the	   tracheobronchial	   tree	   as	   distal	   as	   possible	   to	   lung	  
parenchyma.	  
2. Homogenisation	  of	  the	  lung	  in	  the	  largest	  possible	  fluid	  volume	  (2mls	  
of	  ice-­‐cold	  fixative	  solution	  added)	  with	  immediate	  dilution	  into	  20mls	  of	  ice-­‐
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cold	  flow	  cytometry	  wash	  buffer.	  This	  would	  significantly	  dilute	  any	  residual	  
excess	  antibody	  and	  the	   low	  temperature	  would	  minimise	  antibody-­‐epitope	  
reaction	  occurs.	  However,	   I	  believe	  that	  these	  potential	   ‘in	  vivo	   leaks’	  or	   ‘in	  
vitro	  contamination’	  effects	  do	  not	  significantly	  influence	  these	  results	  given	  
the	   fact	   that	   intratracheal	   (PE-­‐Cy7)	   and	   intravenous	   (PE)	   CD45	   double	  
positive	  cells	  are	  indeed	  always	  <0.5%	  of	  total	  cells.	  
7.5.3 Resident	  alveolar	  macrophages	  populations	  during	  lung	  injury	  
Resident	   alveolar	  macrophages,	   as	   defined	   by	   a	   CD45+CD11c+CD11b-­‐F4/80+SiglecF+	  
phenotype,	  are	  the	  predominant	  cell	  type	  in	  the	  alveolar	  space.	  We	  found	  that	  there	  
were	  1.5	  million	  alveolar	  macrophages	  in	  the	  right	  lungs	  of	  mice.	  Over	  95%	  of	  these	  
cells	  were	  labelled	  to	  be	  within	  the	  alveolar	  compartment	  and	  5%	  were	  gated	  within	  
the	   interstitial	   compartment.	   The	   total	   resident	   alveolar	   macrophage	   number	  
significantly	   reduced	   after	   acid	   aspiration	   on	   day	   1	   to	   50%	   of	   the	   original	  
macrophage	  number.	  Most	  interestingly,	  nearly	  25%	  of	  this	  population	  is	  present	  in	  
the	   interstitial	   compartment.	   This	   differential	   dynamic	   location	   of	   the	   resident	  
alveolar	   macrophages	   at	   different	   stages	   of	   injury	   suggests	   that	   some	   of	   these	  
resident	   alveolar	   macrophages	   are	   indeed	   resident	   within	   the	   interstitial	   space.	  
There	   are	   a	   number	   of	   reasons	   why	   there	   should	   be	   a	   decline	   in	   alveolar	  
macrophage	  numbers.	  	  
	  
Firstly,	   it	   is	   uncertain	   if	   alveolar	  macrophages	   are	   capable	  of	  migration	   away	   from	  
the	  lung.	  Hence,	  the	  reduction	  in	  macrophage	  number	  could	  represent	  a	  trafficking	  
to	   nearby	   lymph	   nodes.	   The	   increase	   in	   MHCII	   expression	   of	   this	   resident	  
macrophage	  population	  at	  24	  hours	  suggests	  that	  they	  are	  functionally	  different	  on	  
day	  1	  post-­‐injury	  with	  a	  potential	  to	  present	  antigen	  to	  other	  cells.	  Kirby	  et	  al	  have	  
shown,	   albeit	   in	   a	   mouse	   model	   of	   Streptococcus	   pneumoniae	   pneumonia,	   that	  
resident	  alveolar	  macrophages	  are	  able	  to	  deliver	  bacteria	  and	  antigenic	  material	  to	  
secondary	   lymphoid	   tissue	   (440).	   They	   found	   that	   this	   constitutive	   migration	   of	  
alveolar	   macrophages	   precedes	   the	   migration	   of	   conventional	   dendritic	   cells,	   the	  
classic	   route	   for	   antigenic	   delivery	   to	   draining	   lymphoid	   organs.	   Importantly,	   they	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used	   a	   similar	   set	   of	   robust	   markers	   (F4/80,	   SiglecF	   and	   MHCII)	   to	   distinguish	  
resident	  alveolar	  macrophages	  and	  dendritic	  cells.	  	  
	  
The	  second	  potential	  cause	  of	   this	   loss	   is	   through	  apoptosis	  or	  necrosis	  of	  alveolar	  
macrophages.	  Although	  at	  90	  minutes	  of	  acid	  aspiration	  death	  receptor	  activation	  of	  
caspase-­‐8	   was	   not	   detectable	   in	   macrophages	   (figure	   4.4),	   macrophages	   may	   die	  
through	   alternative	   pathways	   including	   the	   intrinsic	   pathway	   (441)	   and	   autophagy	  
(442,	  443).	  Janssen	  et	  al	  showed	  that	  the	  basal	  turnover	  of	  the	  resident	  macrophage	  
pool	   in	   uninjured	  C57BL6	  mice	  was	   very	   slow	  having	   a	   half-­‐life	   of	   greater	   than	  12	  
months	   (112).	  On	  administration	  of	  a	  high	  dose	  of	   intratracheal	  endotoxin	   (200μg)	  
they	   report	   a	   40%	   decline	   in	   the	   resident	  macrophage	   population	   at	   the	   72-­‐hour	  
time-­‐point	   measured,	   but	   showed	   no	   recovery	   in	   macrophage	   number	   despite	   a	  
significant	   increase	   in	  exudative	  macrophages.	  However,	  during	   the	  administration	  
of	   a	   lower	   dose	   of	   endotoxin	   (20	   μg)	   they	   found	   no	   decline	   in	   resident	   alveolar	  
macrophage	   numbers.	   Hence,	   these	   data	   suggest	   contrasting	   effects	   in	   resident	  
alveolar	  macrophage	  numbers	  depending	  potentially	  on	  the	  severity	  of	  the	  insult,	  or	  
the	  degree	  of	  TLR-­‐4	  signalling.	  	  	  
	  
The	  third	  explanation	  for	  a	  loss	  could	  be	  a	  change	  in	  epitopes	  expressed	  by	  alveolar	  
macrophages	   (e.g.	   loss	   of	   CD11c	   expression)	   causing	   a	   proportion	   of	   them	   being	  
outside	  the	  gating	  strategy	  used	  to	  detect	  them	  in	  uninjured	  animals.	  This	  is	  unlikely	  
given	  that	   the	  days	  2	  and	  4	  show	  similar	  phenotypes	  and	  that	  other	   injury	  models	  
show	   that	   these	   cells	   remain	   unchanged	   with	   respect	   to	   the	   markers	   used	   (437,	  
444).	   An	   intratracheal	   labelling	   strategy	   prior	   to	   injury	   (for	   instance,	   using	   PKH26-­‐
Phagocytic	   Cell	   Linker	   system	   as	   used	   by	   a	   number	   of	   investigators	   to	   distinguish	  
resident	  from	  exudative	  macrophages	  (112,	  445)	  may	  resolve	  this	  issue.	  
	  
If	  we	  assume	  this	  loss	  of	  macrophages	  to	  be	  a	  real	  phenomenon,	  it	  is	  interesting	  that	  
their	  number	  normalises	  by	  day	  2.	  There	  may	  be	  a	  number	  of	  explanations	  for	  this.	  
Firstly,	  an	  expansion	  of	  an	  interstitial	  progenitor	  population	  to	  replenish	  lost	  resident	  
alveolar	  macrophages	  at	  day	  1	  could	  account	  for	  these	  results.	  Landsman	  and	  Jung	  
showed	   that	  alveolar	  macrophages	  do	   indeed	  originate	   from	  blood	  monocytes	  but	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have	   an	   indirect	   connection	   through	   an	   obligatory	   parenchymal	   lung	   intermediary	  
phase	  (110).	  
	  
In	   contrast,	   Yona	   et	   al	   have	   recently	   suggested	   that	   the	   resident	   population	   of	  
macrophages	  located	  within	  the	  alveolar	  space	  are	  established	  in	  utero	  in	  mice,	  and	  
remain	  on	  in	  adulthood	  (430).	  Their	  data	  also	  suggest	  that	  the	  replenishment	  of	  this	  
established	  mature	  macrophage	  population	  does	  not	  seem	  to	  be	   influenced	  by	  the	  
blood	   monocyte	   pool.	   Further	   flow	   cytometry	   based	   assays	   investigating	   the	   cell	  
cycle	  of	  resident	  myeloid	  cells	  (cell	  death	  versus	  proliferation)	  may	  shed	  further	  light	  
on	  this	  phenomenon	  of	  alveolar	  macrophage	  disappearance.	  	  
	  
However,	   nearly	   all	   of	   these	   studies	   were	   performed	   under	   steady	   state	   naïve	  
conditions	  and	  the	  influence	  of	  an	  injurious	  or	  inflammatory	  insult	  remains	  unclear.	  
The	   replenishment	   of	   alveolar	   macrophages	   likely	   occurs	   through	   local	   as	   well	   as	  
systemic	  replacement.	  The	  kinetics	  shown	  in	  figure	  7.9	  shows	  that	  Ly-­‐6Chi	  monocytes	  
infiltrate	  the	  interstitial	  compartment	  of	  the	  lung	  (green	  arrow)	  on	  day	  2.	  These	  cells	  
reduce	  in	  number	  on	  day	  4	  but	  there	  is	  an	  increase	  in	  the	  Ly-­‐6Cintermediate	  population	  
in	  the	  alveolar	  space.	  This	  Ly-­‐6Chi	  population	  could	  be	  replenishing	  resident	  alveolar	  
macrophage	  populations,	  which	  also	  show	  a	  Ly-­‐6Cintermediate	  phenotype.	  This	  requires	  
further	  investigation.	  	  
7.5.4 Resident	  interstitial	  monocyte	  populations	  
A	   number	   of	   groups	   have	   confirmed	   the	   presence	   of	   an	   interstitial	  
monocyte/macrophage	   population	   that	   seems	   to	   be	   derived	   from	   circulating	  
monocytes	   (110,	   428).	   For	   the	   purposes	   of	   our	   work	   we	   have	   called	   these	  
CD45+CD11b+Ly6Clo	  cells,	  interstitial	  monocytes,	  given	  their	  relatively	  low	  expression	  
of	   CD11c	   (a	   marker	   of	   mature	   macrophages	   (446,	   447)).	   In	   the	   absence	   of	   this	  
intravenous	   and	   intratracheal	   labelling	   methodology,	   their	   similarity	   to	   vascular	  
monocytes	  produces	  significant	  difficulties	   in	   realising	   their	  existence	  and	   location.	  
Misharin	  et	  al	  performed	  whole	  lung	  flow	  cytometry	  after	  perfusing	  the	  right	  heart	  
with	   PBS	   (423).	   They	   described	   interstitial	   macrophages	   as	   CD11c+CD11b+MHCII+	  
cells,	  potentially	  confusing	  them	  with	  the	  CD11c+CD11b+CD103-­‐MHCII+	  dendritic	  cell	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population,	  and	  depending	  on	  the	  method	  and	  MFI	  of	  MHCII	  labelling,	  with	  vascular	  
monocytes.	  Bedoret	  et	  al	  were	  the	  first	  to	  characterise	  a	  true	  interstitial	  monocyte	  
population	   through	   flow	   cytometry	   and	   they	   ascribed	   a	   similar	   phenotype	   to	   that	  
described	   in	   our	   experiments	   –	   CD11b+CD11c-­‐MHCII+.	   They	   confirmed	   that	   these	  
were	   present	   only	   in	   the	   interstitial	   compartment	   through	   concurrent	  
immunohistochemistry	  of	  lung	  sections	  (428).	  	  
7.5.5 Resident	  interstitial	  dendritic	  cell	  populations	  
Lung	  dendritic	  cells	  are	  divided	  into	  conventional	  (cDC)	  and	  plasmacytoid	  (pDC)	  cells.	  
Lambrecht	   describes	   two	   main	   phenotypes	   of	   conventional	   cDCs	   within	   the	   lung	  
(421,	  448)	  (both	  expressing	  high	  levels	  of	  CD11c)	  and	  one	  pDC	  type	  (expressing	  low	  
levels	   of	   CD11c).	   The	   two	   types	   of	   cDC	   are	   called	   epithelial	   (CD11b-­‐CD103+)	   and	  
lamina	   propria	   (CD11b+CD103-­‐),	   in	   accordance	   to	   their	   location.	   The	   epithelial	  
dendritic	   cell	   type	   samples	   the	   alveolar	   environment	   by	   extending	   dendrites	  
between	   alveolar	   epithelial	   cells	   through	   interactions	   between	  CD103	   and	   its	   only	  
known	  ligand,	  E-­‐cadherin	  (which	  is	  found	  in	  the	  tight	   junctions	  in	  between	  alveolar	  
epithelial	   cells)	   (449).	   The	   predominant	   interstitial	   localisation	   of	   these	   CD11c	  
positive	   cDC	   populations	   enabled	   robust	   confirmation	   that	   the	   exclusion	   of	   the	  
vascular	   and	   alveolar	   compartments	   (vascular	   PE	   anti-­‐CD45	   labelled	   and	  
intratracheal	   PECy7	   anti-­‐CD45	   labelled,	   respectively)	   through	   negative	   gating	  
strategies	  allowed	  a	  clear	  identification	  of	  the	  interstitial	  compartment.	  Over	  95%	  of	  
dendritic	   cells	  were	   located	  within	   the	   lung	   interstitium	  with	  5%	  being	   labelled	  by	  
the	   intratracheal	  PECy7	  anti-­‐CD45	  antibody.	  However,	   it	   is	   important	  to	  appreciate	  
that	   their	   apparent	  detection	   in	   the	  alveolar	   compartment	  may	  not	  necessarily	  be	  
due	  to	  their	  actual	  localisation	  there	  but	  rather	  may	  inherently	  be	  an	  artefact	  of	  the	  
intratracheal	   labelling	   technique	  given	   that	   a	  proportion	  of	   their	   surface	  dendrites	  
sample	   the	   alveolar	   space	   and	   hence	  may	   well	   be	   exposed	   to	   intratracheal	   CD45	  
antibody.	   However,	   this	   is	   unlikely	   to	   be	   the	   case	   given	   a	   similar	  MFI	   (in	   PE-­‐Cy7)	  
between	   these	   alveolar	   localised	   cDCs	   and	   resident	   alveolar	   macrophages	   –	  
suggesting	  an	  equivalent	  exposure	  to	  the	  intratracheal	  antibody.	  Hence,	  I	  feel	  that	  a	  
proportion	  of	   the	  cDCs	  are	   likely	   localised	   in	   the	  alveolar	  compartment,	   consistent	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with	   Vermaelen	   and	   Pauwels	   who	   also	   showed	   a	   similar	   distribution	   of	   DC	  
populations	  (447).	  
	  
The	  epithelial	  type	  (CD11b-­‐CD103+MHCII+)	  cDCs	  dramatically	  reduce	  in	  numbers	  and	  
unlike	  resident	  alveolar	  macrophages	  remain	  lowered	  through	  out	  the	  4-­‐day	  period	  
studied.	   This	   either	   represents	   a	   disappearance	   reaction	   (potentially	   to	   nearby	  
lymph	  nodes)	  or	  a	  change	  in	  phenotype	  (similar	  to	  that	  discussed	  with	  the	  reduction	  
in	   resident	   alveolar	  macrophages).	   The	   numbers	   of	   this	   DC	   subset	   in	   the	   alveolar	  
compartment	  does	  not	  seem	  to	  be	  affected	  during	  injury,	  as	  seen	  in	  figure	  7.6	  C.	  	  
	  
The	   lamina	   propria	   type	   (CD11b+CD11c+MHCII+)	   cDCs	   are	   inherently	   difficult	   to	  
distinguish	  during	  states	  of	  injury.	  As	  can	  be	  seen	  in	  figure	  7.10	  C,	  Ly-­‐6Clo	  monocytes	  
increase	   their	   MHCII	   and	   CD11c	   expression	   as	   they	   traverse	   into	   the	   interstitial	  
compartment	  and	  hence,	  make	  it	  difficult	  for	  MHCII	  to	  be	  used	  as	  a	  reliable	  marker	  
to	  distinguish	  CD11b+	  monocyte	  and	  DC	  phenotypes.	   Indeed,	  DC	  populations	  have	  
also	   been	   suggested	   to	   recover	   as	   a	   result	   of	   replenishment	   from	   blood-­‐derived	  
monocytes.	   Hence,	   the	   potential	   difficulties	   in	   finding	   distinguishing	   features	  
between	   infiltrating	  Ly-­‐6Clo	  monocytes	  and	  CD11b+CD103-­‐	   cDCs.	  Recently,	   the	  high	  
affinity	   IgE	   α	   chain	   receptor	   (FcεRIα)	   has	   been	   proposed	   to	   distinguish	   between	  
these	  cell	  types	  but	  only	  in	  models	  of	  virus-­‐induced	  airway	  inflammation	  (448,	  450).	  
Preliminary	  experiments	  utilising	  the	  Mar-­‐1	  antibody	  against	  this	  epitope	  have	  failed	  
potentially	  secondary	  to	  effects	  of	  the	  fixation	  protocol	  on	  the	  FcεRIα	  (possibly	  in	  a	  
similar	  manner	  to	  its	  effect	  on	  the	  Ly-­‐6G	  component	  of	  Gr-­‐1).	  
7.5.6 Two	  phases	  of	  myeloid	  infiltration	  
The	  pulmonary	  capillary	  network	  can	  be	  as	  small	  as	  2μm	  in	  diameter	  and	  hence,	   is	  
able	  to	  trap	  many	  PMNs,	  slowing	  their	  transit	  time	  and	  providing	  an	  intimate	  contact	  
with	   the	   capillary	   endothelium.	   The	   acute	   ventilated	   and	   resolution	  models	   seem	  
comparable	  in	  terms	  of	  the	  proton	  dose	  (50μl	  of	  0.15M	  for	  acute	  ventilated	  and	  75μl	  
of	   0.1M	   for	   resolving	   non-­‐ventilated	   model)	   and	   severity	   of	   lung	   protein	  
permeability.	  The	  influence	  of	  mechanical	  ventilation	  in	  the	  acute	  model	   is	  unlikely	  
to	  be	   injurious,	   given	   that	  we	  have	  previously	   shown	   that	   the	   surgical	  preparation	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for	   ventilation	   at	   10ml/kg	   in	   mice	   does	   not	   induce	   pro-­‐inflammatory	  
cytokine/chemokine	   upregulation	   in	   the	   alveolar	   space	   (239,	   451).	   Furthermore,	  
baseline	   neutrophil	   numbers	   are	   consistent	   between	   the	   acute	   ventilated	   and	   the	  
non-­‐ventilated	   resolution	   model	   implying	   robust	   and	   comparable	   flow	   cytometry	  
counts.	   Hence,	   the	   kinetic	   gained	   on	   combining	   data	   from	   the	   acute	   ventilated	   3-­‐
hour	  model	  and	  the	  longer-­‐term	  resolution	  model	  shows	  that	  4	  million	  neutrophils	  
and	   6.5	   million	   monocytes	   are	   recruited	   to	   the	   right	   lung	   at	   3	   hours	   after	   acid	  
aspiration.	  This	  declines	  to	  680,000	  and	  410,000,	  respectively,	  at	  24	  hours,	  and	  then	  
subsequently	  rises	  to	  2.7	  and	  7.3	  million,	  respectively,	  on	  day	  2	  (figure	  7.7	  A).	  These	  
data	  confirm	   two	  phases	  of	  neutrophil	   and	  monocyte	   sequestration	   to	   the	   lung	  as	  
has	  been	  suggested	  by	  a	  number	  of	  investigators	  (97,	  452).	  	  
Phase	  one	  
It	  is	  well	  established	  that	  neutrophils	  are	  sequestered	  to	  the	  lung	  at	  very	  early	  time	  
points	  in	  a	  variety	  of	  models	  of	  lung	  injury	  including	  endotoxin	  (313,	  401,	  453-­‐459),	  
VILI	  (224,	  225,	  227,	  228,	  451,	  460,	  461),	  acid	  aspiration	  (88,	  195,	  257,	  260,	  261,	  462),	  
and	   oleic	   acid	   (463,	   464).	   Reutershan	   et	   al	   found	   pronounced	   PMN	   recruitment	  
between	  2	  and	  4	  hours	  in	  an	  LPS	  model	  of	  lung	  inflammation,	  which	  reached	  over	  6	  
million	   at	   4	   hours,	   and	   steadily	   declined	   at	   16	   hours	   (458).	   Consistent	   with	   our	  
model,	   Kennedy	   found	   an	   initial	   increase	   in	   PMN	   in	   the	   lungs	   at	   4	   hours	   that	  
decreased	  by	  15	  hours	  in	  a	  rat	  model	  of	  acid	  aspiration	  (195).	  	  
	  
An	   interesting	   observation	   is	   that	   both	   phases	   of	   neutrophil	   sequestration	   to	   the	  
lung	  are	  associated	  with	  concomitant	  rises	  in	  monocyte	  numbers	  suggesting	  that	  the	  
sequestration	   of	   these	   cell	   types	   share	   similar	   mechanisms	   and	   that	   one	   may	   be	  
dependant	  on	  the	  other.	  The	  high	  number	  of	  Ly-­‐6Chi	  monocytes	  infiltrating	  the	  lung	  
within	  3	  hours	  of	  insult	  has	  only	  recently	  been	  appreciated.	  Interestingly,	  our	  group	  
was	  the	  first	  to	  show	  that	  these	  ‘inflammatory’	  blood	  monocytes	  ‘marginate’	  to	  the	  
lung	  endothelium	  and	  promote	  alveolar	  capillary	  barrier	  dysfunction	   in	  a	  variety	  of	  
experimental	   models	   of	   ARDS	   (89,	   237,	   241,	   399,	   415).	   The	   in	   vivo	   labelling	  
technique	  has	  not	  as	  yet	  been	  applied	  at	  three	  hours	  and	  hence,	  the	  fate	  and	  exact	  
location	  of	   these	  early	   cells	   during	   this	   first	   phase	   remains	  uncertain	   (i.e.	  whether	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they	   transmigrate	   into	   the	   pulmonary	   interstitium,	   or	   continue	   to	   be	   recirculate	  
after	   a	  period	  of	   attachment	   to	   the	   capillary	  endothelium).	   The	   source	  of	   the	   first	  
monocyte	  sequestration	  phase	  (measured	  as	  early	  as	  90	  minutes)	  is	  most	  likely	  to	  be	  
from	  monocytes	   already	  present	   in	   the	   vasculature.	  However,	   the	  number	  of	   lung	  
sequestered	   monocytes	   far	   exceeds	   the	   circulating	   pool	   and	   hence,	   a	   large	  
proportion	   are	   also	   likely	   to	   be	   derived	   from	   immature	   bone	   marrow	   precursors	  
(415).	   Hence,	   the	   decline	   at	   24	   hours	   may	   suggest	   a	   relative	   depletion	   of	   bone	  
marrow	  stores.	  	  
Phase	  Two	  
There	   is	   much	   less	   known	   about	   the	   second	   phase	   of	   neutrophil/monocyte	  
infiltration.	  The	  kinetic	  of	  the	  acid	  model	  suggests	  that	  the	  first	  phase	  is	  over	  before	  
the	  second	  phase	  even	  begins.	   Importantly,	  each	   is	  associated	  with	  quite	  different	  
and	   distinct	   phases	   of	   lung	   injury.	   The	   first	   is	   associated	   with	   the	   initiation	   and	  
amplification	  phase	  of	  lung	  injury	  whereas	  the	  second	  seems	  to	  be	  intimately	  linked	  
to	   the	   recovery	   and	   resolution	   phase,	   given	   that	   lung	   physiology	   improves	   on	   the	  
following	  day.	  	  
	  
Numerous	   publications	   using	   depletion	   strategies	   have	   shown	   that	   a	   reduction	   in	  
neutrophil	   and	   monocyte	   sequestration	   to	   the	   lung	   prior	   to	   injury	   leading	   to	   a	  
reduction	   in	   the	   first	   phase	   of	   neutrophil/monocyte	   influx,	   seems	   to	   confer	  
significant	   protection	   against	   oedema	   formation	   in	   experimental	   models	   of	   ARDS	  
(237,	   256,	   400,	   402,	   465).	  However,	   depletion	   of	   the	   second	  phase	   has	   only	   been	  
investigated	  more	  recently.	  Dhaliwal	  et	  al	  were	  the	  first	  to	  deplete	  monocytes	  after	  
injury	   induction	   in	   an	   endotoxin	   induced	   lung	   injury	   model.	   This	   group	   of	  
investigators	  showed	  that	  depletion	  of	  blood	  monocytes	  led	  to	  a	  reduction	  in	  second	  
phase	  of	  neutrophil	   sequestration	   to	   the	   lung.	  Additionally,	   this	   led	   to	   significantly	  
reduced	  protein	  permeability	  and	  improved	  oxygenation	  (97).	  In	  contrast,	  exudative	  
monocytes	   have	   been	   shown	   to	   pro-­‐resolving	   in	   nature	   by	   a	   number	   of	   other	  
groups.	  Janssen	  shows	  exudative	  macrophages	  appearing	   in	  the	  airspaces	  on	  day	  3	  
and	   disappear	   by	   day	   6	   through	   Fas	   mediated	   apoptosis	   and	   this	   coincides	   with	  
resolution	   and	   repair.	   D’Allessio	   showed	   a	   similar	   profile	   but	   at	   day	   4	   (100).	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Unfortunately,	  most	  studies	  have	  only	  examined	  the	  endotoxin	  model	  of	  lung	  injury	  
and	  these	  studies	  have	  used	  different	  doses	  of	  endotoxin	  in	  different	  strains	  of	  mice	  
(97,	   100).	   Hence,	   the	   contrasting	   effects	   (injurious	   versus	   protective)	   may	   be	  
secondary	   to	   the	   variability	   in	   type,	   preparation	   and	   instillation	   of	   endotoxin	  
between	   investigators	   and	   the	   subsequent	   subtle	   differences	   in	   severity	   of	   illness	  
and	  kinetics	  in	  leukocyte	  migration.	  
	  
This	  acid-­‐induced	   lung	   injury	  model	  shows	  a	  second	  phase	  of	  neutrophil/monocyte	  
influx	   that	   occurs	   earlier	   (day	   2)	   and	   seems	   to	   be	   associated	  with	   resolution.	   This	  
may	  be	  due	  to	  endotoxin	  having	  potentially	  very	  different	  recruitment	  kinetics	  to	  the	  
acid	  model.	  For	   instance,	  endotoxin	  could	  cause	  a	  more	  sustained	  TLR-­‐4	  activation	  
leading	   to	   a	   protracted	   inflammatory	   response	   over	   days.	   In	   comparison,	   acid	   is	  
likely	   buffered	   within	   24	   hours	   (466)	   and	   hence,	   a	   limited	   activation	   period	   may	  
allow	  resolution	  mechanisms	  to	  occur	  earlier.	  Furthermore,	  the	  acid	  model	  shows	  a	  
much	   greater	   disturbance	   to	   the	   endothelial	   and	   epithelial	   surfaces	   and	   hence,	  
differences	   between	   sterile	   insults	   and	   endotoxin-­‐based	   insults	   (mimicking	  
“infection”)	   may	   have	   different	   effects	   on	   leukocyte	   recruitment	   and	   different	  
consequences.	  
	  
Hence,	   the	   literature	   suggests	   quite	   conflicting	   roles	   for	   leukocytes	   and	   it	   is	  
reasonable	   to	   suggest	   that	   neutrophils	   and	   monocytes	   can	   be	   directed	   to	   be	  
injurious	   and	   protective	   depending	   on	   signalling	   from	   within	   the	   cell	   as	   well	   as	  
communication	  with	  extrinsic	  mediators.	  Translating	  this	  “cellular	   language”	  that	   is	  
used	   by	   different	   leukocytes	   will	   be	   an	   important	   step	   in	   the	   discovery	   of	   the	  
mechanisms	  that	  promote	  resolution	  and	  repair	  and	  the	  development	  of	  strategies	  
to	  promote	  the	  reestablishment	  of	  tissue	  homeostasis	  after	  severe	  injury.	  One	  such	  
‘language’	   that	   research	   has	   made	   significant	   strides	   in	   deciphering	   is	   how	  
neutrophil	  apoptosis	  and	  its	  recognition	  by	  macrophages	  can	  promote	  resolution	  of	  
inflammation.	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7.5.7 Neutrophil	  apoptosis	  may	  promote	  a	  resolving	  second	  phase	  
Controlled	   neutrophil	   elimination	   from	   tissues	   through	   apoptosis	   marks	   the	  
beginning	  of	  resolution	  and	  promotes	  changes	  to	  macrophage	  phenotype	  (14).	  This	  
constitutive	  apoptosis	  programme	  is	  delayed	  in	  clinical	  ARDS	  (103)	  through	  a	  variety	  
of	  mechanisms	  (467,	  468)	  including	  increased	  Granulocyte-­‐Colony	  Stimulating	  factor	  
(G-­‐CSF)	  levels	  in	  the	  alveolar	  space	  (103).	  Indeed,	  it	  is	  G-­‐CSF	  and	  GM-­‐CSF	  that	  drives	  
the	   maturation	   of	   neutrophils	   from	   the	   bone-­‐marrow	   progenitors	   (469).	   This	  
potential	  of	   the	  bone	  marrow	   to	   supply	  neutrophils	   is	   immense	  given	   the	  average	  
half-­‐life	  of	  a	  neutrophil	  being	  6-­‐8	  hours	  (48).	  	  
	  
The	   limited	   lifespan	   of	   ‘first	   responder’	   neutrophils	   through	   constitutive	   apoptosis	  
programmes	  likely	  accounts	  for	  the	  decline	  in	  lung	  neutrophil	  numbers	  from	  the	  first	  
phase.	   Despite	   a	   relative	   abundance	   of	   blood	   neutrophils,	   a	   lower	   number	   were	  
present	   in	   the	   lung	  during	   the	   second	  phase,	   as	   compared	   to	   the	   first	  phase	   (at	  3	  
hours),	  suggesting	  a	  potential	  restriction	  to	  lung	  neutrophil	  sequestration	  during	  this	  
second	   phase.	   In	   contrast,	   despite	   the	   significant	   monocytopenia	   observed,	   lung	  
monocyte	  number	  tripled	  lung	  neutrophil	  number	  on	  day	  2.	  	  
	  
Overall,	   these	   observations	   suggest	   very	   different	   lifespan	   between	   these	   two	  
myeloid	  cells	  with	  neutrophil	  turnover	  being	  quicker	  than	  that	  of	  monocytes.	  Indeed,	  
preliminary	  data	  suggests	  that	  nearly	  25%	  of	  all	  alveolar	  neutrophils	  on	  day	  2	  stain	  
positive	   for	   Annexin	   V,	   a	   marker	   of	   apoptosis	   that	   is	   recognised	   by	   phagocytes	  
enabling	   efferocytosis.	   Annexin	   V	   binds	   to	   phosphatidylserine	   (PS),	   a	   molecule	  
usually	  found	  on	  the	  inner	  side	  of	  the	  cell	  membrane,	  which	  during	  the	  early	  stages	  
of	  apoptosis,	  translocates	  to	  the	  outer	  surface	  (470).	  In	  addition,	  phosphatydylserine	  
is	   a	   recognition	   marker	   for	   phagocytes	   to	   engulf	   apoptotic	   leukocytes,	   a	   process	  
known	   as	   efferocytosis	   (130).	   This	   leads	   to	   a	   shift	   in	   the	   phenotype	   of	   such	  
macrophages	  to	  a	  pro-­‐resolution	  and	  healing	  phenotype	  (14,	  15,	  129,	  403,	  467,	  471,	  
472).	  
	  
There	   is	   significant	   evidence	   suggesting	   neutrophils	   to	   be	   instigators	   of	   resolution	  
and	  repair,	  independent	  to	  apoptosis	  pathways.	  For	  instance,	  neutrophils	  have	  been	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shown	  to	  release	  lipid	  mediators	  that	  also	  promote	  resolution	  of	  inflammation	  (104-­‐
106,	  124,	  473).	  More	   recently,	   neutrophils	  have	  been	   shown	   to	  promote	   repair	  of	  
the	   lung	   epithelium	   during	   endotoxin	   induced	   lung	   inflammation	   (96).	   Such	   work	  
suggesting	   that	   neutrophils	   may	   not	   always	   be	   injurious	   questions	   the	   simple	  
measurement	   of	   neutrophil	   number	   and	   activity	   (myeloperoxidase	   assay)	   as	  
monitors	  of	  proinflammatory	  and	  injurious	  responses.	  
7.5.8 Myeloid	  and	  T-­‐cell	  interactions	  may	  enable	  healing	  and	  resolution	  
A	  major	  observation	  is	  the	  loss	  of	  CD4+	  T-­‐cells	  on	  day	  1	  after	  injury.	  This	  potentially	  
suggests	   that	   these	   lymphocytes	  migrate	  out	  of	   the	   lung	   into	  either	  nearby	   lymph	  
nodes	  or	  the	  spleen	  to	  interact	  with	  macrophages	  or	  dendritic	  cells	  through	  MHCII-­‐
CD4	  interactions.	  They	  then	  return	  to	  the	  lung	  interstitium	  and	  alveolar	  space	  on	  day	  
2	   to	   direct	   the	   repair	   process	   within	   the	   lung.	   Indeed,	   the	   increasing	   MHCII	  
expression	  of	  Ly-­‐6Clo	  monocytes	  (on	  day	  2)	  as	  they	  traverse	  from	  the	  vascular	  to	  the	  
alveolar	  space	  also	  suggests	  important	  antigen	  presenting	  function	  to	  such	  a	  CD4+	  T-­‐
cell	  population.	  D’Alessio	  et	  al	  were	  the	  first	  to	  show	  such	  a	  relationship	  by	  elegantly	  
showing	   that	   T-­‐regulatory	   cells	   (CD4+CD25+FoxP3+)	   interact	   with	   macrophages	   to	  
produce	   TGF-­‐beta,	   initiating	   the	   resolution	   of	   inflammation	   in	   endotoxin	   induced	  
lung	   injury	   (98).	   Hence,	   interactions	   between	   myeloid	   cells	   and	   T-­‐helper	   cells	  
certainly	  promote	  repair	  and	  resolution	  of	   inflammation,	  and	  present	  an	  important	  
potential	  for	  therapeutic	  intervention.	  
	  
7.6 Concluding	  remarks	  
It	   is	   interesting	   that	   despite	   its	   significant	   severity	   of	   injury	   this	   model	   of	   acid	  
aspiration	   shows	   spontaneous	   resolution.	   Ascertaining	   this	   trigger	   for	   repair	   and	  
resolution	  and	  which	  factors	  delay	  resolution;	  how	  neutrophils,	  monocytes,	  dendritic	  
cells	  may	  be	  influencing,	  interacting,	  and	  being	  influenced	  by	  other	  leukocytes;	  how	  
the	   lung	  endothelium	  and	  epithelium	  fit	   into	  this	  cellular	  communication;	  and	  how	  
other	   leukocyte	   stores,	   in	  particular,	   regional	   lymph	  nodes,	  bone	  marrow,	  and	   the	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This	  model	   shows	   the	   potential	   to	   investigate	   this	   complex	   cellular	   and	  molecular	  
matrix	   in	   a	   clinically	   relevant	   insult	   with	   significant	   disturbance	   to	   respiratory	  
physiology.	   The	   model	   could	   be,	   in	   future	   combined	   with	   the	   application	   of	  
bacterial/viral/fungal	   infection	   (mimicking	   nosocomial	   infection)	   to	   allow	   further	  
characterisation	   of	   mediators	   that	   distract	   the	   respiratory	   system	   from	   normal	  
resolution	   and	   repair.	   Importantly,	   this	  model	  may	  allow	   the	   link	  between	   cellular	  
inflammation	  and	  clinically	  relevant	  physiological	  disturbances	  (such	  as	  hypoxaemia	  
and	  alveolar	  fluid	  clearance)	  to	  be	  mechanistically	  investigated.	  This	  is	  an	  important	  
relationship	  to	   investigate	   in	  the	  search	  for	   future	  therapeutics	  targeting	   leukocyte	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8 Final	  thoughts	  –	  where	  to	  now	  in	  ARDS	  research…	  
	  
8.1 The	  translation	  of	  p55	  blockade	  to	  the	  ICU	  bedside	  
ARDS	   remains	   a	   major	   problem	   on	   the	   ICU	   and	   physiological	   consequences	   are	  
currently	   only	   treated	   through	   therapies	   including	   mechanical	   ventilatory,	  
extracorporeal,	  and	  multi-­‐organ	  support.	  Despite	  improvements	  in	  general	  ICU	  care,	  
the	   implementation	   of	   ultra-­‐protective	   lung	   ventilation	   strategies,	   and	   the	  
improvement	   in	   extracorporeal	   support	   technologies,	   mortality	   remains	  
unacceptably	   high.	   TNF	  has	   been	   consistently	   implicated	   in	  ARDS	   and	  our	   findings	  
suggest	   that	   total	   TNF	   blockade	  may	   be	   deleterious	   due	   to	   the	   receptors	   for	   TNF	  
showing	  divergent	   roles	   in	   the	   formation	  of	  alveolar	  oedema,	  a	  cardinal	   feature	  of	  
ARDS.	  
	  
Chapter	  3,	  4	  and	  5	  describe	  the	  divergent	  roles	  for	  the	  receptors	  in	  a	  model	  of	  acid-­‐
induced	   lung	   injury	   and	   puts	   forward	   a	   mechanism	   through	   which	   the	   p55	   TNF	  
receptor	   specifically	  mediates	   the	   formation	   of	   alveolar	   oedema	   by	   TNF.	  We	   also	  
show	  that	  the	  injurious	  effect	  of	  p55	  TNF	  receptor	  activation	  is	  likely	  to	  be	  due	  to	  the	  
activation	   of	   death	   signalling	   as	   opposed	   to	   inflammatory	   signalling.	   Most	  
interestingly,	   this	  death	  signalling	   is	  activated	  at	  a	  very	  early	   time	  point	   (within	  90	  
minutes),	   well	   before	   inflammatory	   cells	   enter	   the	   lung	   from	   the	   circulation.	  
Furthermore,	  this	  caspase-­‐8	  death	  signal,	  induced	  by	  the	  p55	  TNF	  receptor,	  seems	  to	  
be	  confined	  to	  the	  type	  1	  alveolar	  epithelium.	  This	   is	  also	  at	  a	  stage	  when	  there	   is	  
minimal	   detectable	   completed	   cell	   death.	   Pharmacological	   blockade	   of	   caspase-­‐8	  
activation	   suggest	   that	   the	   extent	   to	   which	   caspase-­‐8	   activity	   is	   upregulated	  
determines	   the	   functional	   deficit	   seen	   within	   the	   alveolar	   epithelium	   (i.e.	  
deteriorations	  in	  AFC)	  in	  injured	  mouse	  lungs.	  If	  cell	  death	  has	  not	  occurred	  then	  the	  
consequent	  epithelial	  dysfunction	  may	  be	  reversible	  during	  this	  phase	  of	  “apoptotic	  
limbo”.	  Hence,	  this	  work	  delivers	  a	  compelling	  rationale	  for	  the	  specific	  blockade	  of	  
the	   p55	   TNF	   receptor	   at	   the	   alveolar	   epithelial	   surface	   to	   rescue	   alveolar	   fluid	  
clearance	  and	  reduce	  permeability.	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8.2 	  The	  p55	  DAb	  in	  acute	  ARDS	  
The	  potential	  for	  specific	  blockade	  of	  the	  p55	  TNF	  receptor	  in	  ARDS	  has	  been	  opened	  
by	   the	   development	   of	   a	   compound,	   p55	   DAb	   (GSK1995057),	   by	   GlaxoSmithKline	  
(GSK)	  (474).	  This	  compound	  is	  a	  novel	  IgG	  fragment	  called	  a	  domain	  antibody	  (figure	  
8.1).	   Advantages	   for	   its	   use	   as	   compared	   with	   conventional	   antibodies	   are	   the	  
monovalent	  binding	  capacity	  to	  the	  p55	  TNF	  receptor,	  small	  size	  (12kDa)	  and	  hence,	  
potential	  for	  large	  quantities	  to	  be	  delivered	  with	  good	  tissue	  penetration	  and	  high	  
local	   alveolar	   concentration	   (in	   particular,	   if	   delivered	   through	   the	   aerosolised	  
route).	   Initial	   data	   suggests	   that	   intra-­‐tracheal	   administration	   of	   the	   p55	   DAb	  
attenuates	  oedema	  formation	  and	  inflammatory	  activation	  (neutrophil	  recruitment,	  
ICAM-­‐1	   upregulation	   on	   alveolar	  macrophages,	   and	   IL-­‐6/MCP-­‐1	   levels	   in	   BAL)	   in	   a	  




Figure	  8.1.	  Domain	  antibody	  (DAb)	  fragment	  in	  comparison	  to	  an	  IgG	  molecule	  
	  	  
Our	  laboratory	  has	  recently	  shown	  that	  that	  pre-­‐treatment	  with	  the	  p55	  DAb	  might	  
be	  therapeutic	  at	  3	  hours	  in	  acid-­‐induced	  lung	  injury	  (475).	  When	  the	  DAb	  is	  applied	  
1	  hour	  prior	  to	  acid	  aspiration	  there	  is	  improved	  respiratory	  mechanics,	  oxygenation	  
and	  alveolar	  protein	  at	  this	  time	  point.	  These	  all	  suggest	  improved	  alveolar-­‐capillary	  
barrier	   integrity.	   Interestingly,	   this	   pre-­‐injury	   application	   also	   led	   to	   a	   reduced	  
neutrophil	   and	   lavage	  cytokine	   level.	  This	  difference	  between	   the	  DAb	   treated	  WT	  
animals	  and	  the	  p55	  TNFR	  knockout	  animals	  after	  acid	  aspiration	  may	  be	  secondary	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Hence,	   acute	   inhibition	   of	   the	   p55	   TNF	   receptor	  may	   also	   attenuate	   inflammatory	  
events,	  for	  instance,	  through	  an	  inhibition	  of	  the	  p55	  TNFR	  on	  alveolar	  macrophages	  
leading	  to	  reduced	  activation	  and	  reduced	  cytokine	  storm.	  Consistent	  with	  this	  is	  the	  
aforementioned	   reduction	   in	   ICAM-­‐1	   expression	   on	   alveolar	   macrophages	   by	   the	  
p55	  DAb	   in	  the	  VILI	  model	   (252).	  Levels	  of	  TNF	  were	  not	  measured	   in	  the	  BAL	  and	  
hence,	  these	  studies	  did	  not	  exclude	  the	  potential	  for	  a	  reduced	  upregulation	  of	  TNF	  
from	  alveolar	  macrophages	  in	  the	  protected	  groups.	  
	   	  
Most	   recently,	   O’Kane	   et	   al	   applied	   the	   DAb	   in	   an	   in	   vivo	   human	   model	   of	   lung	  
inflammation	   induced	  by	   inhaled	  endotoxin	   in	  healthy	  volunteers	   (476).	  This	   study	  
pre-­‐treated	   healthy	   volunteers	   (subsequently	   exposed	   to	   endotoxin)	   with	   inhaled	  
p55	  DAb	  versus	  placebo	  (in	  a	  randomised	  double	  blind	  manner)	  and	  found	  that	  the	  
upregulation	   of	   pulmonary	   and	   systemic	  markers	   of	   inflammation	   (including	   BALF	  
neutrophils	  and	  BALF	  chemokines	  (MIP-­‐1α,	  MCP-­‐1)	  and	  cytokines	  (IL-­‐1β,	   IL-­‐6,	   IL-­‐8))	  
were	   significantly	   attenuated.	   Additionally	   there	   was	   reduced	   von	   Willebrand’s	  
factor	   (a	   marker	   of	   endothelial	   activation).	   However,	   BALF	   TNF	   levels	   were	   not	  
measured	   and	   hence,	   it	   is	   not	   known	   if	   this	   anti-­‐inflammatory	   effect	   manifest	  
through	   reduced	   p55	   TNFR	   activation	   on	   alveolar	   macrophages	   or	   was	   through	   a	  
direct	  effect	  on	  the	  p55	  TNFR	  on	  the	  alveolar	  epithelium.	  Indeed,	  as	  epithelial	  injury	  
within	  this	  model	  is	  minimal,	  RAGE	  is	  not	  upregulated	  and	  hence,	  was	  not	  measured	  
in	  this	  study.	  
	  
A	   model	   in	   which	   epithelial	   injury	   does	   indeed	   occur	   is	   the	   one-­‐lung	   ventilation	  
model	   of	   lung	   injury.	   These	   include	   patients	   undergoing	   one-­‐lung	   ventilation	   for	  
thoracic	   surgical	   procedures,	   in	  which	   there	   is	   an	   incidence	   of	   ARDS	   of	   2-­‐4%	   post	  
lobectomy,	   8%	   post	   pneumonectomy,	   and	   23%	   post-­‐oesophagectomy	   (187).	  
Application	   of	   the	   p55	   DAb	   to	   these	   patients	   may	   help	   define	   the	   treatment	   in	  
models	  with	   epithelial	   injury	   and	  RAGE	  upregulation.	   Importantly,	   these	  pre-­‐injury	  
treatment	  effects	  seen	  in	  the	  stretch	  and	  acid-­‐induced	  mouse	  lung	  injury	  models	  as	  
well	   as	   the	   human	   endotoxin	   model	   suggests	   that	   the	   p55	   DAb	   could	   be	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8.3 	  The	  p55	  DAb	  -­‐	  epithelial	  rescue	  versus	  non-­‐resolution	  of	  inflammation	  
in	  ARDS	  
A	  further	  exciting	  direction	  that	  has	  been	  opened	  by	  the	  research	  presented	  in	  this	  
thesis	   takes	   into	   account	   that	   alveolar	   cell	   death	   is	   minimal	   in	   early	   ARDS	   and	  
accounts	  for	  less	  than	  10%	  of	  all	  cells.	  It	  appears	  from	  our	  data	  that	  the	  epithelial	  cell	  
enters	  a	  phase	  of	   ‘apoptotic	   limbo’	  and	   lies	   in	  a	   state	  of	  dysfunction	  but	  does	  not	  
actually	  die	  through	  completed	  apoptosis.	  Excitingly,	  this	  may	  present	  a	  therapeutic	  
window	  in	  which	  the	  epithelium	  could	  be	  potentially	  rescued.	  Preliminary	  evidence	  
suggests	   that	   there	   is	   minimal	   TUNEL	   staining	   at	   24	   hours	   after	   acid	   aspiration	  
(resolution	  model)	  and	  hence,	  this	  window	  may	  be	  longer	  than	  the	  three	  hour	  time	  
point	  investigated	  in	  chapter	  4.	  
	  
Application	  of	  intranasal	  DAb	  to	  WT	  animals,	  4	  hours	  prior	  to	  the	  instillation	  of	  acid	  
in	   the	   resolving	   model	   of	   ARDS	   leads	   to	   a	   significant	   improvement	   in	   arterial	  
oxygenation,	  respiratory	  mechanics,	  and	  lung	  water	  content	  (wet/dry	  weight)	  at	  24	  
hours	  (data	  courtesy	  of	  Dr	  Kenji	  Wakabayashi).	  Similar	  to	  data	  presented	  in	  chapter	  
3	   there	   is	   no	  attenuation	   in	   lung	  neutrophils,	   in	   fact,	   there	  was	  a	   tendency	   for	   an	  
increased	   lung	   neutrophil	   count	   (475).	   Neutrophils	   have	   been	   shown	   to	   have	   p55	  
TNF	   receptor	   driven	   apoptosis	   (477-­‐480)	   and	   hence,	   inhibition	   may	   prolong	   their	  
lifespan	   and	   lead	   to	   increased	   injury.	   This	   makes	   it	   crucial	   to	   test	   any	   p55	   DAb	  
therapy	   targeting	   apoptosis	   pathways	   during	   the	   later	   phases	   of	   ARDS	   when	  
neutrophils	  are	  abundant.	  Within	  the	  longer	  term	  model,	  the	  application	  of	  p55	  DAb	  
at	  stages	  where	  resolution	  of	  lung	  injury	  and	  improvement	  in	  AFC	  occurs	  (between	  
day	  2	  and	  3)	  may	  give	  valuable	  insight	  as	  to	  when	  not	  to	  apply	  the	  p55	  DAb.	  These	  
are	   on-­‐going	   experiments	  within	   the	   lab	   and	   should	   further	   elucidate	   this	   double-­‐
edged	   sword	   of	   p55	   TNFR	   blockade.	   Furthermore,	   the	   application	   of	   technologies	  
presented	  in	  chapter	  7	  could	  enable	  the	  elucidation	  of	  p55	  DAb	  effects	  on	  cells	  not	  
only	  within	  the	  alveolar	  space,	  but	  also,	  within	  the	  interstitial	  compartment.	  
	  
With	  respect	  to	  clinical	  application,	  the	  discovery	  of	  an	  epithelial	  biomarker	  may	  be	  
valuable	  in	  stratifying	  which	  patients	  the	  p55	  DAb	  will	  be	  beneficial.	  For	  instance,	  the	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measurement	   of	   BALF	   RAGE	   or	   the	   measurement	   of	   AFC	   may	   allow	   the	   specific	  
testing	  of	  the	  p55	  DAb	  in	  those	  with	  epithelial	  dysfunction.	  Investigation	  in	  the	  one-­‐
lung	  ventilation	  model	  where	  RAGE	  is	  certainly	  raised	  may	  yield	  further	  insights.	  
	  
8.4 	  Translating	  therapies	  to	  ARDS	  
A	  major	  hurdle	  to	  translation	  of	  therapies	  to	  ARDS	  is	  told	  through	  the	  story	  of	  TNF.	  
Although	   implicated	   in	  ARDS	  pathogenesis	  over	  3	  decades	  ago,	   the	   rush	   to	   clinical	  
trials	  of	  anti-­‐TNF	  strategies,	  in	  the	  absence	  of	  mechanisms,	  has	  been	  detrimental	  in	  
sepsis	   and	   ARDS.	   We	   show	   that	   TNF-­‐induced	   death	   signalling	   is	   important	   in	  
epithelial	   dysfunction	  during	  acid-­‐induced	   lung	   injury.	   The	  protective	  effect	  of	  p55	  
TNF	   receptor	   blockade	   has	   now	   been	   proven	   in	  mouse	  models	   of	   stretch-­‐induced	  
oedema	   formation	  and	  acid-­‐induced	   lung	   injury.	  Additionally,	   latest	  data	   suggest	  a	  
beneficial	  effect	  in	  an	  in	  vivo	  human	  lung	  inflammation	  model.	  I	  consider	  the	  manner	  
in	  which	  this	  DAb	  antibody	  has	  been	  investigated	  in	  the	  UK	  prior	  to	  its	  application	  in	  
phase	  2	  studies	  a	  step	  change	  in	  drug	  testing	  in	  critical	  illness.	  In	  particular,	  current	  
on-­‐going	   investigation	   in	   a	   human	   ex	   vivo	   lung	   perfusion	   system	   may	   discover	  
further	  insights	  into	  the	  application	  of	  this	  compound	  to	  clinical	  settings.	  
	  
The	   lack	   of	   robust	   animal	   models	   of	   ARDS	   was	   highlighted	   in	   chapter	   6.	   The	  
resolution	  model	  described	  in	  this	  thesis	  will	  extend	  the	  impact	  of	  therapies	  such	  as	  
this	   to	   more	   clinically	   relevant	   time-­‐points,	   in	   particular,	   when	   severe	   injury	   is	  
combined	   with	   severe	   inflammation.	   A	   clinically	   important	   investigation	   is	   the	  
application	   of	   any	   therapeutic	   compound	   after	   the	   onset	   of	   lung	   injury	   especially	  
with	   respect	   to	   effects	   on	   resolution,	   repair	   and	   fibrosis.	   Furthermore,	   the	  model	  
allows	   investigation	   into	   the	   various	   pathophysiological	   features	   of	   clinical	   ARDS	  
including	   alveolar-­‐capillary	   barrier	   dysfunction,	   leukocyte	   mediated	   injury,	   and	  
resolution	  of	   inflammation.	  Unlike	  other	  models	  of	   lung	   injury,	   this	  acid	  aspiration	  
model	   also	   allows	   the	   measurement	   of	   robust	   physiological	   end-­‐points	   including	  
arterial	   oxygenation,	   respiratory	   mechanics,	   and	   alveolar	   fluid	   clearance.	  
Furthermore,	  the	  application	  of	  the	  model	  to	  the	  ever-­‐increasing	  variety	  of	  knockout	  
strains	  may	   further	  elucidate	   the	   role	  of	  death	  signalling	   in	   lung	   injury.	  Finally,	   the	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development	   of	   models	   using	   other	   clinically	   relevant	   insults	   such	   as	   those	   of	  
bacterial	   and	   viral	   aetiologies	  will	   be	   of	   paramount	   importance.	   The	   greatest	   side	  
effect	  of	  any	  therapy	  targeting	  inflammatory	  and	  apoptosis	  pathways	  is	  a	  potentially	  
increased	  propensity	  to	  infection.	  Given	  that	  nosocomial	  infection	  such	  as	  ventilator-­‐
associated	   pneumonia	   is	   common	   in	   ICU,	   any	   such	   clinical	   risks	   need	   to	   be	  
ascertained	  prior	  to	  phase	  2	  trials.	  An	  adaptation	  of	  such	  an	  acid-­‐induced	  lung	  injury	  
model	  with	  superadded	  infection	  will	  be	  of	  added	  value	  to	  investigate	  the	  underlying	  
mechanisms	  of	  such	  risk.	  	  
	  
8.5 Limitations	  of	  work	  in	  this	  thesis	  
There	  are	  a	  number	  of	  caveats	  that	  require	  discussion	  in	  order	  to	  move	  forward	  with	  
translating	   the	   work	   described	   in	   this	   thesis.	   Firstly,	   the	   acid-­‐induced	   lung	   injury	  
model	  is	  although	  at	  present	  a	  very	  clinically	  translatable	  model,	  it	  only	  represents	  a	  
single	  aetiology	  of	   lung	   injury.	   Further,	   the	  age	  of	  mice	  used	  was	  20-­‐30	  weeks	   i.e.	  
adolescent.	  	  As	  discussed,	  ARDS	  mortality	  increases	  with	  age	  and	  hence,	  using	  older	  
mice	  may	  improve	  the	  translational	  relevance	  of	  this	  model.	  Mouse	  models	  remain	  
the	   mainstay	   of	   pre-­‐clinical	   experimental	   investigation	   in	   critical	   illness	   but	   the	  
disparities	   between	   mice	   and	   men	   require	   appreciation	   given	   their	   genomic	  
responses	   to	   stresses	  may	  well	   be	  different	   (481).	   The	  model	   certainly	   reproduces	  
many	  aspects	  and	  features	  required	  of	  a	  model	  of	  ARDS	  but	  can	  only	  be	  proved	  to	  be	  
the	   ‘gold	   standard’	   if	   a	   therapy	   is	   translated	   from	   the	   bench	   to	   the	   bedside.	   This	  
translational	   pathway	   for	   p55	   receptor	   blockade	   is	   discussed	   further	   in	   the	   next	  
sections.	  	  
	  
The	  methods	  used	  to	  ascertain	  the	  importance	  of	  TNF-­‐p55	  TNFR-­‐caspase-­‐8	  signalling	  
on	  epithelial	  function	  also	  require	  discussion.	  The	  caspase-­‐8	  inhibitor	  and	  clodronate	  
liposomes	  may	  also	  have	  off	  target	  effects.	  For	  instance,	  Z-­‐VAD-­‐IETD	  has	  been	  shown	  
to	  interact	  with	  other	  caspase	  proteases	  (482).	  One	  method	  to	  explore	  these	  effects	  
further	  is	  to	  compare	  the	  impact	  of	  various	  inhibitors	  against	  a	  variety	  of	  caspases.	  
Conditional	   knockout	   of	   caspase-­‐8	   from	   the	   alveolar	   epithelium	   using	   a	   Cre-­‐Lox	  
system	  (as	  has	  been	  done	  in	  the	  gut	  epithelium	  (483))	  may	  be	  a	  better	  alternative	  to	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truly	   elucidate	   the	   role	   of	   caspase-­‐8	   in	   the	   epithelium.	   We	   have	   based	   many	  
conclusions	   on	   the	   impact	   of	   caspase-­‐8	   on	   alveolar	   epithelial	   function	   through	  
correlations	   with	   lung	   caspase-­‐8	   activity	   and	   AFC.	   However,	   these	   relationships	  
include	  multiple	   groups	   rather	   than	   an	   intra-­‐group	   analysis	   and	   hence,	   should	   be	  
interpreted	  with	   caution.	  Although	   caspase-­‐8	   inhibition	   did	   indeed	   rescue	   alveolar	  
fluid	   clearance,	   the	   inhibitor	   dose	   used	   produced	   a	   marginal	   reduction	   in	   lung	  
caspase-­‐8	  activity,	  and	  hence,	  further	  measurements	  of	  AFC	  with	  increasing	  doses	  of	  
caspase-­‐8	   inhibitor	  may	   provide	  more	   insights	   into	   this	   relationship.	   Furthermore,	  
how	   caspase-­‐8	   induced	   the	   changes	   in	   fluid	   clearance	   observed	   remains	   to	   be	  
investigated.	  Clodronate	  may	  also	  have	  cross	  target	  effects	  given	  that	  it	  was	  given	  48	  
hours	  prior	   to	  acid	   instillation.	  Not	  only	  can	   it	  deplete	  alveolar	  macrophages	  but	   it	  
can	   also	   influence	   effects	   through	   alternative	   pathways	   such	   as	   upregulation	   of	  
matrix	  metalloproteinases	  and	  cytotoxic	  T-­‐cell	  responses	  (484).	  
	  
Finally,	  we	  measured	  alveolar	  fluid	  clearance	  with	  an	  aim	  to	  have	  a	  specific	  measure	  
of	  epithelial	  function.	  Although	  clinically	  relevant,	  alveolar	  capillary	  permeability	  is	  a	  
much	  more	  important	  determinant	  of	  lung	  injury	  given	  that	  if	  the	  dam	  had	  not	  been	  
broken	  in	  the	  first	  instance	  then	  the	  pump	  would	  not	  have	  to	  work	  hard.	  However,	  
measurement	  of	  permeability	   in	  experimental	  and	  clinical	  settings	  remains	  difficult	  
and	  requires	  more	  robust	  investigation.	  
	  
8.6 Future	  work	  	  
	  
This	  thesis	  raises	  more	  questions	  than	   it	  answers	  and	  hence,	  a	  discussion	  of	  future	  
investigations	  that	  may	  explore	  these	  further	  would	  seem	  appropriate.	  
1. How	  does	  apoptosis	  signaling	  promote	  epithelial	  injury?	  
	  
• Investigation	   into	   the	   effects	   of	   caspase-­‐8	   inhibition	   (pharmacological)	   and	  
lung	   specific	   genetic	   deletion	   through	   conditional	   alveolar	   epithelial	  
knockouts	   (as	  has	  been	  developed	   in	   the	  gut)	   to	  ascertain	   the	  mechanisms	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through	   which	   caspase-­‐8	   induces	   dysfunction.	   Plausible	   avenues	   include	  
effects	  on	  :	  
− Epithelial	  actin-­‐myosin	  cytoskeletal	  function	  
− Epithelial	  mitochondrial	  function	  
− Epithelial	  ion	  channel	  expression	  
− Epithelial	  tight	  junction	  protein	  expression	  e.g.	  claudins	  and	  occludins	  
− Anti-­‐apoptotic	   pathways	   via	   NF-­‐κB	   activation	   and	   transcription	   of	  
anti-­‐apoptotic	  factors.	  
	  
• Investigate	  the	  role	  for	  leukocyte	  induced	  caspase-­‐8	  activation?	  
− Adoptive	   transfer	   (into	  WT	   animals)	   of	   neutrophils/monocytes	   from	  
Fas	   ligand	  deficient	  (gld	  strain)	  and	  Fas	  receptor	  deficient	  (lpr	  strain)	  
mice.	  
− Utilise	  isolated	  perfused	  lung	  apparatus	  (237).	  	  
	  
• Investigation	   of	   the	   role	   of	   other	   caspases	   (inflammatory	   and	   apoptotic)	   in	  
the	  development	  of	  alveolar	  epithelial	  dysfunction?	  
	  
2. What	  is	  the	  role	  of	  the	  p75	  TNF	  receptor?	  
	  
Unfortunately,	  breeding	  difficulties	  prohibited	  the	  further	  investigation	  of	  the	  role	  of	  
the	   p75	   TNF	   receptor	   as	   an	   anti-­‐inflammatory	   rheostat.	   However,	   further	   studies	  
include:	  
• Flow	   cytometric	   assessment	   of	   resident	   alveolar	   macrophage	   activation	  
during	   acid	   induced	   lung	   injury	   in	   p75KO	   versus	  WT	   animals.	   For	   instance,	  
various	   phenotypes	   of	   macrophages	   have	   been	   described	   (figure	   1.5)	   and	  
measurement	  of	  such	  phenotypic	  markers	  may	  provide	  further	  insights.	  
	  
• The	   impact	   of	   the	   p75	   TNFR	   in	   the	   resolution	   of	   lung	   injury	   through	   T	  
regulatory	   pathways	   requires	   study.	   Preliminary	   investigation	   into	   the	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detection	   of	   Treg	   cells	   in	   spleens	   is	   positive	   and	   the	   FoxP3	   subtype	   has	   a	  
higher	  expression	  of	  the	  p75	  TNFR.	  
	  
3. What	  is	  the	  best	  model	  of	  ARDS	  and	  how	  does	  one	  compare	  against	  the	  other?	  
	  
The	  impact	  of	  secondary	  insults	  and	  a	  study	  comparing	  between	  the	  kinetics	  of	  such	  
a	  resolving	  acid	  model	  and	  a	  resolving	  endotoxin	  model	  (utilising	  similar	  phenotypic	  
markers)	   may	   provide	   further	   insights	   into	   differences	   between	   models.	  
Furthermore,	  we	  only	  had	  access	  to	  a	  seven-­‐channel	  flow	  cytometer	  and	  hence,	  had	  
to	  choose	  the	  markers	  carefully.	  Access	  to	  a	  flow	  cytometer	  with	  more	  channels	  may	  
allow	  a	  more	  in	  depth	  analysis	  of	  a	  greater	  variety	  of	  cellular	  phenotypes	  especially	  if	  
methods	  in	  chapter	  7	  are	  used.	  
4. What	  is	  the	  impact	  of	  co-­‐morbidities	  in	  the	  pathobiology	  of	  ARDS?	  
	  
As	   already	  discussed,	   the	   impact	   of	   co-­‐morbidities	   such	   as	   age	   and	  other	  diseases	  
may	  have	  more	  of	   an	   impact	   in	  ARDS	   than	  previously	   investigated.	  However,	   they	  
remain	  under	  investigated.	  Indeed,	  we	  have	  used	  adolescent	  mice	  in	  our	  studies	  and	  
their	   relevance	   may	   be	   questionable.	   Hence,	   investigation	   in	   older	   mice	   may	   be	  
more	  appropriate.	  	  
	  
The	  primary	  aim	  of	   such	  models	   is	   to	   increase	  our	  knowledge	   into	   the	   capabilities	  
and	  side-­‐effects	  of	  compounds	  prior	  to	  their	  use	  in	  a	  population	  of	  patients	  who	  are	  
at	  the	  extremes	  of	  physiology,	  being	  supported	  by	  mechanical	  devices,	  and	  not	  easy	  
to	   investigate	  given	   their	  high	  mortality.	   The	  development	  and	  application	  of	   such	  
models	   that	  mimic	   patient	   pathways	   will	   be	   integral	   to	   future	   experiments	   that	   I	  
carry	  out	   to	  bridge	   the	  gap	  between	   the	  bedside	  and	   the	  bench	  as	   I	   embark	  on	  a	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